US20220016257A1 - Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate - Google Patents

Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate Download PDF

Info

Publication number
US20220016257A1
US20220016257A1 US17/293,577 US201917293577A US2022016257A1 US 20220016257 A1 US20220016257 A1 US 20220016257A1 US 201917293577 A US201917293577 A US 201917293577A US 2022016257 A1 US2022016257 A1 US 2022016257A1
Authority
US
United States
Prior art keywords
amino acid
acid sequence
seq
antibody
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/293,577
Inventor
Atsuko Saito
Naoya HARADA
Kozo Yoneda
Ichiro Hayakawa
Masaki Meguro
Fuminao DOI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Assigned to DAIICHI SANKYO COMPANY, LIMITED reassignment DAIICHI SANKYO COMPANY, LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YONEDA, Kozo, DOI, Fuminao, HARADA, NAOYA, HAYAKAWA, ICHIRO, MEGURO, MASAKI, SAITO, ATSUKO
Publication of US20220016257A1 publication Critical patent/US20220016257A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to an antibody-drug conjugate useful as an antitumor drug, obtained by connecting an anti-CDH6 antibody, which binds to CDH6 and has an internalization effect, and a pyrrolobenzodiazepine derivative via a linker structure moiety.
  • Cadherins are glycoproteins present on the surface of cell membranes and function as cell-cell adhesion molecules through the calcium ion-dependent binding of their N-terminal extracellular domains, or as signal molecules responsible for cell-cell interaction.
  • Classic cadherins are in the cadherin superfamily and are single-pass transmembrane proteins composed of five extracellular domains (EC domains), one transmembrane region, and an intracellular domain.
  • the classic cadherins are classified into the type I family typified by E-cadherin and N-cadherin, and the type II family according to the homologies of their amino acid sequences.
  • Cadherin-6 is a single-pass transmembrane protein composed of 790 amino acids, which is classified into the type II cadherin family, and this protein has N-terminal extracellular and C-terminal intracellular domains.
  • the human CDH6 gene was cloned for the first time in 1995 (Non Patent Literature 1), and its sequence can be referred to under, for example, accession Nos. NM_004932 and NP_004923 (NCBI).
  • CDH6 is specifically expressed in the brain and the kidney during development and has been reported to play an important role in the circuit formation of the central nervous system (Non Patent Literature 2 and 3) and nephron development in the kidney (Non Patent Literature 4 and 5).
  • the expression of CDH6 in the normal tissues of adult humans is localized to the tubules of the kidney, bile duct epithelial cells, and the like.
  • CDH6 is specifically overexpressed at tumor sites in some types of human adult cancers.
  • the correlation of CDH6 expression with poor prognosis and its applicability as a tumor marker has been reported with respect to human renal cell carcinoma, particularly, renal clear cell carcinoma (Non Patent Literature 6 and 7).
  • the high expression of CDH6 has also been reported with respect to human ovarian cancer (Non Patent Literature 8).
  • Non Patent Literature 9 It has also been reported that CDH6 is involved in the epithelial-mesenchymal transition of human thyroid cancer.
  • CDH6 is also expressed in human bile duct cancer and human small-cell lung cancer (Non Patent Literature 12 and 13).
  • the problems of conventional chemotherapeutics are that: due to their low selectivity, these chemotherapeutics are toxic not only to tumor cells but also to normal cells and thereby have adverse reactions; and the chemotherapeutics cannot be administered in sufficient amounts and thus cannot produce their effects to a sufficient degree.
  • more highly selective molecular target drugs or antibody drugs have been developed, which target molecules that exhibit mutations or a high expression characteristic in cancer cells, or specific molecules involved in malignant transformation of cells.
  • Antibodies are highly stable in blood, and specifically bind to their target antigens. For these reasons, a reduction in adverse reactions is expected, and a large number of antibody drugs have been developed for molecules highly expressed on the surface of cancer cells.
  • ADC antibody-drug conjugate
  • An ADC is a conjugate in which an antibody that binds to an antigen expressed on the surface of cancer cells and can internalize the antigen into the cell through such binding is conjugated to a drug having cytotoxic activity.
  • An ADC can efficiently deliver the drug to cancer cells, and can thereby be expected to kill the cancer cells by accumulating the drug in the cancer cells (Non Patent Literature 10 and Patent Literature 1 and 2).
  • AdcetrisTM (brentuximab vedotin) comprising an anti-CD30 monoclonal antibody conjugated to monomethyl auristatin E has, for example, been approved as a therapeutic drug for Hodgkin's lymphoma and anaplastic large cell lymphoma.
  • KadcylaTM (trastuzumab emtansine) comprising an anti-HER2 monoclonal antibody conjugated to emtansine is used in the treatment of HER2-positive progressive or recurrent breast cancer.
  • a target antigen suitable for an ADC as an antitumor drug are that: the antigen is specifically highly expressed on the surface of cancer cells but has low expression or is not expressed in normal cells; the antigen can be internalized into cells; the antigen is not secreted from the cell surface; etc.
  • the important features of an antibody suitable for an ADC are that the antibody has high internalization ability in addition to specifically binding to the target antigen.
  • the internalization ability of the antibody depends on the properties of both the target antigen and the antibody. It is difficult to predict an antigen-binding site suitable for internalization from the molecular structure of a target or to predict an antibody having high internalization ability from binding strength, physical properties, and the like of the antibody.
  • an important challenge in developing an ADC having high efficacy is obtaining an antibody having high internalization ability against the target antigen (Non Patent Literature 11).
  • An ADC comprising DM4 conjugated to an anti-CDH6 antibody specifically binding to EC domain 5 (EC5) of CDH6 is known as an ADC targeting CDH6 (Patent Literature 3).
  • PBDs pyrrolobenzodiazepines
  • PBDs exhibit cytotoxicity, for example, by binding to the PuGPu sequence in the DNA minor groove.
  • PBDs different in the number of, types of, and sites of substituents in the A and C ring parts, and those different in degree of unsaturation in the B and C ring parts.
  • Non Patent Literatures 18, 19 various ADCs with a dimer PBD have been reported (Patent Literatures 4 to 16).
  • Patent Literatures 4 to 16 a PBD having a spiro ring at its C2-position and an ADC form thereof have not been known.
  • the present inventors have conducted intensive studies directed towards achieving the above-described object, and found that, surprisingly, an antibody specifically binding to extracellular domain 3 (in the present description, also referred to as EC3) of CDH6 has exceedingly high internalization activity against cells expressing CDH6 and is useful as an antibody for ADCs.
  • the present inventors also succeeded in obtaining an anti-CDH6 antibody-drug conjugate by connecting the anti-CDH6 antibody to a novel PBD derivative, and found that the anti-CDH6 antibody-drug conjugate has strong antitumor activity.
  • the present invention relates to the following.
  • n 2 represents an integer of 1 or 2
  • Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof,
  • L represents a linker linking a glycan bonding to N297 of Ab (N297 glycan) and D,
  • N297 glycan may be a remodeled glycan
  • an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 23 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 26,
  • an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67, and
  • an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
  • CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12
  • CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13
  • CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14
  • CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17
  • CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 18
  • CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19
  • CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12
  • CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13
  • CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14
  • CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17
  • CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 30
  • CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19
  • CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12
  • CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13
  • CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14
  • CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57
  • CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58
  • CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59
  • CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12
  • CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13
  • CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14
  • CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 62
  • CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 63
  • CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 64.
  • variable regions (5) to (11) any one heavy chain variable region selected from the group consisting of the following variable regions (5) to (11):
  • L is represented by -Lb-La-Lp-NH—B—CH 2 —O(C ⁇ O)—*, wherein the asterisk * represents bonding to the nitrogen atom at the N10′-position of D,
  • B represents a 1,4-phenyl group, a 2,5-pyridyl group, a 3,6-pyridyl group, a 2,5-pyrimidyl group or a 2,5-thienyl group,
  • Lp represents any one selected from the group consisting of:
  • La represents any one selected from the group consisting of:
  • Lb represents the following formula:
  • each asterisk * represents bonding to La and each wavy line represents bonding to the glycan presented by Ab or a remodeled glycan.
  • Z 2 represents the following structural formula:
  • Z 3 represents the following structural formula:
  • each asterisk * represents bonding to the C( ⁇ O), O or CH 2 neighboring Z 1 , Z 2 or Z 3 ; each wavy line represents bonding to the glycan presented by Ab or a remodeled glycan, and
  • B represents a 1,4-phenyl group.
  • each asterisk * represents bonding to the C( ⁇ O) neighboring Z 1
  • each wavy line represents bonding to the glycan bonding to N297 of Ab (N297 glycan) or bonding to a remodeled glycan.
  • N297 glycan is N297-(Fuc)MSG1, N297-(Fuc)MSG2, or a mixture thereof, or N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
  • *-L (PEG)- in the N297 glycan represents *—(CH 2 CH 2 -0)n 5 -CH 2 CH 2 —NH—, wherein n 5 represents an integer of 2 to 5, the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the 03-Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the individual structural formulas.
  • n 2 represents an integer of 1 or 2
  • Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof,
  • the N297 glycan of Ab represents any one of N297-(Fuc)MSG1, N297-(Fuc)MSG2, and a mixture thereof, and N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
  • each wavy line represents bonding to Asn297 (N297) of the antibody
  • *-L(PEG)- in the N297 glycan represents *—(CH 2 CH 2 —O) 3 —CH 2 CH 2 —NH—, wherein
  • the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the 0-Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the corresponding structural formula.
  • n 2 represents an integer of 1 or 2
  • Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof, and
  • the N297 glycan of Ab represents any one of N297-(Fuc)MSG1, N297-(Fuc)MSG2, and a mixture thereof, and N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
  • each wavy line represents bonding to Asn297 (N297) of the antibody
  • *-L(PEG)- in the N297 glycan represents *—(CH 2 CH 2 —O) 3 —CH 2 CH 2 —NH—, wherein the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the ⁇ -Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the individual structural formulas.
  • n 2 represents an integer of 1 or 2
  • Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof, and
  • the N297 glycan of Ab represents any one of N297-(Fuc)MSG1, N297-(Fuc)MSG2, and a mixture thereof, and N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
  • each wavy line represents bonding to Asn297 (N297) of the antibody
  • *-L(PEG)- in the N297 glycan represents *—(CH 2 CH 2 —O) 3 —CH 2 CH 2 —NH—, wherein the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the ⁇ -Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the individual structural formulas.
  • n 2 represents an integer of 1 or 2
  • Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof, and
  • the N297 glycan of Ab represents any one of N297-(Fuc)MSG1, N297-(Fuc)MSG2, and a mixture thereof, and N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
  • each wavy line represents bonding to Asn297 (N297) of the antibody
  • *-L(PEG)- in the N297 glycan represents *—(CH 2 CH 2 —O) 3 —CH 2 CH 2 —NH—, wherein the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the ⁇ -Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the individual structural formulas.
  • CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12
  • CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13
  • CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14
  • CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17
  • CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 18
  • CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19
  • CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12
  • CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13
  • CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14
  • CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17
  • CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 30
  • CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19
  • CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12
  • CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13
  • CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14
  • CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57
  • CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58
  • CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59
  • CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12
  • CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13
  • CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14
  • CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 62
  • CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 63
  • CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 64.
  • the antibody-drug conjugate according to [31], wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43.
  • the antibody-drug conjugate according to [31], wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67.
  • the antibody-drug conjugate according to [31], wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
  • a method for producing a glycan-remodeled antibody comprising the steps of:
  • step ii) treating the antibody obtained in step i) with hydrolase to produce a (Fuc ⁇ 1,6)GlcNAc-antibody;
  • glycan donor molecule obtained by introducing a PEG linker having an azide group to the carbonyl group of carboxylic acid at the 2-position of a sialic acid in MSG (9) or SG (10) and oxazolinating the reducing terminal, or
  • glycan donor molecule obtained by introducing a PEG linker having an azide group to the carbonyl group of carboxylic acid at the 2-position of a sialic acid in (MSG-)Asn or (SG-)Asn with an ⁇ -amino group optionally protected and to the carbonyl group of carboxylic acid in the Asn, causing action of hydrolase, and then oxazolinating the reducing terminal.
  • An antibody or a functional fragment thereof comprising a light chain variable region, which contains CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14, and a heavy chain variable region, which contains CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59.
  • An antibody or a functional fragment thereof comprising a light chain variable region, which contains CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14; and a heavy chain variable region, which contains CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 62, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 63 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 64.
  • [48] The antibody or a functional fragment thereof according to [46], comprising a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 55.
  • [49] The antibody or a functional fragment thereof according to [47], comprising a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 60.
  • [50] The antibody or a functional fragment thereof according to [46] or [48], having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67.
  • [51] The antibody or a functional fragment thereof according to [47] or [49], having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
  • An antibody or a functional fragment thereof having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65.
  • a method for producing the antibody or a functional fragment thereof according to [46] to [52], comprising a step of culturing the host cell according to [55] and collecting the targeted antibody from the culture obtained from the step of culturing.
  • the tumor is renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, bile duct cancer, lung cancer, small-cell lung cancer, non-small cell lung cancer, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor or neuroblastoma.
  • a method for treating a tumor which comprises administering the antibody-drug conjugate according to any one of [1] to [42] and [45], the antibody or a functional fragment thereof according to any one of [46] to [52] and [57] or the pharmaceutical composition according to any one of [58] to [61] to an individual.
  • the tumor is renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, bile duct cancer, lung cancer, small-cell lung cancer, non-small cell lung cancer, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor or neuroblastoma.
  • anti-CDH6 antibody of the present invention are to recognize EC domain 3 (EC3) of CDH6 specifically and to have high internalization activity.
  • An anti-CDH6 antibody-drug conjugate which is prepared by connecting the anti-CDH6 antibody of the present invention and a novel PBD derivative of the present invention via a linker, can be expected to achieve excellent antitumor effects and safety by administration to patients having cancer cells expressing CDH6.
  • the anti-CDH6 antibody-drug conjugate of the present invention is useful as an antitumor agent.
  • FIG. 1 shows flow cytometry results of examining the binding of each of rat anti-CDH6 monoclonal antibody rG019 and a negative control antibody rat IgG2b to control cells (shaded) or hCDH6 transfected 293T cells (open solid line).
  • the abscissa depicts FITC fluorescence intensity indicating the amount of the antibody bound, and the ordinate depicts cell count.
  • FIG. 2-1 The figure (1) shows the binding activity of rat anti-CDH6 monoclonal antibody rG019 or negative control antibody Rat IgG2b against control cells (shaded) or full-length hCDH6-transfected 293 cells (open solid line).
  • the figure (2) shows the binding activity of rat anti-CDH6 monoclonal antibody rG019 or negative control antibody Rat IgG2b against control cells (shaded) or EC1-deleted hCDH6-transfected 293 cells (open solid line).
  • the figure (3) shows the binding activity of rat anti-CDH6 monoclonal antibody rG019 or negative control antibody Rat IgG2b against control cells (shaded) or EC2-deleted hCDH6-transfected 293 cells (open solid line).
  • the abscissa depicts FITC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 2-2 The figure (4) shows the binding activity of rat anti-CDH6 monoclonal antibody rG019 or negative control antibody Rat IgG2b against control cells (shaded) or EC3-deleted hCDH6-transfected 293 cells (open solid line).
  • the figure (5) shows the binding activity of rat anti-CDH6 monoclonal antibody rG019 or negative control antibody Rat IgG2b against control cells (shaded) or EC4-deleted hCDH6-transfected 293 cells (open solid line).
  • the figure (6) shows the binding activity of rat anti-CDH6 monoclonal antibody rG019 or negative control antibody Rat IgG2b against control cells (shaded) or EC5-deleted hCDH6-transfected 293 cells (open solid line).
  • the abscissa depicts FITC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 3 shows flow cytometry results of evaluating the expression of CDH6 on the cell membrane surface of 5 types of human tumor cell lines (human ovarian tumor cell lines NIH:OVCAR-3, PA-1, and OV-90 and human renal cell tumor cell line 786-O, Caki-1).
  • the abscissa depicts FITC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • the shaded histogram shows that the negative control mIgG1 was used in staining, and the open solid line histogram shows that the anti-human CDH6 antibody was used in staining.
  • FIG. 4 shows the binding of human chimeric anti-CDH6 antibody chG019 to human CDH6 and monkey CDH6.
  • the abscissa depicts antibody concentration, and the ordinate depicts the amount of antibody bound based on mean fluorescence intensity.
  • FIG. 5-1 shows the binding activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control antibody hIgG1 against control cells (shaded) or full-length hCDH6-transfected 293 ⁇ cells (open solid line).
  • the abscissa depicts APC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 5-2 shows the binding activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control antibody hIgG1 against control cells (shaded) or EC1-deleted hCDH6-transfected 293 ⁇ cells (open solid line).
  • the abscissa depicts APC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 5-3 shows the binding activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control antibody hIgG1 against control cells (shaded) or EC2-deleted hCDH6-transfected 293 ⁇ cells (open solid line).
  • the abscissa depicts APC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 5-4 shows the binding activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control antibody hIgG1 against control cells (shaded) or EC3-deleted hCDH6-transfected 293 ⁇ cells (open solid line).
  • the abscissa depicts APC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 5-5 shows the binding activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control antibody hIgG1 against control cells (shaded) or EC4-deleted hCDH6-transfected 293 ⁇ cells (open solid line).
  • the abscissa depicts APC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 5-6 shows the binding activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control antibody hIgG1 against control cells (shaded) or EC5-deleted hCDH6-transfected 293 ⁇ cells (open solid line).
  • the abscissa depicts APC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 6 shows flow cytometry results of examining the expression of human CDH6 in a 786-O/hCDH6 stably expressing cell line (open solid line) and its parent cell line 786-O (shaded).
  • the abscissa depicts Alexa Fluor 647 fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 7 shows the binding competition assay of four unlabeled humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control hIgG1 using labeled NOV0712 (upper stage) or labeled H01L02 (lower stage).
  • the abscissa depicts the final concentration of the added unlabeled antibody, and the ordinate depicts the amount of antibody bound based on mean fluorescence intensity.
  • FIG. 8 shows the results on which the internalization activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 and a negative control antibody was evaluated in NIH:OVCAR-3 cells, 786-O cells or PA-1 cells using anti-human IgG reagent Hum-ZAP conjugated with a toxin (saporin) inhibiting protein synthesis, or F(ab′)2 Fragment Goat Anti-human IgG, Fc (gamma) Fragment Specific unconjugated with the toxin as a negative control.
  • a cell survival rate (%) calculated as a relative survival rate when the number of live cells in a well supplemented with the negative control instead of Hum-ZAP was defined as 100%, is shown below each entry.
  • FIG. 9 shows the IC50 (50% inhibition concentration) (nM) of each of anti-LPS antibody-PBD (ADC11), H01L02-PBD (ADC1), H01L02A-PBD (ADC5), H11L02A-PBD (ADC7) and H31L02A-PBD (ADC6) relative to CDH6 positive human ovarian tumor cell lines NIH: OVCAR-3, OV-90, PA-1 and CDH6 positive human renal-cell carcinoma cell line 786-O.
  • ADC11 anti-LPS antibody-PBD
  • ADC1 H01L02-PBD
  • ADC5 H01L02A-PBD
  • ADC7 H11L02A-PBD
  • ADC6 H31L02A-PBD
  • FIG. 10 shows the in vivo anti-tumor effect of each of H01L02-PBD (ADC1), NOV0712-DM4 and anti-LPS antibody-PBD (ADC11).
  • ADC1 H01L02-PBD
  • NOV0712-DM4 NOV0712-DM4
  • ADC11 anti-LPS antibody-PBD
  • the evaluation was conducted using animal models in which CDH6-positive human ovarian tumor cell line OV-90 was inoculated into immunodeficient mice.
  • the abscissa depicts the number of days, and the ordinate depicts tumor volume.
  • the error range depicts a SE value.
  • FIG. 11 shows the in vivo anti-tumor effect of each of H01L02-PBD (ADC1), NOV0712-DM4 and anti-LPS antibody-PBD (ADC11).
  • ADC1 H01L02-PBD
  • ADC11 anti-LPS antibody-PBD
  • the evaluation was conducted using animal models in which CDH6-positive human renal tumor cell line Caki-1 was inoculated into immunodeficient mice.
  • the abscissa depicts the number of days, and the ordinate depicts tumor volume.
  • the error range depicts a SE value.
  • FIG. 12 shows the in vivo anti-tumor effect of each of H01L02-PBD (ADC1), H01L02A-PBD (ADC5), H31L02A-PBD (ADC6) and anti-LPS antibody-PBD (ADC11).
  • ADC1 H01L02-PBD
  • ADC5 H01L02A-PBD
  • ADC6 anti-LPS antibody-PBD
  • the evaluation was conducted using animal models in which CDH6-positive human ovarian tumor cell line NIH: OVCAR-3 was inoculated into immunodeficient mice.
  • the abscissa depicts the number of days, and the ordinate depicts tumor volume.
  • the error range depicts a SE value.
  • FIG. 13 shows the in vivo anti-tumor effect of each of H01L02-PBD (ADC1), H01L02A-PBD (ADC5), H31L02A-PBD (ADC6) and H11L02A-PBD (ADC7).
  • ADC1 H01L02-PBD
  • ADC5 H01L02A-PBD
  • ADC6 H31L02A-PBD
  • ADC7 H11L02A-PBD
  • FIG. 14 shows the in vivo anti-tumor effect of each of H01L02A-PBD (ADC5), H31L02A-PBD (ADC6) and anti-LPS antibody-PBD (ADC11).
  • ADC5 H01L02A-PBD
  • ADC6 H31L02A-PBD
  • ADC11 anti-LPS antibody-PBD
  • the evaluation was conducted using animal models in which CDH6-positive human ovarian tumor cell line PA-1 was inoculated into immunodeficient mice.
  • the abscissa depicts the number of days, and the ordinate depicts tumor volume.
  • the error range depicts a SE value.
  • FIG. 15 shows the in vivo anti-tumor effect of each of H01L02A-PBD (ADC5), H31L02A-PBD (ADC6) and anti-LPS antibody-PBD (ADC11).
  • ADC5 H01L02A-PBD
  • ADC6 H31L02A-PBD
  • ADC11 anti-LPS antibody-PBD
  • the evaluation was conducted using animal models in which CDH6-positive human renal tumor cell line 786-O was inoculated into immunodeficient mice.
  • the abscissa depicts the number of days, and the ordinate depicts tumor volume.
  • the error range depicts a SE value.
  • cancer is used to have the same meaning as that of the term “carcinoma” and “tumor”.
  • the term “gene” is used to include not only DNA but also its mRNA and cDNA, and cRNA thereof.
  • polynucleotide or “nucleotide” is used to have the same meaning as that of a nucleic acid, and also includes DNA, RNA, a probe, an oligonucleotide, and a primer.
  • polynucleotide and nucleotide can be used interchangeably with each other unless otherwise specified.
  • polypeptide and “protein” can be used interchangeably with each other.
  • cell includes cells in an individual animal, and cultured cells.
  • CDH6 can be used to have the same meaning as that of the CDH6 protein.
  • human CDH6 is also referred to as “hCDH6”.
  • cytotoxic activity is used to mean that a pathologic change is caused to cells in any given way.
  • the term not only means a direct trauma, but also means all types of structural or functional damage caused to cells, such as DNA cleavage, formation of a base dimer, chromosomal cleavage, damage to cell mitotic apparatus, and a reduction in the activities of various types of enzymes.
  • the phrase “exerting toxicity in cells” is used to mean that toxicity is exhibited in cells in any given way.
  • the term not only means a direct trauma, but also means all types of structural, functional, or metabolic influences caused to cells, such as DNA cleavage, formation of a base dimer, chromosomal cleavage, damage to cell mitotic apparatus, a reduction in the activities of various types of enzymes, and suppression of effects of cell growth factors.
  • the term “functional fragment of an antibody”, also called “antigen-binding fragment of an antibody”, is used to mean a partial fragment of the antibody having binding activity against an antigen, and includes Fab, F(ab′)2, Fv, scFv, a diabody, a linear antibody and a multispecific antibody formed from antibody fragments, and the like.
  • Fab′ which is a monovalent fragment of antibody variable regions obtained by treating F(ab′)2 under reducing conditions, is also included in the antigen-binding fragment of an antibody.
  • the antigen-binding fragment of an antibody is not limited to these molecules, as long as the antigen-binding fragment has antigen-binding ability.
  • These antigen-binding fragments include not only those obtained by treating a full-length molecule of an antibody protein with an appropriate enzyme, but proteins produced in appropriate host cells using a genetically engineered antibody gene.
  • the functional fragment of the present invention includes a functional fragment that has well conserved asparagine (Asn297 or N297) to be modified with an N-linked glycan in the IgG heavy chain Fc region and amino acids around Asn297, while retaining binding activity to an antigen.
  • epitope is used to mean the specific partial peptide or partial three-dimensional structure of CDH6, to which an anti-CDH6 antibody binds.
  • an epitope which is the above-described partial peptide of CDH6, can be determined by a method well known to a person skilled in the art, such as an immunoassay.
  • various partial structures of an antigen are produced. As regards production of such partial structures, a known oligonucleotide synthesis technique can be applied.
  • polypeptides in which CDH6 has been successively truncated at an appropriate length from the C-terminus or N-terminus thereof, are produced by a genetic recombination technique well known to a person skilled in the art. Thereafter, the reactivity of an antibody to such polypeptides is studied, and recognition sites are roughly determined. Thereafter, further shorter peptides are synthesized, and the reactivity thereof to these peptides can then be studied, so as to determine an epitope.
  • the domain to which the antibody binds can be determined by modifying the amino acid sequence of a specific extracellular domain, and thereby modifying the three-dimensional structure.
  • the epitope which is a partial three-dimensional structure of an antigen that binds to a specific antibody, can also be determined by specifying the amino acid residues of an antigen adjacent to the antibody by X-ray structural analysis.
  • the phrase “antibodies binding to the same epitope” is used to mean antibodies that bind to a common epitope. If a second antibody binds to a partial peptide or a partial three-dimensional structure to which a first antibody binds, it can be determined that the first antibody and the second antibody bind to the same epitope. Alternatively, by confirming that a second antibody competes with a first antibody for the binding of the first antibody to an antigen (i.e., a second antibody interferes with the binding of a first antibody to an antigen), it can be determined that the first antibody and the second antibody bind to the same epitope, even if the specific sequence or structure of the epitope has not been determined.
  • the phrase “binding to the same epitope” refers to the case where it is determined that the first antibody and the second antibody bind to a common epitope by any one or both of these determination methods.
  • the first antibody and a second antibody bind to the same epitope and further, the first antibody has special effects such as antitumor activity or internalization activity
  • the second antibody can be expected to have the same activity as that of the first antibody.
  • CDR complementarity determining region
  • the heavy chain and light chain of an antibody molecule each have three CDRs.
  • Such a CDR is also referred to as a hypervariable region, and is located in the variable regions of the heavy chain and light chain of an antibody. These regions have a particularly highly variable primary structure and are separated into three sites on the primary structure of the polypeptide chain in each of the heavy chain and light chain.
  • the CDRs of a heavy chain are referred to as CDRH1, CDRH2 and CDRH3, respectively, from the amino-terminal side of the amino acid sequence of the heavy chain
  • the CDRs of a light chain are referred to as CDRL1, CDRL2 and CDRL3, respectively, from the amino-terminal side of the amino acid sequence of the light chain.
  • hybridizing under stringent conditions is used to mean that hybridization is carried out in the commercially available hybridization solution ExpressHyb Hybridization Solution (manufactured by Clontech Laboratories, Inc.) at 68° C., or that hybridization is carried out under conditions in which hybridization is carried out using a DNA-immobilized filter in the presence of 0.7 to 1.0 M NaCl at 68° C., and the resultant is then washed at 68° C. with a 0.1- to 2-fold concentration of SSC solution (wherein 1-fold concentration of SSC consists of 150 mM NaCl and 15 mM sodium citrate) for identification, or conditions equivalent thereto.
  • the term “one to several” is used to mean 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2.
  • Cadherins are glycoproteins present on the surface of cell membranes and function as cell-cell adhesion molecules through the calcium ion-dependent binding of their N-terminal extracellular domains, or as signal molecules responsible for cell-cell interaction.
  • Classic cadherins are in the cadherin superfamily and are single-pass transmembrane proteins composed of five extracellular domains (EC domains), one transmembrane region, and an intracellular domain.
  • CDH6 (cadherin-6) is a single-pass transmembrane protein composed of 790 amino acids, which is classified into the type II cadherin family, and this protein has N-terminal extracellular and C-terminal intracellular domains.
  • the human CDH6 gene was cloned for the first time in 1995 (Non Patent Literature 1), and its sequence can be referred to under, for example, accession Nos. NM_004932 and NP_004923 (NCBI).
  • the CDH6 protein used in the present invention can be directly purified from the CDH6-expressing cells of a human or a non-human mammal (e.g., a rat, a mouse or a monkey) and can then be used, or a cell membrane fraction of the aforementioned cells can be prepared and can be used as the CDH6 protein.
  • CDH6 can also be obtained by synthesizing it in vitro, or by allowing host cells to produce CDH6 by genetic manipulation.
  • the CDH6 protein can be obtained, specifically, by incorporating CDH6 cDNA into a vector capable of expressing the CDH6 cDNA, and then synthesizing CDH6 in a solution containing enzymes, substrate and energetic materials necessary for transcription and translation, or by transforming host cells of other prokaryotes or eukaryotes, so as to allow them to express CDH6.
  • CDH6-expressing cells based on the above-described genetic manipulation, or a cell line expressing CDH6 may be used to present the CDH6 protein.
  • the expression vector into which CDH6 cDNA has been incorporated can be directly administered to an animal to be immunized, and CDH6 can be expressed in the body of the animal thus immunized.
  • CDH6 a protein which consists of an amino acid sequence comprising a substitution, deletion and/or addition of one or several amino acids in the above-described amino acid sequence of CDH6, and has a biological activity equivalent to that of the CDH6 protein, is also included within the term “CDH6”.
  • the human CDH6 protein has the amino acid sequence shown in SEQ ID NO: 1.
  • the extracellular region of the human CDH6 protein is constituted of extracellular domain 1 (in the specification, also referred to as EC1) having the 54th to 159th amino acids in the amino acid sequence shown in SEQ ID NO: 1, extracellular domain 2 (in the specification, also referred to as EC2) having the 160th to 268th amino acids in the amino acid sequence shown in SEQ ID NO: 1, extracellular domain 3 (in the specification, also referred to as EC3) having the 269th to 383rd amino acids in the amino acid sequence shown in SEQ ID NO: 1, extracellular domain 4 (in the specification, also referred to as EC4) having the 384th to 486th amino acids in the amino acid sequence shown in SEQ ID NO: 1 and extracellular domain 5 (in the specification, also referred to as EC5) having the 487th to 608th amino acids in the amino acid sequence shown in SEQ ID NO: 1.
  • One example of the anti-CDH6 antibody of the present invention can include an anti-CDH6 antibody which recognizes an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4, and has internalization activity.
  • One example of the anti-CDH6 antibody of the present invention can include an anti-CDH6 antibody which specifically recognizes an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4, and has internalization activity.
  • One example of the anti-CDH6 antibody of the present invention can include an anti-CDH6 antibody which recognizes an amino acid sequence consisting of the amino acid sequence shown in SEQ ID NO: 4, and has internalization activity.
  • anti-CDH6 antibody of the present invention can include an anti-CDH6 antibody which specifically recognizes an amino acid sequence consisting of the amino acid sequence shown in SEQ ID NO: 4, and has internalization activity.
  • the phrase “specifically recognize an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4” or “specifically recognize an EC3 domain” as applied to an antibody is used to mean that the antibody strongly recognizes or strongly binds to the EC3 domain of CDH6 compared with the other extracellular domains of CDH6.
  • the anti-CDH6 antibody of the present invention may be derived from any species. Preferred examples of the species can include humans, monkeys, rats, mice and rabbits. When the anti-CDH6 antibody of the present invention is derived from a species other than humans, it is preferred to chimerize or humanize the anti-CDH6 antibody by a well-known technique.
  • the antibody of the present invention may be a polyclonal antibody or may be a monoclonal antibody, and a monoclonal antibody is preferred.
  • the anti-CDH6 antibody of the present invention is an antibody that can target tumor cells.
  • the anti-CDH6 antibody of the present invention possesses the property of being able to recognize tumor cells, the property of being able to bind to tumor cells, and/or the property of being internalized into tumor cells by cellular uptake, and the like.
  • the anti-CDH6 antibody of the present invention can be conjugated to a compound having antitumor activity via a linker to prepare an antibody-drug conjugate.
  • the binding activity of an antibody against tumor cells can be confirmed by flow cytometry.
  • the uptake of an antibody into tumor cells can be confirmed by (1) an assay of visualizing a cellularly taken-up antibody under a fluorescent microscope using a secondary antibody (fluorescently labeled) binding to the antibody (Cell Death and Differentiation, 2008, 15, 751-761), (2) an assay of measuring the amount of cellularly taken-up fluorescence using a secondary antibody (fluorescently labeled) binding to the antibody (Molecular Biology of the Cell Vol.
  • a recombinant conjugated protein of a catalytic region of diphtheria toxin and protein G may be used as the immunotoxin.
  • the term “high internalization ability” is used to mean that the survival rate (which is indicated by a ratio relative to a cell survival rate without antibody addition defined as 100%) of CDH6-expressing cells to which the aforementioned antibody and a saporin-labeled anti-rat IgG antibody have been administered is preferably 70% or less, and more preferably 60% or less.
  • the antibody-drug conjugate comprises a conjugated compound exerting an antitumor effect. Therefore, it is preferred, but not essential, that the antibody itself should have an antitumor effect. For the purpose of specifically and/or selectively exerting the cytotoxicity of the antitumor compound in tumor cells, it is important and preferred that the antibody should have a property of being internalized and transferred into tumor cells.
  • the anti-CDH6 antibody can be obtained by immunizing an animal with a polypeptide serving as an antigen by a method usually performed in this field, and then collecting and purifying an antibody produced in the living body thereof. It is preferred to use CDH6 retaining a three-dimensional structure as an antigen. Examples of such a method can include a DNA immunization method.
  • the origin of the antigen is not limited to a human, and thus, an animal can also be immunized with an antigen derived from a non-human animal such as a mouse or a rat.
  • an antibody applicable to the disease of a human can be selected by examining the cross-reactivity of the obtained antibody binding to the heterologous antigen with the human antigen.
  • antibody-producing cells that produce an antibody against the antigen can be fused with myeloma cells according to a known method (e.g., Kohler and Milstein, Nature (1975) 256, 495-497; and Kennet, R. ed., Monoclonal Antibodies, 365-367, Plenum Press, N. Y. (1980)) to establish hybridomas, so as to obtain a monoclonal antibody.
  • a known method e.g., Kohler and Milstein, Nature (1975) 256, 495-497; and Kennet, R. ed., Monoclonal Antibodies, 365-367, Plenum Press, N. Y. (1980)
  • the antigen can be obtained by allowing host cells to produce a gene encoding the antigen protein according to genetic manipulation. Specifically, a vector capable of expressing the antigen gene is produced, and the vector is then introduced into host cells, so that the gene is expressed therein, and thereafter, the expressed antigen may be purified.
  • the antibody can also be obtained by a method of immunizing an animal with the antigen-expressing cells based on the above-described genetic manipulation, or a cell line expressing the antigen.
  • the antibody can also be obtained, without the use of the antigen protein, by incorporating cDNA of the antigen protein into an expression vector, then administering the expression vector to an animal to be immunized, and expressing the antigen protein in the body of the animal thus immunized, so that an antibody against the antigen protein is produced therein.
  • the anti-CDH6 antibody used in the present invention is not particularly limited.
  • an antibody specified by an amino acid sequence shown in the sequence listing of the present application can suitably be used.
  • the anti-CDH6 antibody used in the present invention is desirably an antibody having the following properties:
  • the method for obtaining the antibody against CDH6 of the present invention is not particularly limited as long as an anti-CDH6 antibody can be obtained. It is preferred to use CDH6 retaining its conformation as an antigen.
  • the method for obtaining the antibody can include a DNA immunization method.
  • the DNA immunization method is an approach which involves transfecting an animal (e.g., mouse or rat) individual with an antigen expression plasmid, and then expressing the antigen in the individual to induce immunity against the antigen.
  • the transfection approach includes a method of directly injecting the plasmid into a muscle, a method of injecting a transfection reagent such as a liposome or polyethylenimine into a vein, an approach using a viral vector, an approach of injecting gold particles attached to the plasmid using a gene gun, a hydrodynamic method of rapidly injecting a plasmid solution in a large amount into a vein, and the like.
  • hybridoma production can be performed by a known method, and can also be performed using, for example, a Hybrimune Hybridoma Production System (Cyto Pulse Sciences, Inc.).
  • immune response can be induced by incorporating CDH6 cDNA into an expression vector (e.g., pcDNA3.1; Thermo Fisher Scientific Inc.), and directly administering the vector to an animal (e.g., a rat or a mouse) to be immunized by a method such as electroporation or a gene gun, so as to express CDH6 in the body of the animal.
  • an expression vector e.g., pcDNA3.1; Thermo Fisher Scientific Inc.
  • an animal e.g., a rat or a mouse
  • the administration of the vector by electroporation or the like may be performed one or more times, preferably a plurality of times, if necessary for enhancing antibody titer;
  • tissue e.g., a lymph node
  • myelomas preparation of myeloma cells (hereinafter, referred to as “myelomas”) (e.g., mouse myeloma SP2/0-ag14 cells);
  • Examples of the method for measuring the antibody titer used herein can include, but are not limited to, flow cytometry and Cell-ELISA.
  • Examples of the hybridoma strain thus established can include anti-CDH6 antibody-producing hybridoma rG019. It is to be noted that, in the present description, an antibody produced by the anti-CDH6 antibody-producing hybridoma rG019 is referred to as a “rG019 antibody” or simply as “rG019”.
  • the light chain variable region of the rG019 antibody consists of the amino acid sequence shown in SEQ ID NO: 10.
  • the amino acid sequence of the light chain variable region of the rG019 antibody is encoded by the nucleotide sequence shown in SEQ ID NO: 11.
  • the light chain variable region of the rG019 antibody has CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13, and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14.
  • the heavy chain variable region of the rG019 antibody consists of the amino acid sequence shown in SEQ ID NO: 15.
  • the amino acid sequence of the heavy chain variable region of the rG019 antibody is encoded by the nucleotide sequence shown in SEQ ID NO: 16.
  • the heavy chain variable region of the rG019 antibody has CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 18, and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19.
  • an antibody having internalization activity equivalent to that of the rG019 antibody can be obtained.
  • An example of such antibodies is an antibody that binds to an epitope identical to the epitope to which the rG019 antibody binds. If a newly produced monoclonal antibody binds to a partial peptide or partial three-dimensional structure to which the rG019 antibody binds, it can be determined that the monoclonal antibody binds to an epitope identical to the epitope to which the rG019 antibody binds.
  • the monoclonal antibody competes with the rG019 antibody for binding to CDH6 (i.e., the monoclonal antibody interferes with binding between the rG019 antibody and CDH6)
  • it can be determined, even when the specific sequence or structure of an epitope has not been determined, that the monoclonal antibody binds to an epitope identical to the epitope to which the anti-CDH6 antibody binds. If epitope identity has been confirmed, the monoclonal antibody is strongly expected to have antigen-binding ability, biological activity, and/or internalization activity equivalent to that of the rG019 antibody.
  • the antibody of the present invention also includes genetically recombinant antibodies that have been artificially modified for the purpose of reducing heterogenetic antigenicity to humans, such as a chimeric antibody, a humanized antibody and a human antibody, as well as the above-described monoclonal antibody against CDH6. These antibodies can be produced by known methods.
  • chimeric antibody can include antibodies in which a variable region and a constant region are heterologous to each other, such as a chimeric antibody formed by conjugating the variable region of a mouse- or rat-derived antibody to a human-derived constant region (see, Proc. Natl. Acad. Sci. U.S.A., 81, 6851-6855, (1984)).
  • Examples of the chimeric antibody derived from the rat anti-human CDH6 antibody include an antibody consisting of a light chain comprising the light chain variable region of a rat anti-human CDH6 antibody described in the present description (e.g., rG019 antibody) and a human-derived constant region, and a heavy chain comprising the heavy chain variable region of the rat anti-human CDH6 antibody and a human-derived constant region.
  • chimeric antibody derived from the rat anti-human CDH6 antibody examples include an antibody consisting of a light chain comprising a light chain variable region having a substitution of one to several residues, 1 to 3 residues, 1 or 2 residues, preferably 1 residue, of amino acids in the light chain variable region of a rat anti-human CDH6 antibody described in the present description (e.g., rG019 antibody) with other amino acid residues, and a heavy chain comprising a heavy chain variable region having a substitution of one to several residues, 1 to 3 residues, 1 or 2 residues, preferably 1 residue, of amino acids in the heavy chain variable region of the rat anti-human CDH6 antibody with other amino acid residues.
  • This antibody may have any given human-derived constant region.
  • chimeric antibody derived from the rat anti-human CDH6 antibody examples include an antibody consisting of a light chain comprising a light chain variable region having a substitution of 1 or 2 residues, preferably 1 residue, of amino acids in any 1 to 3 CDRs in the light chain variable region of a rat anti-human CDH6 antibody described in the present description (e.g., the rG019 antibody) with other amino acid residues, and a heavy chain comprising a heavy chain variable region having a substitution of 1 or 2 residues, preferably 1 residue, of amino acids in any 1 to 3 CDRs in the heavy chain variable region of the rat anti-human CDH6 antibody with other amino acid residues.
  • This antibody may have any given human-derived constant region.
  • Examples of the chimeric antibody derived from the rG019 antibody include an antibody consisting of a light chain comprising a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 10, and a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 15. This antibody may have any given human-derived constant region.
  • chimeric antibody derived from the rG019 antibody examples include an antibody consisting of a light chain comprising a light chain variable region having a substitution of one to several residues, 1 to 3 residues, 1 or 2 residues, preferably 1 residue, of amino acids in the light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 10 with other amino acid residues, and a heavy chain comprising a heavy chain variable region having a substitution of one to several residues, 1 to 3 residues, 1 or 2 residues, preferably 1 residue, of amino acids in the heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 15 with other amino acid residues.
  • This antibody may have any given human-derived constant region.
  • chimeric antibody derived from the rG019 antibody examples include an antibody consisting of a light chain comprising a light chain variable region having a substitution of 1 or 2 residues (preferably 1 residue) of amino acids in any 1 to 3 CDRs in the light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 10 with other amino acid residues, and a heavy chain comprising a heavy chain variable region having a substitution of 1 or 2 residues (preferably 1 residue) of amino acids in any 1 to 3 CDRs in the heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 15 with other amino acid residues.
  • This antibody may have any given human-derived constant region.
  • chimeric antibody derived from the rG019 antibody examples include an antibody consisting of a light chain comprising a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 10, and a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 28.
  • This antibody may have any given human-derived constant region.
  • the amino acid sequence shown in SEQ ID NO: 28 is a sequence with a cysteine residue substituted with a proline residue in CDRH2 in the amino acid sequence shown in SEQ ID NO: 15.
  • chimeric antibody derived from the rG019 antibody examples include an antibody consisting of a light chain consisting of the light chain full-length amino acid sequence shown in SEQ ID NO: 23, and a heavy chain consisting of the heavy chain full-length amino acid sequence shown in SEQ ID NO: 26.
  • this chimeric anti-human CDH6 antibody is referred to as a “chimeric G019 antibody”, a “chG019 antibody” or “chG019”.
  • the light chain full-length amino acid sequence of the chG019 antibody is encoded by the nucleotide sequence shown in SEQ ID NO: 24, and the heavy chain full-length amino acid sequence of the chG019 antibody is encoded by the nucleotide sequence shown in SEQ ID NO: 27.
  • the amino acid sequence of the light chain variable region of the chG019 antibody is identical to the amino acid sequence of the light chain variable region of the rG019 antibody, and consists of the amino acid sequence shown in SEQ ID NO: 10.
  • the light chain of the chG019 antibody has CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13, and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14, which are identical to the light chain CDRL1, CDRL2 and CDRL3, respectively, of rG019.
  • the amino acid of the light chain variable region of the chG019 antibody is encoded by the nucleotide sequence shown in SEQ ID NO: 25.
  • the amino acid sequence of the heavy chain variable region of the chG019 antibody consists of the amino acid sequence shown in SEQ ID NO: 28.
  • the heavy chain of the chG019 antibody has CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 30 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19.
  • the amino acid sequence shown in SEQ ID NO: 28 is a sequence with a cysteine residue substituted with a proline residue in CDRH2 in the amino acid sequence shown in SEQ ID NO: 15.
  • the CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 30 is a sequence with a cysteine residue substituted with a proline residue in the rG019 CDRH2 shown in SEQ ID NO: 18.
  • the amino acid sequence of the heavy chain variable region of the chG019 antibody is encoded by the nucleotide sequence shown in SEQ ID NO: 29.
  • humanized antibody can include an antibody formed by incorporating only complementarity determining regions (CDRs) into a human-derived antibody (see Nature (1986) 321, p. 522-525), an antibody formed by incorporating the amino acid residues from some frameworks, as well as CDR sequences, into a human antibody according to a CDR grafting method (International Publication No. WO90/07861), and an antibody formed by modifying the amino acid sequences of some CDRs while maintaining antigen-binding ability.
  • CDRs complementarity determining regions
  • the humanized antibody derived from the rG019 antibody or the chG019 antibody is not limited to a specific humanized antibody as long as the humanized antibody retains all 6 CDR sequences unique to the rG019 antibody or the chG019 antibody and has internalization activity.
  • the amino acid sequences of some CDRs of this humanized antibody may be further modified as long as the antibody has internalization activity.
  • the humanized antibody of the chG019 antibody can include any given combination of: a light chain comprising a light chain variable region consisting of any one amino acid sequence selected from the group consisting of (1) the light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 or 37, (2) an amino acid sequence having an identity of at least 95% (preferably an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region other than at each CDR sequence) to the above-described amino acid sequence (1), and (3) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the above-described amino acid sequence (1); and a heavy chain comprising a heavy chain variable region consisting of any one amino acid sequence selected from the group consisting of (4) the heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 41, 45, 49, 55 or 60, (5) an amino acid sequence having an identity of at least 95% (preferably an amino acid sequence having a sequence identity of at least 95% to the sequence of
  • an antibody having a humanized heavy chain or light chain and the other chain derived from a rat antibody or a chimeric antibody can also be used.
  • an antibody can include any given combination of: a light chain comprising a light chain variable region consisting of any one amino acid sequence selected from the group consisting of (1) the light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 or 37, (2) an amino acid sequence having an identity of at least 95% (preferably an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region other than at each CDR sequence) to the above-described amino acid sequence (1), and (3) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the above-described amino acid sequence (1); and a heavy chain comprising a heavy chain variable region consisting of any one amino acid sequence selected from the group consisting of (4) the heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 15 or 28, (5) an amino acid sequence having an identity of at least 9
  • an antibody can include any given combination of: a light chain comprising a light chain variable region consisting of any one amino acid sequence selected from the group consisting of (1) the light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 10, (2) an amino acid sequence having an identity of at least 95% (preferably an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region other than at each CDR sequence) to the above-described amino acid sequence (1), and (3) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the above-described amino acid sequence (1); and a heavy chain comprising a heavy chain variable region consisting of any one amino acid sequence selected from the group consisting of (4) the heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 41, 45, 49, 55 or 60, (5) an amino acid sequence having an identity of at least 95% (preferably an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region other than at each CDR sequence) to
  • the amino acid substitution in the present description is preferably a conservative amino acid substitution.
  • the conservative amino acid substitution is a substitution occurring within an amino acid group associated with certain amino acid side chains.
  • Such amino acid substitution is preferably carried out without impairing the properties of a substance having the original amino acid sequence.
  • Examples of the antibody having a preferred combination of the above-described light chains and heavy chains include an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 (in the present description, also referred to as a hL02 light chain variable region amino acid sequence) or a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 (in the present description, also referred to as a hL03 light chain variable region amino acid sequence), and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 41 (in the present description, also referred to as a hH01 heavy chain variable region amino acid sequence), a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 45 (in the present description, also referred to as a hH02 heavy chain variable region amino acid sequence) or a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 49 (in the present description, also referred to as a hH04 heavy chain variable
  • the hH11 heavy chain variable region amino acid sequence shown in SEQ ID NO: 55 has CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59.
  • the hH31 heavy chain variable region amino acid sequence shown in SEQ ID NO: 60 has CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 62, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 63 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 64.
  • Preferred examples of the antibody include:
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 41;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 45;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 49;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 55;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 60;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 41;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 45;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 49;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 55;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 60.
  • More preferred examples of the antibody include:
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 41;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 45;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 49;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 45;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 55;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 60.
  • the antibody having a preferred combination of light chains and heavy chains include an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 (in the present description, also referred to as the hL02 light chain full-length amino acid sequence) or a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 (in the present description, also referred to as the hL03 light chain full-length amino acid sequence), and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 39 (in the present description, also referred to as the hH01 heavy chain full-length amino acid sequence), a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 43 (in the present description, also referred to as the hH02
  • Examples of another preferable antibody include,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 39,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 43,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 47,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 65,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 67,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 69,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 39,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 43,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 47,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 65,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 67, or
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 69.
  • Examples of a more preferable antibody include
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 39 (in the present description, also referred to as the “H01L02 antibody” or “H01L02”),
  • H02L02 antibody an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 43 (in the present description, also referred to as the “H02L02 antibody” or “H02L02”),
  • H04L02 antibody an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 47 (in the present description, also referred to as the “H04L02 antibody” or “H04L02”),
  • H02L03 antibody an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 43 (in the present description, also referred to as the “H02L03 antibody” or “H02L03”),
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 65 (in the present description, also referred to as the “H01L02A antibody” or “H01L02A),
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 67 (in the present description, also referred to as the “H11L02A antibody” or “H11L02A), and
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 69 (in the present description, also referred to as the “H31L02A antibody” or “H31L02A).
  • sequences showing a high identity to the above-described heavy chain amino acid sequences and light chain amino acid sequences it is possible to select an antibody having a biological activity equivalent to that of each of the above-described antibodies.
  • Such an identity is an identity of generally 80% or more, preferably 90% or more, more preferably 95% or more and most preferably 99% or more.
  • amino acid sequences of a heavy chain and a light chain comprising a substitution, deletion or addition of one or several amino acid residues thereof with respect to the amino acid sequence of a heavy chain or a light chain, it is possible to select an antibody having a biological activity equivalent to that of each of the above-described antibodies.
  • the identity between two types of amino acid sequences can be determined by aligning the sequences using the default parameters of Clustal W version 2 (Larkin M A, Blackshields G, Brown N P, Chenna R, McGettigan P A, McWilliam H, Valentin F, Wallace I M, Wilm A, Lopez R, Thompson J D, Gibson T J and Higgins D G (2007), “Clustal W and Clustal X version 2.0”, Bioinformatics.23 (21): 2947-2948).
  • the amino acid sequence consisting of the amino acid residues at positions 1 to 20 is a signal sequence
  • the amino acid sequence consisting of the amino acid residues at positions 21 to 128 is a variable region
  • the amino acid sequence consisting of the amino acid residues at positions 129 to 233 is a constant region.
  • the amino acid sequence consisting of the amino acid residues at positions 1 to 20 is a signal sequence
  • the amino acid sequence consisting of the amino acid residues at positions 21 to 128 is a variable region
  • the amino acid sequence consisting of the amino acid residues at positions 129 to 233 is a constant region.
  • the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is the signal sequence
  • the amino acid sequence consisting of the amino acid residues at positions 20 to 141 is a variable region
  • the amino acid sequence consisting of the amino acid residues at positions 142 to 471 is a constant region.
  • the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence
  • the amino acid sequence consisting of the amino acid residues at positions 20 to 141 is a variable region
  • the amino acid sequence consisting of the amino acid residues at positions 142 to 471 is a constant region.
  • the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence
  • the amino acid sequence consisting of the amino acid residues at positions 20 to 141 is a variable region
  • the amino acid sequence consisting of the amino acid residues at positions 142 to 471 is a constant region.
  • the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence
  • the amino acid sequence consisting of the amino acid residues at positions 20 to 141 is a variable region
  • the amino acid sequence consisting of the amino acid residues at positions 142 to 471 is a constant region.
  • the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence
  • the amino acid sequence consisting of the amino acid residues at positions 20 to 141 is a variable region
  • the amino acid sequence consisting of the amino acid residues at positions 142 to 471 is a constant region.
  • the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence
  • the amino acid sequence consisting of the amino acid residues at positions 20 to 141 is a variable region
  • the amino acid sequence consisting of the amino acid residues at positions 142 to 471 is a constant region.
  • the antibody of the present invention can include a human antibody binding to CDH6.
  • the anti-CDH6 human antibody refers to a human antibody having only the gene sequence of an antibody derived from human chromosomes.
  • the anti-CDH6 human antibody can be obtained by a method using a human antibody-producing mouse having a human chromosomal fragment comprising the heavy chain and light chain genes of a human antibody (see, Tomizuka, K. et al., Nature Genetics (1997) 16, p. 133-143; Kuroiwa, Y. et al., Nucl. Acids Res. (1998) 26, p. 3447-3448; Yoshida, H. et al., Animal Cell Technology: Basic and Applied Aspects vol.
  • Such a human antibody-producing mouse can be specifically produced by using a genetically modified animal, the gene loci of endogenous immunoglobulin heavy chain and light chain of which have been disrupted and instead the gene loci of the human immunoglobulin heavy chain and light chain have been then introduced using a yeast artificial chromosome (YAC) vector or the like, then producing a knock-out animal and a transgenic animal from such a genetically modified animal, and then breeding such animals with one another.
  • YAC yeast artificial chromosome
  • the anti-CDH6 human antibody can also be obtained by transforming eukaryotic cells with cDNA encoding each of the heavy chain and light chain of such a human antibody, or preferably with a vector comprising such cDNA, according to genetic recombination techniques, and then culturing the transformed cells and producing a genetically modified human monoclonal antibody, so that the antibody can be obtained from the culture supernatant.
  • eukaryotic cells and preferably, mammalian cells such as CHO cells, lymphocytes or myelomas can, for example, be used as a host.
  • a phage display method which comprises allowing the variable regions of a human antibody to express as a single chain antibody (scFv) on the surface of phages, and then selecting a phage binding to an antigen, can be applied (Nature Biotechnology (2005), 23, (9), p. 1105-1116).
  • scFv single chain antibody
  • the DNA sequence encoding the variable region of a human antibody binding to the antigen can be determined.
  • an expression vector having the aforementioned sequence is produced, and the produced expression vector is then introduced into an appropriate host and can be allowed to express therein, thereby obtaining a human antibody (International Publication Nos. WO92/01047, WO92/20791, WO93/06213, WO93/11236, WO93/19172, WO95/01438 and WO95/15388, Annu. Rev. Immunol (1994) 12, p. 433-455, Nature Biotechnology (2005) 23 (9), p. 1105-1116).
  • a newly produced human antibody binds to a partial peptide or a partial three-dimensional structure to which any one rat anti-human CDH6 antibody, chimeric anti-human CDH6 antibody or humanized anti-human CDH6 antibody described in the present description (e.g., the rG019 antibody, the chG019 antibody, the H01L02 antibody, the H02L02 antibody, the H02L03 antibody, the H04L02 antibody, the H01L02A antibody, the H11L02A antibody or the H31L02A antibody) binds, it can be determined that the human antibody binds to the same epitope to which the rat anti-human CDH6 antibody, the chimeric anti-human CDH6 antibody or the humanized anti-human CDH6 antibody binds.
  • the human antibody competes with the rat anti-human CDH6 antibody, the chimeric anti-human CDH6 antibody or the humanized anti-human CDH6 antibody described in the present description (e.g., the rG019 antibody, the chG019 antibody, the H01L02 antibody, the H02L02 antibody, the H02L03 antibody, the H04L02 antibody, the H01L02A antibody, the H11L02A antibody or the H31L02A antibody) in the binding of the antibody to CDH6 (e.g., the human antibody interferes with the binding of the rG019 antibody, the chG019 antibody, the H01L02 antibody, the H02L02 antibody, the H02L03 antibody, the H04L02 antibody, the H01L02A antibody, the H11L02A antibody or the H31L02A antibody to CDH6, preferably EC3 of CDH6), it can be determined that the human antibody binds to the same epitope to which the rat anti-
  • the human antibody should have a biological activity equivalent to that of the rat anti-human CDH6 antibody, the chimeric anti-human CDH6 antibody or the humanized anti-human CDH6 antibody (e.g., the rG019 antibody, the chG019 antibody, the H01L02 antibody, the H02L02 antibody, the H02L03 antibody, the H04L02 antibody, the H01L02A antibody, the H11L02A antibody or the H31L02A antibody).
  • the rG019 antibody, the chG019 antibody, the H01L02 antibody, the H02L02 antibody, the H02L03 antibody, the H04L02 antibody, the H01L02A antibody, the H11L02A antibody or the H31L02A antibody e.g., the rG019 antibody, the chG019 antibody, the H01L02 antibody, the H02L02 antibody, the H02L03 antibody, the H04L02 antibody, the H01L02A antibody, the H11L02A antibody
  • the chimeric antibodies, the humanized antibodies or the human antibodies obtained by the above-described methods are evaluated for their binding activity against the antigen according to a known method, etc., so that a preferred antibody can be selected.
  • a differential scanning calorimeter is an apparatus capable of promptly and exactly measuring a thermal denaturation midpoint (Tm) serving as a good indicator for the relative structural stability of a protein.
  • Tm thermal denaturation midpoint
  • DSC differential scanning calorimeter
  • an indicator for selection of an antibody can include high yield in suitable host cells and low agglutination in an aqueous solution. For example, since an antibody with the highest yield does not always exhibit the highest thermal stability, it is necessary to select an antibody most suitable for administration to a human by comprehensively determining it based on the aforementioned indicators.
  • the antibody of the present invention also includes a modification of an antibody.
  • a modification is used to mean an antibody of the present invention, which is chemically or biologically modified. Examples of such a chemical modification include the binding of a chemical moiety to an amino acid skeleton, and the chemical modification of an N-linked or O-linked carbohydrate chain.
  • Examples of such a biological modification include antibodies which have undergone a posttranslational modification (e.g., N-linked or 0-linked glycosylation, N-terminal or C-terminal processing, deamidation, isomerization of aspartic acid, oxidation of methionine, and conversion of N-terminal glutamine or N-terminal glutamic acid to pyroglutamic acid), and antibodies, to the N-terminus of which, a methionine residue is added as a result of having been allowed to be expressed using prokaryote host cells.
  • a posttranslational modification e.g., N-linked or 0-linked glycosylation, N-terminal or C-terminal processing, deamidation, isomerization of aspartic acid, oxidation of methionine, and conversion of N-terminal glutamine or N-terminal glutamic acid to pyroglutamic acid
  • such a modification is also meant to include labeled antibodies for enabling detection or isolation of the antibody of the present invention or an antigen, for example, an enzymatically labeled antibody, a fluorescently labeled antibody, and an affinity-labeled antibody.
  • labeled antibodies for enabling detection or isolation of the antibody of the present invention or an antigen, for example, an enzymatically labeled antibody, a fluorescently labeled antibody, and an affinity-labeled antibody.
  • Such a modification of the antibody of the present invention is useful for the improvement of the stability and retention in blood of an antibody; a reduction in antigenicity; detection or isolation of an antibody or an antigen; etc.
  • antibody-dependent cellular cytotoxic activity can be enhanced.
  • a sugar chain modification glycosylation, de-fucosylation, etc.
  • techniques of regulating the sugar chain modification of an antibody those described in International Publication Nos. WO1999/54342, WO2000/61739, WO2002/31140 and WO2007/133855, etc. are known, though the techniques are not limited thereto.
  • the antibody of the present invention also includes antibodies in respect of which the aforementioned sugar chain modification has been regulated.
  • the gene can be introduced into an appropriate host to produce an antibody, using an appropriate combination of a host and an expression vector.
  • a specific example of the antibody gene can be a combination of a gene encoding the heavy chain sequence of the antibody described in the present description and a gene encoding the light chain sequence of the antibody described therein.
  • a heavy chain sequence gene and a light chain sequence gene may be inserted into a single expression vector, or these genes may instead each be inserted into different expression vectors.
  • animal cells When eukaryotic cells are used as hosts, animal cells, plant cells or eukaryotic microorganisms can be used.
  • animal cells can include mammalian cells such as COS cells which are monkey cells (Gluzman, Y., Cell (1981) 23, p. 175-182, ATCC CRL-1650), mouse fibroblasts NIH3T3 (ATCC No. CRL-1658), a dihydrofolate reductase-deficient cell line of Chinese hamster ovary cells (CHO cells, ATCC CCL-61) (Urlaub, G. and Chasin, L. A. Proc. Natl. Acad. Sci. U.S.A. (1980) 77, p. 4126-4220) and FreeStyle 293F cells (Invitrogen Corp.).
  • COS cells which are monkey cells (Gluzman, Y., Cell (1981) 23, p. 175-182, ATCC CRL-1650), mouse fibroblasts NIH3T3 (ATCC
  • Escherichia coli or Bacillus subtilis can be used, for example.
  • the antibody of the present invention also includes an antibody obtained by the above-described method for producing an antibody, which comprises a step of culturing the transformed host cells and a step of collecting an antibody of interest or a functional fragment of the antibody from the culture obtained in the aforementioned step.
  • the antibody according to the present invention also includes an antibody that has undergone the aforementioned modification, and a functional fragment of the antibody, and specific examples of such an antibody include a deletion mutant comprising a deletion of 1 or 2 amino acids at the heavy chain carboxyl terminus, and a deletion mutant formed by amidating the aforementioned deletion mutant (e.g., a heavy chain in which the proline residue at the carboxyl-terminal site is amidated).
  • deletion mutants involving a deletion at the carboxyl terminus of the heavy chain of the antibody according to the present invention are not limited to the above-described deletion mutants, as long as they retain antigen-binding activity and effector function.
  • Two heavy chains constituting the antibody according to the present invention may be any one type of heavy chain selected from the group consisting of a full-length antibody and the above-described deletion mutants, or may be a combination of any two types selected from the aforementioned group.
  • the ratio of individual deletion mutants can be influenced by the types of cultured mammalian cells that produce the antibody according to the present invention, and the culture conditions.
  • Examples of the main ingredient of the antibody according to the present invention can include antibodies where one amino acid residue is deleted at each of the carboxyl termini of the two heavy chains.
  • Examples of the isotype of the antibody of the present invention can include IgG (IgG1, IgG3 and IgG4). Among others, IgG1, IgG2 and IgG4 are preferable.
  • IgG1 is used as the isotype of the antibody of the present invention
  • the effector function may be adjusted by substituting some amino acid residues in the constant region.
  • variants of IgG1 with the effector function lowered or attenuated may include, but not limited to, IgG1 LALA (IgG1-L234A, L235A) and IgG1 LAGA (IgG1-L235A, G237A) (Journal of Virology, Vol. 75, No. 24 (Dec. 15, 2001), pp. 12161-12168), and a preferred variant of IgG1 is IgG1 LALA.
  • the L234A, L235A indicates substitution of leucine with alanine at the 234- and 235-positions specified by EU-index numbering (Proc. Natl. Acad. Sci. U.S.A., Vol. 63, No. 1 (May 15, 1969), pp. 78-85), and the G237A indicates substitution of glycine with alanine at the 237-position specified by EU-index numbering.
  • Typical examples of bioactivity of antibodies may include, but are not limited to, antigen-binding activity, activity to internalize in cells expressing an antigen by binding to the antigen, activity to neutralize antigen activity, activity to enhance antigen activity, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP), and the function of the antibody according to the present invention is binding activity to CDH6, and preferably activity to internalize in CDH6-expression cells by binding to CDH6.
  • the antibody of the present invention may have activities of ADCC, CDC, and/or ADCP in combination.
  • the antibody obtained may be purified to a homogeneous state.
  • separation/purification methods commonly used for protein can be used.
  • the antibody may be separated/purified by appropriately selecting and combining column chromatography, filter filtration, ultrafiltration, salting-out, dialysis, preparative polyacrylamide gel electrophoresis, isoelectric focusing, and so on (Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Daniel R. Marshak et al. eds., Cold Spring Harbor Laboratory Press (1996); and Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory (1988)), but separation/purification methods are not limited thereto.
  • chromatography may include affinity chromatography, ion-exchange chromatography, hydrophobic chromatography, gel filtration chromatography, reversed-phase chromatography and absorption chromatography.
  • chromatographies may be carried out using liquid chromatography such as HPLC or FPLC.
  • Examples of columns for affinity chromatography may include, but not limited to, a Protein A column and a Protein G column.
  • columns that can be used as a Protein A column include Hyper D, POROS and Sepharose F. F. (Pharmacia).
  • the antibody may be purified by utilizing binding activity to an antigen with a carrier to which the antigen has been immobilized.
  • the present invention relates to a polynucleotide encoding the antibody of the present invention.
  • the polynucleotide of the present invention is preferably a polynucleotide comprising the polynucleotide described in any one of the following (a) to (e):
  • a polynucleotide that is hybridizable with nucleotides consisting of a polynucleotide complementary to the polynucleotide according to any one of (a) to (c) under stringent conditions and is encoding the amino acid sequence of the antibody capable of binding to CDH6, and
  • a polynucleotide encoding the amino acid sequence of a polypeptide obtained by substituting, deleting, adding, or inserting 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, one to eight, one to six, one to five, one to four, one to three, one or two, or one amino acid in the polynucleotide according to any one of (a) to (c) and that is encoding the amino acid sequence of the antibody capable of binding to CDH6.
  • the present invention includes a nucleotide encoding the antibody of the present invention or a functional fragment of the antibody, or a modified variant of the antibody or functional fragment; a recombinant vector including the gene inserted therein; and a cell including the gene or the vector introduced therein.
  • the present invention includes a method for producing an antibody or a functional fragment of the antibody, or a modified variant of the antibody or functional fragment, the method including the steps of: culturing the cell; and collecting from the culture an antibody or a functional fragment of the antibody, or a modified variant of the antibody or functional fragment.
  • amino acid sequences or nucleotide sequences of the antibodies of the present invention and the amino acid sequences or nucleotide sequences of the proteins used in the present invention are listed in Tables 1-1 to Tables 1-14.
  • the antibody-drug conjugate of the present invention is represented by the following formula:
  • n 2 represents an integer of 1 or 2
  • Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof
  • L represents a linker, linking the glycan (N297) bonding to N297 of Ab and D, and
  • the anti-CDH6 antibody obtained in the above “2. Production of anti-CDH6 antibody” can be conjugated to a drug via a linker moiety to prepare an anti-CDH6 antibody-drug conjugate.
  • the drug is not particularly limited as long as it has a substituent or a molecular part that can be connected to a linker
  • the anti-CDH6 antibody-drug conjugate can be used for various purposes according to the conjugated drug. Examples of such a drug can include substances having antitumor activity, substances effective for blood diseases, substances effective for autoimmune diseases, anti-inflammatory substances, antimicrobial substances, antifungal substances, antiparasitic substances, antiviral substances, and anti-anesthetic substances.
  • the antitumor compound is not particularly limited as long as the compound has an antitumor effect and has a substituent or a partial structure that can be connected to a linker structure.
  • the antitumor compound moiety Upon cleavage of a part or the whole of the linker in tumor cells, the antitumor compound moiety is released so that the antitumor compound exhibits an antitumor effect.
  • the linker is cleaved at a connecting position with the drug, the antitumor compound is released in its original structure to exert its original antitumor effect.
  • the released compounds serving as the drug are, e.g., drugs 1 to 4 described in Examples 10-7 to 10-10.
  • the anti-CDH6 antibody obtained in the above “2. Production of anti-CDH6 antibody” can be conjugated to the antitumor compound via a linker structure moiety to prepare an anti-CDH6 antibody-drug conjugate.
  • the antitumor compound to be used in the present invention is represented by any one of the formulas below:
  • the PBD derivative of the present invention has an asymmetric carbon at the 11′-position, and thus there exist optical isomers.
  • these isomers and a mixture of these isomers are all represented by a single formula.
  • the PBD derivatives of the present invention include all the optical isomers and mixtures of the optical isomers at any ratio.
  • the absolute steric configuration at the 11′-position of the PBD derivatives of the present invention can be determined through X-ray crystal structure analysis or NMR such as a Mosher method for its crystalline product or intermediate, or a derivative thereof. Then, the absolute steric configuration may be determined by using a crystalline product or intermediate derivatized with a reagent having an asymmetric center whose steric configuration is known. As desired, stereoisomers of the synthesized compound according to the present invention may be obtained by isolating with a common optical resolution method or separation method.
  • stereoisomers There may exist stereoisomers, optical isomers due to an asymmetric carbon atom, geometric isomers, tautomers, or optical isomers such as d-forms, 1-forms and atropisomers for the antibody-drug conjugate of the present invention, the free drug or production intermediates of the antibody-drug conjugate, and these isomers, optical isomers, and mixtures of them are all included in the present invention.
  • the antitumor compound to be used in the present invention is represented by any one of the formulas below:
  • Linker L is represented by the following formula: -Lb-La-Lp-NH—B—CH 2 —O(C ⁇ O)—*.
  • the asterisk* represents bonding to the nitrogen atom at the N10′-position of the antitumor compound represented by D;
  • Lb represents a spacer which connects La to the glycan or remodeled glycan of Ab.
  • B represents a phenyl group or a heteroaryl group, and is preferably a 1,4-phenyl group, a 2,5-pyridyl group, a 3,6-pyridyl group, a 2,5-pyrimidyl group, or a 2,5-thienyl group, and more preferably a 1,4-phenyl group.
  • Lp represents a linker consisting of an amino acid sequence cleavable in vivo or in a target cell.
  • Lp is, for example, cleaved by the action of an enzyme such as an esterase or peptidase.
  • Lp is a peptide residue composed of two to seven (preferably, two to four) amino acids. That is, Lp is composed of an oligopeptide residue in which two to seven amino acids are connected via a peptide bond.
  • Lp is bound at the N terminal to the carbonyl group of La in Lb-La-, and forms at the C terminal an amide bond with the amino group (—NH—) of the part —NH—B—CH 2 —O(C ⁇ O)— of the linker.
  • the bond between the C terminal of Lp and —NH— is cleaved by an enzyme such as an esterase.
  • the amino acids constituting Lp are not limited to particular amino acids, and, for example are L- or D-amino acids, and preferably L-amino acids.
  • the amino acids may be not only ⁇ -amino acids, but may include an amino acid with structure, for example, of 0-alanine, 6-aminocaproic acid, or ⁇ -aminobutyric acid, and may further include a non-natural amino acid such as an N-methylated amino acid.
  • the amino acid sequence of Lp is not limited to a particular amino acid sequence, and examples of amino acids that constitute Lp may include, but are not limited to, glycine (Gly; G), valine (Val; V), alanine (Ala; A), phenylalanine (Phe; F), glutamic acid (Glu; E), isoleucine (Ile; I), proline (Pro; P), citrulline (Cit), leucine (Leu; L), serine (Ser; S), lysine (Lys; K) and aspartic acid (Asp; D).
  • Preferred among them are glycine (Gly; G), valine (Val; V), alanine (Ala; A) and citrulline (Cit).
  • Lp has an amino acid sequence including arbitrarily selected amino acids.
  • Drug release pattern may be controlled via amino acid type.
  • linker Lp may include, but are not limited to, -GGVA-, -GG-(D-)VA-, -VA-, -GGFG-, -GGPI-, -GGVCit-, -GGVK-, -GG(D-)PI-, -GGPL-, -EGGVA, -PI-, -GGF-, DGGF-, (D-)D-GGF-, -EGGF-, -SGGF-, -KGGF-, -DGGFG-, -GGFGG-, -DDGGFG-, -KDGGFG- and -GGFGGGF-.
  • (D-)V indicates D-valine
  • (D)-P indicates D-proline
  • (D-)D indicates D-aspartic acid
  • Linker Lp is preferably any of the following: -GGVA-, -GG-(D-)VA-, -VA-, -GGFG-, -GGPI-, -GGVCit-, -GGVK-, -GG(D-)PI- and -GGPL-,
  • Linker Lp is more preferably any of the following: -GGVA-, -GGVCit-, and -VA-.
  • Lb represents a spacer which connects La to the glycan or remodeled glycan of Ab.
  • La which is not particularly limited, represents any one selected from the following group.
  • La is more preferably, —C( ⁇ O)—CH 2 CH 2 —C( ⁇ O)— or —C( ⁇ O)—(CH 2 CH 2 ) 2 —C( ⁇ O)—.
  • Spacer Lb is not limited to a particular spacer, and for examples, a spacer represented by the following formulas are included.
  • each asterisk* represents bonding to the —(C ⁇ O) or —(CH 2 )n 4 at the left end of La, and each wavy line represents bonding to the glycan or remodeled glycan of Ab.
  • Lb Lb-1, Lb-2 or Lb-3)
  • the triazole ring site formed through click reaction of an azide group and a cyclooctynyl group provides structures of geometric isomers, and molecules of Lb exist as any one of the two structures or as a mixture of both of them.
  • m 2 is 1 or 2
  • “-L-D” moieties per molecule of the antibody-drug conjugate of the present invention and either one of the two structures exist or both of them coexist as Lb (Lb-1, Lb-2, or Lb-3) in L of each of the “-L-D” moieties.
  • Lb is i
  • L is preferably represented by -Lb-La-Lp-NH—B—CH 2 —O (C ⁇ O)—*
  • L is selected from the following group:
  • Z 2 represents the following structural formula:
  • Z 3 represents the following structural formula:
  • the asterisk * represents bonding to the C( ⁇ O), O or CH 2 neighboring Z 1 , Z 2 or Z 3 and the wavy line represents bonding to the glycan or remodeled glycan of Ab;
  • B represents a 1,4-phenyl group.
  • the antibody-drug conjugate of the present invention is supposed to exhibit antitumor activity through a process in which most molecules of the antibody-drug conjugate migrate into tumor cells, and a linker portion (e.g., Lp) is then cleaved by an enzyme or the like to activate the antibody-drug conjugate, which releases the portion of drug D (hereinafter, referred to as the free drug (described later)).
  • a linker portion e.g., Lp
  • the antibody-drug conjugate of the present invention is stable outside tumor cells.
  • glycan remodeling of the present invention using a hydrolase, heterogeneous glycans bonding to a protein (e.g., an antibody) are cleaved off to leave only GlcNAc at each terminus thereby producing a homogenous protein moiety with GlcNAc (hereinafter, referred to as an “acceptor”).
  • a protein e.g., an antibody
  • an acceptor an arbitrary glycan separately prepared
  • the acceptor and the donor are linked together by using a transglycosidase.
  • a “glycan” refers to a structural unit of two or more monosaccharides bonded together via glycosidic bonds.
  • Specific monosaccharides and glycans are occasionally abbreviated, for example, as “GlcNAc-”, “MSG-”, and so on.
  • GlcNAc- GlcNAc-
  • MSG- GmcNAc-
  • the abbreviation is shown with an intention that an oxygen atom or nitrogen atom involved in a glycosidic bond at the reducing terminal to another structural unit is not included in the abbreviation indicating the glycan, unless specifically defined.
  • a monosaccharide as a basic unit of a glycan is indicated for convenience so that in the ring structure, the position of a carbon atom bonding to an oxygen atom constituting the ring and directly bonding to a hydroxy group (or an oxygen atom involved in a glycosidic bond) is defined as the 1-position (the 2-position only for sialic acids), unless otherwise specified.
  • the names of compounds in the Examples are each provided in view of the chemical structure as a whole, and that rule is not necessarily applied.
  • a glycan is indicated as a sign (e.g., GLY, SG, MSG, GlcNAc) in the present invention, the sign is intended, unless otherwise defined, to include carbon atoms ranging to the reducing terminal and not to include N or O involved in an N- or O-glycosidic bond.
  • a sign e.g., GLY, SG, MSG, GlcNAc
  • a partial structure when a glycan is linking to a side chain of an amino acid is indicated in such a manner that the side chain portion is indicated in parentheses, for example, “(SG-)Asn”.
  • Glycans in Ab of the present invention are N-linked glycans or O-linked glycans, and preferably N-linked glycans.
  • N-linked glycans and O-linked glycans bond to an amino acid side chain of an antibody via an N-glycosidic bond and an O-glycosidic bond, respectively.
  • IgG has a well conserved N-linked glycan on an asparagine residue at the 297-position of the Fc region of the heavy chain (hereinafter, referred to as “Asn297 or N297”), and the N-linked glycan is known to contribute to the activity and kinetics of the antibody molecule (Biotechnol. Prog., 2012, 28, 608-622, Sanglier-Cianferani, S., Anal. Chem., 2013, 85, 715-736).
  • the amino acid sequence in the constant region of IgG is well conserved, and each amino acid is specified by Eu index numbering in Edelman et al. (Proc. Natl. Acad. Sci. U.S.A., Vol. 63, No. 1 (May 15, 1969), pp. 78-85).
  • Asn297 to which an N-linked glycan is added in the Fc region, corresponds to the 297-position in Eu index numbering, and each amino acid is uniquely specified by Eu index numbering, even if the actual position of the amino acid has varied through fragmentation of the molecule or deletion of a region.
  • the antibody or functional fragment of the antibody more preferably bonds to L via a glycan bonding to a side chain of Asn297 thereof (hereinafter, referred to as “N297 glycan”), and the antibody or functional fragment of the antibody even more preferably bonds via the N297 glycan to L, wherein the N297 glycan is a remodeled glycan.
  • An antibody having the remodeled glycan is referred to as a glycan-remodeled antibody.
  • SGP an abbreviation for sialyl glycopeptide
  • SGP can be separated/purified from the yolk of a hen egg, for example, by using a method described in WO 2011/0278681.
  • Purified products of SGP are commercially available (Tokyo Chemical Industry Co., Ltd., FUSHIMI Pharmaceutical Co., Ltd.).
  • disialooctasaccharide Tokyo Chemical Industry Co., Ltd.
  • SG (10) a glycan formed by deleting one GlcNAc at the reducing terminus in the glycan moiety of SG
  • a glycan structure formed by deleting a sialic acid at a non-reducing terminal only in either one of the branched chains of ⁇ -Man in SG (10) refers to MSG (9), and a structure having a sialic acid only in the 1-3 branched chain is called as MSG1, and a structure having a sialic acid only in the 1-6 branched chain is called as MSG2.
  • the remodeled glycan of the present invention is N297-(Fuc)MSG1, N297-(Fuc)MSG2, or a mixture of N297-(Fuc)MSG1 and N297-(Fuc)MSG2, or N297-(Fuc)SG, and is preferably N297-(Fuc)MSG1, N297-(Fuc)MSG2, or N297-(Fuc)SG, and is more preferably N297-(Fuc)MSG1 or N297-(Fuc)MSG2.
  • N297-(Fuc)MSG1 is represented by the following structural formula or sequence formula:
  • each wavy line represents bonding to Asn297 of the antibody
  • L (PEG) represents —(CH 2 CH 2 —O) n 5 -CH 2 CH 2 —NH—, wherein the amino group at the right end represents amide-bonding to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in the 1-3 branched chain of the ⁇ -Man in the N297 glycan,
  • Each asterisk* represents bonding to linker L, in particular, the nitrogen atom at the 1- or 3-position of the 1,2,3-triazole ring of Lb in linker L, and
  • n 5 represents an integer of 2 to 10, and preferably an integer of 2 to 5.
  • N297-(Fuc)MSG2 is represented by the following structural formula or sequence formula.
  • each wavy line represents bonding to Asn297 of the antibody
  • L (PEG) represents —(CH 2 CH 2 —O) n 5 -CH 2 CH 2 —NH—, wherein the amino group at the right end represents amide-bonding to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in the 1-6 branched chain of the ⁇ -Man in the N297 glycan,
  • the asterisk* represents bonding to linker L, in particular, the nitrogen atom at the 1- or 3-position of the 1,2,3-triazole ring of Lb in linker L, and
  • n 5 is an integer of 2 to 10, and preferably an integer of 2 to 5.
  • N297-(Fuc)SG is represented by the following structural formula or sequence formula.
  • each wavy line represents bonding to Asn297 of the antibody
  • L(PEG) represents —(CH 2 CH 2 —O) n 5 -CH 2 CH 2 —NH—, wherein the amino group at the right end represents amide-bonding to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each of the 1-3 and 1-6 branched chains of the ⁇ -Man in the N297 glycan,
  • each asterisk* represents bonding to linker L, in particular, the nitrogen atom at the 1- or 3-position of the 1,2,3-triazole ring of Lb in linker L, and
  • n 5 is an integer of 2 to 10, and preferably an integer of 2 to 5.
  • the N297 glycan of the antibody in the antibody-drug conjugate of the present invention is N297-(Fuc)MSG1, N297-(Fuc)MSG2, or a mixture of them
  • a glycan-remodeled antibody can be produced by using a method as illustrated in the following formula, for example, according to a method described in WO2013/120066.
  • Step R-1 Hydrolysis of glycosidic bond at GlcNAc ⁇ 1-4GlcNAc of chitobiose structure at reducing terminal
  • a targeted antibody (20 mg/mL) in buffer solution (e.g., 50 mM phosphate buffer solution) is subjected to a hydrolysis reaction of the glycosidic bond between GlcNAc ⁇ 1 and 4GlcNAc in the chitobiose structure at the reducing terminal with use of hydrolase such as the enzyme EndoS at 0° C. to 40° C.
  • the reaction time is 10 minutes to 72 hours, and preferably 1 hour to 6 hours.
  • the amount of the wild-type EndoS to be used is 0.1 to 10 mg, preferably 0.1 to 3 mg, to 100 mg of the antibody.
  • Step R-2 Transglycosylation reaction
  • This is a step of producing a glycan-remodeled antibody by bonding the (Fuc ⁇ 1,6)GlcNAc antibody to MSG-(MSG1-, MSG2-) or SG-type glycan oxazoline (hereinafter, referred to as “azide glycan oxazoline”) having a PEG linker including an azide group with use of an enzymatic reaction.
  • the glycan-truncated antibody in buffer solution is subjected to transglycosylation reaction by reacting with an azide glycan oxazoline in the presence of a catalytic amount of transglycosidase such as EndoS (D233Q/Q303L) at 0° C. to 40° C.
  • the reaction time is 10 minutes to 72 hours, and preferably 1 hour to 6 hours.
  • the amount of the EndoS (D233Q/Q303L) to be used is 1 to 10 mg, preferably 1 to 3 mg, to 100 mg of the antibody, and the amount of the azide glycan oxazoline to be used is 2 equivalents to an excess equivalent, preferably 2 equivalents to 20 equivalents.
  • the azide glycan oxazoline form may be prepared according to methods described in Example 11.
  • a reaction known in the field of synthetic organic chemistry e.g., a condensation reaction
  • N 3 —(CH 2 CH 2 —O)n 5 -CH 2 CH 2 —NH 2 a PEG linker including an azide group (N 3 -L(PEG))
  • N 3 -L(PEG) a PEG linker including an azide group
  • carboxylic acid at the 2-position of a sialic acid and the amino group at the right-hand end of N 3 — (CH 2 CH 2 —O)n 5 -CH 2 CH 2 —NH 2 undergo a condensation reaction to form an amide bond.
  • Examples of the condensing agent in using condensation reaction may include, but not limited to, N, N′-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), carbonyldiimidazole (CDI), 2-(2H-benzotriazol-2-yl)-4-(1, 1, 3, 3-tetramethylbutyl)phenol (BOP), 1H-benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and O-(7-azabenzotriazol-1-yl)-N, N, N′, N′-tetramethyluronium hexafluorophosphate (HATU), and examples of the solvent for the reaction may include, but not limited to, dichloromethane, DMF, THF, ethyl acetate and mixed solvent thereof.
  • DCC N′-dicyclo
  • the reaction temperature is typically ⁇ 20° C. to 100° C. or the boiling point of the solvent, and preferably in the range of ⁇ 5° C. to 50° C.
  • an organic base such as triethylamine, diisopropylethylamine, N-methylmorpholine, and 4-dimethylaminopyridine or an inorganic base such as potassium carbonate, sodium carbonate, potassium hydrogen carbonate, and sodium hydrogen carbonate may be added.
  • 1-hydroxybenzotriazole or N-hydroxysuccinimide may be added as a reaction accelerator.
  • MSG1 may be obtained by hydrolysis of the separated/purified (MSG-)Asn (in Example 11) with hydrolase such as EndoM.
  • Oxazolination may be prepared from GlcNAc at the reducing terminal of MSG1 according to a known article (J. Org Chem., 2009, 74(5), 2210-2212. Helv. Chim. Acta, 2012, 95, 1928-1936).
  • EndoS for the hydrolysis reaction of N297 glycan, for example, EndoS or an enzyme variant retaining hydrolysis activity may be used.
  • an antibody of the above-described structure including MSG- (MSG1-, MSG2-) or SG type N297 glycan can be obtained.
  • a glycan donor molecule having MSG, MSG1, or MSG2 as a glycan is employed.
  • a glycan donor molecule having MSG, MSG1, or MSG2 as a glycan is employed.
  • commercially available monosialo-Asn free (1S2G/1G2S-10NC-Asn, GlyTech, Inc., hereinafter, referred to as “(MSG-)Asn”) as a raw material may be separated in accordance with a method described in Example 11 to obtain (MSG-)Asn1 or (MSG2-)Asn, which may each be employed, or a mixture of them may be employed without separation.
  • a glycan donor molecule including SG (10) as glycan is used for the transglycosylation reaction.
  • SG (10) glycan for example, that obtained from SGP through hydrolysis or the like may be used, or SG (10) glycan such as commercially available disialooctasaccharide (Tokyo Chemical Industry Co., Ltd.) may be used.
  • MSG- (MSG1-, MSG2-) or SG-type glycan included in the donor molecule has a PEG linker having an azide group (N 3 -L(PEG)) at the 2-position of a sialic acid therein.
  • a reaction known in the field of synthetic organic chemistry may be used for MSG (MSG (9)), MSG1, or MSG2, or disialooctasaccharide (SG (10)) and the PEG linker having an azide group (N 3 -L (PEG)) N 3 — (CH 2 CH 2 —O)n 5 -CH 2 CH 2 —NH 2 , wherein n 5 is an integer of 2 to 10, and preferably represents an integer of 2 to 5.
  • the carboxylic acid at the 2-position of a sialic acid and the amino group at the right-hand end of N 3 — (CH 2 CH 2 —O)n 5 -CH 2 CH 2 —NH 2 undergo a condensation reaction to from an amide bond.
  • MSG MSG1, MSG2
  • SG-type glycan may be obtained by introducing a PEG linker having an azide group (N 3 —(CH 2 CH 2 —O)n 5 -CH 2 CH 2 —NH 2 ) to the carboxylic acid at the 2-position of a sialic acid of a raw material, such as (MSG1-)Asn, (MSG2-)Asn and (SG-)Asn (GlyTech, Inc.) with an ⁇ -amino group optionally protected or modified, and to carboxylic acid of the Asn with use of a condensation reaction, and utilizing a hydrolase such as EndoM and EndoRp.
  • a PEG linker having an azide group N 3 —(CH 2 CH 2 —O)n 5 -CH 2 CH 2 —NH 2
  • a sialic acid of a raw material such as (MSG1-)Asn, (MSG2-)Asn and (SG-)Asn (G
  • protective groups for ⁇ -amino groups include, but not limited to, an acetyl (Ac) group, a t-butoxycarbonyl (Boc) group, a benzoyl (Bz) group, a benzyl (Bzl) group, a carbobenzoxy (Cbz) group and a 9-fluorenylmethoxycarbonyl (Fmoc) group.
  • the protective group for ⁇ -amino groups is preferably an Fmoc group.
  • modifying groups for ⁇ -amino groups include modifying groups that enhance solubility in water with a hydroxyacetyl group, a PEG structure, or the like.
  • An ⁇ -amino group of (MSG1-)Asn, (MSG-2)Asn, or (SG-)Asn is preferably protected with any of the protective groups. If an ⁇ -amino group is protected with a protective group (e.g., an Fmoc group), the protective group may be removed, as necessary, after introduction of a PEG linker having an azide group and before causing action of a hydrolase.
  • a protective group e.g., an Fmoc group
  • an activated form such as an oxazoline formed by treatment with 2-chloro-1,3-dimethyl-1H-benzimidazol-3-ium-chloride for GlcNAc at the reducing terminal of MSG (MSG1, MSG2) or SG-type glycan included in the molecule.
  • transglycosidases Various enzymes for use in a transglycosylation reaction (transglycosidases) may be employed that have the activity of transferring a complex glycan to N297 glycan; however, EndoS D233Q, a modified product for which a hydrolysis reaction is suppressed by substituting Asp at the 233-position of EndoS with Gln, is a preferred transglycosidase.
  • a transglycosylation reaction using EndoS D233Q is described, for example, in WO 2013/120066.
  • a modified enzyme such as EndoS D233Q/Q303L (WO 2017010559), which is obtained by further adding a mutation to EndoS D233Q, may be used.
  • the purification operation for the antibody after the glycan remodeling for the antibody is intended to separate low-molecular-weight compounds and enzymes used for the reaction, and gel filtration chromatography, ion-exchange chromatography, affinity chromatography, and so on are typically used for such purification, and additional purification with a hydroxyapatite column may be further carried out. That is, the present invention provides a method for producing a drug-conjugate form, the method including, subsequent to the step of purifying an intermediate from the reaction solution after glycohydrolysis of an antibody, the additional step of purifying with a hydroxyapatite column. According to an example of reports on glycan remodeling (J. Am. Chem.
  • the concentration of an aqueous solution of an antibody, measurement of concentration, and buffer exchange may be carried out according to common operations A to C in the following.
  • a solution of an antibody or antibody-drug conjugate was placed in a container of an Amicon Ultra (30,000 to 50,000 MWCO, Millipore Corporation), and the solution of an antibody or antibody-drug conjugate, which is described later, was concentrated through a centrifugation operation (centrifugation at 2000 G to 4000 G for 5 to 20 minutes) using a centrifuge (Allegra X-15R, Beckman Coulter, Inc.).
  • a buffer solution e.g., phosphate buffered saline (pH 6.0), phosphate buffer (pH 6.0)
  • phosphate buffered saline pH 6.0
  • phosphate buffer (pH 6.0) phosphate buffer
  • This production method is a method for producing an antibody-drug conjugate by conjugating the above-described glycan-remodeled antibody to production intermediate (2) through SPAAC (strain-promoted alkyne azide cycloaddition: J. AM. CHEM. SOC. 2004, 126, 15046-15047) reaction.
  • SPAAC strain-promoted alkyne azide cycloaddition: J. AM. CHEM. SOC. 2004, 126, 15046-15047
  • La′, Lp′ and B′ are the same as defined in La, Lp and B, respectively, and
  • J represents any of these structural formulas, wherein the asterisk* represents bonding to La′.
  • J-La′-Lp′-NH—B′—CH 2 —O(C ⁇ O)-PBD can be synthesized by the method described in any one of Examples 10-1 to 10-6.
  • SPAAC reaction proceeds by mixing a buffer solution (sodium acetate solution, sodium phosphate, sodium borate solution, or the like, or a mixture thereof) of antibody Ab and a solution dissolving compound (2) in an appropriate solvent (dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), N-methyl-2-pyridone (NMP), propylene glycol (PG), or the like, or a mixture thereof).
  • DMSO dimethyl sulfoxide
  • DMF dimethylformamide
  • DMA dimethylacetamide
  • NMP N-methyl-2-pyridone
  • PG propylene glycol
  • the amount of moles of compound (2) to be used is 2 mol to an excess amount of moles, preferably 1 mol to 30 mol, per mole of the antibody, and the ratio of the organic solvent is preferably 1 to 200% v/v to the buffer of the antibody.
  • the reaction temperature is 0° C. to 37° C., and preferably 10° C. to 25° C., and the reaction time is 1 to 150 hours, and preferably 6 hours to 100 hours.
  • the pH in the reaction is preferably 5 to 9.
  • Antibody-drug conjugate compounds can be identified from each other through buffer exchange, purification, and measurement of antibody concentration and average number of conjugated drug molecules per antibody molecule (DAR:Drug to Antibody Ratio) according to common operations A to C described above and common operations D to F described later.
  • NAP-25 column was equilibrated with acetate buffer solution (10 mM, pH 5.5; herein, referred to as ABS) containing commercially available sorbitol (5%).
  • acetate buffer solution (10 mM, pH 5.5; herein, referred to as ABS) containing commercially available sorbitol (5%).
  • an aqueous reaction solution of an antibody-drug conjugate (about 1.5 to 2.5 mL) was applied, and eluted with a buffer in an amount specified by the manufacturer to separate and collect an antibody fraction.
  • the fraction separated and collected was again applied to the NAP-25 column, and a gel filtration purification operation to elute with a buffer was repeated twice or three times in total to afford the antibody-drug conjugate with an unbound drug-linker, dimethyl sulfoxide, and propylene glycol removed.
  • the concentration of the solution of the antibody-drug conjugate was adjusted through common operations A to C.
  • the concentration of the conjugated drug in an antibody-drug conjugate can be calculated by using Lambert-Beer's law shown below. Equation (I) using Lambert-Beer's law is as follows:
  • A280 denotes absorbance of an aqueous solution of an antibody-drug conjugate at 280 nm
  • 6280 denotes the molar absorption coefficient of an antibody-drug conjugate at 280 nm
  • C (mol ⁇ L ⁇ 1 ) denotes the molarity of an antibody-drug conjugate. From expression (I), the molarity of an antibody-drug conjugate, C (mol ⁇ L ⁇ 1 ), can be determined by using expression (II) below.
  • both sides are multiplied by the molar mass of the antibody-drug conjugate, MW (g ⁇ mol ⁇ 1 ), to determine the weight concentration of the antibody-drug conjugate, C′ (mg ⁇ mL ⁇ 1 ) (expression (III)).
  • the absorbance A280 used was a measured value of UV absorbance of an aqueous solution of an antibody-drug conjugate at 280 nm.
  • MW g ⁇ mol ⁇ 1
  • an estimated value of the molecular weight of an antibody was calculated from the amino acid sequence of the antibody, and used as an approximate value of the molar mass of an antibody-drug conjugate.
  • the optical path length, 1 (cm) used in measurement was 1 cm.
  • the molar absorption coefficient, 6280, of the antibody-drug conjugate can be determined by using expression (IV) below:
  • ⁇ 280 Molar absorption coefficient of antibody ⁇ Ab,280 +Molar absorption coefficient of drug ⁇ DL,280 ⁇ Number of drug molecules conjugated Expression (IV)
  • ⁇ Ab , 280 denotes the molar absorption coefficient of an antibody at 280 nm and ⁇ DL, 280 denotes the molar absorption coefficient of a drug at 280 nm.
  • ⁇ Ab, 280 can be estimated from the amino acid sequence of an antibody.
  • the molar absorption coefficient of H31L02A antibody used was ⁇ Ab
  • the molar absorption coefficient of H11L02A antibody used was ⁇ Ab
  • ⁇ DL, 280 was calculated for use from a measured value obtained in each UV measurement. Specifically, the absorbance of a solution dissolving a conjugate precursor (drug) with a certain molarity was measured, and expression (I), Lambert-Beer's law, was applied thereto, and the resulting value was used.
  • the average number of conjugated drug molecules per antibody molecule in an antibody-drug conjugate can be determined through high-performance liquid chromatography (HPLC) with the following method.
  • a solution of an antibody-drug conjugate (about 1 mg/mL, 60 ⁇ L) is mixed with an aqueous solution of dithiothreitol (DTT) (100 mM, 15 ⁇ L). The mixture is incubated at 37° C. for 30 minutes to prepare a sample in which the disulfide bond between the L chain and H chain of the antibody-drug conjugate cleaved, and this sample is used for HPLC analysis.
  • DTT dithiothreitol
  • HPLC analysis is carried out under the following conditions.
  • HPLC system Agilent 1290 HPLC system (Agilent Technologies)
  • H chain with a conjugated drug molecule(s) H chain with one conjugated drug molecule: H 1 , H chain with two conjugated drug molecules: H 2
  • H chain with two conjugated drug molecules: H 2 have hydrophobicity increased in proportion to the number of conjugated drug molecules and have longer retention time as compared to the L chain (L 0 ) and H chain (H 0 ) of an antibody without any conjugated drug molecule, and hence L 0 , H 0 , H 1 , and H 2 are eluted in the presented order. Therefore, through comparison of retention time between L 0 and H 0 , each peak detected can be assigned to L 0 , H 0 , H 1 , or H 2 . Whether a drug is conjugated or not can be confirmed by checking absorption at a wavelength of 329 nm characteristic to the drug.
  • H ⁇ - ⁇ chain ⁇ ⁇ peak ⁇ - ⁇ area correction ⁇ ⁇ value ⁇ ( Hi ) Peak area ⁇ H ⁇ - ⁇ chain ⁇ ⁇ molar ⁇ ⁇ absorption ⁇ ⁇ coefficient H ⁇ - ⁇ chain ⁇ ⁇ molar ⁇ ⁇ absorption ⁇ ⁇ coefficient + number ⁇ ⁇ of ⁇ ⁇ drug ⁇ ⁇ molecules ⁇ ⁇ connected ⁇ drug ⁇ - ⁇ linker ⁇ ⁇ molar ⁇ ⁇ absorption ⁇ ⁇ coefficient ⁇ [ Expression ⁇ ⁇ 5 ] ⁇
  • H01L02A antibody similarly, 79829 was used as the molar absorption coefficient of the H chain; in the case of the H31L02A antibody, 80131 was used as the molar absorption coefficient of the H chain; in the case of the H11L02A antibody, 78696 was used as the molar absorption coefficient of the H chain; in the case of the LPS antibody, 77470 was used as the molar absorption coefficient of the H chain; and the molar absorption coefficient (280 nm) measured for drug-linker 1-4, as a conjugate precursor, was used as the molar absorption coefficient (280 nm) of each drug-linker.
  • the anti-CDH6 antibody of the present invention or the functional fragment of the antibody described in the above section “2. Production of anti-CDH6 antibody” and the Examples binds to CDH6 on the surface of tumor cells and has internalization activity, it can be used as a medicament, and in particular, as a therapeutic agent for cancer such as renal cell tumor or ovarian tumor, for example, renal cell carcinoma, clear renal cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, bile duct cancer, lung cancer (e.g., small-cell lung cancer or non-small cell lung cancer), glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor or neuroblastoma, either alone or in combination with an additional drug.
  • cancer such as renal cell tumor or ovarian tumor, for example, renal cell carcinoma, clear renal cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcino
  • anti-CDH6 antibody of the present invention or the functional fragment of the antibody can be used in the detection of cells expressing CDH6.
  • the anti-CDH6 antibody of the present invention or the functional fragment of the antibody has internalization activity, it can be applied as the antibody in an antibody-drug conjugate.
  • the anti-CDH6 antibody-drug conjugate of the present invention described in the above section “3.
  • Anti-CDH6 antibody-drug conjugate” and the Examples is a conjugate of the anti-CDH6 antibody and/or the functional fragment of the antibody having internalization activity, and the drug having antitumor activity such as cytotoxic activity. Since this anti-CDH6 antibody-drug conjugate exhibits antitumor activity against cancer cells expressing CDH6, it can be used as a medicament, and in particular, as a therapeutic agent and/or a prophylactic agent for cancer.
  • the anti-CDH6 antibody-drug conjugate of the present invention may absorb moisture or have adsorption water, for example, to turn into a hydrate when it is left in air or subjected to recrystallization or purification procedures.
  • a compound or a pharmacologically acceptable salt containing water is also included in the present invention.
  • the anti-CDH6 antibody-drug conjugate of the present invention When the anti-CDH6 antibody-drug conjugate of the present invention has a basic group such as an amino group, it can form a pharmacologically acceptable acid-addition salt, if desired.
  • an acid-addition salt can include: hydrohalides such as hydrofluoride, hydrochloride, hydrobromide, and hydroiodide; inorganic acid salts such as nitrate, perchlorate, sulfate, and phosphate; lower alkanesulfonates such as methanesulfonate, trifluoromethanesulfonate, and ethanesulfonate; arylsulfonates such as benzenesulfonate and p-toluenesulfonate; organic acid salts such as formate, acetate, trifluoroacetate, malate, fumarate, succinate, citrate, tartrate, oxalate, and
  • the anti-CDH6 antibody-drug conjugate of the present invention When the anti-CDH6 antibody-drug conjugate of the present invention has an acidic group such as a carboxy group, it can form a pharmacologically acceptable base-addition salt, if desired.
  • a base-addition salt can include: alkali metal salts such as a sodium salt, a potassium salt, and lithium salt; alkaline earth metal salts such as a calcium salt and a magnesium salt; inorganic salts such as an ammonium salt; and organic amine salts such as a dibenzylamine salt, a morpholine salt, a phenylglycine alkyl ester salt, an ethylenediamine salt, an N-methylglucamine salt, a diethylamine salt, a triethylamine salt, a cyclohexylamine salt, a dicyclohexylamine salt, an N,N′-dibenzylethylenediamine salt,
  • the present invention can also include an anti-CDH6 antibody-drug conjugate in which one or more atoms constituting the antibody-drug conjugate are replaced with isotopes of the atoms.
  • isotopes There exist two types of isotopes: radioisotopes and stable isotopes.
  • the isotope can include isotypes of hydrogen (2H and 3H), isotopes of carbon (11C, 13C and 14C), isotopes of nitrogen (13N and 15N), isotopes of oxygen (150, 170 and 180), and isotopes of fluorine (18F).
  • a composition comprising the antibody-drug conjugate labeled with such an isotope is useful as, for example, a therapeutic agent, a prophylactic agent, a research reagent, an assay reagent, a diagnostic agent, and an in vivo diagnostic imaging agent.
  • a therapeutic agent for example, a prophylactic agent, a research reagent, an assay reagent, a diagnostic agent, and an in vivo diagnostic imaging agent.
  • Each and every antibody-drug conjugate labeled with an isotope, and mixtures of antibody-drug conjugates labeled with an isotope at any given ratio are included in the present invention.
  • the antibody-drug conjugate labeled with an isotope can be produced, for example, by using a starting material labeled with an isotope, instead of a starting material for the production method of the present invention mentioned later, according to a method known in the art.
  • In vitro cytotoxicity can be measured based on the activity of suppressing the proliferative responses of cells, for example.
  • a cancer cell line overexpressing CDH6 is cultured, and the anti-CDH6 antibody-drug conjugate is added at different concentrations to the culture system. Thereafter, its suppressive activity against focus formation, colony formation and spheroid growth can be measured.
  • cell growth inhibition activity against renal cell tumor or ovarian tumor can be examined.
  • In vivo therapeutic effects on cancer in an experimental animal can be measured, for example, by administering the anti-CDH6 antibody-drug conjugate to a nude mouse into which a tumor cell line highly expressing CDH6 has been inoculated, and then measuring a change in the cancer cells.
  • a nude mouse into which a tumor cell line highly expressing CDH6 has been inoculated
  • a change in the cancer cells for example, by using an animal model derived from an immunodeficient mouse by the inoculation of renal cell carcinoma-, renal clear cell carcinoma-, papillary renal cell carcinoma-, ovarian cancer-, ovarian serous adenocarcinoma- or thyroid cancer-derived cells
  • therapeutic effects on renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma or thyroid cancer can be measured.
  • the type of cancer to which the anti-CDH6 antibody-drug conjugate of the present invention is applied is not particularly limited as long as CDH6 is expressed in cancer cells to be treated.
  • Examples thereof can include renal cell carcinoma (e.g., renal clear cell carcinoma or papillary renal cell carcinoma), ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, bile duct cancer, lung cancer (e.g., small-cell lung cancer or non-small cell lung cancer), glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor and neuroblastoma, though the cancer is not limited thereto as long as the cancer expresses CDH6.
  • More preferred examples of the cancer can include renal cell carcinoma (e.g., renal clear cell carcinoma and papillary renal cell carcinoma) and ovarian cancer.
  • the anti-CDH6 antibody-drug conjugate of the present invention can preferably be administered to a mammal, and more preferably to a human.
  • a substances used in a pharmaceutical composition comprising the anti-CDH6 antibody-drug conjugate of the present invention can be appropriately selected from pharmaceutical additives and others usually used in this field, in terms of the applied dose or the applied concentration, and then used.
  • the anti-CDH6 antibody-drug conjugate of the present invention can be administered as a pharmaceutical composition comprising one or more pharmaceutically compatible components.
  • the pharmaceutical composition typically comprises one or more pharmaceutical carriers (e.g., sterilized liquids (e.g., water and oil (including petroleum oil and oil of animal origin, plant origin, or synthetic origin (e.g., peanut oil, soybean oil, mineral oil, and sesame oil))).
  • Water is a more typical carrier when the pharmaceutical composition is intravenously administered.
  • An aqueous saline solution, an aqueous dextrose solution, and an aqueous glycerol solution can also be used as a liquid carrier, in particular, for an injection solution.
  • Suitable pharmaceutical vehicles are known in the art.
  • the composition may also comprise a trace amount of a moisturizing agent, an emulsifying agent, or a pH buffering agent.
  • a moisturizing agent such as a sulfate, a sulfate, a sulfate, or a sulfate.
  • Various delivery systems are known, and they can be used for administering the anti-CDH6 antibody-drug conjugate of the present invention.
  • the administration route can include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous routes.
  • the administration can be made by, e.g., injection or bolus injection, for example.
  • the administration of the above-described antibody-drug conjugate is performed by injection.
  • Parenteral administration is a preferred administration route.
  • the pharmaceutical composition is prescribed, as a pharmaceutical composition suitable for intravenous administration to a human, according to conventional procedures.
  • the composition for intravenous administration is typically a solution in a sterile and isotonic aqueous buffer solution.
  • the medicament may also contain a solubilizing agent and a local anesthetic to alleviate pain at an injection area (e.g., lignocaine).
  • the above-described ingredients are provided, either separately or together in a mixture in unit dosage form, as a freeze-dried powder or an anhydrous concentrate contained in a container which is obtained by sealing in, for example, an ampoule or a sachet indicating the amount of the active agent.
  • the medicament When the medicament is to be administered by injection, it may be administered using, for example, an injection bottle containing water or saline of sterile pharmaceutical grade.
  • an ampoule of sterile water or saline for injection may be provided such that the above-described ingredients are admixed with one another before administration.
  • the pharmaceutical composition of the present invention may be a pharmaceutical composition comprising only the anti-CDH6 antibody-drug conjugate of the present application, or may be a pharmaceutical composition comprising the anti-CDH6 antibody-drug conjugate and at least one other therapeutic agent for cancer.
  • the anti-CDH6 antibody-drug conjugate of the present invention can also be administered together with an additional therapeutic agent for cancer, and can thereby enhance an anticancer effect.
  • the additional anticancer agent used for such a purpose may be administered to an individual, simultaneously, separately, or continuously, together with the antibody-drug conjugate. Otherwise, the additional anticancer agent and the anti-CDH6 antibody-drug conjugate may each be administered to the subject at different administration intervals.
  • Examples of such a therapeutic agent for cancer can include tyrosine kinase inhibitors including imatinib, sunitinib, and regorafenib, CDK4/6 inhibitors including palbociclib, HSP90 inhibitors including TAS-116, MEK inhibitors including MEK162, and immune checkpoint inhibitors including nivolumab, pembrolizumab, and ipilimumab, though the therapeutic agent for cancer is not limited thereto as long as the drug has antitumor activity.
  • Such a pharmaceutical composition can be prepared as a formulation having a selected composition and a necessary purity in the form of a freeze-dried formulation or a liquid formulation.
  • the pharmaceutical composition prepared as a freeze-dried formulation may be a formulation containing an appropriate pharmaceutical additive used in this field.
  • the liquid formulation can be prepared such that the liquid formulation contains various pharmaceutical additives used in this field.
  • composition and concentration of the pharmaceutical composition also vary depending on the administration method.
  • affinity of the anti-CDH6 antibody-drug conjugate comprised in the pharmaceutical composition of the present invention for the antigen i.e., the dissociation constant (Kd value) of the anti-CDH6 antibody-drug conjugate to the antigen
  • Kd value dissociation constant
  • the pharmaceutical composition can exert medicinal effects, even if the applied dose thereof is decreased.
  • the applied dose of the antibody-drug conjugate can also be determined by setting the applied dose based on the status of the affinity of the antibody-drug conjugate for the antigen.
  • the antibody-drug conjugate of the present invention When administered to a human, it may be administered at a dose of, for example, from approximately 0.001 to 100 mg/kg once or a plurality of times at intervals of 1 to 180 days. It can be administered preferably at a dose of from 0.1 to 50 mg/kg and more preferably 1 to 50 mg/kg, 1 to 30 mg/kg, 1 to 20 mg/kg, 1 to 15 mg/kg, 2 to 50 mg/kg, 2 to 30 mg/kg, 2 to 20 mg/kg or 2 to 15 mg/kg a plurality of times at intervals of 1 to 4 weeks, preferably 2 to 3 weeks.
  • Example 1 Obtaining of Rat Anti-Human CDH6 Antibody Having Internalization Activity
  • cDNA encoding cynomolgus monkey CDH6 protein was cloned with cDNA synthesized from total RNA of the cynomolgus monkey kidney as a template using primer 1 (5′-CACCATGAGAACTTACCGCTACTTCTTGCTGCTC-3′) (SEQ ID No: 8) and primer 2 (5′-TTAGGAGTCTTTGTCACTGTCCACTCCTCC-3′) (SEQ ID No: 9). It was confirmed that the obtained sequence corresponded to the extracellular region of cynomolgus monkey CDH6 (NCBI, XP_005556691.1).
  • cynomolgus monkey CDH6 (EHH54180.1) registered in EMBL.
  • the cDNA was incorporated into a vector for mammalian expression according to a method known to a person skilled in the art to produce a cynomolgus monkey CDH6 expression vector, pcDNA3.1-cynoCDH6.
  • the amino acid sequence of the cynomolgus monkey CDH6 ORF is shown in SEQ ID No: 7.
  • EndoFree Plasmid Giga Kit (Qiagen N.V.) was used for mass production of the produced plasmid DNA.
  • WKY/Izm female rats (Japan SLC, Inc.) were used.
  • the lower limbs of each rat were pre-treated with hyaluronidase (Sigma-Aldrich Co. LLC), and thereafter, the human CDH6 expression vector pcDNA3.1-hCDH6 produced in Example 1)-1 was intramuscularly injected into the same sites.
  • ECM830 (BTX)
  • in vivo electroporation was carried out on the same sites using a two-needle electrode. Approximately once every two weeks, the same in vivo electroporation was repeated, and thereafter, lymph nodes or the spleen were collected from the rat, and used for producing hybridomas.
  • the lymph node cells or the spleen cells were fused with mouse myeloma SP2/0-ag14 cells (ATCC, No. CRL-1581) according to electrical cell fusion, using a LF301 Cell Fusion Unit (BEX Co., Ltd.), and the cells were then suspended and diluted with ClonaCell-HY Selection Medium D (StemCell Technologies Inc.), and then cultured under conditions of 37° C. and 5% CO 2 . Individual hybridoma colonies that appeared in the culture medium were collected as monoclonal hybridomas, then suspended in ClonaCell-HY Selection Medium E (StemCell Technologies Inc.), and then cultured under conditions of 37° C. and 5% CO 2 . After moderate proliferation of cells, frozen stocks of individual hybridoma cells were produced, while the obtained hybridoma culture supernatant was used to screen for anti-human CDH6 antibody-producing hybridomas.
  • 293 ⁇ cells (a stable expression cell line derived from HEK293 cells expressing integrin ⁇ v and integrin 03) were prepared at 5 ⁇ 10 5 cells/mL in DMEM medium supplemented with 10% FBS.
  • the culture supernatant of the 293 ⁇ cells transfected with the expression vector prepared in Example 1)-4-1 was removed, and the culture supernatant from each hybridoma was then added to the 293 ⁇ cells transfected with pcDNA3.1-hCDH6 or pcDNA3.1-cynoCDH6, or pcDNA3.1.
  • the cells were left standing at 4° C. for 1 hour.
  • the cells in the wells were washed once with PBS (+) supplemented with 5% FBS, and thereafter, Anti-Rat IgG-Peroxidase antibody produced in rabbit (Sigma-Aldrich Co. LLC) that had been 500-fold diluted with PBS (+) supplemented with 5% FBS was added to the wells.
  • the cells were left standing at 4° C. for 1 hour.
  • the cells in the wells were washed three times with PBS (+) supplemented with 5% FBS, and thereafter, OPD coloring solution (which had been prepared by dissolving o-phenylenediamine dihydrochloride (Wako Pure Chemical Industries, Ltd.) and H 2 O 2 in an OPD solution (0.05 M trisodium citrate, 0.1 M disodium hydrogen phosphate 12-water; pH 4.5), so that the substances became 0.4 mg/ml and 0.6% (v/v), respectively) was added in an amount of 100 ⁇ L/well to the wells.
  • a coloring reaction was carried out with occasional stirring.
  • Hybridomas that produced a culture supernatant exhibiting higher absorbance in the 293 ⁇ cells transfected with the pcDNA3.1-hCDH6 or pcDNA3.1-cynoCDH6 expression vector than that in the 293 ⁇ cells transfected with the control pcDNA3.1 were selected as hybridomas producing antibodies binding to human CDH6 and cynomolgus monkey CDH6.
  • 293T cells were seeded in a 225-cm 2 flask (Sumitomo Bakelite Co., Ltd.) at 5 ⁇ 10 4 cells/cm 2 , and the cells were then cultured overnight under conditions of 37° C. and 5% CO 2 in DMEM medium supplemented with 10% FBS.
  • pcDNA3.1-cynoCDH6 or pcDNA3.1 as a negative control was introduced into the 293T cells using Lipofectamine 2000, and the cells were further cultured overnight under conditions of 37° C. and 5% CO 2 .
  • the 293T cells transfected with each vector were treated with TrypLE Express (Thermo Fisher Scientific Corp.), and the cells were washed with DMEM supplemented with 10% FBS, and then suspended in PBS supplemented with 5% FBS. The obtained cell suspension was used in flow cytometry analysis.
  • the binding specificity to cynomolgus monkey CDH6 of an antibody produced from the human CDH6- and cynomolgus monkey CDH6-binding antibody-producing hybridomas that had been selected by Cell-ELISA in Example 1)-4 was further confirmed by flow cytometry.
  • the suspension of the transiently expressing 293T cells prepared in Example 1)-5-1 was centrifuged, and the supernatant was then removed. Thereafter, the cells were suspended by the addition of the culture supernatant from each hybridoma. The cells were left standing at 4° C. for 1 hour.
  • the cells were washed twice with PBS supplemented with 5% FBS, and thereafter, the cells were suspended by the addition of Anti-Rat IgG FITC conjugate (Sigma-Aldrich Co. LLC) that had been 500-fold diluted with PBS supplemented with 5% FBS. The cells were left standing at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, and then re-suspended in PBS supplemented with 5% FBS and 2 ⁇ g/ml 7-aminoactinomycin D (Molecular Probes, Inc.), followed by detection using a flow cytometer (FC500; Beckman Coulter, Inc.).
  • FC500 flow cytometer
  • the data was analyzed using FlowJo (TreeStar, Inc.). After dead cells were removed from analysis by gating out 7-aminoactinomycin D-positive cells, a histogram of the FITC fluorescence intensity of live cells was generated. Hybridomas producing antibodies specifically binding to cynomolgus monkey CDH6 expressed on the cell membrane surface were selected based on results where the histogram for the antibody shifted to the strong fluorescence intensity side in the 293T cells transfected with pcDNA3.1-cynoCDH6 compared with the 293T cells transfected with the control pcDNA3.1.
  • Clone rG019 which appeared to bind specifically and strongly to human CDH6 and monkey CDH6, was selected from among the rat anti-CDH6 antibody-producing hybridomas selected in Example 1)-5, and the isotype of each antibody was identified.
  • the heavy chain subclass and the light chain type of the antibody were determined using a RAT MONOCLONAL ANTIBODY ISOTYPING TEST KIT (DS Pharma Biomedical Co., Ltd.). As a result, it was confirmed that rG019 had a heavy chain of IgG2b subclass and a light chain of K chain type.
  • the rat anti-human CDH6 monoclonal antibody was purified from the hybridoma culture supernatant.
  • the volume of each rat anti-CDH6 monoclonal antibody-producing hybridoma was sufficiently increased with ClonaCell-HY Selection Medium E (StemCell Technologies Inc.), and thereafter, the medium was exchanged with Hybridoma SEM (Thermo Fisher Scientific Corp.) to which 20% of Ultra Low IgG FBS (Thermo Fisher Scientific Corp.) had been added. Thereafter, the hybridoma was cultured for 4 to 5 days. The resulting culture supernatant was harvested, and insoluble matter was removed therefrom by passing through a 0.8- ⁇ m filter, and through a 0.2- ⁇ m filter.
  • An antibody (rat anti-CDH6 antibody (rG019) was purified from the culture supernatant of hybridomas prepared in Example 1)-7-1 according to Protein G affinity chromatography.
  • the antibody was adsorbed on a Protein G column (GE Healthcare Biosciences Corp.), the column was then washed with PBS, and the antibody was then eluted with a 0.1 M glycine/HCl aqueous solution (pH 2.7). 1 M Tris-HCl (pH 9.0) was added to the eluate, so that the pH was adjusted to pH 7.0 to 7.5.
  • the human CDH6-binding activity of the rat anti-CDH6 antibody produced in Example 1)-7 was evaluated by flow cytometry. Using Lipofectamine 2000 (Thermo Fisher Scientific Inc.), pcDNA3.1-hCDH6 produced in Example 1)-1 was transiently introduced into 293T cells (ATCC). The cells were cultured overnight under conditions of 37° C. and 5% C02, treated with TrypLE Express (Thermo Fisher Scientific Inc.), and thereafter, a cell suspension was prepared. The suspension of the transfected 293T cells was centrifuged, and the supernatant was then removed.
  • Lipofectamine 2000 Thermo Fisher Scientific Inc.
  • pcDNA3.1-hCDH6 produced in Example 1)-1 was transiently introduced into 293T cells (ATCC). The cells were cultured overnight under conditions of 37° C. and 5% C02, treated with TrypLE Express (Thermo Fisher Scientific Inc.), and thereafter, a cell suspension was prepared. The suspension of the transfected 293T cells was centr
  • the cells were suspended by the addition of the rat anti-CDH6 monoclonal antibody (clone No: rG019), which had been prepared in Example 1)-7, or rat IgG control (R&D Systems, Inc.) (final concentration: 10 ng/mL).
  • the cells were left standing at 4° C. for 1 hour.
  • the cells were washed twice with PBS supplemented with 5% FBS, and then suspended by the addition of Anti-Rat IgG (whole molecule)-FITC antibody produced in rabbit (Sigma-Aldrich Co. LLC) that had been 50-fold diluted with PBS supplemented with 5% FBS.
  • the cells were left standing at 4° C. for 1 hour.
  • the cells were washed twice with PBS supplemented with 5% FBS, followed by detection using a flow cytometer (FC500; Beckman Coulter, Inc.). The data was analyzed using FlowJo (TreeStar, Inc.). The results are shown in FIG. 1 .
  • the abscissa depicts FITC fluorescence intensity indicating the amount of the antibody bound, and the ordinate depicts a cell count.
  • the shaded histogram shows that negative control 293T cells untransfected with hCDH6 were used, and the open solid line histogram shows that hCDH6-transfected 293T cells were used.
  • the full-length extracellular region of human CDH6 has five extracellular domains, EC1 (SEQ ID NO: 2), EC2 (SEQ ID NO: 3), EC3 (SEQ ID NO: 4), EC4 (SEQ ID NO: 5), and EC5 (SEQ ID NO: 6).
  • a gene to be expressed such that each one of the five EC domains could be deleted from full-length human CDH6 was synthesized by GeneArt, and incorporated into p3 ⁇ FLAG-CMV-9 vectors for mammalian expression (Sigma-Aldrich Co. LLC) according to a method known to a person skilled in the art in order to produce an expression vector for each domain deletion mutant lacking any one of EC1 to EC5.
  • each domain deletion mutant expression vector produced in Example 2)-2-1, or pcDNA3.1-hCDH6 for the expression of full-length human CDH6 was transiently introduced into a 293 ⁇ cell line, which was a cell line derived from HEK293 cells by stable transfection with integrin ⁇ v and integrin 03 expression vectors.
  • the cells were cultured overnight under conditions of 37° C. and 5% CO 2 , treated with TrypLE Express (Thermo Fisher Scientific Inc.), and thereafter, a cell suspension was prepared.
  • the suspension of the transfected 293 ⁇ cells was centrifuged, and a supernatant was then removed. Thereafter, the cells were suspended by the addition of the anti-CDH6 monoclonal antibody (clone No: rG019), which had been prepared in Example 1)-7, or rat IgG control (R&D Systems, Inc.) (final concentration: 20 nM).
  • the cells were left standing at 4° C. for 1 hour.
  • the cells were washed twice with PBS supplemented with 5% FBS, and then suspended by the addition of Anti-Rat IgG (whole molecule)-FITC antibody produced in rabbit (Sigma-Aldrich Co. LLC) that had been 50-fold diluted with PBS supplemented with 5% FBS.
  • FIGS. 2-1 to 2-2 The results are shown in FIGS. 2-1 to 2-2 .
  • the abscissa depicts FITC fluorescence intensity indicating the amount of the antibody bound, and the ordinate depicts cell count.
  • the shaded histogram shows that negative control untransfected 293 ⁇ cells were used, and the open solid line histogram shows that 293 cells expressing full-length hCDH6 or each EC domain deletion mutant were used. Fluorescence intensity is enhanced when the antibody binds to full-length hCDH6 or each EC domain deletion mutant on the surface of cells.
  • the rat IgG control binds to none of the transfected cells.
  • rG019 binds to the full-length hCDH6, the EC1 deletion mutant, the EC2 deletion mutant, the EC4 deletion mutant, and the EC5 deletion mutant, but does not bind to the EC3 deletion mutant. From this result, it was demonstrated that rG019 specifically binds to hCDH6 with EC3 as an epitope.
  • CDH6 expression information was retrieved from a known database, and the expression of CDH6 on the cell membrane surface was evaluated by flow cytometry.
  • Human ovarian tumor cell lines NIH:OVCAR-3, PA-1, OV-90 and human renal cell tumor cell line 786-O and Caki-1 (all obtained from ATCC) were each cultured under conditions of 37° C. and 5% CO 2 , treated with TrypLE Express (Thermo Fisher Scientific Inc.), and thereafter, a cell suspension was prepared. The cells were centrifuged, and the supernatant was then removed.
  • the cells were suspended by the addition of a commercially available anti-human CDH6 antibody (MABU2715, R&D Systems, Inc.) or mouse IgG1 (BD Pharmingen) as a negative control (final concentration: 50 ⁇ g/mL).
  • MABU2715 commercially available anti-human CDH6 antibody
  • mouse IgG1 mouse IgG1 (BD Pharmingen)
  • final concentration: 50 ⁇ g/mL final concentration: 50 ⁇ g/mL.
  • the cells were left standing at 4° C. for 1 hour.
  • the cells were washed twice with PBS supplemented with 5% FBS, and then suspended by the addition of F(ab′)2 Fragment of FITC-conjugated Goat Anti-mouse immunoglobulins (Dako) that had been 50-fold diluted with PBS supplemented with 5% FBS.
  • the cells were left standing at 4° C. for 1 hour.
  • the cells were washed twice with PBS supplemented with 5% FBS, followed by detection using a flow cytometer (Canto II; BD Biosciences). The data was analyzed using FlowJo (TreeStar, Inc.). The results are shown in FIG. 3 .
  • the abscissa depicts FITC fluorescence intensity indicating the amount of the antibody bound, and the ordinate depicts cell count.
  • the shaded histogram shows that the negative control mIgG1 was used in staining, and the open solid line histogram shows that the anti-human CDH6 antibody was used in staining. As seen, fluorescence intensity was enhanced by the binding of the antibody to hCDH6 on the surface of cells.
  • the mIgG1 control binds to none of the cells.
  • the NIH:OVCAR-3, PA-1, OV-90, 786-O and Caki-1 cell lines endogenously express CDH6 on the cell surface.
  • Example 3 Amplification and Sequencing of rG019 Heavy-Chain Variable Region and Light-Chain Variable Region Gene Fragments
  • RNA was prepared from G019 antibody-producing hybridoma using TRIzol Reagent (Ambion, Inc.).
  • cDNA encoding the heavy chain variable region was amplified using approximately 1 ⁇ g of the total RNA prepared in Example 3)-1 and a SMARTer RACE cDNA Amplification Kit (Clontech Laboratories, Inc.).
  • a SMARTer RACE cDNA Amplification Kit (Clontech Laboratories, Inc.).
  • UPM Universal Primer A Mix: included with SMARTer RACE cDNA Amplification Kit
  • primers designed from the sequences of the constant regions of known rat heavy chains were used.
  • the heavy chain variable region-encoding cDNA amplified by 5′-RACE PCR was cloned into a plasmid, and thereafter, the nucleotide sequence of the cDNA of the heavy chain variable region was subjected to sequence analysis.
  • the determined nucleotide sequence of the cDNA encoding the heavy chain variable region of rG019 is shown in SEQ ID NO: 16, and the amino acid sequence thereof is shown in SEQ ID NO: 15.
  • the determined nucleotide sequence of the cDNA encoding the light chain variable region of rG019 is shown in SEQ ID NO: 11, and the amino acid sequence thereof is shown in SEQ ID NO: 10.
  • a neomycin expression unit was removed from pcDNA3.3/LK to construct pCMA-LK.
  • a DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the chG019 heavy chain shown in SEQ ID NO: 27 was synthesized (GENEART). Using an In-Fusion HD PCR cloning kit (Clontech Laboratories, Inc.), the synthesized DNA fragment was inserted into a site of pCMA-G1 that had been cleaved with the restriction enzyme BlpI, so as to construct a chG019 heavy chain expression vector. It is to be noted that, for the chG019 heavy chain, a CDR sequence with cysteine substituted with proline was used in order to prevent unpredictable disulfide bonds.
  • a DNA fragment comprising a DNA sequence (SEQ ID NO: 22) encoding the chG019 light chain was synthesized (GENEART). Using an In-Fusion HD PCR cloning kit (Clontech Laboratories, Inc.), the synthesized DNA fragment was bound to a DNA fragment, which had been obtained by digesting pCMA-LK with XbaI and PmeI to remove the DNA sequence encoding the light chain signal sequence and the human ⁇ chain constant region therefrom, so as to construct a chG019 light chain expression vector.
  • FreeStyle 293F cells (Invitrogen Corp.) were cultured and passaged. 1.2 ⁇ 10 9 FreeStyle 293F cells (Invitrogen Corp.) in the logarithmic growth phase were seeded on a 3-L Fernbach Erlenmeyer Flask (Corning Inc.), then diluted with FreeStyle 293 expression medium (Invitrogen Corp.) at 2.0 ⁇ 10 6 cells/mL. To 40 ml of Opti-Pro SFM medium (Invitrogen Corp.), 0.24 mg of the heavy chain expression vector, 0.36 mg of the light chain expression vector and 1.8 mg of Polyethyleneimine (Polyscience #24765) were added, and the obtained mixture was gently stirred.
  • the mixture was added to the FreeStyle 293F cells.
  • the cells were shake-cultured at 90 rpm in an 8% CO 2 incubator at 37° C. for 4 hours, and thereafter, 600 mL of EX-CELL VPRO medium (SAFC Biosciences Inc.), 18 mL of GlutaMAX I (GIBCO), and 30 mL of Yeastolate Ultrafiltrate (GIBCO) were added to the culture.
  • the cells were further shake-cultured at 90 rpm in an 8% CO 2 incubator at 37° C. for 7 days.
  • the obtained culture supernatant was filtrated through a Disposable Capsule Filter (Advantec #CCS-045-E1H).
  • An antibody was purified from the culture supernatant obtained in Example 4)-2-1 by a one-step process according to rProtein A affinity chromatography.
  • the culture supernatant was applied to a column that had been packed with MabSelectSuRe (GE Healthcare Biosciences Corp.) equilibrated with PBS, and thereafter, the column was washed with PBS in an amount of two or more times the volume of the column. Subsequently, the antibody was eluted with a 2 M arginine hydrochloride solution (pH 4.0), so that a fraction containing an antibody was collected.
  • a 2 M arginine hydrochloride solution pH 4.0
  • the fraction was dialyzed (Thermo Fisher Scientific Inc., Slide-A-Lyzer Dialysis Cassette), so that the buffer was replaced with HBSor (25 mM histidine/5% sorbitol, pH 6.0).
  • HBSor 25 mM histidine/5% sorbitol, pH 6.0.
  • the antibody was concentrated, so that the concentration of IgG was adjusted to 5 mg/ml or more.
  • the antibody was filtrated through a Minisart-Plus filter (Sartorius Inc.) to obtain a purified sample.
  • the CDH6-binding activity of the human chimeric anti-CDH6 antibody chG019 purified in 4)-2 was confirmed by flow cytometry.
  • pcDNA3.1-hCDH6 or pcDNA3.1-cynoCDH6 produced in Example 1)-1, or pcDNA3.1 was transiently introduced into 293 ⁇ cells. The cells were cultured overnight under conditions of 37° C. and 5% CO 2 , treated with TrypLE Express (Thermo Fisher Scientific Inc.), and thereafter, a cell suspension was prepared. chG019 was added to the suspension of each of these cells. The cells were left standing at 4° C. for 1 hour.
  • the cells were washed twice with PBS supplemented with 5% FBS, and then suspended by the addition of PE-labeled F(ab′)2 Fragment anti-human IgG, Fc ⁇ antibody (Jackson ImmunoResearch Laboratories, Inc.) that had been 500-fold diluted with PBS supplemented with 5% FBS.
  • the cells were left standing at 4° C. for 1 hour.
  • the cells were washed twice with PBS supplemented with 5% FBS, and then re-suspended in PBS supplemented with 5% FBS, followed by detection using a flow cytometer (Canto II; BD Biosciences). The data was analyzed using FlowJo (TreeStar, Inc.). As shown in FIG.
  • chG019 did not bind to the 293T cells transfected with pcDNA3.1 as a negative control, but did bind to the 293T cells transfected with pcDNA3.1-hCDH6 or pcDNA3.1-cynoCDH6 in an antibody concentration-dependent manner.
  • the abscissa depicts antibody concentration
  • the ordinate depicts the amount of the antibody bound, based on mean fluorescence intensity. It is evident from this result that chG019 specifically binds to human CDH6 and cynomolgus monkey CDH6 with almost equivalent binding activity.
  • the molecular modeling of the variable regions of chG019 exploited a method known as homology modeling (Methods in Enzymology, 203, 121-153, (1991)).
  • the commercially available protein three-dimensional structure analysis program BioLuminate manufactured by Schrodinger, LLC was employed using, as a template, a structure (PDB ID: 2I9L) registered in Protein Data Bank (Nuc. Acid Res. 35, D301-D303 (2007)) with a high sequence identity to the heavy chain and light chain variable regions of chG019.
  • chG019 was humanized by CDR grafting (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)).
  • the consensus sequences of human gamma chain subgroup 1 and kappa chain subgroup 1 determined by KABAT et al. (Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service National Institutes of Health, Bethesda, Md. (1991)) had high identity to the framework regions of chG019, and based on this, they were selected as acceptors for the heavy chain and the light chain, respectively.
  • Donor residues to be grafted onto the acceptors were selected by analyzing three-dimensional models with reference to, for example, the criteria given by Queen et al. (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)).
  • the three heavy chains thus designed were named hH01, hH02 and hH04.
  • the full-length amino acid sequence of the hH01 heavy chain is shown in SEQ ID NO: 39.
  • the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 39 is shown in SEQ ID NO: 40.
  • the full-length amino acid sequence of the heavy chain hH02 is shown in SEQ ID NO: 43.
  • the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 43 is shown in SEQ ID NO: 44.
  • the full-length amino acid sequence of the heavy chain hH04 is shown in SEQ ID NO: 47.
  • the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 47 is shown in SEQ ID NO: 48.
  • Two light chains thus designed were named hL02 and hL03.
  • the full-length amino acid sequence of the hL02 light chain is shown in SEQ ID NO: 31.
  • the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 31 is shown in SEQ ID NO: 32.
  • the full-length amino acid sequence of the light chain hL03 is shown in SEQ ID NO: 35.
  • the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 35 is shown in SEQ ID NO: 36.
  • An antibody consisting of hH01 and hL02 was named “H01L02 antibody” or “H01L02”.
  • An antibody consisting of hH02 and hL02 was named “H02L02 antibody” or “H02L02”.
  • An antibody consisting of hH02 and hL03 was named “H02L03 antibody” or “H02L03”.
  • An antibody consisting of hH04 and hL02 was named “H04L02 antibody” or “H04L02”.
  • a DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the hH01 heavy chain shown in SEQ ID NO: 40 was synthesized (GENEART).
  • a hH01 heavy chain expression vector was constructed by the same method as that applied in Example 4)-1-3.
  • a DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the hH02 heavy chain shown in SEQ ID NO: 44 was synthesized (GENEART).
  • a hH02 heavy chain expression vector was constructed by the same method as that applied in Example 4)-1-3.
  • a DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the hH04 heavy chain shown in SEQ ID NO: 48 was synthesized (GENEART).
  • a hH04 heavy chain expression vector was constructed by the same method as that applied in Example 4)-1-3.
  • a DNA fragment comprising a hL02 light chain variable region-encoding DNA sequence from nucleotide positions 37 to 399 in the nucleotide sequence of the hL02 light chain shown in SEQ ID NO: 32 was synthesized (GENEART). Using an In-Fusion HD PCR cloning kit (Clontech Laboratories, Inc.), the synthesized DNA fragment was inserted into a site of pCMA-LK that had been cleaved with the restriction enzyme BsiWI, so as to construct a hL02 light chain expression vector.
  • a DNA fragment comprising a hL03 light chain variable region-encoding DNA sequence from nucleotide positions 37 to 399 in the nucleotide sequence of the hL03 light chain shown in SEQ ID NO: 36 was synthesized (GENEART).
  • a hL03 light chain expression vector was constructed by the same method as that applied in Example 5)-5-2-1.
  • the antibodies were produced by the same method as that applied in Example 4)-2-1.
  • H01L02, H02L02, H02L03 and H04L02 were produced by the combination of the heavy chain and the light chain shown in Example 5)-4.
  • the antibody was purified from the culture supernatant obtained in Example 5)-5-3-1, by a two-step process, namely, by rProtein A affinity chromatography and ceramic hydroxyapatite.
  • the culture supernatant was applied to a column that had been packed with MabSelectSuRe (manufactured by GE Healthcare Biosciences Corp.) equilibrated with PBS, and thereafter, the column was washed with PBS in an amount of two or more times the volume of the column. Subsequently, the antibody was eluted using a 2 M arginine hydrochloride solution (pH 4.0).
  • a fraction containing the antibody was dialyzed (Thermo Fisher Scientific Inc., Slide-A-Lyzer Dialysis Cassette), so that the buffer was replaced with PBS.
  • the antibody solution was 5-fold diluted with a buffer of 5 mM sodium phosphate/50 mM MES/pH 7.0, and then applied to a ceramic hydroxyapatite column (Bio-Rad Laboratories, Inc., Bio-Scale CHT Type-1 Hydroxyapatite Column) that had been equilibrated with a buffer of 5 mM NaPi/50 mM MES/30 mM NaCl/pH 7.0. Elution was carried out on a linear concentration gradient of sodium chloride, so that a fraction containing an antibody was collected.
  • This fraction was dialyzed (Thermo Fisher Scientific Inc., Slide-A-Lyzer Dialysis Cassette), so that the buffer was replaced with HBSor (25 mM histidine/5% sorbitol, pH 6.0).
  • the antibody was concentrated with Centrifugal UF Filter Device VIVASPIN20 (molecular weight cutoff: UF10K, Sartorius Inc.), thereby adjusting the IgG concentration to 20 mg/ml. Finally, the antibody was filtrated through a Minisart-Plus filter (Sartorius Inc.) to obtain a purified sample.
  • the anti-CDH6 antibody NOV0712 used in the Examples was produced with reference to the light chain full-length and heavy chain full-length amino acid sequences (SEQ ID NO: 235 and SEQ ID NO: 234, respectively, in International Publication No. WO 2016/024195) of NOV0712 described in International Publication No. WO 2016/024195.
  • a NOV0712 heavy chain variable region-encoding DNA fragment from nucleotide positions 36 to 428 in the nucleotide sequence of the NOV0712 heavy chain shown in SEQ ID NO: 54 was synthesized (GENEART).
  • a NOV0712 heavy chain expression vector was constructed by the same method as that applied in Example 4)-1-3.
  • the amino acid sequence of the NOV0712 heavy chain expressed by the NOV0712 heavy chain expression vector is shown in SEQ ID NO: 53.
  • the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence.
  • a DNA fragment comprising a NOV0712 light chain variable region-encoding DNA sequence from nucleotide positions 37 to 405 in the nucleotide sequence of the NOV0712 light chain shown in SEQ ID NO: 52 was synthesized (GENEART).
  • a NOV0712 light chain expression vector was constructed by the same method as that applied in Example 5)-5-2-1.
  • the amino acid sequence of the NOV0712 light chain expressed by the NOV0712 light chain expression vector is shown in SEQ ID NO: 51.
  • the amino acid sequence consisting of the amino acid residues at positions 1 to 20 is a signal sequence.
  • NOV0712 was produced by the same method as that applied in Example 4)-2-1.
  • the anti-CDH6 antibody NOV0712 was purified from the culture supernatant obtained in Reference Example 1)-2-1 by the same method as that applied in Example 4)-2-2 (antibody concentration: 5 mg/l HBSor).
  • the dissociation constant between the antibody and the antigen was measured by using Biacore T200 (GE Healthcare Biosciences Corp.), according to a capture method, which comprises capturing the antigen as a ligand with the immobilized anti-His antibody and then measuring the dissociation constant using an antibody as an analyte.
  • a capture method which comprises capturing the antigen as a ligand with the immobilized anti-His antibody and then measuring the dissociation constant using an antibody as an analyte.
  • Approximately 1000 RU of the anti-histidine antibody His capture kit, GE Healthcare Biosciences Corp.
  • sensor chip CM5 GE Healthcare Biosciences Corp.
  • the antibody was also immobilized onto reference cells in the same manner as above.
  • HBS-P+(10 mM HEPES pH 7.4, 0.15 M NaCl, 0.05% Surfactant P20) supplemented with 1 mM CaCl 2 was used as a running buffer.
  • the antigen was added onto the anti-histidine antibody-immobilized chip for 60 seconds, and a dilution series solution (0.391 to 100 nM) of the antibody was then added at a flow rate of 30 ⁇ l/min for 300 seconds. Subsequently, the dissociation phase was monitored for 600 seconds.
  • a glycine solution (pH 1.5) supplemented with 5 M MgCl 2 was added twice at a flow rate of 10 ⁇ l/min for 30 seconds.
  • a Steady State Affinity model in analysis software (BIAevaluation software, version 4.1) was used in data analysis, and the dissociation constant (KD) was calculated. The results are shown in Table 2.
  • each domain deletion mutant expression vector produced in Example 2)-2-1, or pcDNA3.1-hCDH6 for the expression of full-length human CDH6 was transiently introduced into cells.
  • the cells were cultured overnight under conditions of 37° C. and 5% CO 2 , and thereafter, a cell suspension was prepared. The suspension of the transfected 293 ⁇ cells was centrifuged, and the supernatant was then removed.
  • the cells were suspended by the addition of each of the 4 humanized hG019 antibodies (clone Nos: H01L02, H02L02, H02L03 and H04L02), which had been prepared in Example 5)-5-3, or the anti-CDH6 antibody NOV0712, which had been prepared in Reference Example 1, or human IgG1 (Calbiochem) as a negative control.
  • the cells were left standing at 4° C. for 1 hour.
  • the cells were washed twice with PBS supplemented with 5% FBS, and then suspended by the addition of APC-anti-human IgG goat F(ab′)2 (Jackson ImmunoResearch Laboratories, Inc.) that had been 500-fold diluted with PBS supplemented with 5% FBS.
  • FIGS. 5-1 to 5-6 The results are shown in FIGS. 5-1 to 5-6 .
  • the abscissa depicts APC fluorescence intensity indicating the amount of the antibody bound, and the ordinate depicts cell count.
  • the shaded histogram shows that negative control untransfected 293 ⁇ cells were used, and the open solid line histogram shows that 293 ⁇ cells expressing full-length hCDH6 or each EC domain deletion mutant were used. Fluorescence intensity is enhanced when the antibody binds to full-length hCDH6 or each EC domain deletion mutant on the cell surface.
  • the human IgG1 control binds to none of the transfected cells.
  • the 4 humanized hG019 antibodies (clone Nos: H01L02, H02L02, H02L03 and H04L02) bind to the full-length hCDH6, the EC1 deletion mutant, the EC2 deletion mutant, the EC4 deletion mutant, and the EC5 deletion mutant, but do not bind to the EC3 deletion mutant. Specifically, it was demonstrated that the 4 humanized hG019 antibodies specifically bind to hCDH6 with EC3 as an epitope.
  • the anti-CDH6 antibody NOV0712 binds to the full-length hCDH6, the EC1 deletion mutant, the EC2 deletion mutant, the EC3 deletion mutant, and the EC4 deletion mutant, but does not bind to the EC5 deletion mutant. Specifically, it was demonstrated that the anti-CDH6 antibody NOV0712 specifically binds to hCDH6 with EC5 as an epitope. This is consistent with epitope information on NOV0712 described in International Publication No. WO 2016/024195. From this result, it was demonstrated that the 4 humanized hG019 antibodies obtained in the present description are anti-CDH6 antibodies that exhibit properties different from those of NOV0712.
  • the 786-O/hCDH6 stably expressing cell line was produced by infecting 786-O cells (ATCC) with a recombinant retrovirus for full-length human CDH6 expression.
  • a human CDH6 expression retrovirus vector (pQCXIN-hCDH6) was produced by using a human CDH6 protein (NP_004923)-encoding cDNA expression vector (OriGene Technologies Inc., RC217889), and incorporating the cDNA into retrovirus vector pQCXIN (Clontech Laboratories, Inc.) according to a method known to a person skilled in the art.
  • pQCXIN-hCDH6 was transiently introduced into retrovirus packaging cells RetroPack PT67 (Clontech Laboratories, Inc.). After 48 hours, a culture supernatant containing recombinant retrovirus was recovered, and then added to the 786-O cell culture system, so that the cells were infected. From 3 days after the infection, the infected cells were cultured under conditions of 37° C. and 5% CO 2 in a medium supplemented with G418 (Gibco) (final concentration: 50 mg/mL) and screened with the drug, so as to establish cell line 786-O/hCDH6 stably expressing human CDH6.
  • G418 Gibco
  • the shaded histogram shows that the negative control mIgG1 was used in staining, and the open solid line histogram shows that the anti-human CDH6 antibody was used in staining.
  • fluorescence intensity was enhanced by the binding of the antibody to hCDH6 on cell surface.
  • the mIgG1 control binds to none of the cells.
  • the 786-O/hCDH6 stably expressing cell line more highly expresses human CDH6 than the parent line 786-O cells.
  • Labeled H01L02 and labeled NOV0712 were produced using an Alexa Fluor 488 Monoclonal Antibody Labeling Kit (Thermo Fisher Scientific Inc.).
  • the cell suspension of the 786-O/hCDH6 stably expressing cell line produced in 6)-2-2-1 was centrifuged, and the supernatant was then removed.
  • the cells were suspended by the addition of labeled NOV0712 or labeled H01L02 (final concentration: 5 nM) and, further, the addition of each of the 4 humanized hG019 antibodies (clone Nos: H01L02, H02L02, H02L03 and H04L02), which had been prepared in Example 5)-5-3, or the anti-CDH6 antibody NOV0712, which had been prepared in Reference Example 1, or human IgG1 (Calbiochem) as a negative control (final concentration: as shown in the abscissa of FIG. 7 ). The cells were left standing at 4° C. for 1 hour.
  • the cells were washed twice with PBS supplemented with 5% FBS, followed by detection using a flow cytometer (Canto II; BD Biosciences). The data was analyzed using FlowJo (TreeStar, Inc.). The results are shown in FIG. 7 .
  • the abscissa depicts the final concentration of the added unlabeled antibody, and the ordinate depicts the amount of the antibody bound based on mean fluorescence intensity.
  • unlabeled NOV0712 is added to cells supplemented with labeled NOV0712, the amount of the labeled antibody bound is decreased by replacement with the unlabeled antibody in an addition concentration-dependent manner because they compete with each other for binding to the same epitope.
  • humanized hG019 and NOV0712 The internalization activity of humanized hG019 and NOV0712 was evaluated using an anti-human IgG reagent Hum-ZAP (Advanced Targeting Systems) conjugated with a toxin (saporin) inhibiting protein synthesis.
  • human CDH6-positive ovarian tumor cell line NIH:OVCAR-3 (ATCC) was seeded at 4 ⁇ 10 3 cells/well on a 96-well plate, and then cultured overnight under conditions of 37° C. and 5% CO 2 .
  • Human CDH6-positive renal cell tumor cell line 786-O was seeded at 1 ⁇ 10 3 cells/well on a 96-well plate, and then cultured overnight.
  • Human CDH6-positive ovarian tumor cell line PA-1 (ATCC) was seeded at 1 ⁇ 10 3 cells/well on a 96-well plate, and then cultured overnight under conditions of 37° C. and 5% CO 2 . On the next day, each anti-CDH6 antibody (final concentration: 1 nM) or human IgG1 antibody (Calbiochem) as a negative control antibody was added to the plate.
  • Hum-ZAP final concentration: 0.5 nM
  • F(ab′)2 Fragment Goat Anti-human IgG, Fc (gamma) Fragment Specific (Jackson ImmunoResearch Laboratories, Inc.) unconjugated with the toxin (final concentration: 0.5 nM) as a negative control was further added to the plate, and the cells were cultured under conditions of 37° C. and 5% CO 2 for 3 days. The number of live cells was measured by the quantification of ATP activity (RLU) using CellTiter-GloTM Luminescent Cell Viability Assay.
  • Hum-ZAP is taken up into cells in a manner dependent on the internalization activity of the humanized anti-CDH6 antibody, so that saporin, which inhibits protein synthesis, is released into the cells, so as to suppress cell growth.
  • a cell growth inhibition effect brought about by the addition of the anti-CDH6 antibody was indicated by a relative survival rate when the number of live cells in a well supplemented with the negative control instead of Hum-ZAP was defined as 100%.
  • FIG. 8 shows a table of the cell survival rate.
  • an antibody having strong internalization activity is considered to offer a low cell survival rate.
  • the 4 humanized hG019 antibodies have an internalization rate of approximately 50 to 75% predicted from the cell survival rates for all of the 3 cell lines.
  • the 4 humanized hG019 antibodies exhibit very high internalization activity and exhibit much higher internalization activity than that of NOV0712. From the mechanism of the medicinal effects of ADC, an antibody having higher internalization activity is considered to be more suitable as an ADC antibody.
  • a heavy chain designed by substituting the 71st tyrosine in the hH01 amino acid sequence described in Example 5)-2, with alanine was designated as hH11 and a heavy chain designed by substituting the 81st glutamine in the sequence with serine and the 123rd phenylalanine with alanine was designated as hH31.
  • the amino acid sequence of the hH11 heavy-chain variable region is shown in SEQ ID No: 55.
  • the nucleotide sequence encoding the amino acid sequence of SEQ ID No: 55 is shown in SEQ ID No: 56.
  • the amino acid sequence of the hH31 heavy-chain variable region is shown in SEQ ID No: 60.
  • the nucleotide sequence encoding the amino acid sequence of SEQ ID No: 60 is shown in SEQ ID No: 61.
  • a heavy chain was designed by substituting leucine residues at positions 234 and 235 (specified by the EU index) of the hH01 amino acid sequence described in Example 5)-2 with alanine residues (referred to herein as “hH01A”).
  • the antibody having hH01A and hL02 is designated as “H01L02A antibody” or “H01L02A”.
  • the antibody having hH11A and hL02 is designated as “H11L02A antibody” or “H11L02A”.
  • the antibody having hH31A and hL02 is designated as “H31L02A antibody” or “H31L02A”.
  • pCMA-G1LALA was constructed in the same manner as in Example 4)-1-2.
  • a DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the hH01A shown in SEQ ID No: 66 was synthesized (GENEART). Using an In-Fusion HD PCR cloning kit (Clontech Laboratories, Inc.), the synthesized DNA fragment was inserted into a site of pCMA-G1LALA that had been cleaved with the restriction enzyme BlpI, so as to construct a hH01A expression vector.
  • a DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the hH31A shown in SEQ ID No: 70 was synthesized (GENEART).
  • An hH31A expression vector was constructed in the same manner as in Example 7)-3-2.
  • Example 7)-2 Production was carried out in the same manner as in Example 4)-2-1. Using the light-chain expression vector constructed in Example 5)-5-2-1 and the heavy-chain expression vector constructed in Example 7)-3, combinations of an H chain expression vector and an L chain expression vector, i.e., H01L02A, H11L02A, H31L02A, which correspond to the combinations of H and L chains described in Example 7)-2, were obtained.
  • Example 8 In Vitro Evaluation of Humanized hG019 Variant Changed in Binding Affinity
  • the dissociation constant of a construct of each of H01L02A, H11L02A and H31L02A prepared in Example 7)-4 and human CDH6 was measured by using Biacore T200 (GE Healthcare Biosciences Corp.), according to a capture method, which comprises capturing the antigen as a ligand with Anti-histidine antibody immobilized by means of a His Capture Kit (manufactured by GE Healthcare Bioscience) and then measuring the dissociation constant using an antibody as an analyte.
  • CM5 manufactured by GE Healthcare Bioscience
  • the running buffer buffer containing 20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl 2 and 0.05% Surfactant P20 (pH7.4), was used.
  • a 1 ⁇ g/mL Recombinant Human Cadherin-6 (KCAD)/Fc Chimera (RD-SYSTEMS) was added at a rate of 10 ⁇ L/minute for 60 seconds, and a dilution series solution (0.11 to 81 ⁇ g/mL) of the antibody prepared in Example 7)-4 was then added at a flow rate of 30 ⁇ l/min for 180 seconds. Subsequently, the dissociation phase was monitored for 180 seconds.
  • An anti-LPS antibody was produced with reference to WO2015/046505.
  • the isotope of the anti-LPS antibody used in the Example is IgG1 (also referred to as an anti-LPS antibody).
  • the amino acid sequences of a light chain and heavy chain of the anti-LPS antibody used in the Example are shown in SEQ ID No: 72 and SEQ ID No: 73, respectively.
  • the resulting residue was extracted with ethyl acetate four times, and the organic layer was washed with brine and then dried over anhydrous sodium sulfate.
  • the resultant was distilled under reduced pressure, and the resulting residue (1-2) (27.9 g, 90%) was directly used for the subsequent reaction.
  • step 1 (1-2) To a solution of the compound obtained in step 1 (1-2) (27.9 g, 107 mmol) and imidazole (14.5 g, 214 mmol) in dichloromethane (300 mL), tert-butyldimethylsilyl chloride (24.2 g, 160 mmol) was added at room temperature, and the resultant was stirred at room temperature for 18 hours.
  • the reaction solution was washed with a saturated aqueous citric acid, a saturated aqueous sodium hydrogen carbonate, and brine, dried over anhydrous sodium sulfate, and then distilled under reduced pressure.
  • step 2 (1-3) To a solution of the compound obtained in step 2 (1-3) (32.5 g, 86.5 mmol) in ethanol (400 mL), 7.5% palladium carbon catalyst (moisture content: 54%, 5.00 g) was added at room temperature, and the resultant was stirred under a hydrogen atmosphere at room temperature for 6 hours. The reaction solution was filtered through Celite, and the filtrate was distilled under reduced pressure to afford the desired compound (1-4) (21.3 g, quantitative).
  • Step 4 [(6S)-6-( ⁇ [tert-Butyl(dimethyl)silyl]oxy ⁇ methyl)-5-azaspiro[2.4]hept-5-yl] (5-methoxy-2-nitro-4- ⁇ [tri(propan-2-yl)silyl]oxy ⁇ phenyl)methanone (1-5)
  • step 3 (1-4) a solution of the compound obtained in step 3 (1-4) (34.1 g, 141 mmol) and triethylamine (29.4 mL, 212 mmol) in dichloromethane (100 mL) was slowly added dropwise thereto. After the reaction solution was stirred at room temperature overnight, saturated aqueous sodium hydrogen carbonate was added to the reaction mixture, and the reaction mixture was extracted with chloroform. The organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate.
  • Step 5 (2-Amino-5-methoxy-4- ⁇ [tri(propan-2-yl)silyl]oxy ⁇ phenyl) [(6S)-6-( ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ methyl)-5-azaspiro[2.4]hept-5-yl]methanone (1-6)
  • step 4 To a solution of the compound obtained in step 4 (1-5) (55.0 g, 92.8 mmol) in ethanol (300 mL), 7.5% palladium carbon (10.0 g) was added under a nitrogen atmosphere. The nitrogen balloon was immediately replaced with a hydrogen balloon, and the reaction mixture was vigorously stirred under a hydrogen atmosphere at room temperature. After the raw materials disappeared, the reaction mixture was filtered, and the filtrate was distilled under reduced pressure to afford the desired compound (1-6) (52.2 g, 100%), which was directly used for the subsequent reaction.
  • Step 6 N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N-[4-( ⁇ [(2- ⁇ [(6S)-6-( ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ methyl)-5-azaspiro[2.4]hept-5-yl]carbonyl ⁇ -4-methoxy-5- ⁇ [tri(propan-2-yl)silyl]oxy ⁇ phenyl)carbamoyl]oxy ⁇ methyl)phenyl]-L-alaninamide (1-7)
  • step 5 (1-6) To a solution of the compound obtained in step 5 (1-6) (18.6 g, 33.0 mmol) and triethylamine (6.26 mL, 45.2 mmol) in THF (300 mL), triphosgene (4.22 g, 14.2 mmol) was slowly added on an ethanol-ice bath.
  • Step 7 N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N-[4-( ⁇ [(2- ⁇ [(6S)-6-(hydroxymethyl)-5-azaspiro[2.4]hept-5-yl]carbonyl ⁇ -4-methoxy-5- ⁇ [tri(propan-2-yl)silyl]oxy ⁇ phenyl)carbamoyl]oxy ⁇ methyl)phenyl]-L-alaninamide (1-8)
  • step 6 To a solution of the compound obtained in step 6 (1-7) (23.5 g, 24.3 mmol) in THF (50 mL), methanol (50 mL) and water (44 mL), acetic acid (200 mL) was added at room temperature. The reaction mixture was stirred at room temperature. After the raw materials disappeared, the reaction mixture was extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over anhydrous sodium sulfate.
  • Step 8 N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N- ⁇ 4-[( ⁇ [(11a′S)-11′-hydroxy-7′-methoxy-5′-oxo-8′- ⁇ [tri(propan-2-yl)silyl]oxy ⁇ -11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl ⁇ oxy)methyl]phenyl ⁇ -L-alaninamide (1-9)
  • Step 9 N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N- ⁇ 4-[( ⁇ [(11a′S)-11′- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -7′-methoxy-5′-oxo-8′- ⁇ [tri(propan-2-yl)silyl]oxy ⁇ -11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl ⁇ oxy)methyl]phenyl ⁇ -L-alaninamide (1-10)
  • step 8 To a solution of the compound obtained in step 8 (1-9) (12.0 g, 14.1 mmol) and 2,6-lutidine (6.58 mL, 56.5 mmol) in dichloromethane (200 mL), tert-butyldimethylsilyl trifluoromethylsulfonate (9.73 mL, 42.3 mmol) was slowly added dropwise under a nitrogen atmosphere at 0° C. After stirring under ice-cooling for 10 minutes, the ice bath was removed, and the reaction mixture was stirred at room temperature. After the raw materials disappeared, water was added to the reaction mixture, which was extracted with chloroform. The organic layer was washed with water and brine, and dried over anhydrous sodium sulfate.
  • Step 10 N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N- ⁇ 4-[( ⁇ [(11a′S)-11′- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -8′-hydroxy-7′-methoxy-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl ⁇ oxy)methyl]phenyl ⁇ -L-alaninamide (1-11)
  • step 9 To a solution of the compound obtained in step 9 (1-10) (8.12 g, 8.42 mmol) in N,N-dimethylformamide (90 mL) and water (2 mL), lithium acetate (0.611 g, 9.26 mmol) was added, and the resultant was stirred at room temperature. After the raw materials disappeared, water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over anhydrous sodium sulfate.
  • Step 1 N-[4-(11,12-Didehydrodibenzo[b,f]azocin-5 (6H)-yl)-4-oxobutanoyl]glycylglycine (2-2)
  • Step 2 (2R,11aS)-8-[(5-Bromopentyl)oxy]-2- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -7-methoxy-10- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -2,3-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11 (10H,11aH)-dione (3-3)
  • Step 4 (11aS)-8-[(5-Bromopentyl)oxy]-7-methoxy-10- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1H-pyrrolo[2,1-c][1,4]benzodiazepin-2,5,11 (3H,10H,11aH)-trione (3-5)
  • step 3 (3-4) The compound obtained in step 3 (3-4) (11.3 g, 20.2 mmol), tetrabutylammonium bromide (0.325 g, 1.01 mmol), and potassium bromide (0.240 g, 2.02 mmol) were dissolved in a saturated aqueous sodium hydrogen carbonate (60 mL)/dichloromethane (60 mL), to which nor-AZADO (0.0279 g, 0.202 mmol) and sodium hypochlorite pentahydrate (2.03 g, 27.2 mmol) were added at 0° C., and the resultant was stirred at 0° C. for 30 minutes.
  • nor-AZADO 0.279 g, 0.202 mmol
  • sodium hypochlorite pentahydrate 2.03 g, 27.2 mmol
  • sodium hypochlorite pentahydrate (1.00 g, 13.4 mmol) was added thereto at 0° C., and the resultant was stirred at 0° C. for 15 minutes.
  • Sodium hypochlorite pentahydrate (0.300 g, 4.03 mmol) was further added thereto at 0° C., and the resultant was stirred at 0° C. for 15 minutes, and the disappearance of the raw materials was confirmed by TLC.
  • An aqueous solution of sodium thiosulfate was added to the reaction solution, which was extracted with chloroform, and the organic layer obtained was dried over sodium sulfate.
  • Step 5 (11aS)-8-[(5-Bromopentyl)oxy]-7-methoxy-5,11-dioxo-10- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl trifluoromethanesulfonate (3-6)
  • step 4 (3-5) To a solution of the compound obtained in step 4 (3-5) (9.74 g, 17.5 mmol) in dichloromethane (160 mL), 2,6-lutidine (8.17 mL, 70.1 mmol) was added at ⁇ 40° C., and the resultant was stirred at ⁇ 40° C. for 10 minutes. Anhydrous trifluoromethanesulfonic acid (8.85 mL, 52.6 mmol) was added to the reaction solution at ⁇ 40° C., and the resultant was stirred at ⁇ 40° C. for 30 minutes. To the reaction solution, a 10% aqueous solution of citric acid was added, which was extracted with chloroform, and the organic layer obtained was dried over sodium sulfate.
  • Step 6 (11aS)-8-[(5-Bromopentyl)oxy]-7-methoxy-2-(4-methoxyphenyl)-10- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11 (10H,11aH)-dione (3-7)
  • Step 7 (11aS)-8-[(5-Bromopentyl)oxy]-7-methoxy-2-(4-methoxyphenyl)-1, 11a-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (3-8)
  • step 6 The compound obtained in step 6 (3-7) (0.789 g, 1.22 mmol) was dissolved in ethanol (10 mL) and THF (10 mL), and 2.0 M tetrahydrofuran solution of lithium borohydride (6.11 mL, 12.2 mmol) was added thereto at 0° C., and the resultant was stirred at 0° C. for 3 hours. Water was added to the reaction solution, which was extracted with chloroform, and the organic layer obtained was dried over sodium sulfate.
  • the resultant was distilled under reduced pressure, and the resulting residue was dissolved in dichloromethane (10 mL), ethanol (20 mL) and water (10 mL), to which silica gel (4 g) was added at room temperature, and the resultant was stirred at room temperature for 4 days.
  • the silica gel was removed through filtration, and water was added thereto, and the resultant was extracted with chloroform.
  • the organic layer obtained was dried over sodium sulfate.
  • Step 8 (11aS)-8-[(5-Bromopentyl)oxy]-7-methoxy-2-(4-methoxyphenyl)-1,10,11,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (3-9)
  • Step 9 Prop-2-en-1-yl (11aS)-8-[(5-bromopentyl)oxy]-7-methoxy-2-(4-methoxyphenyl)-5-oxo-11,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-10 (5H)-carboxylate (3-10)
  • step 8 To a solution of the compound obtained in step 8 (3-9) (0.426 g, 0.849 mmol) in dichloromethane (30 mL), pyridine (0.102 mL 1.27 mmol) and allyl chloroformate (0.374 mL, 3.54 mmol) were added at 0° C., and the resultant was stirred at 0° C. for 15 minutes. To the reaction solution, a 10% aqueous solution of citric acid was added, which was extracted with chloroform, and the organic layer obtained was washed with a saturated aqueous sodium hydrogen carbonate, and then dried over sodium sulfate.
  • Step 10 N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N- ⁇ 4-[( ⁇ [(11a′S)-11′- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -7′-methoxy-8′- ⁇ [5-( ⁇ (11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-[(prop-2-en-1-yloxy)carbonyl]-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl ⁇ oxy)pentyl]oxy ⁇ -5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl ⁇ oxy)methyl]phenyl ⁇ -L-a
  • Step 11 N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N- ⁇ 4-[( ⁇ [(11a′S)-11′-hydroxy-7′-methoxy-8′- ⁇ [5-( ⁇ (11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-[(prop-2-en-1-yloxy)carbonyl]-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl ⁇ oxy)pentyl]oxy ⁇ -5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl ⁇ oxy)methyl]phenyl ⁇ -L-alaninamide (3-12)
  • step 10 To a solution of the compound obtained in step 10 (3-11) (0.1837 g, 0.140 mmol) and acetic acid (0.048 mL, 0.840 mmol) in THF (5.00 mL), a 1 mol/L tetrahydrofuran solution of tetrabutylammonium fluoride (0.700 mL, 0.700 mmol) was added at room temperature, and the resultant was stirred at room temperature for 3 hours. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with a saturated aqueous sodium hydrogen carbonate and brine, and then dried over sodium sulfate.
  • Step 12 L-Valyl-N- ⁇ 4-[( ⁇ [(11a′S)-11′-hydroxy-7′-methoxy-8′-[(5- ⁇ [(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy ⁇ pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl ⁇ oxy)methyl]phenyl ⁇ -L-alaninamide (3-13)
  • Step 13 N-[4-(11,12-Didehydrodibenzo[b,f]azocin-5 (6H)-yl)-4-oxobutanoyl]glycylglycyl-L-valyl-N- ⁇ 4-[( ⁇ [(11a′S)-11′-hydroxy-7′-methoxy-8′-[(5- ⁇ [(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy ⁇ pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl ⁇ oxy)methyl]phenyl ⁇ -L-a
  • Step 1 (2R,11aS)-8-(3-Bromopropoxy)-2- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -7-methoxy-10- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -2,3-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11 (10H,11aH)-dione (4-1)
  • Step 2 (2R,11aS)-8-(3-Bromopropoxy)-2-hydroxy-7-methoxy-10- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -2,3-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11 (10H,11aH)-dione (4-2)
  • step 1 The compound obtained in step 1 (4-1) (4.85 g, 7.54 mmol) was reacted in the same manner as in step 3 of Example 10-3 to afford the desired compound (4-2) (4.05 g, quantitative).
  • Step 3 (11aS)-8-(3-Bromopropoxy)-7-methoxy-10- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1H-pyrrolo[2,1-c][1,4]benzodiazepin-2,5,11 (3H,10H,11aH)-trione (4-3)
  • step 2 The compound obtained in step 2 (4-2) (7.54 mmol) was reacted in the same manner as in step 4 of Example 10-3 to afford the desired compound (4-3) (3.73 g, 93%).
  • Step 4 (11aS)-8-(3-Bromopropoxy)-7-methoxy-5,11-dioxo-10- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl trifluoromethanesulfonate (4-4)
  • step 3 The compound obtained in step 3 (4-3) (3.73 g, 7.08 mmol) was reacted in the same manner as in step 5 of Example 10-3 to afford the desired compound (4-4) (3.27 g, 70%).
  • Step 5 (11aS)-8-(3-Bromopropoxy)-7-methoxy-2-(4-methoxyphenyl-10- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11 (10H,11aH)-dione (4-5)
  • step 4 (4-4) (3.27 g, 4.96 mmol) was reacted in the same manner as in step 6 of Example 10-3 to afford the desired compound (4-5) (2.49 g, 81%).
  • Step 6 (11aS)-8-(3-Bromopropoxy)-7-methoxy-2-(4-methoxyphenyl)-1, 11a-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (4-6)
  • step 5 (4-5) (2.49 g, 4.04 mmol) was reacted in the same manner as in step 7 of Example 10-3 to afford the desired compound (4-6) (1.59 g, 84%).
  • Step 7 (11aS)-8-(3-Bromopropoxy)-7-methoxy-2-(4-methoxyphenyl)-1,10,11,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (4-7)
  • step 6 (4-6) The compound obtained in step 6 (4-6) (1.59 g, 3.38 mmol) was reacted in the same manner as in step 8 of Example 10-3 to afford the desired compound (4-7) (1.39 g, 87%).
  • Step 8 Prop-2-en-1-yl (11aS)-8-(3-bromopropoxy)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-11,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-10 (5H)-carboxylate (4-8)
  • step 7 The compound obtained in step 7 (4-7) (1.40 g, 0.2.95 mmol) was reacted in the same manner as in step 9 of Example 10-3 to afford the desired compound (4-8) (0.885 g, 54%).
  • Step 9 N- ⁇ [(Prop-2-en-1-yl)oxy]carbonyl ⁇ -L-valyl-N-[4-( ⁇ [(11′aS)-11′- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -7′-methoxy-8′-(3- ⁇ [(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10- ⁇ [(prop-2-en-1-yl)oxy]carbonyl ⁇ -5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy ⁇ propoxy)-5′-oxo-11′,11′a-dihydro-1′H,3′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carbonyl]oxy ⁇ methyl)phenyl]-L-alan
  • step 8 The compound obtained in step 8 (4-8) (0.0381 g, 0.0683 mmol) was reacted with the compound obtained in the step 10 of Example 10-1 (1-11) (0.0552 g, 0.0683 mmol) in the same manner as in step 10 of Example 10-3 to afford the desired compound (4-9) (0.0712 g, 81%).
  • Step 10 N- ⁇ [(Prop-2-en-1-yl)oxy]carbonyl ⁇ -L-valyl-N-[4-( ⁇ [(11′aS)-11′-hydroxy-7′-methoxy-8′-(3- ⁇ [(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10- ⁇ [(prop-2-en-1-yl)oxy]carbonyl ⁇ -5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy ⁇ propoxy)-5′-oxo-11′,11′a-dihydro-1′H,3′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carbonyl]oxy ⁇ methyl)phenyl]-L-alaninamide (4-10)
  • step 9 The compound obtained in step 9 (4-9) (0.0712 g, 0.0554 mmol) was reacted in the same manner as in step 11 of Example 10-3 to afford the desired compound (4-10) (0.0671 g, quantitative).
  • Step 11 L-Valyl-N-[4-( ⁇ [(11′aS)-11′-hydroxy-7′-methoxy-8′-(3- ⁇ [(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy ⁇ propoxy)-5′-oxo-11′,11′a-dihydro-1′H,3′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carbonyl]oxy ⁇ methyl)phenyl]-L-alaninamide (4-11)
  • step 10 The compound obtained in step 10 (4-10) (0.0571 mmol) was reacted in the same manner as in step 12 of Example 10-3 to afford the desired compound (4-11) (0.0574 g, 99%).
  • Step 12 N-[4-(11,12-Didehydrodibenzo[b,f]azocin-5 (6H)-yl)-4-oxobutanoyl]glycylglycyl-L-valyl-N-[4-( ⁇ [(11′aS)-11′-hydroxy-7′-methoxy-8′-(3- ⁇ [(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy ⁇ propoxy)-5′-oxo-11′,11′a-dihydro-1′H,3′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carbonyl]oxy ⁇ methyl)phenyl]-L-alaninamide (4-12
  • step 11 The compound obtained in step 11 (4-11) (0.189 g, 0.189 mmol) was reacted with the compound obtained in the step 1 of Example 10-2 (2-2) (0.087 g, 0.207 mmol) in the same manner as in step 13 of Example 10-3 to afford the desired compound (4-12) (0.169 g, 64%).
  • Step 1 Dimethyl(65,6′S)-5,5′- ⁇ 1,5-pentanediylbis[oxy(5-methoxy-2-nitrobenzen-4,1-diyl)carbonyl] ⁇ bis(5-azaspiro[2.4]heptane-6-carboxylate) (5-2)
  • Step 2 ⁇ 1,5-Pentanediylbis[oxy(5-methoxy-2-nitrobenzen-4,1-diyl)] ⁇ bis ⁇ [(6S)-6-(hydroxymethyl)-5-azaspiro[2.4]hept-5-yl]methanone ⁇ (5-3)
  • step 1 (5-2) To a solution of the compound obtained in step 1 (5-2) (8.40 g, 10.9 mmol) in THF (100 mL), lithium borohydride (714 mg, 32.8 mmol) was added, and the resultant was stirred at 0° C. for 30 minutes, and the temperature was raised to room temperature, and stirring was performed for 1 hour. After 1 N hydrochloric acid was added at 0° C., the resultant was extracted with ethyl acetate, and washed with brine, and then dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to afford the desired compound (5-3) (7.70 g, 99%).
  • Step 3 Pentane-1,5-diylbis[oxy(5-methoxy-2-nitrobenzen-4,1-diyl)carbonyl (6S)-5-azaspiro[2.4]heptan-5,6-diylmethanediyl] diazetate (5-4)
  • step 2 The compound obtained in step 2 (5-3) (7.70 g, 10.8 mmol) was dissolved in pyridine (20 mL) and acetic anhydride (10 mL, 105.9 mmol), which was stirred at room temperature. The resultant was distilled under reduced pressure to afford the desired compound (5-4) (8.38 g, 97%).
  • Step 4 1,5-Pentanediylbis[oxy(2-amino-5-methoxybenzen-4,1-diyl)carbonyl (6S)-5-azaspiro[2.4]heptan-5,6-diylmethanediyl] diacetate (5-5)

Abstract

An object of the present invention is to provide an antibody specifically binding to CDH6 and having a high internalization activity, an antibody-drug conjugate comprising the antibody and a high antitumor activity, a pharmaceutical product having the antibody-drug conjugate and having a therapeutic effect on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like.According to the present invention, it is possible to provide an anti-CDH6 antibody prepared having internalization activity, an anti-CDH6 antibody-drug conjugate prepared by connecting the anti-CDH6 antibody and a novel PBD derivative and exhibiting high anti-tumor activity, a pharmaceutical product and a therapeutic method for treating tumors using these.

Description

    TECHNICAL FIELD
  • The present invention relates to an antibody-drug conjugate useful as an antitumor drug, obtained by connecting an anti-CDH6 antibody, which binds to CDH6 and has an internalization effect, and a pyrrolobenzodiazepine derivative via a linker structure moiety.
    • BACKGROUND ART
  • Cadherins are glycoproteins present on the surface of cell membranes and function as cell-cell adhesion molecules through the calcium ion-dependent binding of their N-terminal extracellular domains, or as signal molecules responsible for cell-cell interaction. Classic cadherins are in the cadherin superfamily and are single-pass transmembrane proteins composed of five extracellular domains (EC domains), one transmembrane region, and an intracellular domain. The classic cadherins are classified into the type I family typified by E-cadherin and N-cadherin, and the type II family according to the homologies of their amino acid sequences.
  • Cadherin-6 (CDH6) is a single-pass transmembrane protein composed of 790 amino acids, which is classified into the type II cadherin family, and this protein has N-terminal extracellular and C-terminal intracellular domains. The human CDH6 gene was cloned for the first time in 1995 (Non Patent Literature 1), and its sequence can be referred to under, for example, accession Nos. NM_004932 and NP_004923 (NCBI).
  • CDH6 is specifically expressed in the brain and the kidney during development and has been reported to play an important role in the circuit formation of the central nervous system (Non Patent Literature 2 and 3) and nephron development in the kidney (Non Patent Literature 4 and 5). The expression of CDH6 in the normal tissues of adult humans is localized to the tubules of the kidney, bile duct epithelial cells, and the like.
  • Meanwhile, it is known that CDH6 is specifically overexpressed at tumor sites in some types of human adult cancers. The correlation of CDH6 expression with poor prognosis and its applicability as a tumor marker has been reported with respect to human renal cell carcinoma, particularly, renal clear cell carcinoma (Non Patent Literature 6 and 7). The high expression of CDH6 has also been reported with respect to human ovarian cancer (Non Patent Literature 8). It has also been reported that CDH6 is involved in the epithelial-mesenchymal transition of human thyroid cancer (Non Patent Literature 9). Furthermore, it has been reported that CDH6 is also expressed in human bile duct cancer and human small-cell lung cancer (Non Patent Literature 12 and 13).
  • Cancers rank high in causes of death. Although the number of cancer patients is expected to increase with aging of the population, treatment needs have not yet been sufficiently satisfied. The problems of conventional chemotherapeutics are that: due to their low selectivity, these chemotherapeutics are toxic not only to tumor cells but also to normal cells and thereby have adverse reactions; and the chemotherapeutics cannot be administered in sufficient amounts and thus cannot produce their effects to a sufficient degree. Hence, in recent years, more highly selective molecular target drugs or antibody drugs have been developed, which target molecules that exhibit mutations or a high expression characteristic in cancer cells, or specific molecules involved in malignant transformation of cells.
  • Antibodies are highly stable in blood, and specifically bind to their target antigens. For these reasons, a reduction in adverse reactions is expected, and a large number of antibody drugs have been developed for molecules highly expressed on the surface of cancer cells. One of the techniques that relies on the antigen-specific binding ability of antibodies is the use of an antibody-drug conjugate (ADC). An ADC is a conjugate in which an antibody that binds to an antigen expressed on the surface of cancer cells and can internalize the antigen into the cell through such binding is conjugated to a drug having cytotoxic activity. An ADC can efficiently deliver the drug to cancer cells, and can thereby be expected to kill the cancer cells by accumulating the drug in the cancer cells (Non Patent Literature 10 and Patent Literature 1 and 2). With regard to ADCs, Adcetris™ (brentuximab vedotin) comprising an anti-CD30 monoclonal antibody conjugated to monomethyl auristatin E has, for example, been approved as a therapeutic drug for Hodgkin's lymphoma and anaplastic large cell lymphoma. Also, Kadcyla™ (trastuzumab emtansine) comprising an anti-HER2 monoclonal antibody conjugated to emtansine is used in the treatment of HER2-positive progressive or recurrent breast cancer.
  • The features of a target antigen suitable for an ADC as an antitumor drug are that: the antigen is specifically highly expressed on the surface of cancer cells but has low expression or is not expressed in normal cells; the antigen can be internalized into cells; the antigen is not secreted from the cell surface; etc. Furthermore, the important features of an antibody suitable for an ADC are that the antibody has high internalization ability in addition to specifically binding to the target antigen. The internalization ability of the antibody depends on the properties of both the target antigen and the antibody. It is difficult to predict an antigen-binding site suitable for internalization from the molecular structure of a target or to predict an antibody having high internalization ability from binding strength, physical properties, and the like of the antibody. Hence, an important challenge in developing an ADC having high efficacy is obtaining an antibody having high internalization ability against the target antigen (Non Patent Literature 11).
  • An ADC comprising DM4 conjugated to an anti-CDH6 antibody specifically binding to EC domain 5 (EC5) of CDH6 is known as an ADC targeting CDH6 (Patent Literature 3).
  • Useful examples of drugs to be conjugated for ADCs are pyrrolobenzodiazepines (PBDs). PBDs exhibit cytotoxicity, for example, by binding to the PuGPu sequence in the DNA minor groove. Anthramycin, a naturally-occurring PBD, was first discovered in 1965, and since this discovery various naturally-occurring PBDs and PBD analogs thereof have been discovered (Non Patent Literatures 14 to 17).
  • The general structural formula of PBDs is represented by the following formula:
  • Figure US20220016257A1-20220120-C00001
  • Known are PBDs different in the number of, types of, and sites of substituents in the A and C ring parts, and those different in degree of unsaturation in the B and C ring parts.
  • PBDs are known to exhibit dramatically enhanced cytotoxicity through the formation of a dimer structure (Non Patent Literatures 18, 19), and various ADCs with a dimer PBD have been reported (Patent Literatures 4 to 16). However, a PBD having a spiro ring at its C2-position and an ADC form thereof have not been known.
    • CITATION LIST Patent Literatures
    • Patent Literature 1: WO2014/057687
    • Patent Literature 2: US2016/0297890
    • Patent Literature 3: WO2016/024195
    • Patent Literature 4: WO2013/173496
    • Patent Literature 5: WO2014/130879
    • Patent Literature 6: WO2017/004330
    • Patent Literature 7: WO2017/004025
    • Patent Literature 8: WO2017/020972
    • Patent Literature 9: WO2016/036804
    • Patent Literature 10: WO2015/095124
    • Patent Literature 11: WO2015/052322
    • Patent Literature 12: WO2015/052534
    • Patent Literature 13: WO2016/115191
    • Patent Literature 14: WO2015/052321
    • Patent Literature 15: WO2015/031693
    • Patent Literature 16: WO2011/130613
    Non Patent Literatures
    • Non Patent Literature 1: Shimoyama Y, et al., Cancer Research, 2206-2211, 55, May 15, 1995
    • Non Patent Literature 2: Inoue T, et al., Developmental Biology, 183-194, 1997
    • Non Patent Literature 3: Osterhout J A, et al., Neuron, 632-639, 71, Aug. 25, 2011
    • Non Patent Literature 4: Cho E A, et al., Development, 803-812, 125, 1998
    • Non Patent Literature 5: Mah S P, et al., Developmental Biology, 38-53, 223, 2000
    • Non Patent Literature 6: Paul R, et al., Cancer Research, 2741-2748, July 1, 57, 1997
    • Non Patent Literature 7: Shimazui T, et al., Cancer, 963-968, 101(5), Sep. 1, 2004
    • Non Patent Literature 8: Koebel M, et al., PLoS Medicine, 1749-1760, 5(12), e232, December 2008
    • Non Patent Literature 9: Gugnoni M, et al., Oncogene, 667-677, 36, 2017
    • Non Patent Literature 10: Polakis P., Pharmacological Reviews, 3-19, 68, 2016
    • Non Patent Literature 11: Peters C, et al., Bioscience Reports, 1-20, 35, 2015
    • Non Patent Literature 12: Goeppert B, et al., Epigenetics, 780-790, 11(11), 2016
    • Non Patent Literature 13: Yokoi S, et al., American Journal of Pathology, 207-216, 161, 1, 2002
    • Non Patent Literature 14: Julia Mantaj, et al., Angewandte Chemie International Edition 2016, 55, 2-29
    • Non Patent Literature 15: Dyeison Antonow et. al., Chemical Reviews 2010, 111, 2815-2864
    • Non Patent Literature 16: In Antibiotics III. Springer Verlag, New York, pp. 3-11
    • Non Patent Literature 17: Accounts of Chemical Research 1986, 19, 230
    • Non Patent Literature 18: Journal of the American Chemical Society 1992, 114, 4939
    • Non Patent Literature 19: Journal of Organic Chemistry 1996, 61, 8141
    SUMMARY OF INVENTION Technical Problem
  • It is an object of the present invention to provide an antibody specifically binding to CDH6 and having high internalization activity, an antibody-drug conjugate comprising the antibody and having high antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like.
    • Solution to Problem
  • The present inventors have conducted intensive studies directed towards achieving the above-described object, and found that, surprisingly, an antibody specifically binding to extracellular domain 3 (in the present description, also referred to as EC3) of CDH6 has exceedingly high internalization activity against cells expressing CDH6 and is useful as an antibody for ADCs. The present inventors also succeeded in obtaining an anti-CDH6 antibody-drug conjugate by connecting the anti-CDH6 antibody to a novel PBD derivative, and found that the anti-CDH6 antibody-drug conjugate has strong antitumor activity.
  • The present invention relates to the following.
  • [1] An antibody-drug conjugate represented by the following formula (X):
  • Figure US20220016257A1-20220120-C00002
  • wherein m2 represents an integer of 1 or 2,
  • Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof,
  • L represents a linker linking a glycan bonding to N297 of Ab (N297 glycan) and D,
  • N297 glycan may be a remodeled glycan, and
  • D is any one of the following formulas:
  • Figure US20220016257A1-20220120-C00003
  • wherein the asterisk (*) represents bonding to L.
  • [2] The antibody-drug conjugate according to [1], wherein the antibody or a functional fragment thereof exhibits competitive inhibitory activity, for binding to the amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4, against at least any one antibody selected from the group consisting of the following antibodies (1) to (8):
  • (1) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 23 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 26,
  • (2) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 39,
  • (3) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43,
  • (4) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43,
  • (5) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 47,
  • (6) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65,
  • (7) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67, and
  • (8) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
  • [3] The antibody-drug conjugate according to [1] or [2], wherein the antibody or a functional fragment thereof comprises CDRL1, CDRL2 and CDRL3; and CDRH1, CDRH2 and CDRH3 selected from the group consisting of the following (1) to (4):
  • (1) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14; and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 18 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19,
  • (2) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14; and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 30 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19,
  • (3) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14; and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59, and
  • (4) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14 and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 62, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 63 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 64.
  • [4] The antibody-drug conjugate according to any one of [1] to [3], wherein the antibody or a functional fragment thereof comprises any one light chain variable region selected from the group consisting of the following variable regions (1) to (4):
  • (1) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33,
  • (2) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 37,
  • (3) an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region except CDR sequences in the amino acid sequence of (1) or (2) and
  • (4) an amino acid sequence having a deletion, substitution or addition of one or several amino acids in the sequence of a framework region except CDR sequences in the amino acid sequences of (1) to (3); and
  • any one heavy chain variable region selected from the group consisting of the following variable regions (5) to (11):
  • (5) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 41,
  • (6) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 45,
  • (7) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 49,
  • (8) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 55,
  • (9) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 60,
  • (10) an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region other than at each CDR sequence in the amino acid sequences of (5) to (9), and
  • (11) an amino acid sequence having a deletion, substitution or addition of one or several amino acids in the sequence of a framework region other than at each CDR sequence in the amino acid sequences of (5) to (10).
  • [5] The antibody-drug conjugate according to any one of [1] to [4], wherein the antibody or a functional fragment thereof comprises any one of the following (1) to (6):
  • (1) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 41,
  • (2) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 45,
  • (3) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 37 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 45,
  • (4) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 49,
  • (5) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 55, and
  • (6) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 60.
  • [6] The antibody-drug conjugate according to any one of [1] to [5], wherein the antibody or a functional fragment thereof has any one of the following (1) to (7):
  • (1) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 39,
  • (2) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43,
  • (3) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43,
  • (4) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 47,
  • (5) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65,
  • (6) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67, and
  • (7) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
  • [7] The antibody-drug conjugate according to [6], wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 39.
  • [8] The antibody-drug conjugate according to [6], wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43.
  • [9] The antibody-drug conjugate according to [6], wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43.
  • [10] The antibody-drug conjugate according to [6], wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 47.
  • [11] The antibody-drug conjugate according to [6], wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65
  • [12] The antibody-drug conjugate according to [6], wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67.
  • [13] The antibody-drug conjugate according to [6], wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
  • [14] The antibody-drug conjugate according to any one of [1] to [13], wherein
  • L is represented by -Lb-La-Lp-NH—B—CH2—O(C═O)—*, wherein the asterisk * represents bonding to the nitrogen atom at the N10′-position of D,
  • B represents a 1,4-phenyl group, a 2,5-pyridyl group, a 3,6-pyridyl group, a 2,5-pyrimidyl group or a 2,5-thienyl group,
  • Lp represents any one selected from the group consisting of:
    • -GGVA-, -GG-(D-)VA-, -VA-, -GGFG-, -GGPI-, -GGVCit-, -GGVK- and -GGPL-,
  • La represents any one selected from the group consisting of:
  • —C(═O)—CH2CH2—C(═O)—,
    —C(═O)—(CH2CH2)2—C(═O)—,
    —C(═O)—CH2CH2—C(═O)—NH—(CH2CH2)2—C(═O)—,
    —C(═O)—CH2CH2—C(═O)—NH—(CH2CH2O)2—CH2—C(═O)—,
    —C(═O)—CH2CH2—NH—C(═O)—(CH2CH2O)4—CH2CH2—C(═O)—,
    • —CH2—OC(═O)— and —OC(═O)—,
  • and
  • Lb represents the following formula:
  • Figure US20220016257A1-20220120-C00004
  • wherein, in each structural formula of Lb shown above, each asterisk * represents bonding to La and each wavy line represents bonding to the glycan presented by Ab or a remodeled glycan.
  • [15] The antibody-drug conjugate according to any one of [1] to [14], wherein L represents any one selected from the group consisting of the following structural formulas:
    • —Z1—C(═O)—CH2CH2—C(═O)-GGVA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GG-(D-) VA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—(CH2CH2)2—C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GGPI-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GGFG-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GGVCit-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GGVK-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GGPL-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)—NH—(CH2CH2)2—C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)—NH—(CH2CH2O)2—CH2—C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—NH—C(═O)—(CH2CH2O)4—CH2CH2—C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z2—OC(═O)-GGVA-NH—B—CH2—OC(═O)— and
    • —Z3—CH2—OC(═O)-GGVA-NH—B—CH2—OC(═O)—
      wherein Z1 represents the following structural formula:
  • Figure US20220016257A1-20220120-C00005
  • Z2 represents the following structural formula:
  • Figure US20220016257A1-20220120-C00006
  • Z3 represents the following structural formula:
  • Figure US20220016257A1-20220120-C00007
  • wherein in each structural formula for Z1, Z2 and Z3, each asterisk * represents bonding to the C(═O), O or CH2 neighboring Z1, Z2 or Z3; each wavy line represents bonding to the glycan presented by Ab or a remodeled glycan, and
  • B represents a 1,4-phenyl group.
  • [16] The antibody-drug conjugate according to any one of [1] to [15], wherein L represents any one selected from the group consisting of:
    • —Z1—C(═O)—CH2CH2—C(═O)-GGVA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—(CH2CH2)2—C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GGVCit-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)—NH—(CH2CH2)2—C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)—NH—(CH2CH2O)2—CH2—C(═O)-VA-NH—B—CH2—OC(═O)— and
    • —Z1—C(═O)—CH2CH2—NH—C(═O)—(CH2CH2O)4—CH2CH2—C(═O)-VA-NH—B—CH2—OC(═O)—,
      wherein B represents a 1,4-phenyl group, and Z1 represents the following structural formula:
  • Figure US20220016257A1-20220120-C00008
  • wherein, in the structural formula for Z1, each asterisk * represents bonding to the C(═O) neighboring Z1, and each wavy line represents bonding to the glycan bonding to N297 of Ab (N297 glycan) or bonding to a remodeled glycan.
  • [17] The antibody-drug conjugate according to any one of [1] to [16], wherein the antibody is IgG1, IgG2 or IgG4.
  • [18] The antibody-drug conjugate according to any one of [1] to [17], wherein the N297 glycan is a remodeled glycan.
  • [19] The antibody-drug conjugate according to any one of [1] to [18], wherein the N297 glycan is N297-(Fuc)MSG1, N297-(Fuc)MSG2, or a mixture thereof, or N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
  • Figure US20220016257A1-20220120-C00009
  • wherein the wavy line represents bonding to Asn297 of the antibody,
  • *-L (PEG)- in the N297 glycan represents *—(CH2CH2-0)n5-CH2CH2—NH—, wherein n5 represents an integer of 2 to 5, the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the 03-Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the individual structural formulas.
  • [20] The antibody-drug conjugate according to [19], wherein n3 represents 3.
  • [21] An antibody-drug conjugate represented by the following formula (XII):
  • Figure US20220016257A1-20220120-C00010
  • wherein, in each structural formula shown above,
  • m2 represents an integer of 1 or 2,
  • Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof,
  • the N297 glycan of Ab represents any one of N297-(Fuc)MSG1, N297-(Fuc)MSG2, and a mixture thereof, and N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
  • Figure US20220016257A1-20220120-C00011
  • wherein each wavy line represents bonding to Asn297 (N297) of the antibody,
  • *-L(PEG)- in the N297 glycan represents *—(CH2CH2—O)3—CH2CH2—NH—, wherein
  • the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the 0-Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the corresponding structural formula.
  • [22] The antibody-drug conjugate according to [21], wherein the compound represented by formula (XII) is represented by the following formula (XII′):
  • Figure US20220016257A1-20220120-C00012
  • An antibody-drug conjugate represented by the following formula (XIII):
  • Figure US20220016257A1-20220120-C00013
  • wherein, in each structural formula shown above,
  • m2 represents an integer of 1 or 2,
  • Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof, and
  • the N297 glycan of Ab represents any one of N297-(Fuc)MSG1, N297-(Fuc)MSG2, and a mixture thereof, and N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
  • Figure US20220016257A1-20220120-C00014
  • wherein each wavy line represents bonding to Asn297 (N297) of the antibody,
  • *-L(PEG)- in the N297 glycan represents *—(CH2CH2—O)3—CH2CH2—NH—, wherein the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the β-Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the individual structural formulas.
  • [24] The antibody-drug conjugate according to [23], wherein the compound represented by formula (XIII) is represented by the following formula (XIII′):
  • Figure US20220016257A1-20220120-C00015
  • An antibody-drug conjugate represented by the following formula (XIV):
  • Figure US20220016257A1-20220120-C00016
  • wherein, in each structural formula shown above,
  • m2 represents an integer of 1 or 2,
  • Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof, and
  • the N297 glycan of Ab represents any one of N297-(Fuc)MSG1, N297-(Fuc)MSG2, and a mixture thereof, and N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
  • Figure US20220016257A1-20220120-C00017
  • wherein each wavy line represents bonding to Asn297 (N297) of the antibody,
  • *-L(PEG)- in the N297 glycan represents *—(CH2CH2—O)3—CH2CH2—NH—, wherein the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the β-Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the individual structural formulas.
  • The antibody-drug conjugate according to [25], wherein the compound represented by formula (XIV) is represented by the following formula (XIV′):
  • Figure US20220016257A1-20220120-C00018
  • [27] An antibody-drug conjugate represented by the following formula (XV):
  • Figure US20220016257A1-20220120-C00019
  • wherein, in each structural formula shown above,
  • m2 represents an integer of 1 or 2,
  • Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof, and
  • the N297 glycan of Ab represents any one of N297-(Fuc)MSG1, N297-(Fuc)MSG2, and a mixture thereof, and N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
  • Figure US20220016257A1-20220120-C00020
  • wherein each wavy line represents bonding to Asn297 (N297) of the antibody,
  • *-L(PEG)- in the N297 glycan represents *—(CH2CH2—O)3—CH2CH2—NH—, wherein the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the β-Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the individual structural formulas.
  • The antibody-drug conjugate according to [27], wherein the compound represented by formula (XV) is represented by the following formula (XV′):
  • Figure US20220016257A1-20220120-C00021
  • [29] The antibody-drug conjugate according to any one of [21] to [28], wherein the antibody or a functional fragment thereof comprises CDRL1, CDRL2 and CDRL3 and CDRH1, CDRH2 and CDRH3 selected from the group consisting of the following (1) to (4):
  • (1) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14; and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 18 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19,
  • (2) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14; and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 30 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19,
  • (3) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14; and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59, and
  • (4) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14 and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 62, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 63 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 64.
  • [30] The antibody-drug conjugate according to any one of [21] to [29], wherein the antibody or a functional fragment thereof comprises any one of the following (1) to (6):
  • (1) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 41,
  • (2) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 45,
  • (3) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 37 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 45,
  • (4) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 49,
  • (5) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 55, and
  • (6) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 60.
  • [31] The antibody-drug conjugate according to any one of [21] to [30], wherein the antibody or a functional fragment thereof comprises any one of the following (1) to (7):
  • (1) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 39,
  • (2) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43,
  • (3) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43,
  • (4) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 47,
  • (5) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65,
  • (6) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67, and
  • (7) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
  • [32] The antibody-drug conjugate according to [31], wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 39.
  • [33] The antibody-drug conjugate according to [31], wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43.
  • [34] The antibody-drug conjugate according to [31], wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43.
  • [35] The antibody-drug conjugate according to [31], wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 47.
  • [36] The antibody-drug conjugate according to [31], wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65.
  • [37] The antibody-drug conjugate according to [31], wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67.
  • [38] The antibody-drug conjugate according to [31], wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
  • [39] The antibody-drug conjugate according to any one of [1] to [38], wherein the average number of conjugated drug molecules per antibody molecule in the antibody-drug conjugate is 1 to 3.
  • [40] The antibody-drug conjugate according to any one of [1] to [38], wherein the average number of conjugated drug molecules per antibody molecule in the antibody-drug conjugate is 3 to 5.
  • [41] The antibody-drug conjugate according to any one of [1] to [40], wherein the antibody contains a heavy chain having one or two or more modifications selected from the group consisting of N-linked glycosylation, 0-linked glycosylation, N-terminal processing, C-terminal processing, deamidation, isomerization of aspartic acid, oxidation of methionine, addition of a methionine residue to the N-terminus, amidation of a proline residue, and a deletion of one or two amino acids from the carboxyl terminus.
  • [42] The antibody-drug conjugate according to any one of [1] to [41], wherein the lysine residue at the carboxyl terminus of the heavy chain is deleted.
  • [43] A method for producing a glycan-remodeled antibody, the method comprising the steps of:
  • i) producing an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake or a functional fragment thereof,
  • ii) treating the antibody obtained in step i) with hydrolase to produce a (Fucα1,6)GlcNAc-antibody; and
  • iii)-1 reacting the (Fucα1,6)GlcNAc-antibody and a glycan donor molecule in the presence of a transglycosidase, the glycan donor molecule obtained by introducing a PEG linker having an azide group to the carbonyl group of carboxylic acid at the 2-position of a sialic acid in MSG (9) or SG (10) and oxazolinating the reducing terminal, or
  • iii)-2 reacting the (Fucα1,6)GlcNAc-antibody and a glycan donor molecule in the presence of a transglycosidase, the glycan donor molecule obtained by introducing a PEG linker having an azide group to the carbonyl group of carboxylic acid at the 2-position of a sialic acid in (MSG-)Asn or (SG-)Asn with an α-amino group optionally protected and to the carbonyl group of carboxylic acid in the Asn, causing action of hydrolase, and then oxazolinating the reducing terminal.
  • [44] A method for producing an antibody-drug conjugate according to any one of [1] to [42], comprising the step of reacting the glycan-remodeled antibody obtained by the method according to [43] and a drug linker.
  • [45] The antibody-drug conjugate according to any one of [1] to [42], produced by the method according to [44].
  • [46] An antibody or a functional fragment thereof, comprising a light chain variable region, which contains CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14, and a heavy chain variable region, which contains CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59.
  • [47] An antibody or a functional fragment thereof, comprising a light chain variable region, which contains CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14; and a heavy chain variable region, which contains CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 62, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 63 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 64.
  • [48] The antibody or a functional fragment thereof according to [46], comprising a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 55.
  • [49] The antibody or a functional fragment thereof according to [47], comprising a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 60.
  • [50] The antibody or a functional fragment thereof according to [46] or [48], having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67.
  • [51] The antibody or a functional fragment thereof according to [47] or [49], having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
  • [52] An antibody or a functional fragment thereof having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65.
  • [53] A polynucleotide encoding the antibody according to any one of [46] to [52].
  • [54] An expression vector containing the polynucleotide according to [53].
  • [55] A host cell transformed with the expression vector according to [54].
  • [56] A method for producing the antibody or a functional fragment thereof according to [46] to [52], comprising a step of culturing the host cell according to [55] and collecting the targeted antibody from the culture obtained from the step of culturing.
  • [57] An antibody or a functional fragment thereof, obtained by the method according to [56].
  • [58] A pharmaceutical composition containing the antibody-drug conjugate according to any one of [1] to [42] and [45] or the antibody or a functional fragment thereof according to any one of [46] to [52] and [57].
  • [59] The pharmaceutical composition according to [58], which is an antitumor drug.
  • [60] The pharmaceutical composition according to [59], wherein the tumor is a tumor expressing CDH6.
  • [61] The pharmaceutical composition according to [60], wherein the tumor is renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, bile duct cancer, lung cancer, small-cell lung cancer, non-small cell lung cancer, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor or neuroblastoma.
  • [62] A method for treating a tumor, which comprises administering the antibody-drug conjugate according to any one of [1] to [42] and [45], the antibody or a functional fragment thereof according to any one of [46] to [52] and [57] or the pharmaceutical composition according to any one of [58] to [61] to an individual.
  • [63] The treatment method according to [62], wherein the tumor is a tumor expressing CDH6.
  • [64] The treatment method according to [62] or [63], wherein the tumor is renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, bile duct cancer, lung cancer, small-cell lung cancer, non-small cell lung cancer, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor or neuroblastoma.
  • [65] The treatment method according to any one of [62] to [64], which comprises administering the antibody-drug conjugate according to any one of [1] to [42] and [45]; the antibody or a functional fragment thereof according to any one of [46] to [52] and [57]; or the pharmaceutical composition according to any one of [58] to [61] and at least one antitumor drug to an individual, simultaneously, separately or continuously.
    • Advantageous Effects of Invention
  • Features of the anti-CDH6 antibody of the present invention are to recognize EC domain 3 (EC3) of CDH6 specifically and to have high internalization activity. An anti-CDH6 antibody-drug conjugate, which is prepared by connecting the anti-CDH6 antibody of the present invention and a novel PBD derivative of the present invention via a linker, can be expected to achieve excellent antitumor effects and safety by administration to patients having cancer cells expressing CDH6. Specifically, the anti-CDH6 antibody-drug conjugate of the present invention is useful as an antitumor agent.
    • BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 shows flow cytometry results of examining the binding of each of rat anti-CDH6 monoclonal antibody rG019 and a negative control antibody rat IgG2b to control cells (shaded) or hCDH6 transfected 293T cells (open solid line). The abscissa depicts FITC fluorescence intensity indicating the amount of the antibody bound, and the ordinate depicts cell count.
  • FIG. 2-1 The figure (1) shows the binding activity of rat anti-CDH6 monoclonal antibody rG019 or negative control antibody Rat IgG2b against control cells (shaded) or full-length hCDH6-transfected 293 cells (open solid line). The figure (2) shows the binding activity of rat anti-CDH6 monoclonal antibody rG019 or negative control antibody Rat IgG2b against control cells (shaded) or EC1-deleted hCDH6-transfected 293 cells (open solid line). The figure (3) shows the binding activity of rat anti-CDH6 monoclonal antibody rG019 or negative control antibody Rat IgG2b against control cells (shaded) or EC2-deleted hCDH6-transfected 293 cells (open solid line). In the figures (1) to (3), the abscissa depicts FITC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 2-2 The figure (4) shows the binding activity of rat anti-CDH6 monoclonal antibody rG019 or negative control antibody Rat IgG2b against control cells (shaded) or EC3-deleted hCDH6-transfected 293 cells (open solid line). The figure (5) shows the binding activity of rat anti-CDH6 monoclonal antibody rG019 or negative control antibody Rat IgG2b against control cells (shaded) or EC4-deleted hCDH6-transfected 293 cells (open solid line). The figure (6) shows the binding activity of rat anti-CDH6 monoclonal antibody rG019 or negative control antibody Rat IgG2b against control cells (shaded) or EC5-deleted hCDH6-transfected 293 cells (open solid line). In the figures (4) to (6), the abscissa depicts FITC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 3 shows flow cytometry results of evaluating the expression of CDH6 on the cell membrane surface of 5 types of human tumor cell lines (human ovarian tumor cell lines NIH:OVCAR-3, PA-1, and OV-90 and human renal cell tumor cell line 786-O, Caki-1). The abscissa depicts FITC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count. The shaded histogram shows that the negative control mIgG1 was used in staining, and the open solid line histogram shows that the anti-human CDH6 antibody was used in staining.
  • FIG. 4 shows the binding of human chimeric anti-CDH6 antibody chG019 to human CDH6 and monkey CDH6. The abscissa depicts antibody concentration, and the ordinate depicts the amount of antibody bound based on mean fluorescence intensity.
  • FIG. 5-1 shows the binding activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control antibody hIgG1 against control cells (shaded) or full-length hCDH6-transfected 293α cells (open solid line). The abscissa depicts APC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 5-2 shows the binding activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control antibody hIgG1 against control cells (shaded) or EC1-deleted hCDH6-transfected 293α cells (open solid line). The abscissa depicts APC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 5-3 shows the binding activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control antibody hIgG1 against control cells (shaded) or EC2-deleted hCDH6-transfected 293α cells (open solid line). The abscissa depicts APC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 5-4 shows the binding activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control antibody hIgG1 against control cells (shaded) or EC3-deleted hCDH6-transfected 293α cells (open solid line). The abscissa depicts APC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 5-5 shows the binding activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control antibody hIgG1 against control cells (shaded) or EC4-deleted hCDH6-transfected 293α cells (open solid line). The abscissa depicts APC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 5-6 shows the binding activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control antibody hIgG1 against control cells (shaded) or EC5-deleted hCDH6-transfected 293α cells (open solid line). The abscissa depicts APC fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 6 shows flow cytometry results of examining the expression of human CDH6 in a 786-O/hCDH6 stably expressing cell line (open solid line) and its parent cell line 786-O (shaded). The abscissa depicts Alexa Fluor 647 fluorescence intensity indicating the amount of antibody bound, and the ordinate depicts cell count.
  • FIG. 7 shows the binding competition assay of four unlabeled humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 or negative control hIgG1 using labeled NOV0712 (upper stage) or labeled H01L02 (lower stage). The abscissa depicts the final concentration of the added unlabeled antibody, and the ordinate depicts the amount of antibody bound based on mean fluorescence intensity.
  • FIG. 8 shows the results on which the internalization activity of four humanized hG019 antibodies (H01L02, H02L02, H02L03 and H04L02), anti-CDH6 antibody NOV0712 and a negative control antibody was evaluated in NIH:OVCAR-3 cells, 786-O cells or PA-1 cells using anti-human IgG reagent Hum-ZAP conjugated with a toxin (saporin) inhibiting protein synthesis, or F(ab′)2 Fragment Goat Anti-human IgG, Fc (gamma) Fragment Specific unconjugated with the toxin as a negative control. A cell survival rate (%), calculated as a relative survival rate when the number of live cells in a well supplemented with the negative control instead of Hum-ZAP was defined as 100%, is shown below each entry.
  • FIG. 9 shows the IC50 (50% inhibition concentration) (nM) of each of anti-LPS antibody-PBD (ADC11), H01L02-PBD (ADC1), H01L02A-PBD (ADC5), H11L02A-PBD (ADC7) and H31L02A-PBD (ADC6) relative to CDH6 positive human ovarian tumor cell lines NIH: OVCAR-3, OV-90, PA-1 and CDH6 positive human renal-cell carcinoma cell line 786-O.
  • FIG. 10 shows the in vivo anti-tumor effect of each of H01L02-PBD (ADC1), NOV0712-DM4 and anti-LPS antibody-PBD (ADC11). The evaluation was conducted using animal models in which CDH6-positive human ovarian tumor cell line OV-90 was inoculated into immunodeficient mice. The abscissa depicts the number of days, and the ordinate depicts tumor volume. The error range depicts a SE value.
  • FIG. 11 shows the in vivo anti-tumor effect of each of H01L02-PBD (ADC1), NOV0712-DM4 and anti-LPS antibody-PBD (ADC11). The evaluation was conducted using animal models in which CDH6-positive human renal tumor cell line Caki-1 was inoculated into immunodeficient mice. The abscissa depicts the number of days, and the ordinate depicts tumor volume. The error range depicts a SE value.
  • FIG. 12 shows the in vivo anti-tumor effect of each of H01L02-PBD (ADC1), H01L02A-PBD (ADC5), H31L02A-PBD (ADC6) and anti-LPS antibody-PBD (ADC11). The evaluation was conducted using animal models in which CDH6-positive human ovarian tumor cell line NIH: OVCAR-3 was inoculated into immunodeficient mice. The abscissa depicts the number of days, and the ordinate depicts tumor volume. The error range depicts a SE value.
  • FIG. 13 shows the in vivo anti-tumor effect of each of H01L02-PBD (ADC1), H01L02A-PBD (ADC5), H31L02A-PBD (ADC6) and H11L02A-PBD (ADC7). The evaluation was conducted using animal models in which CDH6-positive human ovarian tumor cell line OV-90 was inoculated into immunodeficient mice. The abscissa depicts the number of days, and the ordinate depicts tumor volume. The error range depicts a SE value.
  • FIG. 14 shows the in vivo anti-tumor effect of each of H01L02A-PBD (ADC5), H31L02A-PBD (ADC6) and anti-LPS antibody-PBD (ADC11). The evaluation was conducted using animal models in which CDH6-positive human ovarian tumor cell line PA-1 was inoculated into immunodeficient mice. The abscissa depicts the number of days, and the ordinate depicts tumor volume. The error range depicts a SE value.
  • FIG. 15 shows the in vivo anti-tumor effect of each of H01L02A-PBD (ADC5), H31L02A-PBD (ADC6) and anti-LPS antibody-PBD (ADC11). The evaluation was conducted using animal models in which CDH6-positive human renal tumor cell line 786-O was inoculated into immunodeficient mice. The abscissa depicts the number of days, and the ordinate depicts tumor volume. The error range depicts a SE value.
    •  DESCRIPTION OF EMBODIMENTS
  • Hereinafter, the preferred embodiments for carrying out the present invention will be described with reference to the drawings. It is to be noted that the embodiments described below merely illustrate the representative embodiments of the present invention, and the scope of the present invention shall not be narrowly interpreted due to these examples.
  • In the present description, the term “cancer” is used to have the same meaning as that of the term “carcinoma” and “tumor”.
  • In the present description, the term “gene” is used to include not only DNA but also its mRNA and cDNA, and cRNA thereof.
  • In the present description, the term “polynucleotide” or “nucleotide” is used to have the same meaning as that of a nucleic acid, and also includes DNA, RNA, a probe, an oligonucleotide, and a primer. In the present description, the terms “polynucleotide” and “nucleotide” can be used interchangeably with each other unless otherwise specified.
  • In the present description, the terms “polypeptide” and “protein” can be used interchangeably with each other.
  • In the present description, the term “cell” includes cells in an individual animal, and cultured cells.
  • In the present description, the term “CDH6” can be used to have the same meaning as that of the CDH6 protein. In the present description, human CDH6 is also referred to as “hCDH6”.
  • In the present description, the term “cytotoxic activity” is used to mean that a pathologic change is caused to cells in any given way. The term not only means a direct trauma, but also means all types of structural or functional damage caused to cells, such as DNA cleavage, formation of a base dimer, chromosomal cleavage, damage to cell mitotic apparatus, and a reduction in the activities of various types of enzymes.
  • In the present description, the phrase “exerting toxicity in cells” is used to mean that toxicity is exhibited in cells in any given way. The term not only means a direct trauma, but also means all types of structural, functional, or metabolic influences caused to cells, such as DNA cleavage, formation of a base dimer, chromosomal cleavage, damage to cell mitotic apparatus, a reduction in the activities of various types of enzymes, and suppression of effects of cell growth factors.
  • In the present invention, the term “functional fragment of an antibody”, also called “antigen-binding fragment of an antibody”, is used to mean a partial fragment of the antibody having binding activity against an antigen, and includes Fab, F(ab′)2, Fv, scFv, a diabody, a linear antibody and a multispecific antibody formed from antibody fragments, and the like. Fab′, which is a monovalent fragment of antibody variable regions obtained by treating F(ab′)2 under reducing conditions, is also included in the antigen-binding fragment of an antibody. However, the antigen-binding fragment of an antibody is not limited to these molecules, as long as the antigen-binding fragment has antigen-binding ability. These antigen-binding fragments include not only those obtained by treating a full-length molecule of an antibody protein with an appropriate enzyme, but proteins produced in appropriate host cells using a genetically engineered antibody gene.
  • The functional fragment of the present invention includes a functional fragment that has well conserved asparagine (Asn297 or N297) to be modified with an N-linked glycan in the IgG heavy chain Fc region and amino acids around Asn297, while retaining binding activity to an antigen.
  • In the present description, the term “epitope” is used to mean the specific partial peptide or partial three-dimensional structure of CDH6, to which an anti-CDH6 antibody binds. Such an epitope, which is the above-described partial peptide of CDH6, can be determined by a method well known to a person skilled in the art, such as an immunoassay. First, various partial structures of an antigen are produced. As regards production of such partial structures, a known oligonucleotide synthesis technique can be applied. For example, a series of polypeptides, in which CDH6 has been successively truncated at an appropriate length from the C-terminus or N-terminus thereof, are produced by a genetic recombination technique well known to a person skilled in the art. Thereafter, the reactivity of an antibody to such polypeptides is studied, and recognition sites are roughly determined. Thereafter, further shorter peptides are synthesized, and the reactivity thereof to these peptides can then be studied, so as to determine an epitope. When an antibody binding to a membrane protein having a plurality of extracellular domains is directed to a three-dimensional structure composed of a plurality of domains as an epitope, the domain to which the antibody binds can be determined by modifying the amino acid sequence of a specific extracellular domain, and thereby modifying the three-dimensional structure. The epitope, which is a partial three-dimensional structure of an antigen that binds to a specific antibody, can also be determined by specifying the amino acid residues of an antigen adjacent to the antibody by X-ray structural analysis.
  • In the present description, the phrase “antibodies binding to the same epitope” is used to mean antibodies that bind to a common epitope. If a second antibody binds to a partial peptide or a partial three-dimensional structure to which a first antibody binds, it can be determined that the first antibody and the second antibody bind to the same epitope. Alternatively, by confirming that a second antibody competes with a first antibody for the binding of the first antibody to an antigen (i.e., a second antibody interferes with the binding of a first antibody to an antigen), it can be determined that the first antibody and the second antibody bind to the same epitope, even if the specific sequence or structure of the epitope has not been determined. In the present description, the phrase “binding to the same epitope” refers to the case where it is determined that the first antibody and the second antibody bind to a common epitope by any one or both of these determination methods. When a first antibody and a second antibody bind to the same epitope and further, the first antibody has special effects such as antitumor activity or internalization activity, the second antibody can be expected to have the same activity as that of the first antibody.
  • In the present description, the term “CDR” is used to mean a complementarity determining region. It is known that the heavy chain and light chain of an antibody molecule each have three CDRs. Such a CDR is also referred to as a hypervariable region, and is located in the variable regions of the heavy chain and light chain of an antibody. These regions have a particularly highly variable primary structure and are separated into three sites on the primary structure of the polypeptide chain in each of the heavy chain and light chain. In the present description, with regard to the CDR of an antibody, the CDRs of a heavy chain are referred to as CDRH1, CDRH2 and CDRH3, respectively, from the amino-terminal side of the amino acid sequence of the heavy chain, whereas the CDRs of a light chain are referred to as CDRL1, CDRL2 and CDRL3, respectively, from the amino-terminal side of the amino acid sequence of the light chain. These sites are located close to one another on the three-dimensional structure, and determine the specificity of the antibody to an antigen to which the antibody binds.
  • In the present description, the phrase “hybridizing under stringent conditions” is used to mean that hybridization is carried out in the commercially available hybridization solution ExpressHyb Hybridization Solution (manufactured by Clontech Laboratories, Inc.) at 68° C., or that hybridization is carried out under conditions in which hybridization is carried out using a DNA-immobilized filter in the presence of 0.7 to 1.0 M NaCl at 68° C., and the resultant is then washed at 68° C. with a 0.1- to 2-fold concentration of SSC solution (wherein 1-fold concentration of SSC consists of 150 mM NaCl and 15 mM sodium citrate) for identification, or conditions equivalent thereto.
  • In the present description, the term “one to several” is used to mean 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2.
  • 1. CDH6
  • Cadherins are glycoproteins present on the surface of cell membranes and function as cell-cell adhesion molecules through the calcium ion-dependent binding of their N-terminal extracellular domains, or as signal molecules responsible for cell-cell interaction. Classic cadherins are in the cadherin superfamily and are single-pass transmembrane proteins composed of five extracellular domains (EC domains), one transmembrane region, and an intracellular domain.
  • CDH6 (cadherin-6) is a single-pass transmembrane protein composed of 790 amino acids, which is classified into the type II cadherin family, and this protein has N-terminal extracellular and C-terminal intracellular domains. The human CDH6 gene was cloned for the first time in 1995 (Non Patent Literature 1), and its sequence can be referred to under, for example, accession Nos. NM_004932 and NP_004923 (NCBI).
  • The CDH6 protein used in the present invention can be directly purified from the CDH6-expressing cells of a human or a non-human mammal (e.g., a rat, a mouse or a monkey) and can then be used, or a cell membrane fraction of the aforementioned cells can be prepared and can be used as the CDH6 protein. Alternatively, CDH6 can also be obtained by synthesizing it in vitro, or by allowing host cells to produce CDH6 by genetic manipulation. According to such genetic manipulation, the CDH6 protein can be obtained, specifically, by incorporating CDH6 cDNA into a vector capable of expressing the CDH6 cDNA, and then synthesizing CDH6 in a solution containing enzymes, substrate and energetic materials necessary for transcription and translation, or by transforming host cells of other prokaryotes or eukaryotes, so as to allow them to express CDH6. Also, CDH6-expressing cells based on the above-described genetic manipulation, or a cell line expressing CDH6 may be used to present the CDH6 protein. Alternatively, the expression vector into which CDH6 cDNA has been incorporated can be directly administered to an animal to be immunized, and CDH6 can be expressed in the body of the animal thus immunized.
  • Moreover, a protein which consists of an amino acid sequence comprising a substitution, deletion and/or addition of one or several amino acids in the above-described amino acid sequence of CDH6, and has a biological activity equivalent to that of the CDH6 protein, is also included within the term “CDH6”.
  • The human CDH6 protein has the amino acid sequence shown in SEQ ID NO: 1. The extracellular region of the human CDH6 protein is constituted of extracellular domain 1 (in the specification, also referred to as EC1) having the 54th to 159th amino acids in the amino acid sequence shown in SEQ ID NO: 1, extracellular domain 2 (in the specification, also referred to as EC2) having the 160th to 268th amino acids in the amino acid sequence shown in SEQ ID NO: 1, extracellular domain 3 (in the specification, also referred to as EC3) having the 269th to 383rd amino acids in the amino acid sequence shown in SEQ ID NO: 1, extracellular domain 4 (in the specification, also referred to as EC4) having the 384th to 486th amino acids in the amino acid sequence shown in SEQ ID NO: 1 and extracellular domain 5 (in the specification, also referred to as EC5) having the 487th to 608th amino acids in the amino acid sequence shown in SEQ ID NO: 1. The amino acid sequences of EC1 to EC5 are respectively represented by SEQ ID NOs: 2 to 6 (Table 1).
  • 2. Production of Anti-CDH6 Antibody
  • One example of the anti-CDH6 antibody of the present invention can include an anti-CDH6 antibody which recognizes an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4, and has internalization activity. One example of the anti-CDH6 antibody of the present invention can include an anti-CDH6 antibody which specifically recognizes an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4, and has internalization activity. One example of the anti-CDH6 antibody of the present invention can include an anti-CDH6 antibody which recognizes an amino acid sequence consisting of the amino acid sequence shown in SEQ ID NO: 4, and has internalization activity. One example of the anti-CDH6 antibody of the present invention can include an anti-CDH6 antibody which specifically recognizes an amino acid sequence consisting of the amino acid sequence shown in SEQ ID NO: 4, and has internalization activity. The phrase “specifically recognize an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4” or “specifically recognize an EC3 domain” as applied to an antibody is used to mean that the antibody strongly recognizes or strongly binds to the EC3 domain of CDH6 compared with the other extracellular domains of CDH6.
  • The anti-CDH6 antibody of the present invention may be derived from any species. Preferred examples of the species can include humans, monkeys, rats, mice and rabbits. When the anti-CDH6 antibody of the present invention is derived from a species other than humans, it is preferred to chimerize or humanize the anti-CDH6 antibody by a well-known technique. The antibody of the present invention may be a polyclonal antibody or may be a monoclonal antibody, and a monoclonal antibody is preferred.
  • The anti-CDH6 antibody of the present invention is an antibody that can target tumor cells. Specifically, the anti-CDH6 antibody of the present invention possesses the property of being able to recognize tumor cells, the property of being able to bind to tumor cells, and/or the property of being internalized into tumor cells by cellular uptake, and the like. Accordingly, the anti-CDH6 antibody of the present invention can be conjugated to a compound having antitumor activity via a linker to prepare an antibody-drug conjugate.
  • The binding activity of an antibody against tumor cells can be confirmed by flow cytometry. The uptake of an antibody into tumor cells can be confirmed by (1) an assay of visualizing a cellularly taken-up antibody under a fluorescent microscope using a secondary antibody (fluorescently labeled) binding to the antibody (Cell Death and Differentiation, 2008, 15, 751-761), (2) an assay of measuring the amount of cellularly taken-up fluorescence using a secondary antibody (fluorescently labeled) binding to the antibody (Molecular Biology of the Cell Vol. 15, 5268-5282, December 2004) or (3) a Mab-ZAP assay using an immunotoxin binding to the antibody, wherein the toxin is released upon cellular uptake, so as to suppress cell growth (Bio Techniques 28: 162-165, January 2000). A recombinant conjugated protein of a catalytic region of diphtheria toxin and protein G may be used as the immunotoxin.
  • In the present description, the term “high internalization ability” is used to mean that the survival rate (which is indicated by a ratio relative to a cell survival rate without antibody addition defined as 100%) of CDH6-expressing cells to which the aforementioned antibody and a saporin-labeled anti-rat IgG antibody have been administered is preferably 70% or less, and more preferably 60% or less.
  • The antibody-drug conjugate comprises a conjugated compound exerting an antitumor effect. Therefore, it is preferred, but not essential, that the antibody itself should have an antitumor effect. For the purpose of specifically and/or selectively exerting the cytotoxicity of the antitumor compound in tumor cells, it is important and preferred that the antibody should have a property of being internalized and transferred into tumor cells.
  • The anti-CDH6 antibody can be obtained by immunizing an animal with a polypeptide serving as an antigen by a method usually performed in this field, and then collecting and purifying an antibody produced in the living body thereof. It is preferred to use CDH6 retaining a three-dimensional structure as an antigen. Examples of such a method can include a DNA immunization method.
  • The origin of the antigen is not limited to a human, and thus, an animal can also be immunized with an antigen derived from a non-human animal such as a mouse or a rat. In this case, an antibody applicable to the disease of a human can be selected by examining the cross-reactivity of the obtained antibody binding to the heterologous antigen with the human antigen.
  • Furthermore, antibody-producing cells that produce an antibody against the antigen can be fused with myeloma cells according to a known method (e.g., Kohler and Milstein, Nature (1975) 256, 495-497; and Kennet, R. ed., Monoclonal Antibodies, 365-367, Plenum Press, N. Y. (1980)) to establish hybridomas, so as to obtain a monoclonal antibody.
  • Hereinafter, the method for obtaining an antibody against CDH6 will be specifically described.
  • (1) Preparation of Antigen
  • The antigen can be obtained by allowing host cells to produce a gene encoding the antigen protein according to genetic manipulation. Specifically, a vector capable of expressing the antigen gene is produced, and the vector is then introduced into host cells, so that the gene is expressed therein, and thereafter, the expressed antigen may be purified. The antibody can also be obtained by a method of immunizing an animal with the antigen-expressing cells based on the above-described genetic manipulation, or a cell line expressing the antigen.
  • Alternatively, the antibody can also be obtained, without the use of the antigen protein, by incorporating cDNA of the antigen protein into an expression vector, then administering the expression vector to an animal to be immunized, and expressing the antigen protein in the body of the animal thus immunized, so that an antibody against the antigen protein is produced therein.
  • (2) Production of Anti-CDH6 Monoclonal Antibody
  • The anti-CDH6 antibody used in the present invention is not particularly limited. For example, an antibody specified by an amino acid sequence shown in the sequence listing of the present application can suitably be used. The anti-CDH6 antibody used in the present invention is desirably an antibody having the following properties:
  • (1) an antibody having the following properties:
      • (a) specifically binding to CDH6, and
      • (b) having the activity of being internalized into CDH6-expressing cells by binding to CDH6;
  • (2) the antibody according to the above (1) or the aforementioned antibody, wherein the CDH6 is human CDH6; or
  • (3) specifically recognizing EC3 of human CDH6, and having internalization activity.
  • The method for obtaining the antibody against CDH6 of the present invention is not particularly limited as long as an anti-CDH6 antibody can be obtained. It is preferred to use CDH6 retaining its conformation as an antigen.
  • One preferred example of the method for obtaining the antibody can include a DNA immunization method. The DNA immunization method is an approach which involves transfecting an animal (e.g., mouse or rat) individual with an antigen expression plasmid, and then expressing the antigen in the individual to induce immunity against the antigen. The transfection approach includes a method of directly injecting the plasmid into a muscle, a method of injecting a transfection reagent such as a liposome or polyethylenimine into a vein, an approach using a viral vector, an approach of injecting gold particles attached to the plasmid using a gene gun, a hydrodynamic method of rapidly injecting a plasmid solution in a large amount into a vein, and the like. With regard to the transfection method of injecting the expression plasmid into a muscle, a technique called in vivo electroporation, which involves applying electroporation to the intramuscular injection site of the plasmid, is known as an approach for improving expression levels (Aihara H, Miyazaki J. Nat Biotechnol. 1998 September; 16 (9): 867-70 or Mir L M, Bureau M F, Gehl J, Rangara R, Rouy D, Caillaud J M, Delaere P, Branellec D, Schwartz B, Scherman D. Proc Natl Acad Sci USA. 1999 Apr. 13; 96 (8): 4262-7). This approach further improves the expression level by treating the muscle with hyaluronidase before the intramuscular injection of the plasmid (McMahon J M1, Signori E, Wells K E, Fazio V M, Wells D J., Gene Ther. 2001 August; 8 (16): 1264-70). Furthermore, hybridoma production can be performed by a known method, and can also be performed using, for example, a Hybrimune Hybridoma Production System (Cyto Pulse Sciences, Inc.).
  • Specific examples of obtaining a monoclonal antibody can include the following procedures:
  • (a) immune response can be induced by incorporating CDH6 cDNA into an expression vector (e.g., pcDNA3.1; Thermo Fisher Scientific Inc.), and directly administering the vector to an animal (e.g., a rat or a mouse) to be immunized by a method such as electroporation or a gene gun, so as to express CDH6 in the body of the animal. The administration of the vector by electroporation or the like may be performed one or more times, preferably a plurality of times, if necessary for enhancing antibody titer;
  • (b) collection of tissue (e.g., a lymph node) containing antibody-producing cells from the aforementioned animal in which the immune response has been induced;
  • (c) preparation of myeloma cells (hereinafter, referred to as “myelomas”) (e.g., mouse myeloma SP2/0-ag14 cells);
  • (d) cell fusion between the antibody-producing cells and the myelomas;
  • (e) selection of a hybridoma group producing an antibody of interest;
  • (f) division into single cell clones (cloning);
  • (g) optionally, the culture of hybridomas for the mass production of monoclonal antibodies, or the breeding of animals into which the hybridomas are inoculated; and/or
  • (h) study of the physiological activity (internalization activity) and binding specificity of the monoclonal antibody thus produced, or examination of the properties of the antibody as a labeling reagent.
  • Examples of the method for measuring the antibody titer used herein can include, but are not limited to, flow cytometry and Cell-ELISA.
  • Examples of the hybridoma strain thus established can include anti-CDH6 antibody-producing hybridoma rG019. It is to be noted that, in the present description, an antibody produced by the anti-CDH6 antibody-producing hybridoma rG019 is referred to as a “rG019 antibody” or simply as “rG019”.
  • The light chain variable region of the rG019 antibody consists of the amino acid sequence shown in SEQ ID NO: 10. The amino acid sequence of the light chain variable region of the rG019 antibody is encoded by the nucleotide sequence shown in SEQ ID NO: 11. The light chain variable region of the rG019 antibody has CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13, and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14. The heavy chain variable region of the rG019 antibody consists of the amino acid sequence shown in SEQ ID NO: 15. The amino acid sequence of the heavy chain variable region of the rG019 antibody is encoded by the nucleotide sequence shown in SEQ ID NO: 16. The heavy chain variable region of the rG019 antibody has CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 18, and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19.
  • Further, even if a monoclonal antibody was independently obtained by steps (a) to (h) in “2.Production of anti-CDH6 antibody” again, or a monoclonal antibody was separately obtained by using another method, an antibody having internalization activity equivalent to that of the rG019 antibody can be obtained. An example of such antibodies is an antibody that binds to an epitope identical to the epitope to which the rG019 antibody binds. If a newly produced monoclonal antibody binds to a partial peptide or partial three-dimensional structure to which the rG019 antibody binds, it can be determined that the monoclonal antibody binds to an epitope identical to the epitope to which the rG019 antibody binds. By confirming that the monoclonal antibody competes with the rG019 antibody for binding to CDH6 (i.e., the monoclonal antibody interferes with binding between the rG019 antibody and CDH6), it can be determined, even when the specific sequence or structure of an epitope has not been determined, that the monoclonal antibody binds to an epitope identical to the epitope to which the anti-CDH6 antibody binds. If epitope identity has been confirmed, the monoclonal antibody is strongly expected to have antigen-binding ability, biological activity, and/or internalization activity equivalent to that of the rG019 antibody.
  • (3) Other Antibodies
  • The antibody of the present invention also includes genetically recombinant antibodies that have been artificially modified for the purpose of reducing heterogenetic antigenicity to humans, such as a chimeric antibody, a humanized antibody and a human antibody, as well as the above-described monoclonal antibody against CDH6. These antibodies can be produced by known methods.
  • Examples of the chimeric antibody can include antibodies in which a variable region and a constant region are heterologous to each other, such as a chimeric antibody formed by conjugating the variable region of a mouse- or rat-derived antibody to a human-derived constant region (see, Proc. Natl. Acad. Sci. U.S.A., 81, 6851-6855, (1984)).
  • Examples of the chimeric antibody derived from the rat anti-human CDH6 antibody include an antibody consisting of a light chain comprising the light chain variable region of a rat anti-human CDH6 antibody described in the present description (e.g., rG019 antibody) and a human-derived constant region, and a heavy chain comprising the heavy chain variable region of the rat anti-human CDH6 antibody and a human-derived constant region.
  • Other examples of the chimeric antibody derived from the rat anti-human CDH6 antibody include an antibody consisting of a light chain comprising a light chain variable region having a substitution of one to several residues, 1 to 3 residues, 1 or 2 residues, preferably 1 residue, of amino acids in the light chain variable region of a rat anti-human CDH6 antibody described in the present description (e.g., rG019 antibody) with other amino acid residues, and a heavy chain comprising a heavy chain variable region having a substitution of one to several residues, 1 to 3 residues, 1 or 2 residues, preferably 1 residue, of amino acids in the heavy chain variable region of the rat anti-human CDH6 antibody with other amino acid residues. This antibody may have any given human-derived constant region.
  • Other examples of the chimeric antibody derived from the rat anti-human CDH6 antibody include an antibody consisting of a light chain comprising a light chain variable region having a substitution of 1 or 2 residues, preferably 1 residue, of amino acids in any 1 to 3 CDRs in the light chain variable region of a rat anti-human CDH6 antibody described in the present description (e.g., the rG019 antibody) with other amino acid residues, and a heavy chain comprising a heavy chain variable region having a substitution of 1 or 2 residues, preferably 1 residue, of amino acids in any 1 to 3 CDRs in the heavy chain variable region of the rat anti-human CDH6 antibody with other amino acid residues. This antibody may have any given human-derived constant region.
  • Examples of the chimeric antibody derived from the rG019 antibody include an antibody consisting of a light chain comprising a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 10, and a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 15. This antibody may have any given human-derived constant region.
  • Other examples of the chimeric antibody derived from the rG019 antibody include an antibody consisting of a light chain comprising a light chain variable region having a substitution of one to several residues, 1 to 3 residues, 1 or 2 residues, preferably 1 residue, of amino acids in the light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 10 with other amino acid residues, and a heavy chain comprising a heavy chain variable region having a substitution of one to several residues, 1 to 3 residues, 1 or 2 residues, preferably 1 residue, of amino acids in the heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 15 with other amino acid residues. This antibody may have any given human-derived constant region.
  • Other examples of the chimeric antibody derived from the rG019 antibody include an antibody consisting of a light chain comprising a light chain variable region having a substitution of 1 or 2 residues (preferably 1 residue) of amino acids in any 1 to 3 CDRs in the light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 10 with other amino acid residues, and a heavy chain comprising a heavy chain variable region having a substitution of 1 or 2 residues (preferably 1 residue) of amino acids in any 1 to 3 CDRs in the heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 15 with other amino acid residues. This antibody may have any given human-derived constant region.
  • Other examples of the chimeric antibody derived from the rG019 antibody include an antibody consisting of a light chain comprising a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 10, and a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 28. This antibody may have any given human-derived constant region. The amino acid sequence shown in SEQ ID NO: 28 is a sequence with a cysteine residue substituted with a proline residue in CDRH2 in the amino acid sequence shown in SEQ ID NO: 15.
  • Specific examples of the chimeric antibody derived from the rG019 antibody include an antibody consisting of a light chain consisting of the light chain full-length amino acid sequence shown in SEQ ID NO: 23, and a heavy chain consisting of the heavy chain full-length amino acid sequence shown in SEQ ID NO: 26. In the present description, this chimeric anti-human CDH6 antibody is referred to as a “chimeric G019 antibody”, a “chG019 antibody” or “chG019”. The light chain full-length amino acid sequence of the chG019 antibody is encoded by the nucleotide sequence shown in SEQ ID NO: 24, and the heavy chain full-length amino acid sequence of the chG019 antibody is encoded by the nucleotide sequence shown in SEQ ID NO: 27.
  • The amino acid sequence of the light chain variable region of the chG019 antibody is identical to the amino acid sequence of the light chain variable region of the rG019 antibody, and consists of the amino acid sequence shown in SEQ ID NO: 10. The light chain of the chG019 antibody has CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13, and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14, which are identical to the light chain CDRL1, CDRL2 and CDRL3, respectively, of rG019. The amino acid of the light chain variable region of the chG019 antibody is encoded by the nucleotide sequence shown in SEQ ID NO: 25.
  • The amino acid sequence of the heavy chain variable region of the chG019 antibody consists of the amino acid sequence shown in SEQ ID NO: 28. The heavy chain of the chG019 antibody has CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 30 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19. The amino acid sequence shown in SEQ ID NO: 28 is a sequence with a cysteine residue substituted with a proline residue in CDRH2 in the amino acid sequence shown in SEQ ID NO: 15. The CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 30 is a sequence with a cysteine residue substituted with a proline residue in the rG019 CDRH2 shown in SEQ ID NO: 18. The amino acid sequence of the heavy chain variable region of the chG019 antibody is encoded by the nucleotide sequence shown in SEQ ID NO: 29.
  • Examples of the humanized antibody can include an antibody formed by incorporating only complementarity determining regions (CDRs) into a human-derived antibody (see Nature (1986) 321, p. 522-525), an antibody formed by incorporating the amino acid residues from some frameworks, as well as CDR sequences, into a human antibody according to a CDR grafting method (International Publication No. WO90/07861), and an antibody formed by modifying the amino acid sequences of some CDRs while maintaining antigen-binding ability.
  • In the present description, the humanized antibody derived from the rG019 antibody or the chG019 antibody is not limited to a specific humanized antibody as long as the humanized antibody retains all 6 CDR sequences unique to the rG019 antibody or the chG019 antibody and has internalization activity. The amino acid sequences of some CDRs of this humanized antibody may be further modified as long as the antibody has internalization activity.
  • Concrete examples of the humanized antibody of the chG019 antibody can include any given combination of: a light chain comprising a light chain variable region consisting of any one amino acid sequence selected from the group consisting of (1) the light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 or 37, (2) an amino acid sequence having an identity of at least 95% (preferably an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region other than at each CDR sequence) to the above-described amino acid sequence (1), and (3) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the above-described amino acid sequence (1); and a heavy chain comprising a heavy chain variable region consisting of any one amino acid sequence selected from the group consisting of (4) the heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 41, 45, 49, 55 or 60, (5) an amino acid sequence having an identity of at least 95% (preferably an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region other than at each CDR sequence) to the above-described amino acid sequence (4), and (6) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the above-described amino acid sequence (4).
  • Alternatively, an antibody having a humanized heavy chain or light chain and the other chain derived from a rat antibody or a chimeric antibody can also be used. Examples of such an antibody can include any given combination of: a light chain comprising a light chain variable region consisting of any one amino acid sequence selected from the group consisting of (1) the light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 or 37, (2) an amino acid sequence having an identity of at least 95% (preferably an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region other than at each CDR sequence) to the above-described amino acid sequence (1), and (3) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the above-described amino acid sequence (1); and a heavy chain comprising a heavy chain variable region consisting of any one amino acid sequence selected from the group consisting of (4) the heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 15 or 28, (5) an amino acid sequence having an identity of at least 95% (preferably an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region other than at each CDR sequence) to the above-described amino acid sequence (4), and (6) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the above-described amino acid sequence (4). Other examples of such an antibody can include any given combination of: a light chain comprising a light chain variable region consisting of any one amino acid sequence selected from the group consisting of (1) the light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 10, (2) an amino acid sequence having an identity of at least 95% (preferably an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region other than at each CDR sequence) to the above-described amino acid sequence (1), and (3) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the above-described amino acid sequence (1); and a heavy chain comprising a heavy chain variable region consisting of any one amino acid sequence selected from the group consisting of (4) the heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 41, 45, 49, 55 or 60, (5) an amino acid sequence having an identity of at least 95% (preferably an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region other than at each CDR sequence) to the above-described amino acid sequence (4), and (6) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the above-described amino acid sequence (4).
  • The amino acid substitution in the present description is preferably a conservative amino acid substitution. The conservative amino acid substitution is a substitution occurring within an amino acid group associated with certain amino acid side chains. Preferred amino acid groups are the following: acidic group=aspartic acid and glutamic acid; basic group=lysine, arginine and histidine; non-polar group=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine and tryptophan; and uncharged polar family=glycine, asparagine, glutamine, cysteine, serine, threonine and tyrosine. Other preferred amino acid groups are the following: aliphatic hydroxy group=serine and threonine; amide-containing group=asparagine and glutamine; aliphatic group=alanine, valine, leucine and isoleucine; and aromatic group=phenylalanine, tryptophan and tyrosine. Such amino acid substitution is preferably carried out without impairing the properties of a substance having the original amino acid sequence.
  • Examples of the antibody having a preferred combination of the above-described light chains and heavy chains include an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 (in the present description, also referred to as a hL02 light chain variable region amino acid sequence) or a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 (in the present description, also referred to as a hL03 light chain variable region amino acid sequence), and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 41 (in the present description, also referred to as a hH01 heavy chain variable region amino acid sequence), a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 45 (in the present description, also referred to as a hH02 heavy chain variable region amino acid sequence) or a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 49 (in the present description, also referred to as a hH04 heavy chain variable region amino acid sequence), a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 55 (in the present description, also referred to as a hH11 heavy chain variable region amino acid sequence) or a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 60 (in the present description, also referred to as a hH31 heavy chain variable region amino acid sequence).
  • The hH11 heavy chain variable region amino acid sequence shown in SEQ ID NO: 55 has CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59. The hH31 heavy chain variable region amino acid sequence shown in SEQ ID NO: 60 has CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 62, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 63 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 64.
  • Preferred examples of the antibody include:
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 41;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 45;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 49;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 55;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 60;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 41;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 45;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 49;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 55; and
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 60.
  • More preferred examples of the antibody include:
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 41;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 45;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 49;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 37 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 45;
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 55; and
  • an antibody consisting of a light chain having the light chain variable region amino acid sequence shown in SEQ ID NO: 33 and a heavy chain having the heavy chain variable region amino acid sequence shown in SEQ ID NO: 60.
  • Other examples of the antibody having a preferred combination of light chains and heavy chains include an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 (in the present description, also referred to as the hL02 light chain full-length amino acid sequence) or a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 (in the present description, also referred to as the hL03 light chain full-length amino acid sequence), and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 39 (in the present description, also referred to as the hH01 heavy chain full-length amino acid sequence), a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 43 (in the present description, also referred to as the hH02 heavy chain full-length amino acid sequence), a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 47 (in the present description, also referred to as the hH04 heavy chain full-length amino acid sequence), a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 65 (in the present description, also referred to as the hH01A heavy chain full-length amino acid sequence), a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 67 (in the present description, also referred to as the hH11A heavy chain full-length amino acid sequence) or a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 69 (in the present description, also referred to as the hH31A heavy chain full-length amino acid sequence).
  • Examples of another preferable antibody include,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 39,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 43,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 47,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 65,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 67,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 69,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 39,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 43,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 47,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 65,
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 67, or
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 69.
  • Examples of a more preferable antibody include
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 39 (in the present description, also referred to as the “H01L02 antibody” or “H01L02”),
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 43 (in the present description, also referred to as the “H02L02 antibody” or “H02L02”),
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 47 (in the present description, also referred to as the “H04L02 antibody” or “H04L02”),
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 43 (in the present description, also referred to as the “H02L03 antibody” or “H02L03”),
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 65 (in the present description, also referred to as the “H01L02A antibody” or “H01L02A),
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 67 (in the present description, also referred to as the “H11L02A antibody” or “H11L02A), and
  • an antibody consisting of a light chain consisting of the amino acid sequence at positions 21 to 233 in the light chain full-length amino acid sequence shown in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in the heavy chain full-length amino acid sequence shown in SEQ ID NO: 69 (in the present description, also referred to as the “H31L02A antibody” or “H31L02A).
  • By combining together sequences showing a high identity to the above-described heavy chain amino acid sequences and light chain amino acid sequences, it is possible to select an antibody having a biological activity equivalent to that of each of the above-described antibodies. Such an identity is an identity of generally 80% or more, preferably 90% or more, more preferably 95% or more and most preferably 99% or more. Moreover, also by combining amino acid sequences of a heavy chain and a light chain comprising a substitution, deletion or addition of one or several amino acid residues thereof with respect to the amino acid sequence of a heavy chain or a light chain, it is possible to select an antibody having a biological activity equivalent to that of each of the above-described antibodies.
  • The identity between two types of amino acid sequences can be determined by aligning the sequences using the default parameters of Clustal W version 2 (Larkin M A, Blackshields G, Brown N P, Chenna R, McGettigan P A, McWilliam H, Valentin F, Wallace I M, Wilm A, Lopez R, Thompson J D, Gibson T J and Higgins D G (2007), “Clustal W and Clustal X version 2.0”, Bioinformatics.23 (21): 2947-2948).
  • It is to be noted that, in the hL02 light chain full-length amino acid sequence shown in SEQ ID NO: 31, the amino acid sequence consisting of the amino acid residues at positions 1 to 20 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 21 to 128 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 129 to 233 is a constant region.
  • In the hL03 light chain full-length amino acid sequence shown in SEQ ID NO: 35, the amino acid sequence consisting of the amino acid residues at positions 1 to 20 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 21 to 128 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 129 to 233 is a constant region.
  • In the hH01 heavy chain full-length amino acid sequence shown in SEQ ID NO: 39, the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is the signal sequence, the amino acid sequence consisting of the amino acid residues at positions 20 to 141 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 142 to 471 is a constant region.
  • In the hH02 heavy chain full-length amino acid sequence shown in SEQ ID NO: 43, the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 20 to 141 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 142 to 471 is a constant region.
  • In the hH04 heavy chain full-length amino acid sequence shown in SEQ ID NO: 47, the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 20 to 141 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 142 to 471 is a constant region.
  • In the hH01A heavy chain full-length amino acid sequence shown in SEQ ID NO: 65, the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 20 to 141 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 142 to 471 is a constant region.
  • In the hH11A heavy chain full-length amino acid sequence shown in SEQ ID NO: 67, the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 20 to 141 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 142 to 471 is a constant region.
  • In the hH31A heavy chain full-length amino acid sequence shown in SEQ ID NO: 69, the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 20 to 141 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 142 to 471 is a constant region.
  • Further example of the antibody of the present invention can include a human antibody binding to CDH6. The anti-CDH6 human antibody refers to a human antibody having only the gene sequence of an antibody derived from human chromosomes. The anti-CDH6 human antibody can be obtained by a method using a human antibody-producing mouse having a human chromosomal fragment comprising the heavy chain and light chain genes of a human antibody (see, Tomizuka, K. et al., Nature Genetics (1997) 16, p. 133-143; Kuroiwa, Y. et al., Nucl. Acids Res. (1998) 26, p. 3447-3448; Yoshida, H. et al., Animal Cell Technology: Basic and Applied Aspects vol. 10, p. 69-73 (Kitagawa, Y., Matsuda, T. and Iijima, S. eds.), Kluwer Academic Publishers, 1999; Tomizuka, K. et al., Proc. Natl. Acad. Sci. USA (2000) 97, p. 722-727; etc.).
  • Such a human antibody-producing mouse can be specifically produced by using a genetically modified animal, the gene loci of endogenous immunoglobulin heavy chain and light chain of which have been disrupted and instead the gene loci of the human immunoglobulin heavy chain and light chain have been then introduced using a yeast artificial chromosome (YAC) vector or the like, then producing a knock-out animal and a transgenic animal from such a genetically modified animal, and then breeding such animals with one another.
  • Otherwise, the anti-CDH6 human antibody can also be obtained by transforming eukaryotic cells with cDNA encoding each of the heavy chain and light chain of such a human antibody, or preferably with a vector comprising such cDNA, according to genetic recombination techniques, and then culturing the transformed cells and producing a genetically modified human monoclonal antibody, so that the antibody can be obtained from the culture supernatant.
  • In this context, eukaryotic cells, and preferably, mammalian cells such as CHO cells, lymphocytes or myelomas can, for example, be used as a host.
  • Also known is a method of obtaining a phage display-derived human antibody that has been selected from a human antibody library (see Wormstone, I. M. et al., Investigative Ophthalmology & Visual Science. (2002) 43 (7), p. 2301-2308; Carmen, S. et al., Briefings in Functional Genomics and Proteomics (2002), 1 (2), p. 189-203; Siriwardena, D. et al., Ophthalmology (2002) 109 (3), p. 427-431; etc.).
  • For example, a phage display method, which comprises allowing the variable regions of a human antibody to express as a single chain antibody (scFv) on the surface of phages, and then selecting a phage binding to an antigen, can be applied (Nature Biotechnology (2005), 23, (9), p. 1105-1116).
  • By analyzing the phage gene that has been selected because of its binding ability to the antigen, the DNA sequence encoding the variable region of a human antibody binding to the antigen can be determined.
  • Once the DNA sequence of scFv binding to the antigen is determined, an expression vector having the aforementioned sequence is produced, and the produced expression vector is then introduced into an appropriate host and can be allowed to express therein, thereby obtaining a human antibody (International Publication Nos. WO92/01047, WO92/20791, WO93/06213, WO93/11236, WO93/19172, WO95/01438 and WO95/15388, Annu. Rev. Immunol (1994) 12, p. 433-455, Nature Biotechnology (2005) 23 (9), p. 1105-1116).
  • If a newly produced human antibody binds to a partial peptide or a partial three-dimensional structure to which any one rat anti-human CDH6 antibody, chimeric anti-human CDH6 antibody or humanized anti-human CDH6 antibody described in the present description (e.g., the rG019 antibody, the chG019 antibody, the H01L02 antibody, the H02L02 antibody, the H02L03 antibody, the H04L02 antibody, the H01L02A antibody, the H11L02A antibody or the H31L02A antibody) binds, it can be determined that the human antibody binds to the same epitope to which the rat anti-human CDH6 antibody, the chimeric anti-human CDH6 antibody or the humanized anti-human CDH6 antibody binds. Alternatively, by confirming that the human antibody competes with the rat anti-human CDH6 antibody, the chimeric anti-human CDH6 antibody or the humanized anti-human CDH6 antibody described in the present description (e.g., the rG019 antibody, the chG019 antibody, the H01L02 antibody, the H02L02 antibody, the H02L03 antibody, the H04L02 antibody, the H01L02A antibody, the H11L02A antibody or the H31L02A antibody) in the binding of the antibody to CDH6 (e.g., the human antibody interferes with the binding of the rG019 antibody, the chG019 antibody, the H01L02 antibody, the H02L02 antibody, the H02L03 antibody, the H04L02 antibody, the H01L02A antibody, the H11L02A antibody or the H31L02A antibody to CDH6, preferably EC3 of CDH6), it can be determined that the human antibody binds to the same epitope to which the rat anti-human CDH6 antibody, the chimeric anti-human CDH6 antibody or the humanized anti-human CDH6 antibody described in the present description binds, even if the specific sequence or structure of the epitope has not been determined. In the present description, when it is determined by at least one of these determination methods that the human antibody “binds to the same epitope”, it is concluded that the newly prepared human antibody “binds to the same epitope” as that for the rat anti-human CDH6 antibody, the chimeric anti-human CDH6 antibody or the humanized anti-human CDH6 antibody described in the present description. When it is confirmed that the human antibody binds to the same epitope, then it is expected that the human antibody should have a biological activity equivalent to that of the rat anti-human CDH6 antibody, the chimeric anti-human CDH6 antibody or the humanized anti-human CDH6 antibody (e.g., the rG019 antibody, the chG019 antibody, the H01L02 antibody, the H02L02 antibody, the H02L03 antibody, the H04L02 antibody, the H01L02A antibody, the H11L02A antibody or the H31L02A antibody).
  • The chimeric antibodies, the humanized antibodies or the human antibodies obtained by the above-described methods are evaluated for their binding activity against the antigen according to a known method, etc., so that a preferred antibody can be selected.
  • One example of another indicator for comparison of the properties of antibodies can include the stability of an antibody. A differential scanning calorimeter (DSC) is an apparatus capable of promptly and exactly measuring a thermal denaturation midpoint (Tm) serving as a good indicator for the relative structural stability of a protein. By using DSC to measure Tm values and making a comparison regarding the obtained values, differences in thermal stability can be compared. It is known that the preservation stability of an antibody has a certain correlation with the thermal stability of the antibody (Lori Burton, et al., Pharmaceutical Development and Technology (2007) 12, p. 265-273), and thus, a preferred antibody can be selected using thermal stability as an indicator. Other examples of an indicator for selection of an antibody can include high yield in suitable host cells and low agglutination in an aqueous solution. For example, since an antibody with the highest yield does not always exhibit the highest thermal stability, it is necessary to select an antibody most suitable for administration to a human by comprehensively determining it based on the aforementioned indicators.
  • The antibody of the present invention also includes a modification of an antibody. A modification is used to mean an antibody of the present invention, which is chemically or biologically modified. Examples of such a chemical modification include the binding of a chemical moiety to an amino acid skeleton, and the chemical modification of an N-linked or O-linked carbohydrate chain. Examples of such a biological modification include antibodies which have undergone a posttranslational modification (e.g., N-linked or 0-linked glycosylation, N-terminal or C-terminal processing, deamidation, isomerization of aspartic acid, oxidation of methionine, and conversion of N-terminal glutamine or N-terminal glutamic acid to pyroglutamic acid), and antibodies, to the N-terminus of which, a methionine residue is added as a result of having been allowed to be expressed using prokaryote host cells. In addition, such a modification is also meant to include labeled antibodies for enabling detection or isolation of the antibody of the present invention or an antigen, for example, an enzymatically labeled antibody, a fluorescently labeled antibody, and an affinity-labeled antibody. Such a modification of the antibody of the present invention is useful for the improvement of the stability and retention in blood of an antibody; a reduction in antigenicity; detection or isolation of an antibody or an antigen; etc.
  • Moreover, by regulating a sugar chain modification (glycosylation, de-fucosylation, etc.) that binds to the antibody of the present invention, antibody-dependent cellular cytotoxic activity can be enhanced. As techniques of regulating the sugar chain modification of an antibody, those described in International Publication Nos. WO1999/54342, WO2000/61739, WO2002/31140 and WO2007/133855, etc. are known, though the techniques are not limited thereto. The antibody of the present invention also includes antibodies in respect of which the aforementioned sugar chain modification has been regulated.
  • Once an antibody gene is isolated, the gene can be introduced into an appropriate host to produce an antibody, using an appropriate combination of a host and an expression vector. A specific example of the antibody gene can be a combination of a gene encoding the heavy chain sequence of the antibody described in the present description and a gene encoding the light chain sequence of the antibody described therein. Upon transformation of host cells, such a heavy chain sequence gene and a light chain sequence gene may be inserted into a single expression vector, or these genes may instead each be inserted into different expression vectors.
  • When eukaryotic cells are used as hosts, animal cells, plant cells or eukaryotic microorganisms can be used. In particular, examples of the animal cells can include mammalian cells such as COS cells which are monkey cells (Gluzman, Y., Cell (1981) 23, p. 175-182, ATCC CRL-1650), mouse fibroblasts NIH3T3 (ATCC No. CRL-1658), a dihydrofolate reductase-deficient cell line of Chinese hamster ovary cells (CHO cells, ATCC CCL-61) (Urlaub, G. and Chasin, L. A. Proc. Natl. Acad. Sci. U.S.A. (1980) 77, p. 4126-4220) and FreeStyle 293F cells (Invitrogen Corp.).
  • When prokaryotic cells are used as hosts, Escherichia coli or Bacillus subtilis can be used, for example.
  • An antibody gene of interest is introduced into these cells for transformation, and the transformed cells are then cultured in vitro to obtain an antibody. In the aforementioned culture, there are cases where yield is different depending on the sequence of the antibody, and thus, it is possible to select an antibody, which is easily produced as a medicament, from antibodies having equivalent binding activity, using the yield as an indicator. Accordingly, the antibody of the present invention also includes an antibody obtained by the above-described method for producing an antibody, which comprises a step of culturing the transformed host cells and a step of collecting an antibody of interest or a functional fragment of the antibody from the culture obtained in the aforementioned step.
  • It is known that the lysine residue at the carboxyl terminal of the heavy chain of an antibody produced by culturing mammalian cells is deleted (Journal of Chromatography A, 705: 129-134 (1995)), and also, it is known that the two amino acid residues at the heavy chain carboxyl terminus, glycine and lysine, are deleted, and that the proline residue newly positioned at the carboxyl terminus is amidated (Analytical Biochemistry, 360: 75-83 (2007)). However, such deletion and modification of these heavy chain sequences does not have an influence on the antigen-binding activity and effector function (activation of complement, antibody-dependent cellular cytotoxicity, etc.) of an antibody. Accordingly, the antibody according to the present invention also includes an antibody that has undergone the aforementioned modification, and a functional fragment of the antibody, and specific examples of such an antibody include a deletion mutant comprising a deletion of 1 or 2 amino acids at the heavy chain carboxyl terminus, and a deletion mutant formed by amidating the aforementioned deletion mutant (e.g., a heavy chain in which the proline residue at the carboxyl-terminal site is amidated). However, deletion mutants involving a deletion at the carboxyl terminus of the heavy chain of the antibody according to the present invention are not limited to the above-described deletion mutants, as long as they retain antigen-binding activity and effector function. Two heavy chains constituting the antibody according to the present invention may be any one type of heavy chain selected from the group consisting of a full-length antibody and the above-described deletion mutants, or may be a combination of any two types selected from the aforementioned group. The ratio of individual deletion mutants can be influenced by the types of cultured mammalian cells that produce the antibody according to the present invention, and the culture conditions. Examples of the main ingredient of the antibody according to the present invention can include antibodies where one amino acid residue is deleted at each of the carboxyl termini of the two heavy chains.
  • Examples of the isotype of the antibody of the present invention can include IgG (IgG1, IgG3 and IgG4). Among others, IgG1, IgG2 and IgG4 are preferable.
  • If IgG1 is used as the isotype of the antibody of the present invention, the effector function may be adjusted by substituting some amino acid residues in the constant region. Examples of variants of IgG1 with the effector function lowered or attenuated may include, but not limited to, IgG1 LALA (IgG1-L234A, L235A) and IgG1 LAGA (IgG1-L235A, G237A) (Journal of Virology, Vol. 75, No. 24 (Dec. 15, 2001), pp. 12161-12168), and a preferred variant of IgG1 is IgG1 LALA. The L234A, L235A indicates substitution of leucine with alanine at the 234- and 235-positions specified by EU-index numbering (Proc. Natl. Acad. Sci. U.S.A., Vol. 63, No. 1 (May 15, 1969), pp. 78-85), and the G237A indicates substitution of glycine with alanine at the 237-position specified by EU-index numbering.
  • Typical examples of bioactivity of antibodies may include, but are not limited to, antigen-binding activity, activity to internalize in cells expressing an antigen by binding to the antigen, activity to neutralize antigen activity, activity to enhance antigen activity, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP), and the function of the antibody according to the present invention is binding activity to CDH6, and preferably activity to internalize in CDH6-expression cells by binding to CDH6. In addition to cellular internalization activity, the antibody of the present invention may have activities of ADCC, CDC, and/or ADCP in combination.
  • The antibody obtained may be purified to a homogeneous state. For separation/purification of the antibody, separation/purification methods commonly used for protein can be used. For example, the antibody may be separated/purified by appropriately selecting and combining column chromatography, filter filtration, ultrafiltration, salting-out, dialysis, preparative polyacrylamide gel electrophoresis, isoelectric focusing, and so on (Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Daniel R. Marshak et al. eds., Cold Spring Harbor Laboratory Press (1996); and Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory (1988)), but separation/purification methods are not limited thereto.
  • Examples of chromatography may include affinity chromatography, ion-exchange chromatography, hydrophobic chromatography, gel filtration chromatography, reversed-phase chromatography and absorption chromatography.
  • These chromatographies may be carried out using liquid chromatography such as HPLC or FPLC.
  • Examples of columns for affinity chromatography may include, but not limited to, a Protein A column and a Protein G column. Examples of columns that can be used as a Protein A column include Hyper D, POROS and Sepharose F. F. (Pharmacia).
  • Alternatively, the antibody may be purified by utilizing binding activity to an antigen with a carrier to which the antigen has been immobilized.
  • The present invention relates to a polynucleotide encoding the antibody of the present invention. The polynucleotide of the present invention is preferably a polynucleotide comprising the polynucleotide described in any one of the following (a) to (e):
  • (a) a combination of a polynucleotide encoding a heavy chain amino acid sequence and a polynucleotide encoding a light chain amino acid sequence of the CDH6 antibody of the present invention,
  • (b) a combination of a polynucleotide encoding a heavy chain amino acid sequence including the sequences of CDRH1 to CDRH3 and a polynucleotide encoding a light chain amino acid sequence including the sequences of CDRL1 to CDRL3 of any one of CDH6 antibodies of the present invention,
  • (c) a combination of a polynucleotide encoding a heavy chain amino acid sequence comprising the amino acid sequence of the heavy chain variable region and a polynucleotide encoding a light chain amino acid sequence comprising the amino acid sequence of the light chain variable region of the CDH6 antibody of the present invention,
  • (d) a polynucleotide that is hybridizable with nucleotides consisting of a polynucleotide complementary to the polynucleotide according to any one of (a) to (c) under stringent conditions and is encoding the amino acid sequence of the antibody capable of binding to CDH6, and
  • (e) a polynucleotide encoding the amino acid sequence of a polypeptide obtained by substituting, deleting, adding, or inserting 1 to 50, 1 to 45, 1 to 40, 1 to 35, 1 to 30, 1 to 25, 1 to 20, 1 to 15, 1 to 10, one to eight, one to six, one to five, one to four, one to three, one or two, or one amino acid in the polynucleotide according to any one of (a) to (c) and that is encoding the amino acid sequence of the antibody capable of binding to CDH6.
  • The present invention includes a nucleotide encoding the antibody of the present invention or a functional fragment of the antibody, or a modified variant of the antibody or functional fragment; a recombinant vector including the gene inserted therein; and a cell including the gene or the vector introduced therein.
  • The present invention includes a method for producing an antibody or a functional fragment of the antibody, or a modified variant of the antibody or functional fragment, the method including the steps of: culturing the cell; and collecting from the culture an antibody or a functional fragment of the antibody, or a modified variant of the antibody or functional fragment.
  • The amino acid sequences or nucleotide sequences of the antibodies of the present invention and the amino acid sequences or nucleotide sequences of the proteins used in the present invention are listed in Tables 1-1 to Tables 1-14.
  • TABLE 1-1
    SEQ ID NO Sequence
    1 Amino acid MRTYRYFLLLFWVGQPYPTLSTPLSKRTSGFPAKKRALELSGNSKNELNRSKRSWMW
    sequence of NQFFLLEEYTGSDYQYVGKLHSDQDRGDGSLKYUILSGDGAGDLFIINENTGDIQAT
    human KRLDREEKPVYILRAQAINRRTGRPVEPESEFIIKIHDINDNEPIFTKEVYTATVPE
    CDH6 ORF MSDVGTFVVQVTATDADDPTYGNSAKVVYSILQGQPYFSVESETGIIKTALLNMDRE
    NREQYQVVIQAKDMGGQMGGLSGTTTVNITLTDVNDNPPRFPQSTYQFKTPESSPPG
    TPIGRIKASDADVGENAEIEYSITDGEGLDMFDVITDQETQEGIITVKKLLDFEKKK
    VYTLKVEASNPYVEPRFLYLGPFKDSATVRIVVEDVDEPPVFSKLAYILQIREDAQI
    NTTIGSVTAQDPDAARNPVKYSVDRHTDMDRIFNIDSGNGSIFTSKLLDRETLLWHN
    ITVIATEINNPKQSSRVPLYIKVLDVNDNAPEFAEFYETFVCEKAKADQLIQTLHAV
    DKDDPYSGHQFSFSLAPEAASGSNFTIQDNKDNTAGILTRKNGYNRHEMSTYLLPVV
    ISDNDYPVQSSTGTVTVRVCACDHHGNMQSCHAEALIHPTGLSTGALVAILLCIVIL
    LVTVVLFAALRRQRKKEPLIISKEDIRDNIVSYNDEGGGEEDTQAFDIGTLRNPEAI
    EDNKLRRDIVPEALFLPRRTPTARDNTDVRDFINQRLKENDTDPTAPPYDSLATYAY
    EGTGSVADSLSSLESVTTDADQDYDYLSDWGPRFKKLADMYGGVDSDKDS
    2 Human CDH6 SWMWNQFFLLEEYTGSDYQYVGKLHSDQDRGDGSLKYILSGDGAGDLFIINENTGDI
    EC1 QATKRLDREEKPVYILRAQAINRRTGRPVEPESEFIIKIHDINDNEPIF
    3 Human CDH6 TKEVYTATVEPMSDVGTFVVQVTATDADDPTYGNSAKVVYSILQGQPYFSVESETGI
    EC2 IKTALLNMDRENREQYQVVIQAKDMGGQMGGLSGTTTVNITLTDVNDNPPRF
    4 Human CDH6 PQSTYQFKTPESSPPGTPIGRIKASDADVGENAEIEYSITDGEGLDMFDVITDQETQ
    EC3 EGIITVKKLLDFEKKKVYTLKVEASNPYVEPRFLYLGPFKDSATVRIVVEDVDEPPV
    F
    5 Human CDH6 SKLAYILQIREDAQINTTIGSVTAQDPDAARNPVKYSVDRHTDMDRIFNIDSGNGSI
    EC4 FTSKLLDRETLLWHNITVIATEINNPKQSSRVPLYIKVLDVNDNAP
    6 Human CDH6 EFAEFYETFVCEKAKADQLIQTLHAVDKDDPYSGHQFSFSLAPEAASGSNFTIQDNK
    EC5 DNTAGILTRKNGYNRHEMSTYLLPVVISDNDYPVQSSTGTVTVRVCACDHHGNMQSC
    HAELIHP
    7 Amino acid MRTYRYFLLLFWVGQPYPTLSTPLSKRTSGFPAKKRALELSGNSKNELNRSKRSWMW
    sequence of NQFFLLEEYTGSDYQYVGKLHSDQDRGDGSLKYILSGDGAGDLFIINENTGDIQATK
    cynomolgus RLDREEKPVYILRAQAINRRTGRPVEPESEFIIKIHDINDNEPIFTKEVYTATVPEM
    CDH6 ORF SDVGTFWQVTATDADDPTYGNSAKVVYSILQGQPYFSVESETGIIKTALLNMDRENR
    EQYQVVIQAKDMGGQMGGLSGTTTVNITLTDVNDNPPRFPQSTYQFKTPESSPPGTP
    IGRIKASDADVGENAEIEYSITDGEGLDMFDVITDQETQEGIITVKKLLDFEKKKVY
    TLKVEASNPHVEPRFLYLGPFKDSATVRIVVEDVDEPPVFSKLAYILQIREDAQINT
    TIGSVTAQDPDAARNPVKYSVDRHTDMDRIFNIDSGNGSIFTSKLLDRETLLWHNIT
    VIATEINNPKQSSRVPLYIKVLDVNDNAPEFAEFYETFVCEKAKADQLIQTLRAVDK
    DDPYSGHQFSFSLAPEAASGSNFTIQDNKDNTAGILTRKNGYNRHEMSTYLLPVVIS
    DNDYPVQSSTGTVTVRVCACDHHGNMQSCHAEALIHPTGLSTGALVAILLCIVILLV
    TVVLFAALRRQRKKEPLIISKEDIRDNIVSYNDEGGGEEDTQAFDIGTLRNPEAIED
    NKLRRDIVPEALFLPRRTPTARDNTDVRDFINGRLKENDTDPTAPPYDSLATYAYEG
    TGSVADSLSSLESVTTDGDQDYDYLSDWGPRFKKLADMYGGVDSDKDS
    8 Cynomolgus CACCATGAGAACTTACCGCTACTTCTTGCTGCTC
    CDH6 primer
     1
  • TABLE 1-2
     9 Cynomolgus TTAGGAGTCTTTGTCACTGTCCACTCCTCC
    CDH6 primer
     2
    10 rG019 light- DIQMTQSPSLLSASVGDRVTLNCKASQNIYKNLAWYQQKLGEGPKLLIYDANTLQTQ
    chain variable IPSRFSGSGSGSGDFTLTISSLQPEDVATYFCQQYYSGWAFGGVTNLELKRA
    region amino
    acid sequence
    11 rG019 light- GACATCCAGATGACCCAGTCTCCTTCACTCCTGTCTGCATCTGTGGGAGACAGAGTC
    chain variable ACTCTCAACTGCAAAGCAAGTCAGAATATTTATAAGAACTTAGCCTGGTATCAGCAA
    region nucleotide AAGCTTGGAGAAGGTCCCAAACTCCTGATTTATGATGCAAACACTTTGCAAACGGGC
    sequence ATCCCATCAAGGTTCAGTGGCAGTGGATCTGGTTCAGATTTCACACTCACCATCAGC
    AGCCTGCAGCCTGAAGATGTTGCCACATATTTCTGCCAGCAGTACTATAGCGGGTGG
    GCGTTCGGTGGAGTCACCAACCTGGAATTGAAACGGGCT
    12 rG019 CDRL1 KASQNIYKNLA
    13 rG019 CDRL2 DANTLQT
    14 rG019 CDRL3 QQYYSGWA
    15 rG019 heavy- QVQLQQSGAELVKPGSSVKISCKASGYTFTRNFMHWIKQQPGNGLEWIGQIYCGDGE
    chain variable TEYNQKFNGKATLTADRSSSTAYMELSRLTSEDSAVYFCARGVYGGFAGGYFDFWGQ
    region amino GVMVTVSS
    acid sequence
    16 rG019 heavy- CAGGTACAGCTGCAGCAATCTGGGGCTGAACTGGTGAAGCCTGGGTCCTCAGTGAAA
    chain variable ATTTCCTGCAAGGCTTCTGGCTACACCTTCACCAGGAACTTTATGCACTGGATAAAA
    region nucleotide CAGCAGCCTGGAAATGGCCTTGAGTGGATTGGGTGGATTTATTGTGGAGATGGTGAG
    sequence ACAGAGTACAATCAAAAGTTCAATGGGAAGGCAACACTCACTGCGGACAGATCCTCC
    AGCACAGCCTATATGGAGCTCAGCAGACTGACATCTGAGGACTCTGCAGTCTATTTC
    TGTGCAAGAGGGGTTTACGGAGGGTTTGCCGGGGGCTACTTTGATTTCTGGGGCCAA
    GGAGTCATGGTCACAGTCTCCTCA
    17 rG019 CDRH1 GYTFTRNFMH
    18 rG019 CDRH2 WIYCGDGETE
    19 rG019 CDRH3 GVYGGFAGGYFDF
    20 DNA fragment gcctccggactctagagccaccATGGTGCTGCAGACCCAGGTGTTCATCTCCCTGCT
    comprising DNA GCTGTGGATCTCCGGCGCGTACGGCGATATCGTGATGATTAAACGTACGGTGGCCGC
    sequence encoding CCCCTCCGTGTTCATCTTCCCCCCCTCCGACGAGCAGCTGAAGTCCGGCACCGCCTC
    human light-chain CGTGGTGTGCCTGCTGAATAACTTCTACCCCAGAGAGGCCAAGGTGCAGTGGAAGGT
    signal sequence GGACAACGCCCTGCAGTCCGGGAACTCCCAGGAGAGCGTGACCGAGCAGGACAGCAA
    and human κ-chain GGACAGCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAAGCCGACTACGAGAA
    constant region GCACAAGGTGTACGCCTGCGAGGTGACCCACCAGGGCCTGAGCTCCCCCGTCACCAA
    GAGCTTCAACAGGGGGGAGTGTtaggggcccgtttaaacgggggaggcta
  • TABLE 1-3
    21 DNA fragment gcctccggactctagagccaccATGAAACACCTGTGGTTCTTCCTCCTGCTGGTGGC
    comprising DNA AGCTCCCAGATGGGTGCTGAGCCAGGTGCAATTGTGCAGGCGGTTAGCTCAGCCTCC
    sequence encoding ACCAAGGGCCCAAGCGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGCGGC
    human heavy-chain ACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCCGTGACCGTGAGC
    signal sequence TGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCCGCTGTCCTGCAGTCC
    and human IgG1 TCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACC
    constant region CAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGA
    GTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCCTGCCCAGCACCTGAA
    CTCCTGGGGGGACCCTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATG
    ATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCT
    GAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAG
    CCCCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTG
    CACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTC
    CCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGCCAGCCCCGGGAACCACAG
    GTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACC
    TGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGC
    CAGCCCGAGAACAACTACAAGACCACCCCTCCCGTGCTGGACTCCGACGGCTCCTTC
    TTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGCAACGTCTTC
    TCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACCCAGAAGAGCCTCTCC
    CTGTCTCCCGGCAAAtgagatatcgggcccgtttaaacgggggaggcta
    22 DNA fragment ccagcctccggactctagagccaccATGGTGCTGCAGACCCAGGTGTTCATCAGCCT
    comprising DNA GCTGCTGTGGATCAGCGGCGCCTACGGCGACATCCAGATGACCCAGAGCCCTAGCCT
    sequence encoding GCTGAGCGCCAGCGTGGGCGATAGAGTGACCCTGAACTGCAAGGCCAGCCAGAACAT
    chG019 light-chain CTACAAGAACCTGGCCTGGTATCAGCAGAAGCTGGGCGAGGGCCCCAAGCTGCTGAT
    CTACGACGCCAACACCCTGCAGACCGGCATCCCCAGCAGATTTTCTGGCAGCGGCAG
    CGGCTCCGACTTCACCCTGACAATCAGCAGCCTGCAGCCCGAGGACGTGGCCACCTA
    CTTTTGCCAGCAGTACTACAGCGGCTGGGCCTTCGGCGGCGTGACCAACCTGGAACT
    GAAGAGAGCCGTGGCCGCTCCCTCCGTGTTCATCTTCCCACCTAGCGACGAGCAGCT
    GAAGTCCGGCACAGCCTCTGTCGTGTGCCTGCTGAACAACTTCTACCCCCGCGAGGC
    CAAGGTGCAGTGGAAGGTGGACAATGCCCTGCAGTCTGGCAACAGCCAGGAAAGCGT
    GACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACCCTGAG
    CAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCT
    GTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGTtgagtttaaacggggga
    ggctaact
    23 chG019 light MVLQTQVFISLLLWISGAYGDIQMTQSPSLLSASVGDRVTLNCKASQNIYKNLAWYQ
    chain full-length QKLGEGPKLLIYDANTLQTGIPSRFSGSGSGSDFTLTISSLQPEDVATYFGQQYYSG
    amino acid WAFGGVTNLELKRAVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN
    sequence ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF
    NRGEC
  • TABLE 1-4
    24 chG019 light ATGGTGCTGCAGACCCAGGTGTTCATCAGCCTGCTGCTGTGGATCAGCGGCGCCTAC
    chain full-length GGCGACATCCAGATGACCCAGAGCCCTAGCCTGCTGAGCGCCAGCGTGGGCGATAGA
    nucleotide sequence GTGACCCTGAACTGCAAGGCCAGCCAGAACATCTACAAGAACCTGGCCTGGTATCAG
    CAGAAGCTGGGCGAGGGCCCCAAGCTGCTGATCTACGACGCCAACACCCTGCAGACC
    GGCATCCCCAGCAGATTTTCTGGCAGCGGCAGCGGCTCCGACTTCACCCTGACAATC
    AGCAGCCTGCAGCCCGAGGACGTGGCCACCTACTTTTGCCAGCAGTACTACAGCGGC
    TGGGCCTTCGGCGGCGTGACCAACCTGGAACTGAAGAGAGCCGTGGCCGCTCCCTCC
    GTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCGTG
    TGCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAGGTGCAGTGGAAGGTGGACAAT
    GCCCTGCAGTCTGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCC
    ACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAGGCCGACTACGAGAAGCACAAG
    GTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTC
    AACCGGGGCGAGTGT
    25 chG019 light-chain GACATCCAGATGACCCAGAGCCCTAGCCTGCTGAGCGCCAGCGTGGGCGATAGAGTG
    variable region ACCCTGAACTGCAAGGCCAGCCAGAACATCTACAAGAACCTGGCCTGGTATCAGCAG
    nucleotide sequence AAGCTGGGCGAGGGCCCCAAGCTGCTGATCTACGACGCCAACACCCTGCAGACCGGC
    ATCCCCAGCAGATTTTCTGGCAGCGGCAGCGGCTCCGACTTCACCCTGACAATCAGC
    AGCCTGCAGCCCGAGGACGTGGCCACCTACTTTTGCCAGCAGTACTACAGCGGCTGG
    GCCTTCGGCGGCGTGACCAACCTGGAACTGAAGAGAGCC
    26 chG019 heavy chain MKHLWFFLLLVAAPRWVLSQVQLQQSGAELVKPGSSVKISCKASGYTFTRNFMHWIK
    full-length amino QQPGNGLEWIGWIYPGDGETEYNQKFNGKATLTADRSSSTAYMELSRLTSEDSAVYF
    acid sequence CARGVYGGFAGGYFDFWGGGVHVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTGTYICNVNH
    KPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
    VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
    YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
    HNHYTQKSLSLSPGK
  • TABLE 1-5
    27 chG019 ATGAAACACCTGTGGTTCTTCCTCCTGCTGGTGGCAGCTCCCAGATGGGTGCTGAGC
    heavy-chain CAGGTGCAGCTGCAGCAGTCTGGCGCCGAGCTCGTGAAGCCTGGCAGCAGCGTGAAG
    full-length ATCAGCTGCAAGGCCAGGGGCTACAGCTTCACCCGGAACTTCATGCACTGGATGAAG
    nucleotide sequence CAGCAGCCCGGCAACGGCCTGGAATGGATCGGCTGGATCTATCCCGGCGACGGCGAG
    ACAGAGTACAACCAGAAGTTCAACGGCAAGGCCACCCTGACCGCCGACAGAAGCAGC
    TGCACCGCCTACATGGAACTGAGGCGGCTGACCAGGGAGGACAGCGCCGTGTACTTT
    TGCGCCAGAGGCGTGTACGGCGGCTTCGCTGGCGGGTACTTCGATTTTTGGGGCCAG
    GGCGTGATGGTCACCGTCAGCTCAGCCTCCACCAAGGGCCCAAGCGTCTTCCCCCTG
    GCACCCTCCTCCAAGAGCACCTCTGGCGGCACAGCCGCCCTGGGCTGCCTGGTCAAG
    GACTACTTCCCCGAACCCGTGACCGTGAGCTGGAACTCAGGCGCCCTGACCAGCGGC
    GTGCACACCTTCCCCGCTGTCCTGCAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG
    GTGACCGTGCCCTCCAGGAGCTTGGGCACCCAGACGTACATCTGCAACGTGAATCAC
    AAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACT
    CACACATGCCCACCCTGGCCAGCACCTGAACTCCTGGGGGGACCCTCAGTCTTCCTC
    TTCCCCCCAAAACCCAAGGACACCCTCATGATCTCGCGGACCCCTGAGGTCACATGC
    GTGGTGGTGGACGTGAGGCACGAAGACGCTGAGGTGAAGTTCAACTGGTACGTGGAC
    GGCGTGGAGGTGCATAATGCCAAGAGAAAGCCCGGGGAGGAGCAGTACAACAGGACG
    TACCGGGTGGTCAGCGTGCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
    TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCC
    AAAGCCAAAGGCCAGCCCCGGGAACGACAGGTGTACACCCTGCCCCCATCCCGGGAG
    GAGATGACGAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGGTTCTATGCCAGC
    GACATCGCCGTGGAGTGGGAGAGCAATGGCCAGCCGGAGAACAACTACAAGACCACC
    CCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGAC
    AAGAGCAGGTGGCAGCAGGGCAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTG
    CACAACCACTACACCCAGAAGAGCCTCTCCCTGTCTCCCGGCAAA
    28 chG019 heavy chain QVQLQQSGAELVKPGSSVKISCKASGYTFTRNFMHWIKQQPGNGLEWIGWIYPGDGE
    variable region TEYNQKFNGKATLTADRSSSTAYHELSRLTSEDSAVYFCARGVYGGFAGGYFDFWGQ
    amino acid sequence GVMVTVSS
    29 chG019 heavy chain CAGGTGCAGCTGCAGCAGTCTGGCGCCGAGCTCGTGAAGCCTGGCAGCAGCGTGAAG
    variable sequence ATCAGCTGCAAGGCCAGCGGCTACACCTTCACCCGGAACTTCATGCACTGGATCAAG
    nucleotide sequence CAGCAGCCCGGCAACGGCCTGGAATGGATCGGCTGGATCTATCCCGGCGACGGCGAG
    ACAGAGTAGAACCAGAAGTTCAAGGGCAAGGGCACGCTGACGGGCGAGAGAAGGAGC
    TCCACCGCCTACATGGAACTGAGGCGGCTGACGAGGGAGGACAGCGCCGTGTAGTTT
    TGCGCCAGAGGCGTGTACGGCGGCTTCGCTGGCGGGTACTTCGATTTTTGGGGCCAG
    GGCGTGATGGTCACCGTGAGCTCA
    30 chG019 CDRH2
    31 hL02 light chain MVLQTQVFISLLLWISGAYGDIQMTQSPSSLSASVGDRVTITCKASQNIYKNLAWYQ
    full-length amino QKPGKAPKLLIYDANTLQTGVPSRFSGSGSGSDFTLTISSLQPEDFATYFCQQYYSG
    acid sequence WAFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN
    ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF
    NRGEC
  • TABLE 1-6
    32 hL02 light ATGGTGCTGCAGACCCAGGTGTTCATCTCCCTGCTGCTGTGGATCTCCGGCGCGTAC
    chain full-length GGCGACATCCAGATGACCCAGAGCCCTAGCAGCGTGAGCGCCAGCGTGGGCGACAGA
    nucleotide sequence GTGACCATCAGATGCAAGGCCAGCCAGAACATCTACAAGAACCTGGCCTGGTATCAG
    CAGAAGCCCGGCAAGGCCGCCAAGCTGGTGATCTAGGACGCCAACACCGTGCAGAGC
    GGCGTGCCCAGCAGATTTTCTGGCAGCGGCAGCGGCTCCGACTTCACCCTGACAATC
    AGCAGCCTGCAGGCCGAGGACTTCGCCACCTACTTTTGCCAGCAGTACTACAGCGGC
    TGGGCGTTCGGCGAGGGCACCAAGGTGGAAATGAAGCGTACGGTGGCCGCCCCCTGG
    GTGTTCATCTTCGCCCCCTCCGACGAGGAGCTGAAGTCCGGCACCGCCTCCGTGGTG
    TGCCTGCTGAATAACTTCTACCCCAGAGAGGCCAAGGTGCAGTGGAAGGTGGACAAC
    GCCCTGCAGTCCGGGAACTCCCAGGAGAGCGTGACGGAGCAGGACAGCAAGGACAGC
    ACCTACAGCCTGAGCAGCACGCTGACCGTGAGCAAAGCCGACTACGAGAAGCACAAG
    GTGTACGCCTGCGAGGTGACGCACCAGGGCCTGAGCTCCGCCGTCACCAAGAGCTTG
    AACAGGGGGGAGTGT
    33 hL02 light-chain DIQMTQSPSSLSASVGDRVTITCKASQNIYKNLAWYQQKPGKAPKLLIYDANTLQTG
    variable region VPSRFSGSGSGSDFTLTISSLQPEDFATYFCQQYYSGWAFGQGTKVEIKRT
    amino acid sequence
    34 hL02 light-chain GACATCCAGATGACGCAGAGGCCTAGCAGCCTGAGGGGCAGCGTGGGCGAGAGAGTG
    variable region ACCATCACATGCAAGGCCAGGCAGAACATCTACAAGAACCTGGCCTGGTATCAGCAG
    nucleotide sequence AAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACGAGGCCAACACCCTGGAGACCGGC
    GTGCCCAGCAGATTTTGTGGCAGCGGCAGCGGCTGGGACTTCACCCTGACAATCAGC
    AGCCTGCAGCCCGAGGACTTCGCCACCTACTTTTGCCAGCAGTACTACAGCGGCTGG
    GGCTTCGGCCAGGGCACCAAGGTGGAAATCAAGCGTACG
    35 hL03 light chain MVLQTQVFISLLLWISGAYGDIQMTQSPSSLSASVGDRVTITCKASQNIYKNLAWYQ
    full-length amino GKLGEGPKLLIYDANTLQTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSG
    acid sequence WAFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN
    ALQSGNSGESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF
    NRGEC
    36 hL03 light chain ATGGTGCTGCAGACCCAGGTGTTCATCTCCCTGGTGCTGTGGATCTCCGGCGCGTAC
    full-length GGCGACATCCAGATGACCCAGAGCCCTAGCAGCGTGAGCGCCAGCGTGGGCGACAGA
    nucleotide sequence GTGACCATCACATGCAAGGCCAGCCAGAACATCTACAAGAACCTGGCCTGGTATCAG
    CAGAAGCTGGGCGAGGGCCCCAAGCTGCTGATCTACGACGCCAACACCCTGCAGAGC
    GGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATC
    AGCAGCCTGCAGGCCGAGGAGTTCGCCACCTACTAGTGCCAGCAGTACTACAGCGGG
    TGGGCCTTTGGCGAGGGCACCAAGGTGGAAATCAAGCGTAGGGTGGCCGCGCCCTGC
    GTGTTCATCTTCCCCCCCTCCGACGAGCAGCTGAAGTCCGGCACCGCCTCCGTGGTG
    TGCCTGCTGAATAACTTCTAGCCCAGAGAGGCCAAGGTGGAGTGGAAGGTGGACAAC
    GCCCTGCAGTCCGGGAAGTCCCAGGAGAGCGTGACGGAGCAGGACAGCAAGGACAGC
    ACCTACAGCCTGAGCAGCACGCTGACCCTGAGCAAAGCCGACTACGAGAAGCACAAG
    GTGTACGCCTGCGAGGTGACCCACCAGGGCCTGAGCTCCCCCGTCACCAAGAGCTTC
    AACAGGGGGGAGTGT
    37 hL03 light-chain DIQMTQSPSSLSASVGDRVTITCKASQNIYKNLAWYQQKLGEGPKLLYDANTLQTG
    variable region VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSGWAFGQGTKVEIKRT
    amino acid sequence
  • TABLE 1-7
    38 hL03 light-chain GACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGCGACAGAGTG
    variable region ACCATCAGATGCAAGGCCAGCCAGAACATCTAGAAGAACCTGGCCTGGTATCAGCAG
    nucleotide sequence AAGCTGGGCGAGGGCCCCAAGCTGCTGATCTACGACGCCAACACCCTGCAGACCGGC
    GTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGC
    AGCCTGCAGCCCGAGGAGTTCGCCACCTACTACTGCCAGCAGTACTACAGCGGGTGG
    GCCTTTGGCCAGGGCACCAAGGTGGAAATCAAGCGTACG
    39 hH01 heavy chain MKHLWFFLLLVAAPRWVLSEVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVR
    full-length amino QAPGQGLEWMGWIYPGDGETEYAQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYY
    acid sequence CARGVYGGFAGGYFDFWGGGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
    KPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
    VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
    YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
    HNHYTQKSLSLSPGK
    40 hH01 heavy chain ATGAAACACCTGTGGTTCTTCCTCCTGCTGGTGGCAGCTCCCAGATGGGTGCTGAGC
    full-length GAAGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAAACCAGGCGCCAGCGTGAAG
    nucleotide sequence GTGTCCTGCAAGGCCAGCGGCTACACCTTTACCCGGAACTTCATGCACTGGGTGCGC
    CAGGCTCCAGGCCAGGGACTGGAATGGATGGGCTGGATCTATCCCGGCGACGGCGAG
    ACAGAGTACGCCCAGAAATTCCAGGGCAGAGTGACCATCACCGCCGACACCAGCACC
    TCCACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAGGACACCGCCGTGTACTAT
    TGTGCCAGAGGCGTGTACGGCGGCTTCGCTGGCGGCTACTTCGATTTTTGGGGCCAG
    GGCACCCTCGTGACCGTCAGCTCAGCCTCCACCAAGGGCCCAAGCGTCTTCCCCCTG
    GCACCCTCCTCCAAGAGCACCTCTGGCGGCACAGCCGCCCTGGGCTGCCTGGTCAAG
    GACTACTTCCCCGAACCCGTGACCGTGAGCTGGAACTCAGGCGCCCTGACCAGCGGC
    GTGCACACCTTCCCCGCTGTCCTGCAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG
    GTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCAC
    AAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACT
    CACACATGCGCACGCTGGCGAGCACCTGAAGTGCTGGGGGGACCGTCAGTCTTCCTC
    TTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
    GTGGTGGTGGAGGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC
    GGCGTGGAGGTGCATAATGCCAAGACAAAGCCCCGGGAGGAGCAGTACAACAGCAGG
    TACCGGGTGGTCAGCGTCGTCACCGTCCTGCACCAGGACTGGGTGAATGGCAAGGAG
    TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCC
    AAAGCCAAAGGCCAGCCCCGGGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAG
    GAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGC
    GACATCGCCGTGGAGTGGGAGAGCAATGGCCAGCCCGAGAACAACTACAAGACCACC
    CCTCCCGTGCTGGACTCCGACGGCTCCTTCTTGCTCTACAGCAAGCTCACCGTGGAC
    AAGAGCAGGTGGCAGCAGGGCAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTG
    CACAAGCACTACACCCAGAAGAGCCTCTGCGTGTCTCCCGGCAAA
    41 hH01 light-chain EVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVRQAPGQGLEWMGWIYPGDGE
    variable region TEYAQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCARGVYGGFAGGYFDFWGQ
    amino acid sequence GTLVTVSS
  • TABLE 1-8
    42 hL01 heavy-chain GAAGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAAACCAGGCGCCAGCGTGAAG
    variable region GTGTCCTGCAAGGCCAGCGGCTACACCTTTACCCGGAACTTCATGCACTGGGTGCGC
    nucleotide sequence CAGGCTCCAGGCCAGGGACTGGAATGGATGGGCTGGATCTATCCCGGCGACGGCGAG
    AGAGAGTACGCCGAGAAATTCCAGGGGAGAGTGACCATGACGGCCGACAGCAGCACC
    TGCACGGCCTACATGGAAGTGAGCAGCCTGCGGAGCGAGGAGAGCGCCGTGTACTAT
    TGTGCCAGAGGCGTGTACGGCGGCTTGGGTGGCGGCTACTTGGATTTTTGGGGGCAG
    GGCACCCTCGTGACGGTCAGCTCA
    43 hH02 heavy chain MKHLWFFLLLVAAPRWVLSEVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVR
    full-length amino QAPGQGLEWMGWIYPGDGETEYNQKFQGRVTITADRSTSTAYMELSSLRSEDTAVYF
    acid sequence CARGVYGGFAGGYFDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
    KPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
    VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
    YKCKVSNKALPAPIEKTISKAKGGPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
    HNHYTQKSLSLSPGK
    44 hH02 heavy chain ATGAAACACCTGTGGTTCTTCCTCCTGCTGGTGGCAGCTCCCAGATGGGTGCTGAGC
    full-length GAAGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAAACCAGGCGCCAGCGTGAAG
    nucleotide sequence GTGTCCTGCAAGGCCAGCGGCTACACCTTTACCCGGAACTTCATGCACTGGGTGCGC
    CAGGCTCCAGGCCAGGGACTGGAATGGATGGGCTGGATCTATCCCGGCGACGGCGAG
    ACAGAGTACAACCAGAAATTCCAGGGCAGAGTGACCATCACCGCCGACAGAAGCACC
    AGCACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAGGATACCGCCGTGTACTTC
    TGTGCCAGAGGCGTGTACGGCGGCTTCGCTGGCGGCTACTTCGATTTTTGGGGCCAG
    GGCACCCTCGTGACCGTCAGCTCAGCCTCCACCAAGGGCCCAAGCGTCTTCCCCCTG
    GCACCCTCCTCCAAGAGCACCTCTGGCGGCACAGCCGCCCTGGGCTGCCTGGTCAAG
    GACTACTTCCCCGAACCCGTGACCGTGAGCTGGAACTCAGGCGCCCTGACCAGCGGC
    GTGCACACCTTCCCCGCTGTCCTGCAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG
    GTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCAC
    AAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACT
    CACACATGCCCACCCTGCCCAGCACCTGAACTCCTGGGGGGACCCTCAGTCTTCCTC
    TTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
    GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC
    GGCGTGGAGGTGCATAATGCCAAGACAAAGCCCCGGGAGGAGCAGTACAACAGCACG
    TACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
    TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCC
    AAAGCCAAAGGCCAGCCCCGGGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAG
    GAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGC
    GACATCGCCGTGGAGTGGGAGAGCAATGGCCAGCCCGAGAACAACTACAAGACCACC
    CCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGAC
    AAGAGCAGGTGGCAGCAGGGCAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTG
    CACAACCACTACACCCAGAAGAGCCTCTCCCTGTCTCCCGGCAAA
    45 hH02 heavy-chain EVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVRQAPGQGLEWMGWIYPGDGE
    variable reigon TEYNQKFQGRVTITADRSTSTAYMELSSLRSEDTAVYFCARGVYGGFAGGYFDFWGQ
    amino acid sequence GTLVTVSS
  • TABLE 1-9
    46 hH02 heavy-chain GAAGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAAACCAGGCGCCAGCGTGAAG
    variable region GTGTCCTGCAAGGCCAGCGGCTACACCTTTACCCGGAACTTCATGCACTGGGTGCGC
    nucleotide sequence CAGGCTCCAGGCCAGGGACTGGAATGGATGGGCTGGATCTATCCCGGCGACGGCGAG
    ACAGAGTACAACCAGAAATTCCAGGGCAGAGTGACCATCACCGCCGACAGAAGCACC
    AGCACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAGGATACCGCCGTGTACTTC
    TGTGCCAGAGGCGTGTACGGCGGCTTCGCTGGCGGCTACTTCGATTTTTGGGGCCAG
    GGCACCCTCGTGACCGTCAGCTCA
    47 hH04 heavy chain MKHLWFFLLLVAAPRWVLSQVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWIR
    full-length amino GAPGQGLEWMGWIYPGDGETEYAQKFGGRVTLTADRSTSTAYMELSSLRSEDTAVYY
    acid sequence CARGVYGGFAGGYFDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
    KPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC
    VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
    YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWGQGNVFSCSVMHEAL
    HNHYTQKSLSLSPGK
    48 hH04 heavy chain ATGAAACACCTGTGGTTCTTCCTGCTGCTGGTGGCAGCTCCCAGATGGGTGCTGAGC
    full-length CAGGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAAACCAGGCGCCAGCGTGAAG
    nucleotide sequence GTGTCCTGCAAGGCCAGCGGCTACACCTTTACCCGGAACTTCATGCACTGGATCCGG
    CAGGCCCGTGGACAGGGCCTGGAATGGATGGGCTGGATCTATCCCGGCGACGGCGAG
    ACAGAGTAGGCCCAGAAATTCCAGGGCAGAGTGACCCTGACCGCCGACAGAAGCACC
    AGCACCGGCTACATGGAACTGAGGAGCCTGCGGAGCGAGGACACCGCCGTGTACTAT
    TGTGCCAGAGGGGTGTACGGCGGGTTCGCTGGCGGGTACTTCGATTTTTGGGGCCAG
    GGCACCCTCGTGACCGTCAGCTCAGCCTCCACCAAGGGCCCAAGCGTCTTCCCCGTG
    GCACCCTGCTGCAAGAGCAGCTCTGGCGGCACAGCCGGCCTGGGCTGCCTGGTCAAG
    GACTACTTCCCCGAACCCGTGACGGTGAGCTGGAACTCAGGCGCCCTGACCAGCGGC
    GTGCACACCTTCCCCGCTGTCCTGCAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG
    GTGACGGTGCCCTCCAGCAGCTTGGGCACCCAGACGTACATCTGCAACGTGAATCAC
    AAGCCCAGCAACACCAAGGTGGAGAAGAGAGTTGAGCGCAAATCTTGTGACAAAACT
    CACACATGCCCACCCTGCCCAGCACCTGAACTCCTGGGGGGACCCTCAGTCTTCCTC
    TTCCCGCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGC
    GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC
    GGCGTGGAGGTGCATAATGCCAAGACAAAGCCCCGGGAGGAGCAGTACAACAGCACG
    TACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
    TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCC
    AAAGCCAAAGGCCAGCCCCGGGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAG
    GAGATGACCAAGAACCAGGTCAGGCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGC
    GACATGGCCGTGGAGTGGGAGAGCAATGGCCAGCCCGAGAACAACTACAAGACCACC
    CCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGAC
    AAGAGCAGGTGGCAGCAGGGCAACGTCTTCTCATGCTGCGTGATGCATGAGGCTCTG
    CACAACCACTACACCCAGAAGAGGCTCTCCGTGTGTCGCGGCAAA
    49 hH04 heavy-chain QVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWIRQAPGQGLEWMGWIYPGDGE
    variable region TEYAQKFQGRVTLTADRSTSTAYMELSSLRSEDTAVYYCARGVYGGFAGGYFDFWGQ
    amino acid sequence GTLVTVSS
  • TABLE 1-10
    50 hH04 heavy-chain CAGGTGCAGCTGGTGCAGTCTGGCGCCGAAGTGAAGAAACCAGGCGCCAGCGTGAAG
    variable region GTGTCCTGCAAGGCCAGCGGCTACACCTTTACCCGGAACTTCATGCACTGGATCCGG
    nucleotide sequence CAGGCCCCTGGACAGGGCCTGGAATGGATGGGCTGGATCTATCCCGGCGACGGCGAG
    ACAGAGTACGCCCAGAAATTCCAGGGCAGAGTGACCCTGACCGCCGACAGAAGCACC
    AGCACCGCCTACATGGAACTGAGCAGCCTGCGGAGCGAGGACACCGCCGTGTACTAT
    TGTGCCAGAGGCGTGTACGGCGGCTTCGCTGGCGGCTACTTCGATTTTTGGGGCCAG
    GGCACCCTCGTGACCGTCAGCTCA
    51 NOVO0172 MVLQTQVFISLLLWISGAYGDIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQ
    light chain QKPGKAPKLLIYAVSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSGTF
    full-length amino PPTTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKV
    acid sequence DNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK
    SFNRGEC
    52 Nucleotide sequence ATGGTGCTGCAGACCCAGGTGTTCATCTCCCTGCTGCTGTGGATCTCCGGCGCGTAC
    encoding amino acid GGCGACATCCAGATGACCCAGAGCCCTAGCAGCCTGAGCGCCAGCGTGGGCGACAGA
    sequence shown in GTGACCATCACCTGTAGAGCCAGCCAGAGCATCAGCAGCTACCTGAACTGGTATCAG
    SEQ ID NO: 51 CAGAAGCCCGGCAAGGCCCCCAAACTGCTGATCTACGCCGTGTCCACACTGCAGAGC
    GGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATC
    AGCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGTCAGCAGTCCGGCACCTTC
    CCCCCCACCACATTTGGCCAGGGCACCAAGGTGGAAATCAAGCGTACGGTGGCCGCC
    CCCTCCGTGTTCATCTTCCCCCCCTCCGACGAGCAGCTGAAGTCCGGCACCGCCTCC
    GTGGTGTGCCTGCTGAATAACTTCTACCCCAGAGAGGCCAAGGTGCAGTGGAAGGTG
    GACAACGCCCTGCAGTCCGGGAACTCCCAGGAGAGCGTGACCGAGCAGGACAGCAAG
    GACAGCACCTACAGCCTGAGCAGCACCCTGACCCTGAGCAAAGCCGACTACGAGAAG
    CACAAGGTGTACGCCTGCGAGGTGACCCACCAGGGCCTGAGCTCCCCCGTCACCAAG
    AGCTTCAACAGGGGGGAGTGT
    53 NOVO0712 MKHLWFFLLLVAAPRWVLSQVQLLESGGGLVQPGGSLRLSCAASGFTFSSHGMHWVR
    heavy chain QAPGKGLEWVSVISGSGSNTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY
    full-length amino CARQWGSYAFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFP
    acid sequence EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN
    TKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
    VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK
    VSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTGLVKGFYPSDIAV
    EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY
    TQKSLSLSPGK
  • TABLE 1-11
    54 Nucleotide ATGAAACACCTGTGGTTCTTCCTCCTGCTGGTGGCAGCTCCCAGATGGGTGCTGAGC
    sequence encoding CAGGTGCAGCTGCTGGAATCTGGCGGAGGACTGGTGCAGCCTGGCGGCTCTCTGAGA
    amino acid CTGTCTTGTGCCGCCAGCGGCTTCACCTTCAGCAGCCACGGAATGCACTGGGTGCGC
    sequence shown CAGGCCCCTGGAAAGGGACTGGAATGGGTGTCCGTGATCAGCGGCAGCGGCTCCAAT
    in SEQ ID NO: 53 ACCGGCTACGCCGATAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAG
    AACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTAT
    TGTGCCAGACAGTGGGGCAGCTACGCCTTCGATTCTTGGGGCCAGGGCACCCTCGTG
    ACCGTCAGCTCAGCCTCCACCAAGGGCCCAAGCGTCTTCCCCCTGGCACCCTCCTCC
    AAGAGCACCTCTGGCGGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCC
    GAACCCGTGACCGTGAGCTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTC
    CCCGCTGTCCTGCAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCC
    TCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAAC
    ACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCA
    CCCTGCCCAGCACCTGAACTCCTGGGGGGACCCTCAGTCTTCCTCTTCCCCCCAAAA
    CCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGAC
    GTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
    CATAATGCCAAGACAAAGCCCCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTC
    AGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAG
    GTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGC
    CAGCCCCGGGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAG
    AACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTG
    GAGTGGGAGAGCAATGGCCAGCCCGAGAACAACTACAAGACCACCCCTCCCGTGCTG
    GACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGG
    CAGCAGGGCAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTAC
    ACCCAGAAGAGCCTCTCCCTGTCTCCCGGCAAA
    55 hH11 heavy-chain EVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVRQAPGQGLEWMGWIAPGDGE
    variable region TEYAQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCARGVYGGFAGGYFDFWGQ
    amino acid sequence GTLVTVSS
    56 hH11 heavy-chain GAAGTGCAGCTGGTTCAGTCTGGCGCCGAAGTGAAAAAGCCTGGCGCCTCTGTGAAG
    variable region GTGTCCTGCAAGGCCTCTGGCTACACATTCACCCGGAACTTCATGCACTGGGTCCGA
    nucleotide sequence CAGGCTCCAGGACAGGGACTTGAATGGATGGGATGGATTGCTCCCGGCGACGGCGAG
    ACAGAGTACGCCCAGAAATTCCAGGGCAGAGTGACCATCACCGCCGACACCTCTACA
    AGCACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTAT
    TGTGCCAGAGGCGTGTACGGCGGATTCGCTGGCGGCTACTTTGATTTTTGGGGCCAG
    GGCACCCTGGTCACCGTGAGCTCA
    57 hH11 CDRH1 GYTFTRNFMH
    58 hH11 CDRH2 WIAPGDGETE
    59 hH11 CDRH3 GVYGGFAGGYFDF
    60 hH31 heavy-chain EVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVRQAPGQGLEWMGWIYPGDGE
    variable region TEYASKFQGRVTITADTSTSTAYMELSSLRSEDTAVYYCARGVYGGAAGGYFDFWGQ
    amino acid sequence GTLVTVSS
  • TABLE 1-12
    61 hH31 heavy-chain GAAGTGCAGCTGGTTCAGTCTGGCGCCGAAGTGAAAAAGCCTGGCGCCTCTGTGAAG
    variable region GTGTCCTGCAAGGCCTCTGGCTACACATTCACCCGGAACTTCATGCACTGGGTCCGA
    nucleotide sequence CAGGCTCCAGGACAGGGACTTGAATGGATGGGCTGGATGTATCCCGGCGACGGCGAG
    ACAGAGTACGCCAGCAAATTTCAGGGCAGAGTGACGATGACCGCGGACACCTCTACA
    AGCACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTAT
    TGTGCCAGAGGCGTTTACGGCGGAGGCGCTGGCGGCTACTTTGATTTTTGGGGCCAG
    GGCACCCTGGTCACCGTGAGCTCA
    62 hH31 CDRH1 GYTFTRNFMH
    63 hH31 CDRH2 WIYPGDGETE
    64 hH31 CDRH3 GVYGGAAGYFDF
    65 hH01A heavy chain MKHLWFFLLLVAAPRWVLSEVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVR
    full-length amino QAPGQGLEWMGWIYPGDGETEYAQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYY
    acid sequence CARGVYGGFAGGVFDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
    KPSNTKVDKRVEPKSGDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTC
    VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
    YKCKVSNKALPAPIEKTISKAKGGPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
    DIAVEWESNGGPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQGGNVFSCSVMHEAL
    HNHYTQKSLSLSPGK
    66 hH01A heavy chain ATGAAACACCTGTGGTTCTTCCTCCTGCTGGTGGCAGCTCCCAGATGGGTGCTGAGC
    full-length GAAGTGCAGCTGGTTCAGTCTGGCGCCGAAGTGAAAAAGCCTGGCGCCTCTGTGAAG
    nucleotide sequence GTGTCGTGCAAGGCCTCTGGCTACACATTCACCCGGAAGTTCATGCACTGGGTCCGA
    CAGGCTCCAGGACAGGGACTTGAATGGATGGGCTGGATGTATCCCGGCGACGGCGAG
    ACAGAGTACGCCCAGAAATTCCAGGGCAGAGTGACCATCACCGCGGACACCTCTACA
    AGCACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTAT
    TGTGCCAGAGGCGTGTACGGCGGATTCGCTGGCGGCTACTTTGATTTTTGGGGCCAG
    GGCACCCTGGTCACCGTGAGCTCAGCCTCCACCAAGGGGCCAAGGGTCTTCCCCCTG
    GCACCCTCCTCCAAGAGCACCTCTGGCGGCACAGCGGCGCTGGGCTGCCTGGTCAAG
    GACTACTTCCCCGAACCCGTGACCGTGAGCTGGAAGTCAGGCGCCCTGACCAGCGGC
    GTGCAGACCTTCCCCGGTGTCCTGCAGTGCTCAGGACTGTACTCCGTCAGCAGCGTG
    GTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCAC
    AAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAAGT
    CACACATGCCCACCCTGCCCAGCACCTGAAGCCGCGGGGGGACCCTCAGTCTTCCTC
    TTCCCCCCAAAACCCAAQGACACCCTCATGATCTCCCGGACCCCTGAGGTCAGATGC
    GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC
    GGCGTGGAGGTGCATAATGCCAAGACAAAGCCCCGGGAGGAGCAGTACAACAGCACG
    TACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
    TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCC
    AAAGCCAAAGGCCAGGCCCGGGAACCACAGGTGTAGACGCTGCCCCCATCCCGGGAG
    GAGATGACCAAGAACGAGGTCAGCCTGACCTGCCTGGTCAAAGGGTTCTATCCCAGC
    GACATGGCCGTGGAGTGGGAGAGCAATGGCCAGCCGGAGAACAACTACAAGACCACC
    CCTCCGGTGCTGGACTCGGACGGCTCCTTCTTCGTCTACAGCAAGCTCACCGTGGAG
    AAGAGGAGGTGGCAGGAGGGCAACGTCTTCTCATGCTGGGTGATGCATGAGGCTCTG
    CACAACCACTACACCCAGAAGAGCCTCTCCCTGTCTCCCGGCAAA
  • TABLE 1-13
    67 hH11A heavy chain MKHLWFFLLLVAAPRWVLSEVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVR
    full-length amino QAPGQGLEWMGWIAPGDGETEYAQKFQGRVTITADTSTSTAYMELSSLRSEDTAVYY
    acid sequence CARGVYGGFAGGYFDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
    KPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTC
    VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
    YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
    HNHYTQKSLSLSPGK
    68 hH11A heavy chain ATGAAACACCTGTGGTTCTTCCTCCTGCTGGTGGCAGCTCCCAGATGGGTGCTGAGC
    full-length GAAGTGCAGCTGGTTGAGTCTGGCGCGGAAGTGAAAAAGCCTGGGGGCTCTGTGAAG
    nucleotide sequence GTGTCCTGCAAGGCGTCTGGCTACACATTCAGGCGGAACTTCATGCACTGGGTCCGA
    CAGGCTCGAGGACAGGGACTTGAATGGATGGGATGGATTGCTCCCGGCGAGGGCGAG
    ACAGAGTACGCCCAGAAATTCCAGGGCAGAGTGACCATCACCGCCGACACCTCTACA
    AGCACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTACTAT
    TGTGCCAGAGGCGTGTACGGGGGATTCGCTGGGGGCTAGTTTGATTTTTGGGGCCAG
    GGCACCCTGGTCACCGTGAGGTCAGCCTCCACCAAGGGCCCAAGGGTCTTCCCCCTG
    GCACCCTGGTCCAAGAGCACGTCTGGCGGCACAGGCGCCCTGGGGTGCCTGGTCAAG
    GACTACTTCCCCGAACCCGTGACCGTGAGCTGGAACTCAGGCGCCCTGACCAGCGGC
    GTGCACAGGTTGCCCGCTGTGCTGGAGTCCTGAGGACTCTACTCGCTCAGCAGCGTG
    GTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCAC
    AAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACT
    CACACATGCCCACCCTGCCCAGCACCTGAAGCCGGGGGGGGACCCTCAGTGTTCCTC
    TTCCCCCGAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTGACATGC
    GTGGTGGTGGAGGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTAGGTGGAC
    GGCGTGGAGGTGCATAATGCCAAGACAAAGCCCCGGGAGGAGCAGTACAACAGCACG
    TACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
    TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCC
    AAAGCCAAAGGCCAGCCCCGGGAACCACAGGTGTACACCCTGCCCCCATCGCGGGAG
    GAGATGACGAAGAACCAGGTGAGCGTGACCTGGCTGGTCAAAGGCTTCTATCCCAGC
    GACATCGGGGTGGAGTGGGAGAGCAATGGCCAGCGCGAGAACAAGTACAAGACCAGC
    CCTCCCGTGCTGGAGTCCGAGGGCTCGTTCTTCCTCTACAGCAAGCTCACGGTGGAC
    AAGAGCAGGTGGCAGCAGGGCAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTG
    CACAACCACTACACCCAGAAGAGCCTCTCCCTGTCTCCCGGCAAA
    69 hH31A heavy chain MKHLWFFLLLVAAPRWVLSEVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVR
    full-length amino QAPGQGLEWMGWIYPGDGETEYASKFQGRVTITADTSTSTAYMELSSLRSEDTAVYY
    acid sequence CARGVYGGAAGGYFDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
    DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNH
    KPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTC
    VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
    YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPS
    DIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
    HNHYTGKSLSLSPGK
  • TABLE 1-14
    70 hH31A heavy chain ATGAAACAGCTGTGGTTCTTCCTCCTGCTGGTGGCAGCTCCCAGATGGGTGCTGAGG
    full-length GAAGTGCAGCTGGTTCAGTCTGGCGCCGAAGTGAAAAAGCCTGGCGCCTCTGTGAAG
    nucleotide sequence GTGTCCTGCAAGGCCTCTGGCTACACATTCAGCCGGAACTTCATGCACTGGGTCCGA
    CAGGCTCCAGGACAGGGACTTGAATGGATGGGCTGGATCTATCCCGGCGACGGCGAG
    ACAGAGTACGCCAGCAAATTTCAGGGCAGAGTGACCATCACCGCCGACACCTCTACA
    AGCACCGCCTACATGGAACTGAGCAGCGTGAGAAGCGAGGAGACCGCCGTGTACTAT
    TGTGCCAGAGGCGTTTACGGCGGAGCCGCTGGCGGCTACTTTGATTTTTGGGGCCAG
    GGCACCCTGGTCACCGTGAGCTCAGCCTCGAGCAAGGGCCCAAGCGTCTTCCCCCTG
    GCACCCTCCTGCAAGAGCACCTCTGGCGGGAGAGCCGCCCTGGGCTGCGTGGTCAAG
    GACTACTTCCGCGAAGCCGTGACCGTGAGCTGGAACTCAGGCGCCCTGACCAGCGGG
    GTGCACACCTTCCCCGCTGTCCTGCAGTCCTGAGGACTCTACTCGCTCAGCAGCGTG
    GTGACCGTGCGCTCCAGCAGCTTGGGCAGCCAGACCTAGATCTGCAACGTGAATCAC
    AAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACT
    CACACATGCCCACCCTGCCCAGCACCTGAAGCCGCGGGGGGACCCTCAGTCTTCCTC
    TTGGGGGGAAAAGGGAAGGAGAGGGTGATGATGTGGGGGAGGGGTGAGGTGAGATGG
    GTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGAC
    GGCGTGGAGGTGCATAATGCCAAGACAAAGCCCCGGGAGGAGCAGTACAACAGCACG
    TACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAG
    TACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCG
    AAAGCCAAAGGCCAGCCCCGGGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAG
    GAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGC
    GACATCGCGGTGGAGTGGGAGAGCAATGGGGAGCCCGAGAACAACTACAAGACCACC
    CCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGAC
    AAGAGCAGGTGGCAGCAGGGCAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTG
    CACAACCACTACACCCAGAAGAGCCTCTCCCTGTCTCCCGGCAAA
    71 DNA fragment ccagcctccggactctagagccaccATGAAACACCTGTGGTTCTTCCTCCTGCTGGT
    comprising DNA GGCAGCTCCCAGATGGGTGCTGAGCCAGGTGCAATTGTGCAGGCGGTTAGCTCAGCC
    sequence encoding TCCACCAAGGGCCCAAGGGTCTTCCCCCTGGGACCCTCCTCCAAGAGCACCTCTGGC
    amino acid sequence GGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCCGTGACCGTG
    of human heavy AGCTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCCGCTGTCCTGCAG
    chain signal TCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCGAGCAGCTTGGGC
    sequence and human ACCCAGACCTACATCTGCAACGTGAATCACAAGCGCAGCAACACCAAGGTGGACAAG
    IgG1 LALA constant AGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCT
    region GAAGCCGCGGGGGGACCCTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTC
    ATGATCTGCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGAC
    GCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACA
    AAGCCCCGGGAGGAGGAGTACAACAGCACGTACCGGGTGGTCAGCGTGGTCACCGTC
    CTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCC
    GTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGCCAGCCCGGGGAACCA
    CAGGTGTACAGCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTG
    ACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
    GGCCAGCCCGAGAACAACTACAAGACCACCCCTCCCGTGCTGGACTCCGACGGCTCC
    TTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGCAACGTC
    TTCTCATGCTGCGTGATGCATGAGGCTCTGCACAACCACTACACCCAGAAGAGCCTC
    TCCCTGTCTCCCGGCAAAtgagatatcgggcccgtttaaacgggggaggctaac
  • 3. Anti-CDH6 Antibody-Drug Conjugate
  • The antibody-drug conjugate of the present invention is represented by the following formula:
  • Figure US20220016257A1-20220120-C00022
  • wherein
  • m2 represents an integer of 1 or 2,
  • Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof
  • L represents a linker, linking the glycan (N297) bonding to N297 of Ab and D, and
  • D is any one of the following formulas:
  • Figure US20220016257A1-20220120-C00023
  • wherein the asterisk (*) represents bonding to L.
  • <Drug>
  • The anti-CDH6 antibody obtained in the above “2. Production of anti-CDH6 antibody” can be conjugated to a drug via a linker moiety to prepare an anti-CDH6 antibody-drug conjugate. The drug is not particularly limited as long as it has a substituent or a molecular part that can be connected to a linker The anti-CDH6 antibody-drug conjugate can be used for various purposes according to the conjugated drug. Examples of such a drug can include substances having antitumor activity, substances effective for blood diseases, substances effective for autoimmune diseases, anti-inflammatory substances, antimicrobial substances, antifungal substances, antiparasitic substances, antiviral substances, and anti-anesthetic substances.
  • <Antitumor Compound>
  • Examples using an antitumor compound as the compound to be used in the anti-CDH6 antibody-drug conjugate of the present invention will be described below. The antitumor compound is not particularly limited as long as the compound has an antitumor effect and has a substituent or a partial structure that can be connected to a linker structure. Upon cleavage of a part or the whole of the linker in tumor cells, the antitumor compound moiety is released so that the antitumor compound exhibits an antitumor effect. As the linker is cleaved at a connecting position with the drug, the antitumor compound is released in its original structure to exert its original antitumor effect. The released compounds serving as the drug are, e.g., drugs 1 to 4 described in Examples 10-7 to 10-10.
  • The anti-CDH6 antibody obtained in the above “2. Production of anti-CDH6 antibody” can be conjugated to the antitumor compound via a linker structure moiety to prepare an anti-CDH6 antibody-drug conjugate.
  • The antitumor compound to be used in the present invention is represented by any one of the formulas below:
  • Figure US20220016257A1-20220120-C00024
  • wherein the asterisk (*) represents bonding to L.
  • The PBD derivative of the present invention has an asymmetric carbon at the 11′-position, and thus there exist optical isomers. Herein, these isomers and a mixture of these isomers are all represented by a single formula. Accordingly, the PBD derivatives of the present invention include all the optical isomers and mixtures of the optical isomers at any ratio. The absolute steric configuration at the 11′-position of the PBD derivatives of the present invention can be determined through X-ray crystal structure analysis or NMR such as a Mosher method for its crystalline product or intermediate, or a derivative thereof. Then, the absolute steric configuration may be determined by using a crystalline product or intermediate derivatized with a reagent having an asymmetric center whose steric configuration is known. As desired, stereoisomers of the synthesized compound according to the present invention may be obtained by isolating with a common optical resolution method or separation method.
  • There may exist stereoisomers, optical isomers due to an asymmetric carbon atom, geometric isomers, tautomers, or optical isomers such as d-forms, 1-forms and atropisomers for the antibody-drug conjugate of the present invention, the free drug or production intermediates of the antibody-drug conjugate, and these isomers, optical isomers, and mixtures of them are all included in the present invention.
  • The antitumor compound to be used in the present invention is represented by any one of the formulas below:
  • Figure US20220016257A1-20220120-C00025
  • wherein the asterisk (*) represents bonding to L.
    • <Linker Structure>
  • The linker structure to bond the antitumor drug to an antibody in the antibody-drug conjugate of the present invention will be described.
  • Linker L is represented by the following formula: -Lb-La-Lp-NH—B—CH2—O(C═O)—*.
  • The asterisk* represents bonding to the nitrogen atom at the N10′-position of the antitumor compound represented by D; Lb represents a spacer which connects La to the glycan or remodeled glycan of Ab.
  • B represents a phenyl group or a heteroaryl group, and is preferably a 1,4-phenyl group, a 2,5-pyridyl group, a 3,6-pyridyl group, a 2,5-pyrimidyl group, or a 2,5-thienyl group, and more preferably a 1,4-phenyl group.
  • Lp represents a linker consisting of an amino acid sequence cleavable in vivo or in a target cell. Lp is, for example, cleaved by the action of an enzyme such as an esterase or peptidase.
  • Lp is a peptide residue composed of two to seven (preferably, two to four) amino acids. That is, Lp is composed of an oligopeptide residue in which two to seven amino acids are connected via a peptide bond.
  • Lp is bound at the N terminal to the carbonyl group of La in Lb-La-, and forms at the C terminal an amide bond with the amino group (—NH—) of the part —NH—B—CH2—O(C═O)— of the linker. The bond between the C terminal of Lp and —NH— is cleaved by an enzyme such as an esterase.
  • The amino acids constituting Lp are not limited to particular amino acids, and, for example are L- or D-amino acids, and preferably L-amino acids. The amino acids may be not only α-amino acids, but may include an amino acid with structure, for example, of 0-alanine, 6-aminocaproic acid, or γ-aminobutyric acid, and may further include a non-natural amino acid such as an N-methylated amino acid.
  • The amino acid sequence of Lp is not limited to a particular amino acid sequence, and examples of amino acids that constitute Lp may include, but are not limited to, glycine (Gly; G), valine (Val; V), alanine (Ala; A), phenylalanine (Phe; F), glutamic acid (Glu; E), isoleucine (Ile; I), proline (Pro; P), citrulline (Cit), leucine (Leu; L), serine (Ser; S), lysine (Lys; K) and aspartic acid (Asp; D). Preferred among them are glycine (Gly; G), valine (Val; V), alanine (Ala; A) and citrulline (Cit).
  • Any of these amino acids may appear multiple times, and Lp has an amino acid sequence including arbitrarily selected amino acids. Drug release pattern may be controlled via amino acid type.
  • Specific examples of linker Lp may include, but are not limited to, -GGVA-, -GG-(D-)VA-, -VA-, -GGFG-, -GGPI-, -GGVCit-, -GGVK-, -GG(D-)PI-, -GGPL-, -EGGVA, -PI-, -GGF-, DGGF-, (D-)D-GGF-, -EGGF-, -SGGF-, -KGGF-, -DGGFG-, -GGFGG-, -DDGGFG-, -KDGGFG- and -GGFGGGF-.
  • Here, “(D-)V” indicates D-valine, “(D)-P” indicates D-proline, and “(D-)D” indicates D-aspartic acid.
  • Linker Lp is preferably any of the following: -GGVA-, -GG-(D-)VA-, -VA-, -GGFG-, -GGPI-, -GGVCit-, -GGVK-, -GG(D-)PI- and -GGPL-,
  • Linker Lp is more preferably any of the following: -GGVA-, -GGVCit-, and -VA-.
  • Lb represents a spacer which connects La to the glycan or remodeled glycan of Ab.
  • La, which is not particularly limited, represents any one selected from the following group.
    • —C(═O)—CH2CH2—C(═O)—,
    • —C(═O)—(CH2CH2)2—C(═O)—,
    • —C(═O)—CH2CH2—C(═O)—NH—(CH2CH2)2—C(═O)—,
    • —C(═O)—CH2CH2—C(═O)—NH—(CH2CH2O)2—CH2—C(═O)—,
    • —C(═O)—CH2CH2—NH—C(═O)—(CH2CH2O)4—CH2CH2—C(═O)—,
    • —CH2—OC(═O)— and
    • —OC(═O)—.
  • La is more preferably, —C(═O)—CH2CH2—C(═O)— or —C(═O)—(CH2CH2)2—C(═O)—.
  • Spacer Lb is not limited to a particular spacer, and for examples, a spacer represented by the following formulas are included.
  • Figure US20220016257A1-20220120-C00026
  • In the structural formulas for Lb shown above, each asterisk* represents bonding to the —(C═O) or —(CH2)n4 at the left end of La, and each wavy line represents bonding to the glycan or remodeled glycan of Ab.
  • In each structural formula for Lb (Lb-1, Lb-2 or Lb-3) shown above, the triazole ring site formed through click reaction of an azide group and a cyclooctynyl group provides structures of geometric isomers, and molecules of Lb exist as any one of the two structures or as a mixture of both of them. There exist two or four (m2 is 1 or 2) “-L-D” moieties per molecule of the antibody-drug conjugate of the present invention, and either one of the two structures exist or both of them coexist as Lb (Lb-1, Lb-2, or Lb-3) in L of each of the “-L-D” moieties.
  • If Lb is i), L is preferably represented by -Lb-La-Lp-NH—B—CH2—O (C═O)—*
  • L is selected from the following group:
    • —Z1—C(═O)—CH2CH2—C(═O)-GGVA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GG-(D-)VA-NH—B—CH2—OC(═O)—
    • —Z1—C(═O)—CH2CH2—C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—(CH2CH2)2—C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GGPI-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GGFG-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GGVCit-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GGVK-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)-GGPL-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)—NH—(CH2CH2) 2-C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—C(═O)—NH—(CH2CH2O)2—CH2—C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z1—C(═O)—CH2CH2—NH—C(═O)—(CH2CH2O)4—CH2CH2—C(═O)-VA-NH—B—CH2—OC(═O)—,
    • —Z2—OC(═O)-GGVA-NH—B—CH2—OC(═O)— and
    • —Z3—CH2—OC(═O)-GGVA-NH—B—CH2—OC(═O)—,
      wherein Z1 represents the following structural formula:
  • Figure US20220016257A1-20220120-C00027
  • Z2 represents the following structural formula:
  • Figure US20220016257A1-20220120-C00028
  • Z3 represents the following structural formula:
  • Figure US20220016257A1-20220120-C00029
  • wherein, in the structural formulas Z1, Z2 and Z3, the asterisk * represents bonding to the C(═O), O or CH2 neighboring Z1, Z2 or Z3 and the wavy line represents bonding to the glycan or remodeled glycan of Ab; and
  • B represents a 1,4-phenyl group.
  • The antibody-drug conjugate of the present invention is supposed to exhibit antitumor activity through a process in which most molecules of the antibody-drug conjugate migrate into tumor cells, and a linker portion (e.g., Lp) is then cleaved by an enzyme or the like to activate the antibody-drug conjugate, which releases the portion of drug D (hereinafter, referred to as the free drug (described later)).
  • Therefore, it is preferable that the antibody-drug conjugate of the present invention is stable outside tumor cells.
  • <Glycan Remodeling>
  • Recently has been reported a method for remodeling heterogeneous glycoproteins of an antibody by enzymatic reaction or the like to introduce a homogeneous glycan having a functional group (ACS Chemical Biology 2012, 7, 110, ACS Medicinal Chemistry Letters 2016, 7, 1005). In addition, an attempt with use of this glycan remodeling technique has been made to site-specifically introduce a drug to synthesize a homogeneous ADC (Bioconjugate Chemistry 2015, 26, 2233, Angew. Chem. Int. Ed. 2016, 55, 2361-2367, US 2016361436).
  • In the glycan remodeling of the present invention, using a hydrolase, heterogeneous glycans bonding to a protein (e.g., an antibody) are cleaved off to leave only GlcNAc at each terminus thereby producing a homogenous protein moiety with GlcNAc (hereinafter, referred to as an “acceptor”). Subsequently, an arbitrary glycan separately prepared (hereinafter, referred to as a “donor”) is provided, and the acceptor and the donor are linked together by using a transglycosidase. Thereby, a homogeneous glycoprotein with an arbitrary glycan structure can be synthesized.
  • In the present invention, a “glycan” refers to a structural unit of two or more monosaccharides bonded together via glycosidic bonds. Specific monosaccharides and glycans are occasionally abbreviated, for example, as “GlcNAc-”, “MSG-”, and so on. When any of these abbreviations is used in a structural formula, the abbreviation is shown with an intention that an oxygen atom or nitrogen atom involved in a glycosidic bond at the reducing terminal to another structural unit is not included in the abbreviation indicating the glycan, unless specifically defined.
  • In the present invention, a monosaccharide as a basic unit of a glycan is indicated for convenience so that in the ring structure, the position of a carbon atom bonding to an oxygen atom constituting the ring and directly bonding to a hydroxy group (or an oxygen atom involved in a glycosidic bond) is defined as the 1-position (the 2-position only for sialic acids), unless otherwise specified. The names of compounds in the Examples are each provided in view of the chemical structure as a whole, and that rule is not necessarily applied.
  • When a glycan is indicated as a sign (e.g., GLY, SG, MSG, GlcNAc) in the present invention, the sign is intended, unless otherwise defined, to include carbon atoms ranging to the reducing terminal and not to include N or O involved in an N- or O-glycosidic bond.
  • In the present invention, unless specifically stated, a partial structure when a glycan is linking to a side chain of an amino acid is indicated in such a manner that the side chain portion is indicated in parentheses, for example, “(SG-)Asn”.
  • Glycans in Ab of the present invention are N-linked glycans or O-linked glycans, and preferably N-linked glycans.
  • N-linked glycans and O-linked glycans bond to an amino acid side chain of an antibody via an N-glycosidic bond and an O-glycosidic bond, respectively.
  • IgG has a well conserved N-linked glycan on an asparagine residue at the 297-position of the Fc region of the heavy chain (hereinafter, referred to as “Asn297 or N297”), and the N-linked glycan is known to contribute to the activity and kinetics of the antibody molecule (Biotechnol. Prog., 2012, 28, 608-622, Sanglier-Cianferani, S., Anal. Chem., 2013, 85, 715-736).
  • The amino acid sequence in the constant region of IgG is well conserved, and each amino acid is specified by Eu index numbering in Edelman et al. (Proc. Natl. Acad. Sci. U.S.A., Vol. 63, No. 1 (May 15, 1969), pp. 78-85). For example, Asn297, to which an N-linked glycan is added in the Fc region, corresponds to the 297-position in Eu index numbering, and each amino acid is uniquely specified by Eu index numbering, even if the actual position of the amino acid has varied through fragmentation of the molecule or deletion of a region.
  • In the antibody-drug conjugate of the present invention, the antibody or functional fragment of the antibody more preferably bonds to L via a glycan bonding to a side chain of Asn297 thereof (hereinafter, referred to as “N297 glycan”), and the antibody or functional fragment of the antibody even more preferably bonds via the N297 glycan to L, wherein the N297 glycan is a remodeled glycan.
  • An antibody having the remodeled glycan is referred to as a glycan-remodeled antibody.
  • SGP, an abbreviation for sialyl glycopeptide, is a representative N-linked complex glycan. SGP can be separated/purified from the yolk of a hen egg, for example, by using a method described in WO 2011/0278681. Purified products of SGP are commercially available (Tokyo Chemical Industry Co., Ltd., FUSHIMI Pharmaceutical Co., Ltd.). For example, disialooctasaccharide (Tokyo Chemical Industry Co., Ltd.), a glycan formed by deleting one GlcNAc at the reducing terminus in the glycan moiety of SG (hereinafter, referred to as “SG (10)”, is commercially available.
  • In the present invention, a glycan structure formed by deleting a sialic acid at a non-reducing terminal only in either one of the branched chains of β-Man in SG (10) refers to MSG (9), and a structure having a sialic acid only in the 1-3 branched chain is called as MSG1, and a structure having a sialic acid only in the 1-6 branched chain is called as MSG2.
  • The remodeled glycan of the present invention is N297-(Fuc)MSG1, N297-(Fuc)MSG2, or a mixture of N297-(Fuc)MSG1 and N297-(Fuc)MSG2, or N297-(Fuc)SG, and is preferably N297-(Fuc)MSG1, N297-(Fuc)MSG2, or N297-(Fuc)SG, and is more preferably N297-(Fuc)MSG1 or N297-(Fuc)MSG2.
  • N297-(Fuc)MSG1 is represented by the following structural formula or sequence formula:
  • Figure US20220016257A1-20220120-C00030
  • In the formulas, each wavy line represents bonding to Asn297 of the antibody,
  • L (PEG) represents —(CH2CH2—O) n5-CH2CH2—NH—, wherein the amino group at the right end represents amide-bonding to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in the 1-3 branched chain of the β-Man in the N297 glycan,
  • Each asterisk* represents bonding to linker L, in particular, the nitrogen atom at the 1- or 3-position of the 1,2,3-triazole ring of Lb in linker L, and
  • n5 represents an integer of 2 to 10, and preferably an integer of 2 to 5.
  • N297-(Fuc)MSG2 is represented by the following structural formula or sequence formula.
  • Figure US20220016257A1-20220120-C00031
  • In the formulas, each wavy line represents bonding to Asn297 of the antibody,
  • L (PEG) represents —(CH2CH2—O) n5-CH2CH2—NH—, wherein the amino group at the right end represents amide-bonding to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in the 1-6 branched chain of the β-Man in the N297 glycan,
  • The asterisk* represents bonding to linker L, in particular, the nitrogen atom at the 1- or 3-position of the 1,2,3-triazole ring of Lb in linker L, and
  • n5 is an integer of 2 to 10, and preferably an integer of 2 to 5.
  • N297-(Fuc)SG is represented by the following structural formula or sequence formula.
  • Figure US20220016257A1-20220120-C00032
  • In the formulas, each wavy line represents bonding to Asn297 of the antibody,
  • L(PEG) represents —(CH2CH2—O) n5-CH2CH2—NH—, wherein the amino group at the right end represents amide-bonding to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each of the 1-3 and 1-6 branched chains of the β-Man in the N297 glycan,
  • each asterisk* represents bonding to linker L, in particular, the nitrogen atom at the 1- or 3-position of the 1,2,3-triazole ring of Lb in linker L, and
  • n5 is an integer of 2 to 10, and preferably an integer of 2 to 5.
  • If the N297 glycan of the antibody in the antibody-drug conjugate of the present invention is N297-(Fuc)MSG1, N297-(Fuc)MSG2, or a mixture of them, the antibody-drug conjugate is a molecule to which two molecules of linker L and two molecules of drug D have been conjugated (m2=1) since the antibody is a dimer.
  • <Preparation of Antibody>
  • A glycan-remodeled antibody can be produced by using a method as illustrated in the following formula, for example, according to a method described in WO2013/120066.
  • Figure US20220016257A1-20220120-C00033
  • Step R-1: Hydrolysis of glycosidic bond at GlcNAcβ1-4GlcNAc of chitobiose structure at reducing terminal
  • This is a step of preparing a glycan-truncated antibody by cleaving N-linked glycan bonding to asparagine at the 297-position of the amino acid sequence of a targeted antibody (N297-linked glycan) with use of a known enzymatic reaction.
  • A targeted antibody (20 mg/mL) in buffer solution (e.g., 50 mM phosphate buffer solution) is subjected to a hydrolysis reaction of the glycosidic bond between GlcNAcβ1 and 4GlcNAc in the chitobiose structure at the reducing terminal with use of hydrolase such as the enzyme EndoS at 0° C. to 40° C. The reaction time is 10 minutes to 72 hours, and preferably 1 hour to 6 hours. The amount of the wild-type EndoS to be used is 0.1 to 10 mg, preferably 0.1 to 3 mg, to 100 mg of the antibody. After the completion of the reaction, purification with affinity chromatography and/or purification with a hydroxyapatite column, each described later, are/is carried out to produce a (Fucα1,6)GlcNAc antibody with the glycan hydrolyzed between GlcNAcβ1 and 4GlcNAc.
  • Step R-2: Transglycosylation reaction
  • This is a step of producing a glycan-remodeled antibody by bonding the (Fucα1,6)GlcNAc antibody to MSG-(MSG1-, MSG2-) or SG-type glycan oxazoline (hereinafter, referred to as “azide glycan oxazoline”) having a PEG linker including an azide group with use of an enzymatic reaction.
  • The glycan-truncated antibody in buffer solution (e.g., phosphate buffer solution) is subjected to transglycosylation reaction by reacting with an azide glycan oxazoline in the presence of a catalytic amount of transglycosidase such as EndoS (D233Q/Q303L) at 0° C. to 40° C. The reaction time is 10 minutes to 72 hours, and preferably 1 hour to 6 hours. The amount of the EndoS (D233Q/Q303L) to be used is 1 to 10 mg, preferably 1 to 3 mg, to 100 mg of the antibody, and the amount of the azide glycan oxazoline to be used is 2 equivalents to an excess equivalent, preferably 2 equivalents to 20 equivalents.
  • After the completion of the reaction, purification with affinity chromatography and purification with a hydroxyapatite column are carried out to afford a purified glycan-remodeled antibody.
  • The azide glycan oxazoline form may be prepared according to methods described in Example 11. By using a reaction known in the field of synthetic organic chemistry (e.g., a condensation reaction), N3—(CH2CH2—O)n5-CH2CH2—NH2, a PEG linker including an azide group (N3-L(PEG)), may be introduced to MSG1. Specifically, carboxylic acid at the 2-position of a sialic acid and the amino group at the right-hand end of N3— (CH2CH2—O)n5-CH2CH2—NH2 undergo a condensation reaction to form an amide bond.
  • Examples of the condensing agent in using condensation reaction may include, but not limited to, N, N′-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), carbonyldiimidazole (CDI), 2-(2H-benzotriazol-2-yl)-4-(1, 1, 3, 3-tetramethylbutyl)phenol (BOP), 1H-benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and O-(7-azabenzotriazol-1-yl)-N, N, N′, N′-tetramethyluronium hexafluorophosphate (HATU), and examples of the solvent for the reaction may include, but not limited to, dichloromethane, DMF, THF, ethyl acetate and mixed solvent thereof.
  • The reaction temperature is typically −20° C. to 100° C. or the boiling point of the solvent, and preferably in the range of −5° C. to 50° C. As necessary, an organic base such as triethylamine, diisopropylethylamine, N-methylmorpholine, and 4-dimethylaminopyridine or an inorganic base such as potassium carbonate, sodium carbonate, potassium hydrogen carbonate, and sodium hydrogen carbonate may be added. Further, for example, 1-hydroxybenzotriazole or N-hydroxysuccinimide may be added as a reaction accelerator.
  • MSG1 may be obtained by hydrolysis of the separated/purified (MSG-)Asn (in Example 11) with hydrolase such as EndoM.
  • Oxazolination may be prepared from GlcNAc at the reducing terminal of MSG1 according to a known article (J. Org Chem., 2009, 74(5), 2210-2212. Helv. Chim. Acta, 2012, 95, 1928-1936).
  • For the enzyme for the hydrolysis reaction of N297 glycan, for example, EndoS or an enzyme variant retaining hydrolysis activity may be used.
  • By reacting the (Fucα1,6)GlcNAc-antibody obtained in the above hydrolysis reaction, as a glycan acceptor molecule, and an MSG- (MSG1-, MSG2-) or SG-type glycan donor molecule by use of a glycosyltransferase (e.g., WO 2017010559) such as an EndoS D233Q or EndoS D233Q/Q303L variant, an antibody of the above-described structure including MSG- (MSG1-, MSG2-) or SG type N297 glycan can be obtained.
  • If the number of conjugated drug molecules per antibody molecule, m2, in the antibody-drug conjugate is 1, a glycan donor molecule having MSG, MSG1, or MSG2 as a glycan is employed. For such a glycan, commercially available monosialo-Asn free (1S2G/1G2S-10NC-Asn, GlyTech, Inc., hereinafter, referred to as “(MSG-)Asn”) as a raw material may be separated in accordance with a method described in Example 11 to obtain (MSG-)Asn1 or (MSG2-)Asn, which may each be employed, or a mixture of them may be employed without separation.
  • If the number of conjugated drug molecules per antibody molecule, m2, in the antibody-drug conjugate is 2, a glycan donor molecule including SG (10) as glycan is used for the transglycosylation reaction. For such SG (10) glycan, for example, that obtained from SGP through hydrolysis or the like may be used, or SG (10) glycan such as commercially available disialooctasaccharide (Tokyo Chemical Industry Co., Ltd.) may be used.
  • MSG- (MSG1-, MSG2-) or SG-type glycan included in the donor molecule has a PEG linker having an azide group (N3-L(PEG)) at the 2-position of a sialic acid therein. To introduce a PEG linker having an azide group (N3-L(PEG)) to the 2-position of a sialic acid, a reaction known in the field of synthetic organic chemistry (e.g., a condensation reaction) may be used for MSG (MSG (9)), MSG1, or MSG2, or disialooctasaccharide (SG (10)) and the PEG linker having an azide group (N3-L (PEG)) N3— (CH2CH2—O)n5-CH2CH2—NH2, wherein n5 is an integer of 2 to 10, and preferably represents an integer of 2 to 5. Specifically, the carboxylic acid at the 2-position of a sialic acid and the amino group at the right-hand end of N3— (CH2CH2—O)n5-CH2CH2—NH2 undergo a condensation reaction to from an amide bond.
  • Alternatively, MSG (MSG1, MSG2) or SG-type glycan may be obtained by introducing a PEG linker having an azide group (N3—(CH2CH2—O)n5-CH2CH2—NH2) to the carboxylic acid at the 2-position of a sialic acid of a raw material, such as (MSG1-)Asn, (MSG2-)Asn and (SG-)Asn (GlyTech, Inc.) with an α-amino group optionally protected or modified, and to carboxylic acid of the Asn with use of a condensation reaction, and utilizing a hydrolase such as EndoM and EndoRp. Examples of protective groups for α-amino groups include, but not limited to, an acetyl (Ac) group, a t-butoxycarbonyl (Boc) group, a benzoyl (Bz) group, a benzyl (Bzl) group, a carbobenzoxy (Cbz) group and a 9-fluorenylmethoxycarbonyl (Fmoc) group. The protective group for α-amino groups is preferably an Fmoc group.
  • Examples of modifying groups for α-amino groups include modifying groups that enhance solubility in water with a hydroxyacetyl group, a PEG structure, or the like.
  • An α-amino group of (MSG1-)Asn, (MSG-2)Asn, or (SG-)Asn is preferably protected with any of the protective groups. If an α-amino group is protected with a protective group (e.g., an Fmoc group), the protective group may be removed, as necessary, after introduction of a PEG linker having an azide group and before causing action of a hydrolase.
  • It is preferred to use an activated form such as an oxazoline formed by treatment with 2-chloro-1,3-dimethyl-1H-benzimidazol-3-ium-chloride for GlcNAc at the reducing terminal of MSG (MSG1, MSG2) or SG-type glycan included in the molecule.
  • Various enzymes for use in a transglycosylation reaction (transglycosidases) may be employed that have the activity of transferring a complex glycan to N297 glycan; however, EndoS D233Q, a modified product for which a hydrolysis reaction is suppressed by substituting Asp at the 233-position of EndoS with Gln, is a preferred transglycosidase. A transglycosylation reaction using EndoS D233Q is described, for example, in WO 2013/120066. Alternatively, a modified enzyme such as EndoS D233Q/Q303L (WO 2017010559), which is obtained by further adding a mutation to EndoS D233Q, may be used.
  • The purification operation for the antibody after the glycan remodeling for the antibody (glycohydrolysis and the transglycosylation reaction) is intended to separate low-molecular-weight compounds and enzymes used for the reaction, and gel filtration chromatography, ion-exchange chromatography, affinity chromatography, and so on are typically used for such purification, and additional purification with a hydroxyapatite column may be further carried out. That is, the present invention provides a method for producing a drug-conjugate form, the method including, subsequent to the step of purifying an intermediate from the reaction solution after glycohydrolysis of an antibody, the additional step of purifying with a hydroxyapatite column. According to an example of reports on glycan remodeling (J. Am. Chem. Soc. 2012, 134, 12308-12318., Angew. Chem. Int. Ed. 2016, 55, 2361-2367), a reaction solution after treatment of an antibody with hydrolase can be purified with a Protein A column (affinity chromatography column) only; however, this purification method has been proved to be incapable of completely removing hydrolase (e.g., EndoS), which affects the subsequent transglycosylation reaction because of the residual enzyme. In view of such a result, purification methods were examined, resulting in finding that when purification of a reaction solution after treatment of an antibody with hydrolase was carried out using a Protein A column and a hydroxyapatite column (CHT column, Bio-Rad Laboratories, Inc.) in the order presented, the reaction efficiency of the subsequent glycosylation reaction was enhanced, without the influence of any residual enzyme.
  • In preparing the glycan-remodeled antibody, the concentration of an aqueous solution of an antibody, measurement of concentration, and buffer exchange may be carried out according to common operations A to C in the following.
  • (Common Operation A: Concentration of Aqueous Solution of Antibody)
  • A solution of an antibody or antibody-drug conjugate was placed in a container of an Amicon Ultra (30,000 to 50,000 MWCO, Millipore Corporation), and the solution of an antibody or antibody-drug conjugate, which is described later, was concentrated through a centrifugation operation (centrifugation at 2000 G to 4000 G for 5 to 20 minutes) using a centrifuge (Allegra X-15R, Beckman Coulter, Inc.).
  • (Common Operation B: Measurement of Antibody Concentration)
  • Measurement of antibody concentration was carried out by using a UV measurement apparatus (Nanodrop 1000, Thermo Fisher Scientific Inc.) according to a method specified by the manufacturer. Then, 280 nm absorption coefficients, being different among antibodies (1.3 mL mg−1 cm−1 to 1.8 mL mg−1 cm−1), were used.
  • (Common Operation C: Buffer Exchange for Antibody)
  • A buffer solution (e.g., phosphate buffered saline (pH 6.0), phosphate buffer (pH 6.0)) was added to an aqueous solution of an antibody, which was concentrated according to common operation A. This operation was carried out several times, and the antibody concentration was then measured by using common operation B, and adjusted to 10 mg/mL with a buffer solution (e.g., phosphate buffered saline (pH 6.0), phosphate buffer (pH 6.0)).
  • <Conjugation>
  • This production method is a method for producing an antibody-drug conjugate by conjugating the above-described glycan-remodeled antibody to production intermediate (2) through SPAAC (strain-promoted alkyne azide cycloaddition: J. AM. CHEM. SOC. 2004, 126, 15046-15047) reaction.
  • Figure US20220016257A1-20220120-C00034
  • wherein Ab represents the glycan-remodeled antibody,
  • La′, Lp′ and B′ are the same as defined in La, Lp and B, respectively, and
  • J represents any of these structural formulas, wherein the asterisk* represents bonding to La′.
  • Figure US20220016257A1-20220120-C00035
  • J-La′-Lp′-NH—B′—CH2—O(C═O)-PBD can be synthesized by the method described in any one of Examples 10-1 to 10-6.
  • SPAAC reaction proceeds by mixing a buffer solution (sodium acetate solution, sodium phosphate, sodium borate solution, or the like, or a mixture thereof) of antibody Ab and a solution dissolving compound (2) in an appropriate solvent (dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), N-methyl-2-pyridone (NMP), propylene glycol (PG), or the like, or a mixture thereof).
  • The amount of moles of compound (2) to be used is 2 mol to an excess amount of moles, preferably 1 mol to 30 mol, per mole of the antibody, and the ratio of the organic solvent is preferably 1 to 200% v/v to the buffer of the antibody. The reaction temperature is 0° C. to 37° C., and preferably 10° C. to 25° C., and the reaction time is 1 to 150 hours, and preferably 6 hours to 100 hours. The pH in the reaction is preferably 5 to 9.
  • Antibody-drug conjugate compounds (ADCs) can be identified from each other through buffer exchange, purification, and measurement of antibody concentration and average number of conjugated drug molecules per antibody molecule (DAR:Drug to Antibody Ratio) according to common operations A to C described above and common operations D to F described later.
  • (Common Operation D: Purification of Antibody-Drug Conjugate)
  • An NAP-25 column was equilibrated with acetate buffer solution (10 mM, pH 5.5; herein, referred to as ABS) containing commercially available sorbitol (5%). To this NAP-25 column, an aqueous reaction solution of an antibody-drug conjugate (about 1.5 to 2.5 mL) was applied, and eluted with a buffer in an amount specified by the manufacturer to separate and collect an antibody fraction. The fraction separated and collected was again applied to the NAP-25 column, and a gel filtration purification operation to elute with a buffer was repeated twice or three times in total to afford the antibody-drug conjugate with an unbound drug-linker, dimethyl sulfoxide, and propylene glycol removed. As necessary, the concentration of the solution of the antibody-drug conjugate was adjusted through common operations A to C.
  • (Common Operation E: Measurement of Antibody Concentration of Antibody-Drug Conjugate)
  • The concentration of the conjugated drug in an antibody-drug conjugate can be calculated by using Lambert-Beer's law shown below. Equation (I) using Lambert-Beer's law is as follows:
  • [ Expression ⁢ ⁢ 1 ] A 280 Absorbance ⁢ = = ⁢ ɛ 280 ⁡ ( L ⁢ · mol - 1 · cm - 1 ) Molar ⁢ ⁢ absorption coefficient ⁢     ⁢ · x   ⁢   C ⁡ ( mol ⁢ · L 01 ) Molar concentration ⁢ · x ⁢ I ⁡ ( cm ) Optical ⁢ ⁢ path length Expression ⁢ ⁢ ( I )
  • Here, A280 denotes absorbance of an aqueous solution of an antibody-drug conjugate at 280 nm, 6280 denotes the molar absorption coefficient of an antibody-drug conjugate at 280 nm, and C (mol·L−1) denotes the molarity of an antibody-drug conjugate. From expression (I), the molarity of an antibody-drug conjugate, C (mol·L−1), can be determined by using expression (II) below.
  • [ Expression ⁢ ⁢ 2 ] C ⁡ ( mol · L - 1 ) = A 280 ɛ 280 ⁡ ( L · mol - 1 · cm - 1 ) · I ⁡ ( cm ) Expression ⁢ ⁢ ( II )
  • Further, the both sides are multiplied by the molar mass of the antibody-drug conjugate, MW (g·mol−1), to determine the weight concentration of the antibody-drug conjugate, C′ (mg·mL−1) (expression (III)).
  • [ Expression ⁢ ⁢ 3 ] C ′ ⁡ ( mg ⁢ · ⁢ mL - 1 ) = MW ⁡ ( g · mol - 1 ) · C ⁡ ( mol ⁢ · L - 1 ) = A 280 · MW ⁡ ( g · mol - 1 ) ɛ 280 ⁡ ( L · mol - 1 · cm - 1 ) · I ⁡ ( cm ) Expression ⁢ ⁢ ( III )
  • Values used for the expression and applied to Examples will be described.
  • The absorbance A280 used was a measured value of UV absorbance of an aqueous solution of an antibody-drug conjugate at 280 nm. For molar mass, MW (g·mol−1), an estimated value of the molecular weight of an antibody was calculated from the amino acid sequence of the antibody, and used as an approximate value of the molar mass of an antibody-drug conjugate. The optical path length, 1 (cm), used in measurement was 1 cm.
  • The molar absorption coefficient, 6280, of the antibody-drug conjugate can be determined by using expression (IV) below:

  • [Expression 4]

  • ε280=Molar absorption coefficient of antibody εAb,280+Molar absorption coefficient of drug εDL,280×Number of drug molecules conjugated  Expression (IV)
  • Here, εAb, 280 denotes the molar absorption coefficient of an antibody at 280 nm and εDL, 280 denotes the molar absorption coefficient of a drug at 280 nm.
  • By using a known calculation method (Protein Science, 1995, vol. 4, 2411-2423), εAb, 280 can be estimated from the amino acid sequence of an antibody. In the Examples, the molar absorption coefficient of H01L02 antibody used was εAb, 280=223400 (calculated estimated value). The molar absorption coefficient of H01L02A antibody used was εAb, 280=223674 (calculated estimated value), the molar absorption coefficient of H31L02A antibody used was εAb, 280=223314 (calculated estimated value), the molar absorption coefficient of H11L02A antibody used was εAb, 280=220490 (calculated estimated value), and the molar absorption coefficient of LPS antibody used was εAb, 280=230300 (calculated estimated value).
  • εDL, 280 was calculated for use from a measured value obtained in each UV measurement. Specifically, the absorbance of a solution dissolving a conjugate precursor (drug) with a certain molarity was measured, and expression (I), Lambert-Beer's law, was applied thereto, and the resulting value was used.
  • (Common Operation F: Measurement of Average Number of Conjugated Drug Molecules Per Antibody Molecule in Antibody-Drug Conjugate
  • The average number of conjugated drug molecules per antibody molecule in an antibody-drug conjugate can be determined through high-performance liquid chromatography (HPLC) with the following method.
  • (F-1 Preparation of Sample for HPLC Analysis (Reduction of Antibody-Drug Conjugate))
  • A solution of an antibody-drug conjugate (about 1 mg/mL, 60 μL) is mixed with an aqueous solution of dithiothreitol (DTT) (100 mM, 15 μL). The mixture is incubated at 37° C. for 30 minutes to prepare a sample in which the disulfide bond between the L chain and H chain of the antibody-drug conjugate cleaved, and this sample is used for HPLC analysis.
  • (F-2. HPLC Analysis)
  • HPLC analysis is carried out under the following conditions.
  • HPLC system: Agilent 1290 HPLC system (Agilent Technologies)
  • Detector: Ultraviolet absorption spectrometer (measurement wavelength: 280 nm, 329 nm)
  • Column: BEH Phenyl (2.1×50 mm, 1.7 μm, Waters Acquity)
  • Column temperature: 75° C.
  • Mobile phase A: 0.1% trifluoroacetic acid (TFA) −15% isopropyl alcohol aqueous solution
  • Mobile phase B: 0.075% TFA-15% isopropyl alcohol acetonitrile solution
  • Gradient program: 14%-36% (0 min to 15 min), 36%-80% (15 min to 17 min), 80%-14% (17 min to 17.1 min), 14%-14% (17.1 min to 23 min)
  • Sample injection volume: 5 μL
  • (F-3. Data Analysis)
  • (F-3-1) An H chain with a conjugated drug molecule(s) (H chain with one conjugated drug molecule: H1, H chain with two conjugated drug molecules: H2) have hydrophobicity increased in proportion to the number of conjugated drug molecules and have longer retention time as compared to the L chain (L0) and H chain (H0) of an antibody without any conjugated drug molecule, and hence L0, H0, H1, and H2 are eluted in the presented order. Therefore, through comparison of retention time between L0 and H0, each peak detected can be assigned to L0, H0, H1, or H2. Whether a drug is conjugated or not can be confirmed by checking absorption at a wavelength of 329 nm characteristic to the drug.
  • (F-3-2) Since each drug-linker absorbs UV, peak area values are corrected by using the following expression with the molar absorption coefficients of an H chain and drug-linker according to the number of conjugated drug-linker molecules.
  • H ⁢ - ⁢ chain ⁢ ⁢ peak ⁢ - ⁢ area correction ⁢ ⁢ value ⁢ ( Hi ) = Peak area × H ⁢ - ⁢ chain ⁢ ⁢ molar ⁢ ⁢ absorption ⁢ ⁢ coefficient H ⁢ - ⁢ chain ⁢ ⁢ molar ⁢ ⁢ absorption ⁢ ⁢ coefficient + number ⁢ ⁢ of ⁢ ⁢ drug ⁢ ⁢ molecules ⁢ ⁢ connected × drug ⁢ - ⁢ linker ⁢ ⁢ molar ⁢ ⁢ absorption ⁢ ⁢ coefficient ⁢ [ Expression ⁢ ⁢ 5 ] ⁢
  • Here, for the molar absorption coefficients (280 nm) of the L chain and H chain of each antibody, values estimated from the amino acid sequences of the L chain and H chain of the antibody by using a known calculation method (Protein Science, 1995, vol. 4, 2411-2423). In the case of H01L02 antibody, 81480 was used as the molar absorption coefficient of the H chain estimated from the amino acid sequence. In the case of the H01L02A antibody, similarly, 79829 was used as the molar absorption coefficient of the H chain; in the case of the H31L02A antibody, 80131 was used as the molar absorption coefficient of the H chain; in the case of the H11L02A antibody, 78696 was used as the molar absorption coefficient of the H chain; in the case of the LPS antibody, 77470 was used as the molar absorption coefficient of the H chain; and the molar absorption coefficient (280 nm) measured for drug-linker 1-4, as a conjugate precursor, was used as the molar absorption coefficient (280 nm) of each drug-linker.
  • (F-3-3) The peak area ratios (%) of each chain to the total of corrected peak areas are calculated by using the following expression.
  • H ⁢ - ⁢ chain ⁢ ⁢ peak ⁢ - ⁢ area correction ⁢ ⁢ value = A Hi A HO + A H ⁢ ⁢ 1 + A H ⁢ ⁢ 2 × 100 [ Expression ⁢ ⁢ 6 ]
  • AHi: Hi Corrected peak area value of each chain
  • (F-3-4) The average number of conjugated drug molecules per antibody molecule in an antibody-drug conjugate is calculated by using the following expression.

  • Average number of drug molecules conjugated=(H 0 peak area ratio×0+H 1 peak area ratio×1+H 2 peak area ratio×2)/100×2  [Expression 7]
  • 4. Medicament
  • Since the anti-CDH6 antibody of the present invention or the functional fragment of the antibody described in the above section “2. Production of anti-CDH6 antibody” and the Examples binds to CDH6 on the surface of tumor cells and has internalization activity, it can be used as a medicament, and in particular, as a therapeutic agent for cancer such as renal cell tumor or ovarian tumor, for example, renal cell carcinoma, clear renal cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, bile duct cancer, lung cancer (e.g., small-cell lung cancer or non-small cell lung cancer), glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor or neuroblastoma, either alone or in combination with an additional drug.
  • Furthermore, the anti-CDH6 antibody of the present invention or the functional fragment of the antibody can be used in the detection of cells expressing CDH6.
  • Moreover, since the anti-CDH6 antibody of the present invention or the functional fragment of the antibody has internalization activity, it can be applied as the antibody in an antibody-drug conjugate.
  • When a drug having antitumor activity such as cytotoxic activity is used as the drug, the anti-CDH6 antibody-drug conjugate of the present invention described in the above section “3. Anti-CDH6 antibody-drug conjugate” and the Examples is a conjugate of the anti-CDH6 antibody and/or the functional fragment of the antibody having internalization activity, and the drug having antitumor activity such as cytotoxic activity. Since this anti-CDH6 antibody-drug conjugate exhibits antitumor activity against cancer cells expressing CDH6, it can be used as a medicament, and in particular, as a therapeutic agent and/or a prophylactic agent for cancer.
  • The anti-CDH6 antibody-drug conjugate of the present invention may absorb moisture or have adsorption water, for example, to turn into a hydrate when it is left in air or subjected to recrystallization or purification procedures. Such a compound or a pharmacologically acceptable salt containing water is also included in the present invention.
  • When the anti-CDH6 antibody-drug conjugate of the present invention has a basic group such as an amino group, it can form a pharmacologically acceptable acid-addition salt, if desired. Examples of such an acid-addition salt can include: hydrohalides such as hydrofluoride, hydrochloride, hydrobromide, and hydroiodide; inorganic acid salts such as nitrate, perchlorate, sulfate, and phosphate; lower alkanesulfonates such as methanesulfonate, trifluoromethanesulfonate, and ethanesulfonate; arylsulfonates such as benzenesulfonate and p-toluenesulfonate; organic acid salts such as formate, acetate, trifluoroacetate, malate, fumarate, succinate, citrate, tartrate, oxalate, and maleate; and amino acid salts such as ornithine salt, glutamate, and aspartate.
  • When the anti-CDH6 antibody-drug conjugate of the present invention has an acidic group such as a carboxy group, it can form a pharmacologically acceptable base-addition salt, if desired. Examples of such a base-addition salt can include: alkali metal salts such as a sodium salt, a potassium salt, and lithium salt; alkaline earth metal salts such as a calcium salt and a magnesium salt; inorganic salts such as an ammonium salt; and organic amine salts such as a dibenzylamine salt, a morpholine salt, a phenylglycine alkyl ester salt, an ethylenediamine salt, an N-methylglucamine salt, a diethylamine salt, a triethylamine salt, a cyclohexylamine salt, a dicyclohexylamine salt, an N,N′-dibenzylethylenediamine salt, a diethanolamine salt, an N-benzyl-N-(2-phenylethoxy)amine salt, a piperazine salt, tetramethylammonium salt, and a tris(hydroxymethyl)aminomethane salt.
  • The present invention can also include an anti-CDH6 antibody-drug conjugate in which one or more atoms constituting the antibody-drug conjugate are replaced with isotopes of the atoms. There exist two types of isotopes: radioisotopes and stable isotopes. Examples of the isotope can include isotypes of hydrogen (2H and 3H), isotopes of carbon (11C, 13C and 14C), isotopes of nitrogen (13N and 15N), isotopes of oxygen (150, 170 and 180), and isotopes of fluorine (18F). A composition comprising the antibody-drug conjugate labeled with such an isotope is useful as, for example, a therapeutic agent, a prophylactic agent, a research reagent, an assay reagent, a diagnostic agent, and an in vivo diagnostic imaging agent. Each and every antibody-drug conjugate labeled with an isotope, and mixtures of antibody-drug conjugates labeled with an isotope at any given ratio are included in the present invention. The antibody-drug conjugate labeled with an isotope can be produced, for example, by using a starting material labeled with an isotope, instead of a starting material for the production method of the present invention mentioned later, according to a method known in the art.
  • In vitro cytotoxicity can be measured based on the activity of suppressing the proliferative responses of cells, for example. For example, a cancer cell line overexpressing CDH6 is cultured, and the anti-CDH6 antibody-drug conjugate is added at different concentrations to the culture system. Thereafter, its suppressive activity against focus formation, colony formation and spheroid growth can be measured. In this context, for example, by using a renal cell tumor- or ovarian tumor-derived cancer cell line, cell growth inhibition activity against renal cell tumor or ovarian tumor can be examined.
  • In vivo therapeutic effects on cancer in an experimental animal can be measured, for example, by administering the anti-CDH6 antibody-drug conjugate to a nude mouse into which a tumor cell line highly expressing CDH6 has been inoculated, and then measuring a change in the cancer cells. In this context, for example, by using an animal model derived from an immunodeficient mouse by the inoculation of renal cell carcinoma-, renal clear cell carcinoma-, papillary renal cell carcinoma-, ovarian cancer-, ovarian serous adenocarcinoma- or thyroid cancer-derived cells, therapeutic effects on renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma or thyroid cancer can be measured.
  • The type of cancer to which the anti-CDH6 antibody-drug conjugate of the present invention is applied is not particularly limited as long as CDH6 is expressed in cancer cells to be treated. Examples thereof can include renal cell carcinoma (e.g., renal clear cell carcinoma or papillary renal cell carcinoma), ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, bile duct cancer, lung cancer (e.g., small-cell lung cancer or non-small cell lung cancer), glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor and neuroblastoma, though the cancer is not limited thereto as long as the cancer expresses CDH6. More preferred examples of the cancer can include renal cell carcinoma (e.g., renal clear cell carcinoma and papillary renal cell carcinoma) and ovarian cancer.
  • The anti-CDH6 antibody-drug conjugate of the present invention can preferably be administered to a mammal, and more preferably to a human.
  • A substances used in a pharmaceutical composition comprising the anti-CDH6 antibody-drug conjugate of the present invention can be appropriately selected from pharmaceutical additives and others usually used in this field, in terms of the applied dose or the applied concentration, and then used.
  • The anti-CDH6 antibody-drug conjugate of the present invention can be administered as a pharmaceutical composition comprising one or more pharmaceutically compatible components. For example, the pharmaceutical composition typically comprises one or more pharmaceutical carriers (e.g., sterilized liquids (e.g., water and oil (including petroleum oil and oil of animal origin, plant origin, or synthetic origin (e.g., peanut oil, soybean oil, mineral oil, and sesame oil))). Water is a more typical carrier when the pharmaceutical composition is intravenously administered. An aqueous saline solution, an aqueous dextrose solution, and an aqueous glycerol solution can also be used as a liquid carrier, in particular, for an injection solution. Suitable pharmaceutical vehicles are known in the art. If desired, the composition may also comprise a trace amount of a moisturizing agent, an emulsifying agent, or a pH buffering agent. Examples of suitable pharmaceutical carriers are disclosed in “Remington's Pharmaceutical Sciences” by E. W. Martin. The prescription corresponds to an administration mode.
  • Various delivery systems are known, and they can be used for administering the anti-CDH6 antibody-drug conjugate of the present invention. Examples of the administration route can include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous routes. The administration can be made by, e.g., injection or bolus injection, for example. According to a specific preferred embodiment, the administration of the above-described antibody-drug conjugate is performed by injection. Parenteral administration is a preferred administration route.
  • According to a representative embodiment, the pharmaceutical composition is prescribed, as a pharmaceutical composition suitable for intravenous administration to a human, according to conventional procedures. The composition for intravenous administration is typically a solution in a sterile and isotonic aqueous buffer solution. If necessary, the medicament may also contain a solubilizing agent and a local anesthetic to alleviate pain at an injection area (e.g., lignocaine). In general, the above-described ingredients are provided, either separately or together in a mixture in unit dosage form, as a freeze-dried powder or an anhydrous concentrate contained in a container which is obtained by sealing in, for example, an ampoule or a sachet indicating the amount of the active agent. When the medicament is to be administered by injection, it may be administered using, for example, an injection bottle containing water or saline of sterile pharmaceutical grade. When the medicament is to be administered by injection, an ampoule of sterile water or saline for injection may be provided such that the above-described ingredients are admixed with one another before administration.
  • The pharmaceutical composition of the present invention may be a pharmaceutical composition comprising only the anti-CDH6 antibody-drug conjugate of the present application, or may be a pharmaceutical composition comprising the anti-CDH6 antibody-drug conjugate and at least one other therapeutic agent for cancer. The anti-CDH6 antibody-drug conjugate of the present invention can also be administered together with an additional therapeutic agent for cancer, and can thereby enhance an anticancer effect. The additional anticancer agent used for such a purpose may be administered to an individual, simultaneously, separately, or continuously, together with the antibody-drug conjugate. Otherwise, the additional anticancer agent and the anti-CDH6 antibody-drug conjugate may each be administered to the subject at different administration intervals. Examples of such a therapeutic agent for cancer can include tyrosine kinase inhibitors including imatinib, sunitinib, and regorafenib, CDK4/6 inhibitors including palbociclib, HSP90 inhibitors including TAS-116, MEK inhibitors including MEK162, and immune checkpoint inhibitors including nivolumab, pembrolizumab, and ipilimumab, though the therapeutic agent for cancer is not limited thereto as long as the drug has antitumor activity.
  • Such a pharmaceutical composition can be prepared as a formulation having a selected composition and a necessary purity in the form of a freeze-dried formulation or a liquid formulation. The pharmaceutical composition prepared as a freeze-dried formulation may be a formulation containing an appropriate pharmaceutical additive used in this field. Likewise, the liquid formulation can be prepared such that the liquid formulation contains various pharmaceutical additives used in this field.
  • The composition and concentration of the pharmaceutical composition also vary depending on the administration method. With regard to the affinity of the anti-CDH6 antibody-drug conjugate comprised in the pharmaceutical composition of the present invention for the antigen, i.e., the dissociation constant (Kd value) of the anti-CDH6 antibody-drug conjugate to the antigen, as the affinity increases (i.e., the Kd value is low), the pharmaceutical composition can exert medicinal effects, even if the applied dose thereof is decreased. Accordingly, the applied dose of the antibody-drug conjugate can also be determined by setting the applied dose based on the status of the affinity of the antibody-drug conjugate for the antigen. When the antibody-drug conjugate of the present invention is administered to a human, it may be administered at a dose of, for example, from approximately 0.001 to 100 mg/kg once or a plurality of times at intervals of 1 to 180 days. It can be administered preferably at a dose of from 0.1 to 50 mg/kg and more preferably 1 to 50 mg/kg, 1 to 30 mg/kg, 1 to 20 mg/kg, 1 to 15 mg/kg, 2 to 50 mg/kg, 2 to 30 mg/kg, 2 to 20 mg/kg or 2 to 15 mg/kg a plurality of times at intervals of 1 to 4 weeks, preferably 2 to 3 weeks.
    • EXAMPLES
  • Hereinafter, the present invention will be specifically described in the following examples. However, the present invention is not limited to these. Furthermore, these examples should not be construed in a limited manner by any means. It is to be noted that, in the following examples, unless otherwise specified, individual operations regarding genetic manipulation have been carried out according to the method described in “Molecular Cloning” (Sambrook, J., Fritsch, E. F. and Maniatis, T., published by Cold Spring Harbor Laboratory Press in 1989) or other methods described in experimental manuals used by persons skilled in the art, or when commercially available reagents or kits have been used, the examples have been carried out in accordance with the instructions included in the commercially available products. In the present description, reagents, solvents and starting materials are readily available from commercially available sources, unless otherwise specified.
    • Example 1: Obtaining of Rat Anti-Human CDH6 Antibody Having Internalization Activity
  • 1)-1 Construction of Human and Cynomolgus Monkey CDH6 Expression Vectors
  • Using a human CDH6 protein (NP_004923)-encoding cDNA expression vector (OriGene Technologies Inc., RC217889), the cDNA was incorporated into a vector for mammalian expression according to a method known to a person skilled in the art to produce human CDH6 expression vector pcDNA3.1-hCDH6. The amino acid sequence of the human CDH6 ORF (open reading frame) is shown in SEQ ID No: 1.
  • cDNA encoding cynomolgus monkey CDH6 protein was cloned with cDNA synthesized from total RNA of the cynomolgus monkey kidney as a template using primer 1 (5′-CACCATGAGAACTTACCGCTACTTCTTGCTGCTC-3′) (SEQ ID No: 8) and primer 2 (5′-TTAGGAGTCTTTGTCACTGTCCACTCCTCC-3′) (SEQ ID No: 9). It was confirmed that the obtained sequence corresponded to the extracellular region of cynomolgus monkey CDH6 (NCBI, XP_005556691.1). It was also confirmed that the sequence corresponded to the full-length sequence of cynomolgus monkey CDH6 (EHH54180.1) registered in EMBL. The cDNA was incorporated into a vector for mammalian expression according to a method known to a person skilled in the art to produce a cynomolgus monkey CDH6 expression vector, pcDNA3.1-cynoCDH6. The amino acid sequence of the cynomolgus monkey CDH6 ORF is shown in SEQ ID No: 7.
  • EndoFree Plasmid Giga Kit (Qiagen N.V.) was used for mass production of the produced plasmid DNA.
  • 1)-2 Immunization
  • For immunization, WKY/Izm female rats (Japan SLC, Inc.) were used. First, the lower limbs of each rat were pre-treated with hyaluronidase (Sigma-Aldrich Co. LLC), and thereafter, the human CDH6 expression vector pcDNA3.1-hCDH6 produced in Example 1)-1 was intramuscularly injected into the same sites.
  • Subsequently, employing ECM830 (BTX), in vivo electroporation was carried out on the same sites using a two-needle electrode. Approximately once every two weeks, the same in vivo electroporation was repeated, and thereafter, lymph nodes or the spleen were collected from the rat, and used for producing hybridomas.
  • 1)-3 Production of Hybridomas
  • The lymph node cells or the spleen cells were fused with mouse myeloma SP2/0-ag14 cells (ATCC, No. CRL-1581) according to electrical cell fusion, using a LF301 Cell Fusion Unit (BEX Co., Ltd.), and the cells were then suspended and diluted with ClonaCell-HY Selection Medium D (StemCell Technologies Inc.), and then cultured under conditions of 37° C. and 5% CO2. Individual hybridoma colonies that appeared in the culture medium were collected as monoclonal hybridomas, then suspended in ClonaCell-HY Selection Medium E (StemCell Technologies Inc.), and then cultured under conditions of 37° C. and 5% CO2. After moderate proliferation of cells, frozen stocks of individual hybridoma cells were produced, while the obtained hybridoma culture supernatant was used to screen for anti-human CDH6 antibody-producing hybridomas.
  • 1)-4 Antibody-Producing Hybridoma Screening According to Cell-ELISA Method
  • 1)-4-1 Preparation of Antigen Gene-Expressing Cells for Use in Cell-ELISA
  • 293α cells (a stable expression cell line derived from HEK293 cells expressing integrin αv and integrin 03) were prepared at 5×105 cells/mL in DMEM medium supplemented with 10% FBS. In accordance with transduction procedures for using Lipofectamine 2000 (Thermo Fisher Scientific Inc.), DNA of pcDNA3.1-hCDH6 or pcDNA3.1-cynoCDH6, or pcDNA3.1 as a negative control was introduced into the 293α cells, and the cells were dispensed in an amount of 100 μL/well onto a 96-well plate (Corning Inc.). Thereafter, the cells were cultured under conditions of 37° C. and 5% CO2 in DMEM medium supplemented with 10% FBS for 24 to 27 hours. The obtained transfected cells were used for Cell-ELISA in an adhesive state.
  • 1)-4-2 Cell-ELISA
  • The culture supernatant of the 293α cells transfected with the expression vector prepared in Example 1)-4-1 was removed, and the culture supernatant from each hybridoma was then added to the 293α cells transfected with pcDNA3.1-hCDH6 or pcDNA3.1-cynoCDH6, or pcDNA3.1. The cells were left standing at 4° C. for 1 hour. The cells in the wells were washed once with PBS (+) supplemented with 5% FBS, and thereafter, Anti-Rat IgG-Peroxidase antibody produced in rabbit (Sigma-Aldrich Co. LLC) that had been 500-fold diluted with PBS (+) supplemented with 5% FBS was added to the wells. The cells were left standing at 4° C. for 1 hour. The cells in the wells were washed three times with PBS (+) supplemented with 5% FBS, and thereafter, OPD coloring solution (which had been prepared by dissolving o-phenylenediamine dihydrochloride (Wako Pure Chemical Industries, Ltd.) and H2O2 in an OPD solution (0.05 M trisodium citrate, 0.1 M disodium hydrogen phosphate 12-water; pH 4.5), so that the substances became 0.4 mg/ml and 0.6% (v/v), respectively) was added in an amount of 100 μL/well to the wells. A coloring reaction was carried out with occasional stirring. Thereafter, 1 M HCl was added to the plate (100 μL/well) to terminate the coloring reaction, followed by measurement of the absorbance at 490 nm using a plate reader (ENVISION: PerkinElmer, Inc.). Hybridomas that produced a culture supernatant exhibiting higher absorbance in the 293α cells transfected with the pcDNA3.1-hCDH6 or pcDNA3.1-cynoCDH6 expression vector than that in the 293α cells transfected with the control pcDNA3.1 were selected as hybridomas producing antibodies binding to human CDH6 and cynomolgus monkey CDH6.
  • 1)-5 Selective Screening for Antibody Binding to Cynomolgus Monkey CDH6 According to Flow Cytometry
  • 1)-5-1 Preparation of Antigen Gene-Expressing Cells for Use in Flow Cytometry Analysis
  • 293T cells were seeded in a 225-cm2 flask (Sumitomo Bakelite Co., Ltd.) at 5×104 cells/cm2, and the cells were then cultured overnight under conditions of 37° C. and 5% CO2 in DMEM medium supplemented with 10% FBS. pcDNA3.1-cynoCDH6 or pcDNA3.1 as a negative control was introduced into the 293T cells using Lipofectamine 2000, and the cells were further cultured overnight under conditions of 37° C. and 5% CO2. The 293T cells transfected with each vector were treated with TrypLE Express (Thermo Fisher Scientific Corp.), and the cells were washed with DMEM supplemented with 10% FBS, and then suspended in PBS supplemented with 5% FBS. The obtained cell suspension was used in flow cytometry analysis.
  • 1)-5-2 Flow Cytometry Analysis
  • The binding specificity to cynomolgus monkey CDH6 of an antibody produced from the human CDH6- and cynomolgus monkey CDH6-binding antibody-producing hybridomas that had been selected by Cell-ELISA in Example 1)-4 was further confirmed by flow cytometry. The suspension of the transiently expressing 293T cells prepared in Example 1)-5-1 was centrifuged, and the supernatant was then removed. Thereafter, the cells were suspended by the addition of the culture supernatant from each hybridoma. The cells were left standing at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, and thereafter, the cells were suspended by the addition of Anti-Rat IgG FITC conjugate (Sigma-Aldrich Co. LLC) that had been 500-fold diluted with PBS supplemented with 5% FBS. The cells were left standing at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, and then re-suspended in PBS supplemented with 5% FBS and 2 μg/ml 7-aminoactinomycin D (Molecular Probes, Inc.), followed by detection using a flow cytometer (FC500; Beckman Coulter, Inc.). The data was analyzed using FlowJo (TreeStar, Inc.). After dead cells were removed from analysis by gating out 7-aminoactinomycin D-positive cells, a histogram of the FITC fluorescence intensity of live cells was generated. Hybridomas producing antibodies specifically binding to cynomolgus monkey CDH6 expressed on the cell membrane surface were selected based on results where the histogram for the antibody shifted to the strong fluorescence intensity side in the 293T cells transfected with pcDNA3.1-cynoCDH6 compared with the 293T cells transfected with the control pcDNA3.1.
  • 1)-6 Determination of Isotype of Rat Monoclonal Antibody
  • Clone rG019, which appeared to bind specifically and strongly to human CDH6 and monkey CDH6, was selected from among the rat anti-CDH6 antibody-producing hybridomas selected in Example 1)-5, and the isotype of each antibody was identified. The heavy chain subclass and the light chain type of the antibody were determined using a RAT MONOCLONAL ANTIBODY ISOTYPING TEST KIT (DS Pharma Biomedical Co., Ltd.). As a result, it was confirmed that rG019 had a heavy chain of IgG2b subclass and a light chain of K chain type.
  • 1)-7 Preparation of Rat Anti-Human CDH6 Antibody
  • 1)-7-1 Production of Culture Supernatant
  • The rat anti-human CDH6 monoclonal antibody was purified from the hybridoma culture supernatant. First, the volume of each rat anti-CDH6 monoclonal antibody-producing hybridoma was sufficiently increased with ClonaCell-HY Selection Medium E (StemCell Technologies Inc.), and thereafter, the medium was exchanged with Hybridoma SEM (Thermo Fisher Scientific Corp.) to which 20% of Ultra Low IgG FBS (Thermo Fisher Scientific Corp.) had been added. Thereafter, the hybridoma was cultured for 4 to 5 days. The resulting culture supernatant was harvested, and insoluble matter was removed therefrom by passing through a 0.8-μm filter, and through a 0.2-μm filter.
  • 1)-7-2 Purification of Rat Anti-CDH6 Antibody
  • An antibody (rat anti-CDH6 antibody (rG019)) was purified from the culture supernatant of hybridomas prepared in Example 1)-7-1 according to Protein G affinity chromatography. The antibody was adsorbed on a Protein G column (GE Healthcare Biosciences Corp.), the column was then washed with PBS, and the antibody was then eluted with a 0.1 M glycine/HCl aqueous solution (pH 2.7). 1 M Tris-HCl (pH 9.0) was added to the eluate, so that the pH was adjusted to pH 7.0 to 7.5. Thereafter, using Centrifugal UF Filter Device VIVASPIN20 (molecular weight cutoff: UF30K, Sartorius Inc.), the buffer was replaced with HBSor (25 mM histidine/5% sorbitol, pH 6.0), while the antibody was concentrated, so that the concentration of the antibody was adjusted to 1 mg/mL. Finally, the antibody was filtrated through a Minisart-Plus filter (Sartorius Inc.) to obtain a purified sample.
    • Example 2: In-Vitro Evaluation of Rat Anti-CDH6 Antibody
  • 2)-1 Evaluation of Binding Ability of Rat Anti-CDH6 Antibody by Flow Cytometry
  • The human CDH6-binding activity of the rat anti-CDH6 antibody produced in Example 1)-7 was evaluated by flow cytometry. Using Lipofectamine 2000 (Thermo Fisher Scientific Inc.), pcDNA3.1-hCDH6 produced in Example 1)-1 was transiently introduced into 293T cells (ATCC). The cells were cultured overnight under conditions of 37° C. and 5% C02, treated with TrypLE Express (Thermo Fisher Scientific Inc.), and thereafter, a cell suspension was prepared. The suspension of the transfected 293T cells was centrifuged, and the supernatant was then removed. Thereafter, the cells were suspended by the addition of the rat anti-CDH6 monoclonal antibody (clone No: rG019), which had been prepared in Example 1)-7, or rat IgG control (R&D Systems, Inc.) (final concentration: 10 ng/mL). The cells were left standing at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, and then suspended by the addition of Anti-Rat IgG (whole molecule)-FITC antibody produced in rabbit (Sigma-Aldrich Co. LLC) that had been 50-fold diluted with PBS supplemented with 5% FBS. The cells were left standing at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, followed by detection using a flow cytometer (FC500; Beckman Coulter, Inc.). The data was analyzed using FlowJo (TreeStar, Inc.). The results are shown in FIG. 1. In the histogram of FIG. 1, the abscissa depicts FITC fluorescence intensity indicating the amount of the antibody bound, and the ordinate depicts a cell count. The shaded histogram shows that negative control 293T cells untransfected with hCDH6 were used, and the open solid line histogram shows that hCDH6-transfected 293T cells were used. As seen, fluorescence intensity was enhanced by the binding of the antibody to hCDH6 on the cell surface. The rat IgG control binds to neither of the cells. As a result, it was confirmed that the 4 produced rat anti-CDH6 monoclonal antibodies bind to 293T cells transfected with pcDNA3.1-hCDH6.
  • 2)-2 Analysis of CDH6-Binding Site of Rat Anti-CDH6 Antibody by Flow Cytometry
  • 2)-2-1 Construction of Expression Vector for Each Domain Deletion Mutant of Human CDH6
  • The full-length extracellular region of human CDH6 has five extracellular domains, EC1 (SEQ ID NO: 2), EC2 (SEQ ID NO: 3), EC3 (SEQ ID NO: 4), EC4 (SEQ ID NO: 5), and EC5 (SEQ ID NO: 6). A gene to be expressed such that each one of the five EC domains could be deleted from full-length human CDH6 was synthesized by GeneArt, and incorporated into p3×FLAG-CMV-9 vectors for mammalian expression (Sigma-Aldrich Co. LLC) according to a method known to a person skilled in the art in order to produce an expression vector for each domain deletion mutant lacking any one of EC1 to EC5.
  • 2)-2-2 Epitope Analysis of Rat Anti-CDH6 Antibody by Flow Cytometry Using Domain Deletion Mutant
  • The epitopes to which the rat anti-human CDH6 antibodies bound were identified by flow cytometry analysis using a 293α cell line transfected with each EC domain deletion vector. Using Lipofectamine 2000 (Thermo Fisher Scientific Inc.), each domain deletion mutant expression vector produced in Example 2)-2-1, or pcDNA3.1-hCDH6 for the expression of full-length human CDH6 was transiently introduced into a 293α cell line, which was a cell line derived from HEK293 cells by stable transfection with integrin αv and integrin 03 expression vectors. The cells were cultured overnight under conditions of 37° C. and 5% CO2, treated with TrypLE Express (Thermo Fisher Scientific Inc.), and thereafter, a cell suspension was prepared. The suspension of the transfected 293α cells was centrifuged, and a supernatant was then removed. Thereafter, the cells were suspended by the addition of the anti-CDH6 monoclonal antibody (clone No: rG019), which had been prepared in Example 1)-7, or rat IgG control (R&D Systems, Inc.) (final concentration: 20 nM). The cells were left standing at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, and then suspended by the addition of Anti-Rat IgG (whole molecule)-FITC antibody produced in rabbit (Sigma-Aldrich Co. LLC) that had been 50-fold diluted with PBS supplemented with 5% FBS. The cells were left standing at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, followed by detection using a flow cytometer (Canto II; BD Biosciences). The data was analyzed using FlowJo (TreeStar, Inc.). The results are shown in FIGS. 2-1 to 2-2. In the histograms of FIGS. 2-1 to 2-2, the abscissa depicts FITC fluorescence intensity indicating the amount of the antibody bound, and the ordinate depicts cell count. The shaded histogram shows that negative control untransfected 293α cells were used, and the open solid line histogram shows that 293 cells expressing full-length hCDH6 or each EC domain deletion mutant were used. Fluorescence intensity is enhanced when the antibody binds to full-length hCDH6 or each EC domain deletion mutant on the surface of cells. The rat IgG control binds to none of the transfected cells. rG019 binds to the full-length hCDH6, the EC1 deletion mutant, the EC2 deletion mutant, the EC4 deletion mutant, and the EC5 deletion mutant, but does not bind to the EC3 deletion mutant. From this result, it was demonstrated that rG019 specifically binds to hCDH6 with EC3 as an epitope.
  • 2)-3 Confirmation of CDH6 Expression in Human Tumor Cell Line
  • In order to select a CDH6-positive human tumor cell line for use in the evaluation of the obtained antibodies, CDH6 expression information was retrieved from a known database, and the expression of CDH6 on the cell membrane surface was evaluated by flow cytometry. Human ovarian tumor cell lines NIH:OVCAR-3, PA-1, OV-90 and human renal cell tumor cell line 786-O and Caki-1 (all obtained from ATCC) were each cultured under conditions of 37° C. and 5% CO2, treated with TrypLE Express (Thermo Fisher Scientific Inc.), and thereafter, a cell suspension was prepared. The cells were centrifuged, and the supernatant was then removed. Thereafter, the cells were suspended by the addition of a commercially available anti-human CDH6 antibody (MABU2715, R&D Systems, Inc.) or mouse IgG1 (BD Pharmingen) as a negative control (final concentration: 50 μg/mL). The cells were left standing at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, and then suspended by the addition of F(ab′)2 Fragment of FITC-conjugated Goat Anti-mouse immunoglobulins (Dako) that had been 50-fold diluted with PBS supplemented with 5% FBS. The cells were left standing at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, followed by detection using a flow cytometer (Canto II; BD Biosciences). The data was analyzed using FlowJo (TreeStar, Inc.). The results are shown in FIG. 3. In the histogram of FIG. 3, the abscissa depicts FITC fluorescence intensity indicating the amount of the antibody bound, and the ordinate depicts cell count. The shaded histogram shows that the negative control mIgG1 was used in staining, and the open solid line histogram shows that the anti-human CDH6 antibody was used in staining. As seen, fluorescence intensity was enhanced by the binding of the antibody to hCDH6 on the surface of cells. The mIgG1 control binds to none of the cells. As a result, it was confirmed that the NIH:OVCAR-3, PA-1, OV-90, 786-O and Caki-1 cell lines endogenously express CDH6 on the cell surface.
    • Example 3: Amplification and Sequencing of rG019 Heavy-Chain Variable Region and Light-Chain Variable Region Gene Fragments
  • 3)-1 Preparation of Total RNA from rG019 Antibody-Producing Hybridoma
  • In order to amplify cDNA encoding each variable region of rG019, total RNA was prepared from G019 antibody-producing hybridoma using TRIzol Reagent (Ambion, Inc.).
  • 3)-2 Amplification of cDNA Encoding rG019 Heavy-Chain Variable Region by 5′-RACE PCR and Determination of Nucleotide Sequence
  • cDNA encoding the heavy chain variable region was amplified using approximately 1 μg of the total RNA prepared in Example 3)-1 and a SMARTer RACE cDNA Amplification Kit (Clontech Laboratories, Inc.). As primers used to amplify the cDNA of the variable region of the rG019 heavy chain gene according to PCR, UPM (Universal Primer A Mix: included with SMARTer RACE cDNA Amplification Kit) and primers designed from the sequences of the constant regions of known rat heavy chains were used.
  • The heavy chain variable region-encoding cDNA amplified by 5′-RACE PCR was cloned into a plasmid, and thereafter, the nucleotide sequence of the cDNA of the heavy chain variable region was subjected to sequence analysis.
  • The determined nucleotide sequence of the cDNA encoding the heavy chain variable region of rG019 is shown in SEQ ID NO: 16, and the amino acid sequence thereof is shown in SEQ ID NO: 15.
  • 3)-3 Amplification of cDNA Encoding rG019 Light-Chain Variable Region by 5′-RACE PCR and Determination of Nucleotide Sequence
  • Amplification and sequencing were carried out by the same method as that applied in Example 3)-2. However, as primers used to amplify the cDNA of the variable region of the rG019 light chain gene according to PCR, UPM (Universal Primer A Mix: included with SMARTer RACE cDNA Amplification Kit) and primers designed from the sequences of the constant regions of known rat light chains were used.
  • The determined nucleotide sequence of the cDNA encoding the light chain variable region of rG019 is shown in SEQ ID NO: 11, and the amino acid sequence thereof is shown in SEQ ID NO: 10.
    • Example 4: Production of Human Chimeric Anti-CDH6 Antibody chG019
  • 4)-1 Construction of Human Chimeric Anti-CDH6 Antibody chG019 Expression Vector
  • 4)-1-1 Construction of Chimeric and Humanized Light-Chain Expression Vector pCMA-LK
  • An approx. 5.4-kb fragment, which had been obtained by digesting plasmid pcDNA3.3-TOPO/LacZ (Invitrogen Corp.) with the restriction enzymes XbaI and PmeI, was bound to a DNA fragment comprising a DNA sequence (SEQ ID NO: 20) encoding a human light chain signal sequence and a human κ chain constant region, using an In-Fusion Advantage PCR cloning kit (Clontech Laboratories, Inc.), to produce pcDNA3.3/LK.
  • A neomycin expression unit was removed from pcDNA3.3/LK to construct pCMA-LK.
  • 4)-1-2 Construction of Chimeric and Humanized IgG1 Type Heavy-Chain Expression Vector pCMA-G1
  • A DNA fragment, which had been obtained by digesting pCMA-LK with XbaI and PmeI to remove the DNA sequence encoding the light chain signal sequence and the human κ chain constant region therefrom, was bound to a DNA fragment comprising a DNA sequence (SEQ ID NO: 21) encoding a human heavy chain signal sequence and a human IgG1 constant region, using an In-Fusion Advantage PCR cloning kit (Clontech Laboratories, Inc.), to construct pCMA-G1.
  • 4)-1-3 Construction of chG019 Heavy-Chain Expression Vector
  • A DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the chG019 heavy chain shown in SEQ ID NO: 27 was synthesized (GENEART). Using an In-Fusion HD PCR cloning kit (Clontech Laboratories, Inc.), the synthesized DNA fragment was inserted into a site of pCMA-G1 that had been cleaved with the restriction enzyme BlpI, so as to construct a chG019 heavy chain expression vector. It is to be noted that, for the chG019 heavy chain, a CDR sequence with cysteine substituted with proline was used in order to prevent unpredictable disulfide bonds.
  • 4)-1-4 Construction of chG019 Light-Chain Expression Vector
  • A DNA fragment comprising a DNA sequence (SEQ ID NO: 22) encoding the chG019 light chain was synthesized (GENEART). Using an In-Fusion HD PCR cloning kit (Clontech Laboratories, Inc.), the synthesized DNA fragment was bound to a DNA fragment, which had been obtained by digesting pCMA-LK with XbaI and PmeI to remove the DNA sequence encoding the light chain signal sequence and the human κ chain constant region therefrom, so as to construct a chG019 light chain expression vector.
  • 4)-2 Production and Purification of Human Chimeric Anti-CDH6 Antibody chG019
  • 4)-2-1 Production of chG019
  • In accordance with the manual, FreeStyle 293F cells (Invitrogen Corp.) were cultured and passaged. 1.2×109 FreeStyle 293F cells (Invitrogen Corp.) in the logarithmic growth phase were seeded on a 3-L Fernbach Erlenmeyer Flask (Corning Inc.), then diluted with FreeStyle 293 expression medium (Invitrogen Corp.) at 2.0×106 cells/mL. To 40 ml of Opti-Pro SFM medium (Invitrogen Corp.), 0.24 mg of the heavy chain expression vector, 0.36 mg of the light chain expression vector and 1.8 mg of Polyethyleneimine (Polyscience #24765) were added, and the obtained mixture was gently stirred. After incubation for 5 minutes, the mixture was added to the FreeStyle 293F cells. The cells were shake-cultured at 90 rpm in an 8% CO2 incubator at 37° C. for 4 hours, and thereafter, 600 mL of EX-CELL VPRO medium (SAFC Biosciences Inc.), 18 mL of GlutaMAX I (GIBCO), and 30 mL of Yeastolate Ultrafiltrate (GIBCO) were added to the culture. The cells were further shake-cultured at 90 rpm in an 8% CO2 incubator at 37° C. for 7 days. The obtained culture supernatant was filtrated through a Disposable Capsule Filter (Advantec #CCS-045-E1H).
  • 4)-2-2 Purification of chG019
  • An antibody was purified from the culture supernatant obtained in Example 4)-2-1 by a one-step process according to rProtein A affinity chromatography. The culture supernatant was applied to a column that had been packed with MabSelectSuRe (GE Healthcare Biosciences Corp.) equilibrated with PBS, and thereafter, the column was washed with PBS in an amount of two or more times the volume of the column. Subsequently, the antibody was eluted with a 2 M arginine hydrochloride solution (pH 4.0), so that a fraction containing an antibody was collected. The fraction was dialyzed (Thermo Fisher Scientific Inc., Slide-A-Lyzer Dialysis Cassette), so that the buffer was replaced with HBSor (25 mM histidine/5% sorbitol, pH 6.0). Using a Centrifugal UF Filter Device VIVASPIN20 (molecular weight cutoff: UF10K, Sartorius Inc.), the antibody was concentrated, so that the concentration of IgG was adjusted to 5 mg/ml or more. Finally, the antibody was filtrated through a Minisart-Plus filter (Sartorius Inc.) to obtain a purified sample.
  • 4)-3 Evaluation of Binding Activity of Human Chimeric Anti-CDH6 Antibody chG019
  • The CDH6-binding activity of the human chimeric anti-CDH6 antibody chG019 purified in 4)-2 was confirmed by flow cytometry. Using Lipofectamine 2000, pcDNA3.1-hCDH6 or pcDNA3.1-cynoCDH6 produced in Example 1)-1, or pcDNA3.1 was transiently introduced into 293α cells. The cells were cultured overnight under conditions of 37° C. and 5% CO2, treated with TrypLE Express (Thermo Fisher Scientific Inc.), and thereafter, a cell suspension was prepared. chG019 was added to the suspension of each of these cells. The cells were left standing at 4° C. for 1 hour. Thereafter, the cells were washed twice with PBS supplemented with 5% FBS, and then suspended by the addition of PE-labeled F(ab′)2 Fragment anti-human IgG, Fcγ antibody (Jackson ImmunoResearch Laboratories, Inc.) that had been 500-fold diluted with PBS supplemented with 5% FBS. The cells were left standing at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, and then re-suspended in PBS supplemented with 5% FBS, followed by detection using a flow cytometer (Canto II; BD Biosciences). The data was analyzed using FlowJo (TreeStar, Inc.). As shown in FIG. 4, chG019 did not bind to the 293T cells transfected with pcDNA3.1 as a negative control, but did bind to the 293T cells transfected with pcDNA3.1-hCDH6 or pcDNA3.1-cynoCDH6 in an antibody concentration-dependent manner. In FIG. 4, the abscissa depicts antibody concentration, and the ordinate depicts the amount of the antibody bound, based on mean fluorescence intensity. It is evident from this result that chG019 specifically binds to human CDH6 and cynomolgus monkey CDH6 with almost equivalent binding activity.
    • Example 5: Production of Humanized Anti-CDH6 Antibody
  • 5)-1 Design of Humanized Form of Anti-CDH6 Antibody
  • 5)-1-1 Molecular Modeling of chG019 Variable Region
  • The molecular modeling of the variable regions of chG019 exploited a method known as homology modeling (Methods in Enzymology, 203, 121-153, (1991)). The commercially available protein three-dimensional structure analysis program BioLuminate (manufactured by Schrodinger, LLC) was employed using, as a template, a structure (PDB ID: 2I9L) registered in Protein Data Bank (Nuc. Acid Res. 35, D301-D303 (2007)) with a high sequence identity to the heavy chain and light chain variable regions of chG019.
  • 5)-1-2 Design of Amino Acid Sequence of Humanized hG019
  • chG019 was humanized by CDR grafting (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)). The consensus sequences of human gamma chain subgroup 1 and kappa chain subgroup 1 determined by KABAT et al. (Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service National Institutes of Health, Bethesda, Md. (1991)) had high identity to the framework regions of chG019, and based on this, they were selected as acceptors for the heavy chain and the light chain, respectively. Donor residues to be grafted onto the acceptors were selected by analyzing three-dimensional models with reference to, for example, the criteria given by Queen et al. (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)).
  • 5)-2 Humanization of chG019 Heavy Chain
  • The three heavy chains thus designed were named hH01, hH02 and hH04. The full-length amino acid sequence of the hH01 heavy chain is shown in SEQ ID NO: 39. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 39 is shown in SEQ ID NO: 40. The full-length amino acid sequence of the heavy chain hH02 is shown in SEQ ID NO: 43. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 43 is shown in SEQ ID NO: 44. The full-length amino acid sequence of the heavy chain hH04 is shown in SEQ ID NO: 47. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 47 is shown in SEQ ID NO: 48.
  • 5)-3 Humanization of chG019 Light Chain
  • Two light chains thus designed were named hL02 and hL03. The full-length amino acid sequence of the hL02 light chain is shown in SEQ ID NO: 31. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 31 is shown in SEQ ID NO: 32. The full-length amino acid sequence of the light chain hL03 is shown in SEQ ID NO: 35. The nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 35 is shown in SEQ ID NO: 36.
  • 5)-4 Design of Humanized hG019 by Combination of Heavy Chain and Light Chain
  • An antibody consisting of hH01 and hL02 was named “H01L02 antibody” or “H01L02”. An antibody consisting of hH02 and hL02 was named “H02L02 antibody” or “H02L02”. An antibody consisting of hH02 and hL03 was named “H02L03 antibody” or “H02L03”. An antibody consisting of hH04 and hL02 was named “H04L02 antibody” or “H04L02”.
  • 5)-5 Expression of Humanized Anti-CDH6 Antibody
  • 5)-5-1 Construction of Humanized hG019 Heavy-Chain Expression Vector
  • 5)-5-1-1 Construction of hH01 Heavy-Chain Expression Vector
  • A DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the hH01 heavy chain shown in SEQ ID NO: 40 was synthesized (GENEART). A hH01 heavy chain expression vector was constructed by the same method as that applied in Example 4)-1-3.
  • 5)-5-1-2 Construction of hH02 Heavy-Chain Expression Vector
  • A DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the hH02 heavy chain shown in SEQ ID NO: 44 was synthesized (GENEART). A hH02 heavy chain expression vector was constructed by the same method as that applied in Example 4)-1-3.
  • 5)-5-1-3 Construction of hH04 Heavy-Chain Expression Vector
  • A DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the hH04 heavy chain shown in SEQ ID NO: 48 was synthesized (GENEART). A hH04 heavy chain expression vector was constructed by the same method as that applied in Example 4)-1-3.
  • 5)-5-2 Construction of Humanized hG019 Light-Chain Expression Vector
  • 5)-5-2-1 Construction of hL02 Light-Chain Expression Vector
  • A DNA fragment comprising a hL02 light chain variable region-encoding DNA sequence from nucleotide positions 37 to 399 in the nucleotide sequence of the hL02 light chain shown in SEQ ID NO: 32 was synthesized (GENEART). Using an In-Fusion HD PCR cloning kit (Clontech Laboratories, Inc.), the synthesized DNA fragment was inserted into a site of pCMA-LK that had been cleaved with the restriction enzyme BsiWI, so as to construct a hL02 light chain expression vector.
  • 5)-5-2-2 Construction of hL03 Light-Chain Expression Vector
  • A DNA fragment comprising a hL03 light chain variable region-encoding DNA sequence from nucleotide positions 37 to 399 in the nucleotide sequence of the hL03 light chain shown in SEQ ID NO: 36 was synthesized (GENEART). A hL03 light chain expression vector was constructed by the same method as that applied in Example 5)-5-2-1.
  • 5)-5-3 Preparation of Humanized hG019
  • 5)-5-3-1 Production of H01L02, H02L02, H02L03 and H04L02
  • The antibodies were produced by the same method as that applied in Example 4)-2-1. H01L02, H02L02, H02L03 and H04L02 were produced by the combination of the heavy chain and the light chain shown in Example 5)-4.
  • 5)-5-3-2 Two-Step Purification of H01L02, H02L02, H02L03 and H04L02
  • The antibody was purified from the culture supernatant obtained in Example 5)-5-3-1, by a two-step process, namely, by rProtein A affinity chromatography and ceramic hydroxyapatite. The culture supernatant was applied to a column that had been packed with MabSelectSuRe (manufactured by GE Healthcare Biosciences Corp.) equilibrated with PBS, and thereafter, the column was washed with PBS in an amount of two or more times the volume of the column. Subsequently, the antibody was eluted using a 2 M arginine hydrochloride solution (pH 4.0). A fraction containing the antibody was dialyzed (Thermo Fisher Scientific Inc., Slide-A-Lyzer Dialysis Cassette), so that the buffer was replaced with PBS. The antibody solution was 5-fold diluted with a buffer of 5 mM sodium phosphate/50 mM MES/pH 7.0, and then applied to a ceramic hydroxyapatite column (Bio-Rad Laboratories, Inc., Bio-Scale CHT Type-1 Hydroxyapatite Column) that had been equilibrated with a buffer of 5 mM NaPi/50 mM MES/30 mM NaCl/pH 7.0. Elution was carried out on a linear concentration gradient of sodium chloride, so that a fraction containing an antibody was collected. This fraction was dialyzed (Thermo Fisher Scientific Inc., Slide-A-Lyzer Dialysis Cassette), so that the buffer was replaced with HBSor (25 mM histidine/5% sorbitol, pH 6.0). The antibody was concentrated with Centrifugal UF Filter Device VIVASPIN20 (molecular weight cutoff: UF10K, Sartorius Inc.), thereby adjusting the IgG concentration to 20 mg/ml. Finally, the antibody was filtrated through a Minisart-Plus filter (Sartorius Inc.) to obtain a purified sample.
    • Reference Example 1: Production of Anti-CDH6 Antibody NOV0712
  • The anti-CDH6 antibody NOV0712 used in the Examples was produced with reference to the light chain full-length and heavy chain full-length amino acid sequences (SEQ ID NO: 235 and SEQ ID NO: 234, respectively, in International Publication No. WO 2016/024195) of NOV0712 described in International Publication No. WO 2016/024195.
    • Reference Example 1)-1 Anti-CDH6 Antibody NOV0712 Reference Example 1)-1-1 Construction of Anti-CDH6 Antibody NOV0712 Heavy-Chain Expression Vector
  • A NOV0712 heavy chain variable region-encoding DNA fragment from nucleotide positions 36 to 428 in the nucleotide sequence of the NOV0712 heavy chain shown in SEQ ID NO: 54 was synthesized (GENEART). A NOV0712 heavy chain expression vector was constructed by the same method as that applied in Example 4)-1-3. The amino acid sequence of the NOV0712 heavy chain expressed by the NOV0712 heavy chain expression vector is shown in SEQ ID NO: 53. In the amino acid sequence shown in SEQ ID NO: 53, the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence.
    • Reference Example 1)-1-2 Construction of Anti-CDH6 Antibody NOV0712 Light-Chain Expression Vector
  • A DNA fragment comprising a NOV0712 light chain variable region-encoding DNA sequence from nucleotide positions 37 to 405 in the nucleotide sequence of the NOV0712 light chain shown in SEQ ID NO: 52 was synthesized (GENEART). A NOV0712 light chain expression vector was constructed by the same method as that applied in Example 5)-5-2-1. The amino acid sequence of the NOV0712 light chain expressed by the NOV0712 light chain expression vector is shown in SEQ ID NO: 51. In the amino acid sequence shown in SEQ ID NO: 51, the amino acid sequence consisting of the amino acid residues at positions 1 to 20 is a signal sequence.
    • Reference Example 1)-2 Preparation of Anti-CDH6 Antibody NOV0712 Reference Example 1)-2-1 Production of Anti-CDH6 Antibody NOV0712
  • NOV0712 was produced by the same method as that applied in Example 4)-2-1.
    • Reference Example 1)-2-2 One-Step Purification of Anti-CDH6 Antibody NOV0712
  • The anti-CDH6 antibody NOV0712 was purified from the culture supernatant obtained in Reference Example 1)-2-1 by the same method as that applied in Example 4)-2-2 (antibody concentration: 5 mg/l HBSor).
    • Example 6: In Vitro Evaluation of Humanized hG019 and NOV0712
  • 6)-1 Evaluation of Binding Activity of Humanized hG019
  • The dissociation constant between the antibody and the antigen (Recombinant Human CDH6 Fc His chimera, R&D Systems, Inc.) was measured by using Biacore T200 (GE Healthcare Biosciences Corp.), according to a capture method, which comprises capturing the antigen as a ligand with the immobilized anti-His antibody and then measuring the dissociation constant using an antibody as an analyte. Approximately 1000 RU of the anti-histidine antibody (His capture kit, GE Healthcare Biosciences Corp.) was covalently bound to sensor chip CM5 (GE Healthcare Biosciences Corp.) by the amine coupling method. The antibody was also immobilized onto reference cells in the same manner as above. HBS-P+(10 mM HEPES pH 7.4, 0.15 M NaCl, 0.05% Surfactant P20) supplemented with 1 mM CaCl2 was used as a running buffer. The antigen was added onto the anti-histidine antibody-immobilized chip for 60 seconds, and a dilution series solution (0.391 to 100 nM) of the antibody was then added at a flow rate of 30 μl/min for 300 seconds. Subsequently, the dissociation phase was monitored for 600 seconds. As a regeneration solution, a glycine solution (pH 1.5) supplemented with 5 M MgCl2 was added twice at a flow rate of 10 μl/min for 30 seconds. A Steady State Affinity model in analysis software (BIAevaluation software, version 4.1) was used in data analysis, and the dissociation constant (KD) was calculated. The results are shown in Table 2.
  • TABLE 2
    Antibody KD (M)
    1 H01L02 1.5E−09
    2 H02L02 1.1E−09
    3 H02L03 1.4E−09
    4 H04L02 1.1E−09
  • 6)-2 Analysis of CDH6-Binding Sites of Humanized hG019 and NOV0712
  • 6)-2-1 Epitope Analysis Using Domain Defective Mutant
  • Using Lipofectamine 2000 (Thermo Fisher Scientific Inc.), each domain deletion mutant expression vector produced in Example 2)-2-1, or pcDNA3.1-hCDH6 for the expression of full-length human CDH6 was transiently introduced into cells. The cells were cultured overnight under conditions of 37° C. and 5% CO2, and thereafter, a cell suspension was prepared. The suspension of the transfected 293α cells was centrifuged, and the supernatant was then removed. Thereafter, the cells were suspended by the addition of each of the 4 humanized hG019 antibodies (clone Nos: H01L02, H02L02, H02L03 and H04L02), which had been prepared in Example 5)-5-3, or the anti-CDH6 antibody NOV0712, which had been prepared in Reference Example 1, or human IgG1 (Calbiochem) as a negative control. The cells were left standing at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, and then suspended by the addition of APC-anti-human IgG goat F(ab′)2 (Jackson ImmunoResearch Laboratories, Inc.) that had been 500-fold diluted with PBS supplemented with 5% FBS. The cells were left standing at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, followed by detection using a flow cytometer (Canto II; BD Biosciences). The data was analyzed using FlowJo (TreeStar, Inc.). The results are shown in FIGS. 5-1 to 5-6. In the histograms of FIGS. 5-1 to 5-6, the abscissa depicts APC fluorescence intensity indicating the amount of the antibody bound, and the ordinate depicts cell count. The shaded histogram shows that negative control untransfected 293α cells were used, and the open solid line histogram shows that 293α cells expressing full-length hCDH6 or each EC domain deletion mutant were used. Fluorescence intensity is enhanced when the antibody binds to full-length hCDH6 or each EC domain deletion mutant on the cell surface. The human IgG1 control binds to none of the transfected cells. The 4 humanized hG019 antibodies (clone Nos: H01L02, H02L02, H02L03 and H04L02) bind to the full-length hCDH6, the EC1 deletion mutant, the EC2 deletion mutant, the EC4 deletion mutant, and the EC5 deletion mutant, but do not bind to the EC3 deletion mutant. Specifically, it was demonstrated that the 4 humanized hG019 antibodies specifically bind to hCDH6 with EC3 as an epitope. On the other hand, the anti-CDH6 antibody NOV0712 binds to the full-length hCDH6, the EC1 deletion mutant, the EC2 deletion mutant, the EC3 deletion mutant, and the EC4 deletion mutant, but does not bind to the EC5 deletion mutant. Specifically, it was demonstrated that the anti-CDH6 antibody NOV0712 specifically binds to hCDH6 with EC5 as an epitope. This is consistent with epitope information on NOV0712 described in International Publication No. WO 2016/024195. From this result, it was demonstrated that the 4 humanized hG019 antibodies obtained in the present description are anti-CDH6 antibodies that exhibit properties different from those of NOV0712.
  • 6)-2-2 Binding Competition Assay of Antibodies
  • 6)-2-2-1 Production of 786-O/hCDH6 Stably Expressing Cell Line
  • The 786-O/hCDH6 stably expressing cell line was produced by infecting 786-O cells (ATCC) with a recombinant retrovirus for full-length human CDH6 expression. A human CDH6 expression retrovirus vector (pQCXIN-hCDH6) was produced by using a human CDH6 protein (NP_004923)-encoding cDNA expression vector (OriGene Technologies Inc., RC217889), and incorporating the cDNA into retrovirus vector pQCXIN (Clontech Laboratories, Inc.) according to a method known to a person skilled in the art. Using FuGene HD (Promega Corp.), pQCXIN-hCDH6 was transiently introduced into retrovirus packaging cells RetroPack PT67 (Clontech Laboratories, Inc.). After 48 hours, a culture supernatant containing recombinant retrovirus was recovered, and then added to the 786-O cell culture system, so that the cells were infected. From 3 days after the infection, the infected cells were cultured under conditions of 37° C. and 5% CO2 in a medium supplemented with G418 (Gibco) (final concentration: 50 mg/mL) and screened with the drug, so as to establish cell line 786-O/hCDH6 stably expressing human CDH6. The high expression of human CDH6 in the stably expressing line was confirmed by flow cytometry in the same manner as that applied in Example 2)-3-1 (FIG. 6). Goat anti-Mouse IgG1 Secondary Antibody Alexa Fluor 647 (Thermo Fisher Scientific Inc.) that had been 500-fold diluted with PBS supplemented with 5% FBS was used as an antibody for detection. The results are shown in FIG. 6. In the histogram of FIG. 8, the abscissa depicts Alexa Fluor 647 fluorescence intensity indicating the amount of the antibody bound, and the ordinate depicts cell count. The shaded histogram shows that the negative control mIgG1 was used in staining, and the open solid line histogram shows that the anti-human CDH6 antibody was used in staining. As seen, fluorescence intensity was enhanced by the binding of the antibody to hCDH6 on cell surface. The mIgG1 control binds to none of the cells. As a result, it was demonstrated that the 786-O/hCDH6 stably expressing cell line more highly expresses human CDH6 than the parent line 786-O cells.
  • 6)-2-2-2 Binding Competition Assay Using Labeled H01L02 and Labeled NOV0712
  • Labeled H01L02 and labeled NOV0712 were produced using an Alexa Fluor 488 Monoclonal Antibody Labeling Kit (Thermo Fisher Scientific Inc.). The cell suspension of the 786-O/hCDH6 stably expressing cell line produced in 6)-2-2-1 was centrifuged, and the supernatant was then removed. Thereafter, the cells were suspended by the addition of labeled NOV0712 or labeled H01L02 (final concentration: 5 nM) and, further, the addition of each of the 4 humanized hG019 antibodies (clone Nos: H01L02, H02L02, H02L03 and H04L02), which had been prepared in Example 5)-5-3, or the anti-CDH6 antibody NOV0712, which had been prepared in Reference Example 1, or human IgG1 (Calbiochem) as a negative control (final concentration: as shown in the abscissa of FIG. 7). The cells were left standing at 4° C. for 1 hour. Thereafter, the cells were washed twice with PBS supplemented with 5% FBS, followed by detection using a flow cytometer (Canto II; BD Biosciences). The data was analyzed using FlowJo (TreeStar, Inc.). The results are shown in FIG. 7. The abscissa depicts the final concentration of the added unlabeled antibody, and the ordinate depicts the amount of the antibody bound based on mean fluorescence intensity. When unlabeled NOV0712 is added to cells supplemented with labeled NOV0712, the amount of the labeled antibody bound is decreased by replacement with the unlabeled antibody in an addition concentration-dependent manner because they compete with each other for binding to the same epitope. On the other hand, even if each of the 4 humanized hG019 antibodies or human IgG1 as a negative control is added to cells supplemented with labeled NOV0712, there is no change in the amount of the labeled antibody bound, indicating that these antibodies differ in epitope and thus do not compete with each other for binding. Likewise, when each of the 4 unlabeled humanized hG019 antibodies is added to cells supplemented with labeled H01L02, the amount of the labeled antibody bound is decreased by replacement with the unlabeled antibody in an addition concentration-dependent manner because they compete with each other for binding to the same epitope. On the other hand, even if NOV0712 or human IgG1 as a negative control is added to cells supplemented with labeled H01L02, there is no change in the amount of the labeled antibody bound, indicating that these antibodies differ in epitope and thus do not compete with each other for binding.
  • 6)-3 Evaluation of Internalization Activity of Humanized hG019 and NOV0712
  • The internalization activity of humanized hG019 and NOV0712 was evaluated using an anti-human IgG reagent Hum-ZAP (Advanced Targeting Systems) conjugated with a toxin (saporin) inhibiting protein synthesis. Specifically, human CDH6-positive ovarian tumor cell line NIH:OVCAR-3 (ATCC) was seeded at 4×103 cells/well on a 96-well plate, and then cultured overnight under conditions of 37° C. and 5% CO2. Human CDH6-positive renal cell tumor cell line 786-O (ATCC) was seeded at 1×103 cells/well on a 96-well plate, and then cultured overnight. Human CDH6-positive ovarian tumor cell line PA-1 (ATCC) was seeded at 1×103 cells/well on a 96-well plate, and then cultured overnight under conditions of 37° C. and 5% CO2. On the next day, each anti-CDH6 antibody (final concentration: 1 nM) or human IgG1 antibody (Calbiochem) as a negative control antibody was added to the plate. Hum-ZAP (final concentration: 0.5 nM) or F(ab′)2 Fragment Goat Anti-human IgG, Fc (gamma) Fragment Specific (Jackson ImmunoResearch Laboratories, Inc.) unconjugated with the toxin (final concentration: 0.5 nM) as a negative control was further added to the plate, and the cells were cultured under conditions of 37° C. and 5% CO2 for 3 days. The number of live cells was measured by the quantification of ATP activity (RLU) using CellTiter-Glo™ Luminescent Cell Viability Assay. In this evaluation, Hum-ZAP is taken up into cells in a manner dependent on the internalization activity of the humanized anti-CDH6 antibody, so that saporin, which inhibits protein synthesis, is released into the cells, so as to suppress cell growth. A cell growth inhibition effect brought about by the addition of the anti-CDH6 antibody was indicated by a relative survival rate when the number of live cells in a well supplemented with the negative control instead of Hum-ZAP was defined as 100%. FIG. 8 shows a table of the cell survival rate. In this experiment, an antibody having strong internalization activity is considered to offer a low cell survival rate. As a result, the 4 humanized hG019 antibodies have an internalization rate of approximately 50 to 75% predicted from the cell survival rates for all of the 3 cell lines. Thus, the 4 humanized hG019 antibodies exhibit very high internalization activity and exhibit much higher internalization activity than that of NOV0712. From the mechanism of the medicinal effects of ADC, an antibody having higher internalization activity is considered to be more suitable as an ADC antibody.
    • Example 7: Production of Humanized hG019 Variant
  • 7)-1 Design of Humanized hG019 Variant
  • 7)-1-1 Design of Variant Having Modified H01L02 Variable Region
  • A heavy chain designed by substituting the 71st tyrosine in the hH01 amino acid sequence described in Example 5)-2, with alanine was designated as hH11 and a heavy chain designed by substituting the 81st glutamine in the sequence with serine and the 123rd phenylalanine with alanine was designated as hH31. The amino acid sequence of the hH11 heavy-chain variable region is shown in SEQ ID No: 55. The nucleotide sequence encoding the amino acid sequence of SEQ ID No: 55 is shown in SEQ ID No: 56. The amino acid sequence of the hH31 heavy-chain variable region is shown in SEQ ID No: 60. The nucleotide sequence encoding the amino acid sequence of SEQ ID No: 60 is shown in SEQ ID No: 61.
  • 7)-1-2 Design of LALA of Human Heavy Chain
  • A heavy chain was designed by substituting leucine residues at positions 234 and 235 (specified by the EU index) of the hH01 amino acid sequence described in Example 5)-2 with alanine residues (referred to herein as “hH01A”). A heavy chain having the hH11 variable region designed in Example 7)-1-1, i.e., an isotype of IgG1, was designed by substituting leucine residues at position 234 and 235 (specified by the EU index) with alanine residues (referred to herein as “hH11A”). A heavy chain having the hH31 variable region (designed in Example 7)-1-1), i.e., an isotype of IgG1, was designed by substituting leucine residues at positions 234 and 235 (specified by the EU index) with alanine residues (referred to herein as “hH31A”).
  • 7)-2 Design of Variant of Humanized hG019 Changed in Binding Affinity by Using Heavy Chain and Light Chain in Combination
  • The antibody having hH01A and hL02 is designated as “H01L02A antibody” or “H01L02A”. The antibody having hH11A and hL02 is designated as “H11L02A antibody” or “H11L02A”. The antibody having hH31A and hL02 is designated as “H31L02A antibody” or “H31L02A”.
  • 7)-3 Expression of Variant of Humanized hG019 Changed in Binding Affinity
  • 7)-3-1 Construction of Humanized IgG1 LALA Type Heavy-Chain Expression Vector pCMA-G1LALA
  • Using a DNA fragment comprising the DNA sequence encoding amino acid sequence of the human heavy chain signal sequence shown in SEQ ID No: 71 and the human IgG1 LALA constant region, pCMA-G1LALA was constructed in the same manner as in Example 4)-1-2.
  • 7)-3-2 Construction of hH01A Heavy-Chain Expression Vector
  • A DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the hH01A shown in SEQ ID No: 66 was synthesized (GENEART). Using an In-Fusion HD PCR cloning kit (Clontech Laboratories, Inc.), the synthesized DNA fragment was inserted into a site of pCMA-G1LALA that had been cleaved with the restriction enzyme BlpI, so as to construct a hH01A expression vector.
  • 7)-3-3 Construction of hH11A Heavy-Chain Expression Vector
  • A DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the hH11A shown in SEQ ID No: 68 was synthesized (GENEART). An hH11A expression vector was constructed in the same manner as in Example 7)-3-2.
  • 7)-3-4 Construction of hH31A Heavy-Chain Expression Vector
  • A DNA fragment from nucleotide positions 36 to 440 in the nucleotide sequence of the hH31A shown in SEQ ID No: 70 was synthesized (GENEART). An hH31A expression vector was constructed in the same manner as in Example 7)-3-2.
  • 7)-4 Preparation of Variant of Humanized hG019 Changed in Binding Affinity
  • 7)-4-1 Production of H01L02A, H11L02A and H31L02A
  • Production was carried out in the same manner as in Example 4)-2-1. Using the light-chain expression vector constructed in Example 5)-5-2-1 and the heavy-chain expression vector constructed in Example 7)-3, combinations of an H chain expression vector and an L chain expression vector, i.e., H01L02A, H11L02A, H31L02A, which correspond to the combinations of H and L chains described in Example 7)-2, were obtained.
  • 7)-4-2 Two-Step Purification of H01L02A, H11L02A and H31L02A
  • Purification was carried out in the same manner as in Example 5)-5-3-2 using the culture supernatant obtained in Example 7)-4-1.
    • Example 8: In Vitro Evaluation of Humanized hG019 Variant Changed in Binding Affinity
  • 8)-1 Evaluation of Binding Activity of H01L02A, H11L02A, H31L02A
  • The dissociation constant of a construct of each of H01L02A, H11L02A and H31L02A prepared in Example 7)-4 and human CDH6 was measured by using Biacore T200 (GE Healthcare Biosciences Corp.), according to a capture method, which comprises capturing the antigen as a ligand with Anti-histidine antibody immobilized by means of a His Capture Kit (manufactured by GE Healthcare Bioscience) and then measuring the dissociation constant using an antibody as an analyte. As the sensor chip, CM5 (manufactured by GE Healthcare Bioscience) was used. As the running buffer, buffer containing 20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl2 and 0.05% Surfactant P20 (pH7.4), was used. On the chip, a 1 μg/mL Recombinant Human Cadherin-6 (KCAD)/Fc Chimera (RD-SYSTEMS) was added at a rate of 10 μL/minute for 60 seconds, and a dilution series solution (0.11 to 81 μg/mL) of the antibody prepared in Example 7)-4 was then added at a flow rate of 30 μl/min for 180 seconds. Subsequently, the dissociation phase was monitored for 180 seconds. As a regeneration solution, a Glycine 1.5 (GE Healthcare Bioscience made by the company) was added at a flow rate of 20 μl/min for 30 seconds. A Steady State Affinity model was used in data analysis, and the dissociation constant (KD) was calculated. The results are shown in Table 3.
  • TABLE 3
    Name KD (nM)
    H01L02A 2.8
    H11L02A 43.1
    H31L02A 11.1
    • Example 9: Production of Anti-LPS Antibody as Control
  • An anti-LPS antibody was produced with reference to WO2015/046505. The isotope of the anti-LPS antibody used in the Example is IgG1 (also referred to as an anti-LPS antibody). The amino acid sequences of a light chain and heavy chain of the anti-LPS antibody used in the Example are shown in SEQ ID No: 72 and SEQ ID No: 73, respectively.
    • Example 10: Synthesis of Production Intermediate Example 10-1: Intermediate 1
  • Figure US20220016257A1-20220120-C00036
    Figure US20220016257A1-20220120-C00037
    • Step 1: Benzyl (6S)-6-(hydroxymethyl)-5-azaspiro[2.4]heptane-5-carboxylate (1-2)
  • To a solution of 5-benzyl 6-methyl(6S)-5-azaspiro[2.4]heptane-5,6-dicarboxylate (1-1) (104 mmol, WO 2012087596) in THF (500 mL), lithium borohydride (4.30 g, 178 mmol) was added in small portions at 0° C. The solution was stirred at 0° C. for 30 minutes, and then stirred at room temperature for 2 hours. Water (180 mL) and 2 N hydrochloric acid (186 mL) were added at 0° C., and the resultant was distilled under reduced pressure. The resulting residue was extracted with ethyl acetate four times, and the organic layer was washed with brine and then dried over anhydrous sodium sulfate. The resultant was distilled under reduced pressure, and the resulting residue (1-2) (27.9 g, 90%) was directly used for the subsequent reaction.
    • Step 2: Benzyl (6S)-6-({[tert-butyl(dimethyl)silyl]oxy}methyl)-5-azaspiro[2.4]heptane-5-carboxylate (1-3)
  • To a solution of the compound obtained in step 1 (1-2) (27.9 g, 107 mmol) and imidazole (14.5 g, 214 mmol) in dichloromethane (300 mL), tert-butyldimethylsilyl chloride (24.2 g, 160 mmol) was added at room temperature, and the resultant was stirred at room temperature for 18 hours. The reaction solution was washed with a saturated aqueous citric acid, a saturated aqueous sodium hydrogen carbonate, and brine, dried over anhydrous sodium sulfate, and then distilled under reduced pressure. The resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=100:0 (v/v) to 50:50 (v/v)] to afford the desired compound (1-3) (32.5 g, 81%). 1H-NMR (CDCl3) δ: 7.39-7.34 (5H, m), 5.23-5.11 (2H, m), 4.10-3.48 (4H, m), 3.16-3.14 (1H, m), 2.15-2.04 (1H, m), 1.81-1.77 (1H, m), 0.91-0.88 (9H, m), 0.65-0.55 (4H, m), 0.08-0.01 (6H, m).
  • MS (APCI) m/z: 376 (M+H)+
    • Step 3: (6S)-6-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-5-azaspiro[2.4]heptane (1-4)
  • To a solution of the compound obtained in step 2 (1-3) (32.5 g, 86.5 mmol) in ethanol (400 mL), 7.5% palladium carbon catalyst (moisture content: 54%, 5.00 g) was added at room temperature, and the resultant was stirred under a hydrogen atmosphere at room temperature for 6 hours. The reaction solution was filtered through Celite, and the filtrate was distilled under reduced pressure to afford the desired compound (1-4) (21.3 g, quantitative).
  • 1H-NMR (CDCl3) δ: 3.79-3.77 (1H, m), 3.71-3.69 (1H, m), 3.65-3.60 (1H, m), 3.01-2.98 (2H, m), 1.81-1.71 (2H, m), 0.90 (9H, s), 0.65-0.57 (4H, m), 0.08 (3H, s), 0.07 (3H, s).
  • MS (APCI, ESI) m/z: 242 (M+H)+
    • Step 4: [(6S)-6-({[tert-Butyl(dimethyl)silyl]oxy}methyl)-5-azaspiro[2.4]hept-5-yl] (5-methoxy-2-nitro-4-{[tri(propan-2-yl)silyl]oxy}phenyl)methanone (1-5)
  • To a solution of 5-methoxy-2-nitro-4-{tri(propan-2-yl)silyl]oxy}benzoic acid (52.2 g, 141 mmol, US 20150283262) and 1-hydroxybenzotriazole monohydrate (23.8 g, 155 mmol) in dichloromethane (500 mL), N,N′-dicyclohexylcarbodiimide (35.0 g, 170 mmol) was added under ice-cooling. The reaction mixture was stirred at room temperature. After the carboxylic acid disappeared, a solution of the compound obtained in step 3 (1-4) (34.1 g, 141 mmol) and triethylamine (29.4 mL, 212 mmol) in dichloromethane (100 mL) was slowly added dropwise thereto. After the reaction solution was stirred at room temperature overnight, saturated aqueous sodium hydrogen carbonate was added to the reaction mixture, and the reaction mixture was extracted with chloroform. The organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. The resultant was distilled under reduced pressure, and to the resulting residue ethyl acetate and diethyl ether were added, and the solid contents were removed through filtration, and the filtrate was distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=100:0 (v/v) to 25:75 (v/v)] to afford the desired compound (1-5) (55.0 g, 66%).
  • 1H-NMR (CDCl3) δ: 7.72-7.66 (1H, m), 6.80-6.73 (1H, m), 4.53-4.49 (1H, m), 4.04-3.95 (1H, m), 3.91-3.88 (3H, m), 3.59-3.54 (1H, m), 3.36-3.25 (0.5H, m), 3.01-2.96 (1.5H, m), 2.24-2.20 (0.3H, m), 2.09-2.05 (0.7H, m), 2.00-1.97 (0.7H, m), 1.69-1.67 (0.3H, m), 1.32-1.24 (3H, m), 1.12-1.05 (18H, m), 0.93-0.91 (6H, m), 0.79-0.77 (3H, m), 0.71-0.62 (2H, m), 0.57-0.40 (2H, m), 0.12-0.10 (4H, m), 0.11-0.15 (2H, m).
  • MS (APCI, ESI) m/z: 593 (M+H)+
    • Step 5: (2-Amino-5-methoxy-4-{[tri(propan-2-yl)silyl]oxy}phenyl) [(6S)-6-({[tert-butyl(dimethyl)silyl]oxy}methyl)-5-azaspiro[2.4]hept-5-yl]methanone (1-6)
  • To a solution of the compound obtained in step 4 (1-5) (55.0 g, 92.8 mmol) in ethanol (300 mL), 7.5% palladium carbon (10.0 g) was added under a nitrogen atmosphere. The nitrogen balloon was immediately replaced with a hydrogen balloon, and the reaction mixture was vigorously stirred under a hydrogen atmosphere at room temperature. After the raw materials disappeared, the reaction mixture was filtered, and the filtrate was distilled under reduced pressure to afford the desired compound (1-6) (52.2 g, 100%), which was directly used for the subsequent reaction.
  • 1H-NMR (CDCl3) δ: 6.71 (1H, s), 6.25 (1H, s), 4.55-4.28 (2H, m), 3.97 (1H, m), 3.75-3.62 (3H, m), 3.70 (3H, s), 3.09-3.07 (1H, m), 2.24-2.19 (1H, m), 1.81-1.68 (1H, m), 1.27-1.22 (3H, m), 1.09-1.05 (18H, m), 0.90 (9H, s), 0.65-0.46 (4H, m), 0.07-0.03 (6H, m).
  • MS (APCI, ESI) m/z: 563 (M+H)+
    • Step 6: N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N-[4-({[(2-{[(6S)-6-({[tert-butyl(dimethyl)silyl]oxy}methyl)-5-azaspiro[2.4]hept-5-yl]carbonyl}-4-methoxy-5-{[tri(propan-2-yl)silyl]oxy}phenyl)carbamoyl]oxy}methyl)phenyl]-L-alaninamide (1-7)
  • To a solution of the compound obtained in step 5 (1-6) (18.6 g, 33.0 mmol) and triethylamine (6.26 mL, 45.2 mmol) in THF (300 mL), triphosgene (4.22 g, 14.2 mmol) was slowly added on an ethanol-ice bath. After the addition, a solution of N-[(prop-2-en-1-yloxy)carbonyl]-L-valyl-N-[4-(hydroxymethyl)phenyl]-L-alaninamide (11.4 g, 30.2 mmol, WO 2011130598) and triethylamine (6.26 mL, 45.2 mmol) in THF (100 mL) and N,N-dimethylformamide (30 mL) was slowly added dropwise to the ice-cooled reaction mixture. After the dropwise addition, the ice bath was removed, and the reaction mixture was stirred under a nitrogen atmosphere at 40° C. After the raw materials disappeared, water was added to the reaction mixture, and the reaction mixture was extracted with ethyl acetate. The organic layer was washed with brine, and dried over anhydrous sodium sulfate. After filtration followed by distillation under reduced pressure, the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=100:0 (v/v) to 40:60 (v/v)] to afford the desired compound (1-7) (23.5 g, 74%).
  • 1H-NMR (CDCl3) δ: 8.99 (1H, m), 8.58 (1H, s), 7.80 (1H, s), 7.55-7.53 (2H, m), 7.34-7.32 (2H, m), 6.77-6.75 (2H, m), 5.94-5.87 (1H, m), 5.40-5.38 (1H, m), 5.33-5.29 (1H, m), 5.23-5.21 (1H, m), 5.13 (1H, m), 5.10 (2H, m), 4.69-4.64 (1H, m), 4.62-4.52 (2H, m), 4.06-4.03 (1H, m), 3.98 (1H, m), 3.76-3.65 (6H, m), 3.04 (1H, m), 2.28-2.26 (1H, m), 2.18-2.13 (1H, m), 1.46 (3H, m), 1.32-1.25 (3H, m), 1.11-1.09 (18H, m), 0.99-0.84 (15H, m), 0.65-0.40 (4H, m), 0.08-0.00 (6H, m).
  • MS (APCI, ESI) m/z: 966 (M+H)+
    • Step 7: N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N-[4-({[(2-{[(6S)-6-(hydroxymethyl)-5-azaspiro[2.4]hept-5-yl]carbonyl}-4-methoxy-5-{[tri(propan-2-yl)silyl]oxy}phenyl)carbamoyl]oxy}methyl)phenyl]-L-alaninamide (1-8)
  • To a solution of the compound obtained in step 6 (1-7) (23.5 g, 24.3 mmol) in THF (50 mL), methanol (50 mL) and water (44 mL), acetic acid (200 mL) was added at room temperature. The reaction mixture was stirred at room temperature. After the raw materials disappeared, the reaction mixture was extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over anhydrous sodium sulfate. After filtration followed by distillation under reduced pressure, the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=100:0 (v/v) to 0:100 (v/v)] to afford the desired compound (1-8) (18.0 g, 87%).
  • 1H-NMR (CDCl3) δ: 8.64-8.62 (1H, m), 8.50 (1H, m), 7.69 (1H, m), 7.55-7.53 (2H, m), 7.34-7.32 (2H, m), 6.79-6.75 (3H, m), 5.91-5.89 (1H, m), 5.39 (1H, m), 5.32-5.29 (1H, m), 5.23-5.21 (1H, m), 4.68-4.54 (4H, m), 4.31 (1H, m), 4.06-4.04 (1H, m), 3.81-3.79 (3H, m), 3.76 (3H, s), 3.63-3.61 (1H, m), 3.13-3.11 (1H, m), 2.16-2.13 (1H, m), 1.87-1.81 (2H, m), 1.46-1.43 (3H, m), 1.30-1.24 (3H, m), 1.12-1.08 (18H, m), 0.98-0.91 (6H, m), 0.63-0.45 (4H, m).
  • MS (APCI, ESI) m/z: 852 (M+H)+
    • Step 8: N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11a′S)-11′-hydroxy-7′-methoxy-5′-oxo-8′-{[tri(propan-2-yl)silyl]oxy}-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (1-9)
  • To a solution of dimethyl sulfoxide (3.75 mL, 52.8 mmol) in dichloromethane (300 mL), oxalyl chloride (2.17 mL, 25.3 mmol) was slowly added dropwise under a nitrogen atmosphere at −78° C. After the dropwise addition, the reaction mixture was stirred at −78° C. A solution of the compound obtained in step 7 (1-8) (18.0 g, 21.1 mmol) in dichloromethane (50.0 mL) was slowly added to the reaction mixture. Triethylamine (14.6 mL, 105 mmol) was added to the reaction solution at −78° C. After the addition, the cool bath was removed, and the temperature was slowly raised to room temperature. After the raw materials disappeared, water was added to the reaction mixture, and the reaction mixture was extracted with chloroform (200 mL). The organic layer was washed with water and brine, and dried over anhydrous magnesium sulfate. After filtration followed by distillation under reduced pressure, the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=100:0 (v/v) to 0:60 (v/v)] to afford the desired compound (1-9) (16.5 g, 92%).
  • 1H-NMR (CDCl3) δ: 8.51-8.36 (1H, m), 7.54-7.38 (2H, m), 7.22-7.07 (3H, m), 6.73-6.64 (1H, m), 5.94-5.87 (2H, m), 5.33-5.22 (3H, m), 5.09 (1H, m), 4.97 (1H, m), 4.64-4.58 (4H, m), 4.02-4.00 (1H, m), 3.86-3.83 (3H, m), 3.75-3.70 (1H, m), 3.61-3.54 (2H, m), 3.38-3.29 (1H, m), 2.40 (1H, m), 2.16-2.14 (1H, m), 1.74-1.71 (1H, m), 1.44 (3H, m), 1.18-1.16 (3H, m), 1.05-1.00 (18H, m), 0.97-0.92 (6H, m), 0.72-0.60 (4H, m).
  • MS (APCI, ESI) m/z: 850 (M+H)+
    • Step 9: N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-5′-oxo-8′-{[tri(propan-2-yl)silyl]oxy}-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (1-10)
  • To a solution of the compound obtained in step 8 (1-9) (12.0 g, 14.1 mmol) and 2,6-lutidine (6.58 mL, 56.5 mmol) in dichloromethane (200 mL), tert-butyldimethylsilyl trifluoromethylsulfonate (9.73 mL, 42.3 mmol) was slowly added dropwise under a nitrogen atmosphere at 0° C. After stirring under ice-cooling for 10 minutes, the ice bath was removed, and the reaction mixture was stirred at room temperature. After the raw materials disappeared, water was added to the reaction mixture, which was extracted with chloroform. The organic layer was washed with water and brine, and dried over anhydrous sodium sulfate. After filtration followed by distillation under reduced pressure, the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=100:0 (v/v) to 25:75 (v/v)] to afford the desired compound (1-10) (8.12 g, 60%).
  • 1H-NMR (CDCl3) δ: 8.67-8.45 (1H, m), 7.50-7.44 (2H, m), 7.19 (1H, s), 7.13 (2H, m), 6.95 (2H, m), 6.62-6.57 (2H, m), 6.01 (1H, m), 5.95-5.86 (1H, m), 5.33-5.13 (3H, m), 4.82 (1H, m), 4.65-4.54 (3H, m), 4.03-4.01 (1H, m), 3.84-3.82 (3H, m), 3.73-3.66 (1H, m), 3.50-3.48 (1H, m), 3.27 (1H, m), 2.37-2.33 (1H, m), 2.19-2.13 (1H, m), 1.54-1.43 (3H, m), 1.22-1.13 (3H, m), 1.10-1.00 (18H, m), 0.97-0.91 (6H, m), 0.81 (9H, s), 0.76-0.59 (4H, m), 0.19-0.09 (6H, m).
  • MS (APCI, ESI) m/z: 964 (M+H)+
    • Step 10: N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-8′-hydroxy-7′-methoxy-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (1-11)
  • To a solution of the compound obtained in step 9 (1-10) (8.12 g, 8.42 mmol) in N,N-dimethylformamide (90 mL) and water (2 mL), lithium acetate (0.611 g, 9.26 mmol) was added, and the resultant was stirred at room temperature. After the raw materials disappeared, water was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over anhydrous sodium sulfate. After filtration followed by distillation under reduced pressure, the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=100:0 (v/v) to 0:100 (v/v)] to afford the desired compound (1-11) (5.48 g, 81%).
  • 1H-NMR (CDCl3) δ: 8.76-8.60 (1H, m), 8.02-7.56 (1H, m), 7.45-7.44 (2H, m), 7.21 (1H, s), 7.10-7.09 (2H, m), 6.81-6.74 (1H, m), 6.65 (1H, s), 6.23 (1H, s), 6.01-5.99 (1H, m), 5.95-5.84 (1H, m), 5.41-5.20 (2H, m), 5.16 (1H, m), 4.84 (1H, m), 4.67-4.54 (4H, m), 4.05-4.03 (1H, m), 3.87 (3H, s), 3.71 (1H, m), 3.55-3.51 (1H, m), 3.26 (1H, m), 2.35 (1H, m), 2.18-2.12 (1H, m), 1.55-1.42 (3H, m), 0.97-0.92 (6H, m), 0.81 (9H, s), 0.76-0.61 (4H, m), 0.20-0.06 (6H, m).
  • MS (APCI, ESI) m/z: 808 (M+H)+
    • Example 10-2: Intermediate 2
  • Figure US20220016257A1-20220120-C00038
    • Step 1: N-[4-(11,12-Didehydrodibenzo[b,f]azocin-5 (6H)-yl)-4-oxobutanoyl]glycylglycine (2-2)
  • To a solution of glycylglycine (0.328 g, 2.49 mmol), N,N-diisopropylethylamine (0.433 mL, 2.49 mmol) in N,N-dimethylformamide(20 mL), 1-{[4-(11,12-didehydrodibenzo[b,f]azocin-5 (6H)-yl)-4-oxobutanoyl]oxy}pyrrolidin-2,5-dione (2-1) (1.00 g, 2.49 mmol, Click Chemistry Tools) and water (10 mL) were added at room temperature, and the resultant was stirred at room temperature overnight. The resultant was distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [chloroform:CMW=100:0 (v/v) to 0:100 (v/v)] to afford the desired compound (0.930 g, 89%).
  • 1H-NMR (DMSO-D6) δ: 12.58 (1H, s), 8.14-8.12 (1H, m), 8.08-8.07 (1H, m), 7.69-7.68 (1H, m), 7.62-7.61 (1H, m), 7.53-7.45 (3H, m), 7.40-7.29 (3H, m), 5.05-5.01 (1H, m), 3.73-3.72 (2H, m), 3.66-3.60 (3H, m), 2.66-2.60 (1H, m), 2.33-2.24 (1H, m), 2.08-2.04 (1H, m), 1.81-1.77 (1H, m).
  • MS (APCI, ESI) m/z: 420 [(M+H)+].
    • Example 10-3: Drug-linker 1
  • Figure US20220016257A1-20220120-C00039
    Figure US20220016257A1-20220120-C00040
    Figure US20220016257A1-20220120-C00041
    • Step 1: (2R,11aS)-2-{[tert-Butyl (dimethyl) silyl]oxy}-8-hydroxy-7-methoxy-10-{[2-(trimethylsilyl) ethoxy]methyl}-2,3-dihydro-1H-pyrrolo[2,1-c] [1,4]benzodiazepin-5,11 (10H,11aH)-dione (3-2)
  • To a solution of (2R,11aS)-8-(benzyloxy)-2-{[tert-butyl(dimethyl)silyl]oxy}-7-methoxy-10-{[2-(trimethylsilyl) ethoxy]methyl}-2,3-dihydro-1H-pyrrolo[2,1-c] [1,4]benzodiazepin-5,11 (10H,11aH)-dione (3-1) (25.5 g, 41.6 mmol, WO 2016149546) in THF (150 mL) and ethanol (150 mL), 5% palladium carbon (moisture content: 54%, 10.0 g) was added under a nitrogen atmosphere, and the reaction solution was then stirred under a hydrogen atmosphere at room temperature for 3 days. Chloroform was added to the reaction solution, which was filtered through Celite, and the filtrate was then distilled under reduced pressure. The resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=100:0 (v/v) to 50:50 (v/v)] to afford the desired compound (3-2) (19.4 g, 89%).
  • 1H-NMR (CDCl3) δ: 7.36 (1H, s), 7.25 (1H, s), 6.01 (1H, s), 5.45-5.43 (1H, m), 4.69-4.67 (1H, m), 4.60-4.55 (1H, m), 4.23-4.21 (1H, m), 3.96 (3H, s), 3.76-3.68 (2H, m), 3.63-3.61 (1H, m), 3.56-3.53 (1H, m), 2.88-2.83 (1H, m), 2.03-2.00 (1H, m), 1.00-0.98 (2H, m), 0.87 (9H, s), 0.10 (6H, s), 0.02 (9H, s).
  • MS (APCI, ESI) m/z: 523 (M+H)+
    • Step 2: (2R,11aS)-8-[(5-Bromopentyl)oxy]-2-{[tert-butyl(dimethyl)silyl]oxy}-7-methoxy-10-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11 (10H,11aH)-dione (3-3)
  • To a solution of the compound obtained in step 1 (3-2) (10.8 g, 20.7 mmol) in N,N-dimethylformamide (30 mL), 1,5-dibromopentane (23.8 g, 103 mmol) and potassium carbonate (3.43 g, 24.8 mmol) were added at room temperature. After stirring at room temperature for 3 hours, water was added to the reaction solution, which was extracted with ethyl acetate. The organic layer obtained was washed with brine and dried over sodium sulfate, and distilled under reduced pressure. The resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=90:10 (v/v) to 50:50 (v/v)] to afford the desired compound (3-3) (14.5 g, quantitative).
  • 1H-NMR (CDCl3) δ: 7.34 (1H, s), 7.21 (1H, s), 5.52-5.49 (1H, m), 4.63-4.62 (1H, m), 4.58-4.55 (1H, m), 4.24-4.22 (1H, m), 4.07-4.04 (2H, m), 3.92 (3H, s), 3.82-3.64 (3H, m), 3.56-3.53 (1H, m), 3.45-3.43 (2H, m), 2.86-2.84 (1H, m), 2.04-2.00 (1H, m), 1.97-1.87 (4H, m), 1.66-1.62 (2H, m), 1.01-0.98 (2H, m), 0.87 (9H, s), 0.10 (6H, s), 0.04 (9H, s).
  • MS (APCI, ESI) m/z: 673 [81Br, (M+H)+], 671 [79Br, (M+H)+].
    • Step 3: (2R,11aS)-8-[(5-Bromopentyl)oxy]-2-hydroxy-7-methoxy-10-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11 (10H,11aH)-dione (3-4)
  • To a solution of the compound obtained in step 2 (3-3) (21.5 mmol) in THF (40 mL), a 1 mol/L THF solution of tetrabutylammonium fluoride (28.0 mL, 28.0 mmol) was added at 0° C. After stirring at room temperature for 30 minutes, water was added to the reaction solution, which was extracted with ethyl acetate, and the organic layer obtained was washed with brine. The resultant was dried over sodium sulfate, and then distilled under reduced pressure. The resulting residue was purified by silica gel column chromatography [chloroform:methanol=97.5:2.5 (v/v) to 92.5:7.5 (v/v)] to afford the desired compound (3-4) (11.3 g, 94%).
  • 1H-NMR (CDCl3) δ: 7.34 (1H, s), 7.21 (1H, s), 5.53-5.50 (1H, m), 4.69-4.64 (2H, m), 4.32-4.30 (1H, m), 4.10-4.00 (2H, m), 3.91 (3H, s), 3.88-3.75 (2H, m), 3.73-3.64 (2H, m), 3.45-3.44 (2H, m), 2.99-2.96 (1H, m), 2.15-2.09 (1H, m), 1.99-1.85 (5H, m), 1.68-1.62 (2H, m), 1.01-0.95 (2H, m), 0.04 (9H, s).
  • MS (APCI, ESI) m/z: 559 [81Br, (M+H)+], 557 [79Br, (M+H)+].
    • Step 4: (11aS)-8-[(5-Bromopentyl)oxy]-7-methoxy-10-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2,5,11 (3H,10H,11aH)-trione (3-5)
  • The compound obtained in step 3 (3-4) (11.3 g, 20.2 mmol), tetrabutylammonium bromide (0.325 g, 1.01 mmol), and potassium bromide (0.240 g, 2.02 mmol) were dissolved in a saturated aqueous sodium hydrogen carbonate (60 mL)/dichloromethane (60 mL), to which nor-AZADO (0.0279 g, 0.202 mmol) and sodium hypochlorite pentahydrate (2.03 g, 27.2 mmol) were added at 0° C., and the resultant was stirred at 0° C. for 30 minutes. Because the raw materials remained, sodium hypochlorite pentahydrate (1.00 g, 13.4 mmol) was added thereto at 0° C., and the resultant was stirred at 0° C. for 15 minutes. Sodium hypochlorite pentahydrate (0.300 g, 4.03 mmol) was further added thereto at 0° C., and the resultant was stirred at 0° C. for 15 minutes, and the disappearance of the raw materials was confirmed by TLC. An aqueous solution of sodium thiosulfate was added to the reaction solution, which was extracted with chloroform, and the organic layer obtained was dried over sodium sulfate. The resultant was distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=75:25 (v/v) to 40:60 (v/v)] to afford the desired compound (3-5) (9.74 g, 87%).
  • 1H-NMR (CDCl3) δ: 7.33 (1H, s), 7.24 (1H, s), 5.56-5.53 (1H, m), 4.71-4.69 (1H, m), 4.66-4.63 (1H, m), 4.27-4.22 (1H, m), 4.12-4.02 (2H, m), 3.93-3.88 (4H, m), 3.82-3.75 (1H, m), 3.69-3.67 (1H, m), 3.61-3.56 (1H, m), 3.46-3.44 (2H, m), 2.82-2.77 (1H, m), 1.97-1.89 (4H, m), 1.68-1.64 (2H, m), 1.05-0.93 (2H, m), 0.04 (9H, s).
  • MS (APCI, ESI) m/z: 557 [81Br, (M+H)+], 555 [79Br, (M+H)+].
    • Step 5: (11aS)-8-[(5-Bromopentyl)oxy]-7-methoxy-5,11-dioxo-10-{[2-(trimethylsilyl)ethoxy]methyl}-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl trifluoromethanesulfonate (3-6)
  • To a solution of the compound obtained in step 4 (3-5) (9.74 g, 17.5 mmol) in dichloromethane (160 mL), 2,6-lutidine (8.17 mL, 70.1 mmol) was added at −40° C., and the resultant was stirred at −40° C. for 10 minutes. Anhydrous trifluoromethanesulfonic acid (8.85 mL, 52.6 mmol) was added to the reaction solution at −40° C., and the resultant was stirred at −40° C. for 30 minutes. To the reaction solution, a 10% aqueous solution of citric acid was added, which was extracted with chloroform, and the organic layer obtained was dried over sodium sulfate. The resultant was distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=95:5 (v/v) to 70:35 (v/v)] and then purified by NH2 silica gel chromatography [hexane:ethyl acetate=95:5 (v/v) to 65:35 (v/v)] to afford the desired compound (3-6) (7.10 g, 59%).
  • 1H-NMR (CDCl3) δ: 7.32 (1H, s), 7.24 (1H, s), 7.15-7.14 (1H, m), 5.56-5.53 (1H, m), 4.70-4.68 (1H, m), 4.66-4.63 (1H, m), 4.11-4.01 (2H, m), 3.94-3.90 (4H, m), 3.84-3.75 (1H, m), 3.73-3.68 (1H, m), 3.46-3.44 (2H, m), 3.18-3.14 (1H, m), 1.96-1.88 (4H, m), 1.69-1.61 (2H, m), 1.02-0.92 (2H, m), 0.04 (9H, s).
  • MS (APCI, ESI) m/z: 689 [81Br, (M+H)+], 687 [79Br, (M+H)+].
    • Step 6: (11aS)-8-[(5-Bromopentyl)oxy]-7-methoxy-2-(4-methoxyphenyl)-10-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11 (10H,11aH)-dione (3-7)
  • To a mixture of the compound obtained in step 5 (3-6) (2.00 g, 2.91 mmol), 4-methoxyphenylboronic acid (0.884 g, 5.82 mmol), tetrakis(triphenylphosphine)palladium (0) (0.336 g, 0.291 mmol) and sodium carbonate (1.23 g, 11.6 mmol), toluene (20 mL), ethanol (10 mL) and water (10 mL) were added at room temperature. The reaction solution was stirred at room temperature for 30 minutes, and the reaction solution was then extracted with ethyl acetate, and the extract was washed with water and brine. The organic layer was dried over sodium sulfate, and then distilled under reduced pressure. The resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=90:10 (v/v) to 50:50 (v/v)] to afford the desired compound (3-7) (1.71 g, 91%).1H-NMR (CDCl3) δ: 7.38-7.37 (3H, m), 7.33 (1H, s), 7.25 (1H, s), 6.89-6.88 (2H, m), 5.56-5.54 (1H, m), 4.71-4.68 (1H, m), 4.65-4.62 (1H, m), 4.09-4.04 (2H, m), 3.96-3.91 (4H, m), 3.85-3.66 (5H, m), 3.46-3.45 (2H, m), 3.16-3.12 (1H, m), 1.99-1.94 (4H, m), 1.69-1.64 (2H, m), 1.00-0.98 (2H, m), 0.04 (9H, s).
  • MS (APCI, ESI) m/z: 647 [81Br, (M+H)+], 645 [79Br, (M+H)+].
    • Step 7: (11aS)-8-[(5-Bromopentyl)oxy]-7-methoxy-2-(4-methoxyphenyl)-1, 11a-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (3-8)
  • The compound obtained in step 6 (3-7) (0.789 g, 1.22 mmol) was dissolved in ethanol (10 mL) and THF (10 mL), and 2.0 M tetrahydrofuran solution of lithium borohydride (6.11 mL, 12.2 mmol) was added thereto at 0° C., and the resultant was stirred at 0° C. for 3 hours. Water was added to the reaction solution, which was extracted with chloroform, and the organic layer obtained was dried over sodium sulfate. The resultant was distilled under reduced pressure, and the resulting residue was dissolved in dichloromethane (10 mL), ethanol (20 mL) and water (10 mL), to which silica gel (4 g) was added at room temperature, and the resultant was stirred at room temperature for 4 days. The silica gel was removed through filtration, and water was added thereto, and the resultant was extracted with chloroform. The organic layer obtained was dried over sodium sulfate. The resultant was distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=60:40 (v/v) to 25:75 (v/v)] to afford the desired compound (3-8) (0.496 g, 81%).
  • 1H-NMR (CDCl3) δ: 7.90-7.89 (1H, m), 7.53 (1H, s), 7.40-7.40 (1H, m), 7.35-7.34 (2H, m), 6.92-6.90 (2H, m), 6.83-6.81 (1H, m), 4.43-4.40 (1H, m), 4.13-4.06 (2H, m), 3.96 (3H, s), 3.84 (3H, s), 3.61-3.57 (1H, m), 3.47-3.36 (3H, m), 2.00-1.92 (4H, m), 1.67-1.63 (2H, m).
  • MS (APCI, ESI) m/z: 501 [81Br, (M+H)+], 499 [79Br, (M+H)+].
    • Step 8: (11aS)-8-[(5-Bromopentyl)oxy]-7-methoxy-2-(4-methoxyphenyl)-1,10,11,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (3-9)
  • To a solution of the compound obtained in step 7 (3-8) (0.496 g, 0.992 mmol) in dichloromethane (20 mL), sodium triacetoxyborohydride (0.421 g, 1.99 mmol) was added at 0° C. After stirring at room temperature for 2 hours, a saturated aqueous sodium hydrogen carbonate was added thereto, and the resultant was extracted with chloroform. The organic layer was dried over sodium sulfate, and distilled under reduced pressure, and the resulting residue was then purified by silica gel column chromatography [hexane:ethyl acetate=60:40 (v/v) to 25:75 (v/v)] to afford the desired compound (3-9) (0.426 g, 86%).
  • 1H-NMR (CDCl3) δ: 7.53-7.53 (2H, m), 7.32-7.30 (2H, m), 6.89-6.87 (2H, m), 6.05 (1H, s), 4.33-4.27 (2H, m), 4.00-3.98 (2H, m), 3.86 (3H, s), 3.82 (3H, s), 3.57-3.55 (2H, m), 3.42-3.38 (3H, m), 2.76-2.72 (1H, m), 1.96-1.88 (4H, m), 1.65-1.62 (2H, m).
  • MS (APCI, ESI) m/z: 503 [81Br, (M+H)+], 501 [79Br, (M+H)+].
    • Step 9: Prop-2-en-1-yl (11aS)-8-[(5-bromopentyl)oxy]-7-methoxy-2-(4-methoxyphenyl)-5-oxo-11,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-10 (5H)-carboxylate (3-10)
  • To a solution of the compound obtained in step 8 (3-9) (0.426 g, 0.849 mmol) in dichloromethane (30 mL), pyridine (0.102 mL 1.27 mmol) and allyl chloroformate (0.374 mL, 3.54 mmol) were added at 0° C., and the resultant was stirred at 0° C. for 15 minutes. To the reaction solution, a 10% aqueous solution of citric acid was added, which was extracted with chloroform, and the organic layer obtained was washed with a saturated aqueous sodium hydrogen carbonate, and then dried over sodium sulfate. The resultant was distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=90:10 (v/v) to 50:50 (v/v)] to afford the desired compound (3-10) (0.465 g, 94%).
  • 1H-NMR (CDCl3) δ: 7.38 (1H, s), 7.31-7.29 (2H, m), 7.26-7.25 (1H, m), 6.89-6.87 (2H, m), 6.71 (1H, s), 5.80-5.78 (1H, m), 5.14-5.11 (2H, m), 4.65-4.62 (1H, m), 4.39-4.26 (3H, m), 4.03-4.01 (2H, m), 3.92 (3H, s), 3.82 (3H, s), 3.66-3.64 (1H, m), 3.46-3.44 (2H, m), 3.30-3.27 (1H, m), 2.72-2.68 (1H, m), 1.96-1.88 (4H, m), 1.68-1.60 (2H, m).
  • MS (APCI, ESI) m/z: 587 [81Br, (M+H)+], 585 [79Br, (M+H)+].
    • Step 10: N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-8′-{[5-({(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-[(prop-2-en-1-yloxy)carbonyl]-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl}oxy)pentyl]oxy}-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (3-11)
  • To a solution of the compound obtained in Step 10 of Example 10-1 (1-11) (0.130 g, 0.161 mmol) and the compound obtained in step 9 (3-10) (0.104 g, 0.177 mmol) in N,N-dimethylformamide (3 mL), potassium carbonate (0.0266 g, 0.193 mmol) was added at room temperature, and the resultant was stirred at room temperature overnight. The reaction solution was diluted with ethyl acetate, and washed with water and brine, and then dried over sodium sulfate. The resultant was distilled under reduced pressure, and the resulting residue was then purified by NH2-silica gel column chromatography [hexane:ethyl acetate=70:30 (v/v) to 0:100 (v/v)] to afford the desired compound (3-11) (0.184 g, 87%).
  • 1H-NMR (CDCl3) δ: 8.76 (1H, s), 7.58-7.56 (2H, m), 7.39 (1H, s), 7.32-7.30 (2H, m), 7.26-7.24 (2H, m), 7.19-7.17 (3H, m), 6.90-6.88 (2H, m), 6.78 (1H, s), 6.68-6.66 (1H, m), 6.37 (1H, s), 5.99-5.93 (3H, m), 5.34-5.20 (6H, m), 4.66-4.01 (11H, m), 3.90 (3H, s), 3.89 (3H, s), 3.78-3.54 (9H, m), 3.31-3.28 (2H, m), 2.73-2.69 (1H, m), 2.38-2.35 (1H, m), 2.19-2.13 (1H, m), 1.82-1.80 (2H, m), 1.46-1.29 (6H, m), 0.98-0.90 (6H, m), 0.83 (9H, s), 0.69-0.63 (4H, m), 0.19-0.16 (6H, m).
  • MS (APCI, ESI) m/z: 1312 (M+H)+
    • Step 11: N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11a′S)-11′-hydroxy-7′-methoxy-8′-{[5-({(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-[(prop-2-en-1-yloxy)carbonyl]-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl}oxy)pentyl]oxy}-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (3-12)
  • To a solution of the compound obtained in step 10 (3-11) (0.1837 g, 0.140 mmol) and acetic acid (0.048 mL, 0.840 mmol) in THF (5.00 mL), a 1 mol/L tetrahydrofuran solution of tetrabutylammonium fluoride (0.700 mL, 0.700 mmol) was added at room temperature, and the resultant was stirred at room temperature for 3 hours. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with a saturated aqueous sodium hydrogen carbonate and brine, and then dried over sodium sulfate. The resultant was distilled under reduced pressure, and the resulting residue was purified by silica gel chromatography [chloroform:methanol=99.5:0.5 (v/v) to 95:5 (v/v)] to afford the desired compound (3-12) (0.178 g, quantitative).
  • 1H-NMR (CDCl3) δ: 8.86 (1H, s), 7.60-7.59 (2H, m), 7.39 (1H, s), 7.32-7.20 (7H, m), 6.90-6.88 (2H, m), 6.78 (1H, s), 6.68 (1H, s), 6.38 (1H, s), 5.90-5.87 (3H, m), 5.39-5.22 (6H, m), 4.72-4.02 (11H, m), 3.90 (3H, s), 3.88 (3H, s), 3.83 (3H, s), 3.70-3.63 (6H, m), 3.32-3.29 (3H, m), 2.73-2.69 (1H, m), 2.43-2.40 (1H, m), 2.12-2.06 (1H, m), 1.77-1.74 (2H, m), 1.39-1.25 (6H, m), 0.96-0.89 (6H, m), 0.73-0.66 (4H, m).
  • MS (APCI, ESI) m/z: 1198 (M+H)+
    • Step 12: L-Valyl-N-{4-[({[(11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (3-13)
  • To a solution of the compound obtained in step 11 (3-12) (0.140 mmol) in dichloromethane (2 mL), pyrrolidine (0.0579 mL, 0.700 mmol) and tetrakis(triphenylphosphine)palladium (0) (0.0162 g, 0.0140 mmol) were added at room temperature, and the resultant was stirred at room temperature for 15 minutes. After distillation under reduced pressure, the resulting residue was purified by silica gel chromatography [chloroform:methanol=99.5:0.5 (v/v) to 92.5:7.5 (v/v)] to afford the desired compound (3-13) (0.143 g, 99%).
  • 1H-NMR (CDCl3) δ: 9.12 (1H, s), 7.94-7.92 (1H, m), 7.57-7.53 (4H, m), 7.33-7.31 (2H, m), 7.20-7.18 (3H, m), 6.90-6.88 (2H, m), 6.36 (1H, s), 6.07 (1H, s), 5.91-5.88 (1H, m), 5.47-5.44 (1H, m), 5.21-5.13 (1H, m), 4.66-4.58 (3H, m), 4.32 (1H, s), 4.03-3.49 (17H, m), 3.38-3.29 (4H, m), 3.15-3.14 (1H, m), 2.77-2.73 (1H, m), 2.57 (2H, s), 2.43-2.40 (1H, m), 2.32-2.27 (1H, m), 1.81-1.39 (8H, m), 0.98-0.96 (3H, m), 0.85-0.83 (3H, m), 0.75-0.62 (4H, m).
  • MS (APCI, ESI) m/z: 1030 (M+H)+
    • Step 13: N-[4-(11,12-Didehydrodibenzo[b,f]azocin-5 (6H)-yl)-4-oxobutanoyl]glycylglycyl-L-valyl-N-{4-[({[(11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (3-14)
  • To a mixture of the compound obtained in step 1 of Example 10-2 (2-2) (0.0640 g, 0.153 mmol) and N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (0.0446 g, 0.180 mmol), dichloromethane (2 mL) was added at room temperature, and the resultant was stirred at room temperature for 15 minutes. To the reaction solution, a solution of the compound obtained in step 12 (3-13) (0.143 g, 0.139 mmol) in dichloromethane (2 mL) was added, and the resultant was stirred at room temperature for 5 hours, and then distilled under reduced pressure. The resulting residue was purified by silica gel column chromatography [chloroform:methanol=99.5:0.5 (v/v) to 92.5:7.5 (v/v)] to afford the desired compound (3-14) (0.103 g, 52%).
  • 1H-NMR (DMSO-D6) δ: 9.93 (1H, s), 8.21-8.16 (2H, m), 8.07-8.04 (1H, m), 7.83-7.64 (2H, m), 7.60-7.55 (3H, m), 7.51-7.28 (10H, m), 7.19-7.16 (2H, m), 7.10-7.04 (1H, m), 6.92-6.90 (2H, m), 6.76-6.70 (1H, m), 6.39 (1H, s), 5.77-5.75 (1H, m), 5.21-5.18 (1H, m), 5.03-4.99 (1H, m), 4.82-4.79 (1H, m), 4.37-4.35 (1H, m), 4.21-4.20 (2H, m), 4.02-3.24 (26H, m), 3.16-3.13 (1H, m), 2.79-2.59 (2H, m), 2.39-2.28 (2H, m),
    • 2.05-1.97 (2H, m), 1.91-1.77 (4H, m), 1.57-1.54 (3H, m), 1.28-1.23 (3H, m), 0.85-0.80 (6H, m), 0.67-0.61 (4H, m).
  • MS (APCI, ESI) m/z: 1431 (M+H)+
    • Example 10-4: Drug-Linker 2
  • Figure US20220016257A1-20220120-C00042
    Figure US20220016257A1-20220120-C00043
    Figure US20220016257A1-20220120-C00044
    • Step 1: (2R,11aS)-8-(3-Bromopropoxy)-2-{[tert-butyl(dimethyl)silyl]oxy}-7-methoxy-10-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11 (10H,11aH)-dione (4-1)
  • The compound obtained in step 1 of Example 10-3 (3-2) (5.06 g, 9.67 mmol) was reacted with 1,3-dibromopropane (4.93 mL, 48.4 mmol) in the same manner as in step 2 of Example 10-3 to afford the desired compound (4-1) (4.85 g, 78%).
  • 1H-NMR (CDCl3) δ: 7.35 (1H, s), 7.26 (1H, s), 5.52-5.50 (1H, m), 4.65-4.63 (1H, m), 4.61-4.55 (1H, m), 4.25-4.14 (3H, m), 3.92 (3H, s), 3.82-3.62 (5H, m), 3.57-3.54 (1H, m), 2.86-2.84 (1H, m), 2.41-2.39 (2H, m), 2.06-1.99 (1H, m), 1.03-0.97 (2H, m), 0.87 (9H, s), 0.10 (6H, s), 0.04 (9H, s).
  • MS (APCI, ESI) m/z: 645 [81Br, (M+H)+], 643 [79Br, (M+H)+].
    • Step 2: (2R,11aS)-8-(3-Bromopropoxy)-2-hydroxy-7-methoxy-10-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11 (10H,11aH)-dione (4-2)
  • The compound obtained in step 1 (4-1) (4.85 g, 7.54 mmol) was reacted in the same manner as in step 3 of Example 10-3 to afford the desired compound (4-2) (4.05 g, quantitative).
  • 1H-NMR (CDCl3) δ: 7.35 (1H, s), 7.26 (1H, s), 5.53-5.51 (1H, m), 4.66-4.61 (2H, m), 4.32-4.30 (1H, m), 4.21-4.16 (2H, m), 3.91-3.85 (4H, m), 3.82-3.74 (1H, m), 3.71-3.59 (4H, m), 2.99-2.96 (1H, m), 2.43-2.37 (2H, m), 2.15-2.09 (2H, m), 1.04-0.96 (2H, m), 0.04 (9H, s).
  • MS (APCI, ESI) m/z: 531 [81Br, (M+H)+], 529 [79Br, (M+H)+].
    • Step 3: (11aS)-8-(3-Bromopropoxy)-7-methoxy-10-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2,5,11 (3H,10H,11aH)-trione (4-3)
  • The compound obtained in step 2 (4-2) (7.54 mmol) was reacted in the same manner as in step 4 of Example 10-3 to afford the desired compound (4-3) (3.73 g, 93%). 1H-NMR (CDCl3) δ: 7.34 (1H, s), 7.29 (1H, s), 5.56-5.53 (1H, m), 4.72-4.69 (1H, m), 4.67-4.61 (1H, m), 4.23-4.17 (3H, m), 3.97-3.88 (4H, m), 3.82-3.75 (1H, m), 3.74-3.56 (4H, m), 2.82-2.77 (1H, m), 2.43-2.38 (2H, m), 1.06-0.94 (2H, m), 0.08-0.00 (9H, m).
    • Step 4: (11aS)-8-(3-Bromopropoxy)-7-methoxy-5,11-dioxo-10-{[2-(trimethylsilyl)ethoxy]methyl}-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl trifluoromethanesulfonate (4-4)
  • The compound obtained in step 3 (4-3) (3.73 g, 7.08 mmol) was reacted in the same manner as in step 5 of Example 10-3 to afford the desired compound (4-4) (3.27 g, 70%).
  • 1H-NMR (CDCl3) δ: 7.33 (1H, s), 7.29 (1H, s), 7.15-7.15 (1H, m), 5.56-5.54 (1H, m), 4.70-4.65 (2H, m), 4.21-4.18 (2H, m), 3.94-3.91 (4H, m), 3.81-3.79 (1H, m), 3.70-3.64 (3H, m), 3.19-3.15 (1H, m), 2.47-2.38 (2H, m), 1.02-1.00 (2H, m), 0.04 (9H, s).
  • MS (APCI, ESI) m/z: 661 [81Br, (M+H)+], 659 [79Br, (M+H)+].
    • Step 5: (11aS)-8-(3-Bromopropoxy)-7-methoxy-2-(4-methoxyphenyl-10-{[2-(trimethylsilyl)ethoxy]methyl}-1H-pyrrolo[2,1-c][1,4]benzodiazepin-5,11 (10H,11aH)-dione (4-5)
  • The compound obtained in step 4 (4-4) (3.27 g, 4.96 mmol) was reacted in the same manner as in step 6 of Example 10-3 to afford the desired compound (4-5) (2.49 g, 81%).
  • 1H-NMR (DMSO-D6) δ: 7.49-7.47 (2H, m), 7.40 (1H, s), 7.31-7.24 (2H, m), 6.93-6.88 (2H, m), 5.33-5.31 (1H, m), 5.25-5.18 (1H, m), 4.81-4.80 (1H, m), 4.23-4.10 (2H, m), 3.85 (3H, s), 3.77 (3H, s), 3.70-3.59 (3H, m), 3.52-3.40 (2H, m), 3.15-3.08 (1H, m), 2.33-2.27 (2H, m), 0.86-0.74 (2H, m), −0.07 (9H, s).
  • MS (APCI, ESI) m/z: 619 [81Br, (M+H)+], 617 [79Br, (M+H)+].
    • Step 6: (11aS)-8-(3-Bromopropoxy)-7-methoxy-2-(4-methoxyphenyl)-1, 11a-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (4-6)
  • The compound obtained in step 5 (4-5) (2.49 g, 4.04 mmol) was reacted in the same manner as in step 7 of Example 10-3 to afford the desired compound (4-6) (1.59 g, 84%).
  • MS (APCI, ESI) m/z: 473 [81Br, (M+H)+], 471 [79Br, (M+H)+].
    • Step 7: (11aS)-8-(3-Bromopropoxy)-7-methoxy-2-(4-methoxyphenyl)-1,10,11,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one (4-7)
  • The compound obtained in step 6 (4-6) (1.59 g, 3.38 mmol) was reacted in the same manner as in step 8 of Example 10-3 to afford the desired compound (4-7) (1.39 g, 87%).
  • 1H-NMR (CDCl3) δ: 7.54 (1H, s), 7.54-7.51 (1H, m), 7.32-7.29 (2H, m), 6.89-6.87 (2H, m), 6.10 (1H, s), 4.32-4.28 (2H, m), 4.14-4.13 (2H, m), 3.85 (3H, s), 3.82 (3H, s), 3.63-3.62 (2H, m), 3.57-3.55 (2H, m), 3.40-3.36 (1H, m), 2.76-2.72 (1H, m), 2.40-2.37 (2H, m).
  • MS (APCI, ESI) m/z: 475 [81Br, (M+H)+], 473 [79Br, (M+H)+].
    • Step 8: Prop-2-en-1-yl (11aS)-8-(3-bromopropoxy)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-11,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-10 (5H)-carboxylate (4-8)
  • The compound obtained in step 7 (4-7) (1.40 g, 0.2.95 mmol) was reacted in the same manner as in step 9 of Example 10-3 to afford the desired compound (4-8) (0.885 g, 54%).
  • 1H-NMR (CDCl3) δ: 7.34 (1H, s), 7.27-7.25 (2H, m), 7.22 (1H, s), 6.86-6.84 (2H, m), 6.73 (1H, s), 5.76-5.74 (1H, m), 5.11-5.09 (2H, m), 4.62-4.59 (2H, m), 4.33-4.31 (1H, m), 4.16-4.13 (3H, m), 3.88 (3H, s), 3.79 (3H, s), 3.60-3.59 (3H, m), 3.27-3.23 (1H, m), 2.69-2.65 (1H, m), 2.37-2.34 (2H, m).
  • MS (APCI, ESI) m/z: 559 [81Br, (M+H)+], 557 [79Br, (M+H)+].
    • Step 9: N-{[(Prop-2-en-1-yl)oxy]carbonyl}-L-valyl-N-[4-({[(11′aS)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-8′-(3-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-{[(prop-2-en-1-yl)oxy]carbonyl}-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy}propoxy)-5′-oxo-11′,11′a-dihydro-1′H,3′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carbonyl]oxy}methyl)phenyl]-L-alaninamide (4-9)
  • The compound obtained in step 8 (4-8) (0.0381 g, 0.0683 mmol) was reacted with the compound obtained in the step 10 of Example 10-1 (1-11) (0.0552 g, 0.0683 mmol) in the same manner as in step 10 of Example 10-3 to afford the desired compound (4-9) (0.0712 g, 81%).
  • MS (APCI, ESI) m/z: 1284 (M+H)+.
    • Step 10: N-{[(Prop-2-en-1-yl)oxy]carbonyl}-L-valyl-N-[4-({[(11′aS)-11′-hydroxy-7′-methoxy-8′-(3-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-{[(prop-2-en-1-yl)oxy]carbonyl}-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy}propoxy)-5′-oxo-11′,11′a-dihydro-1′H,3′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carbonyl]oxy}methyl)phenyl]-L-alaninamide (4-10)
  • The compound obtained in step 9 (4-9) (0.0712 g, 0.0554 mmol) was reacted in the same manner as in step 11 of Example 10-3 to afford the desired compound (4-10) (0.0671 g, quantitative).
  • MS (APCI, ESI) m/z: 1170 (M+H)+.
    • Step 11: L-Valyl-N-[4-({[(11′aS)-11′-hydroxy-7′-methoxy-8′-(3-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy}propoxy)-5′-oxo-11′,11′a-dihydro-1′H,3′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carbonyl]oxy}methyl)phenyl]-L-alaninamide (4-11)
  • The compound obtained in step 10 (4-10) (0.0571 mmol) was reacted in the same manner as in step 12 of Example 10-3 to afford the desired compound (4-11) (0.0574 g, 99%).
  • 1H-NMR (CDCl3) δ: 9.16 (1H, s), 7.93-7.91 (1H, m), 7.55-7.52 (1H, m), 7.50-7.47 (3H, m), 7.35-7.32 (2H, m), 7.21 (1H, s), 7.13-7.11 (2H, m), 6.90-6.87 (2H, m), 6.40 (1H, s), 6.08 (1H, s), 5.90-5.87 (1H, m), 5.37-5.34 (1H, m), 4.73-4.53 (3H, m), 4.23-4.08 (5H, m), 3.89 (3H, s), 3.82 (3H, s), 3.78-3.72 (5H, m), 3.57-3.51 (3H, m), 3.38-3.30 (3H, m), 2.76-2.71 (1H, m), 2.36-2.24 (4H, m), 1.78-1.42 (6H, m), 1.00-0.98 (3H, m), 0.87-0.84 (3H, m), 0.74-0.62 (4H, m).
  • MS (APCI, ESI) m/z: 1002 (M+H)+.
    • Step 12: N-[4-(11,12-Didehydrodibenzo[b,f]azocin-5 (6H)-yl)-4-oxobutanoyl]glycylglycyl-L-valyl-N-[4-({[(11′aS)-11′-hydroxy-7′-methoxy-8′-(3-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy}propoxy)-5′-oxo-11′,11′a-dihydro-1′H,3′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carbonyl]oxy}methyl)phenyl]-L-alaninamide (4-12)
  • The compound obtained in step 11 (4-11) (0.189 g, 0.189 mmol) was reacted with the compound obtained in the step 1 of Example 10-2 (2-2) (0.087 g, 0.207 mmol) in the same manner as in step 13 of Example 10-3 to afford the desired compound (4-12) (0.169 g, 64%).
  • MS (APCI, ESI) m/z: 1402 (M+H)+.
    • Example 10-5: Drug-Linker 3
  • Figure US20220016257A1-20220120-C00045
    • Step 1: Dimethyl(65,6′S)-5,5′-{1,5-pentanediylbis[oxy(5-methoxy-2-nitrobenzen-4,1-diyl)carbonyl]}bis(5-azaspiro[2.4]heptane-6-carboxylate) (5-2)
  • To a solution of 4,4′-[1,5-pentanediylbis(oxy)]bis (5-methoxy-2-nitro benzoic acid) (5-1) (5.41 g, 10.9 mmol, Journal of Medicinal Chemistry 2004, 47, 1161) in dichloromethane (50 mL), oxalyl chloride (5.63 mL, 65.7 mmol) was added at 0° C., and N,N-dimethylformamide (0.0844 mL, 1.09 mmol) was added dropwise thereto. The temperature of the reaction solution was raised to room temperature, and the reaction solution was stirred for 2 hours. The resultant was distilled under reduced pressure, and the resulting residue was dissolved in dichloromethane (100 mL), which was added dropwise to dichloromethane solution (100 mL) of methyl (6S)-5-azaspiro[2.4]heptane-6-carboxylate hydrochloride (4.28 g, 24.1 mmol, Tetrahedron Letters 2012. 53. 3847) and triethylamine (6.07 mL, 43.8 mmol) under a nitrogen atmosphere at −40° C. The temperature of the reaction solution was raised to 0° C., and the reaction solution was stirred for 2 hours. To the reaction mixture, 1 N hydrochloric acid (100 mL) was added, and the organic layer was washed with water and brine, and dried over anhydrous sodium sulfate. The resultant was distilled under reduced pressure to afford the desired compound (5-2) (8.40 g, quantitative).
  • 1H-NMR (DMSO-D6) δ: 7.71 (2H, s), 6.88 (2H, s), 4.63 (2H, m), 4.15-4.12 (4H, m), 3.94 (6H, s), 3.71 (6H, s), 3.25 (2H, m), 3.10 (2H, m), 2.31-2.28 (2H, m), 1.90-1.83 (6H, m), 1.60-1.58 (2H, m), 0.71-0.49 (8H, m).
  • MS (APCI, ESI) m/z: 769 (M+H)+.
    • Step 2: {1,5-Pentanediylbis[oxy(5-methoxy-2-nitrobenzen-4,1-diyl)]}bis{[(6S)-6-(hydroxymethyl)-5-azaspiro[2.4]hept-5-yl]methanone} (5-3)
  • To a solution of the compound obtained in step 1 (5-2) (8.40 g, 10.9 mmol) in THF (100 mL), lithium borohydride (714 mg, 32.8 mmol) was added, and the resultant was stirred at 0° C. for 30 minutes, and the temperature was raised to room temperature, and stirring was performed for 1 hour. After 1 N hydrochloric acid was added at 0° C., the resultant was extracted with ethyl acetate, and washed with brine, and then dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure to afford the desired compound (5-3) (7.70 g, 99%).
  • 1H-NMR (DMSO-D6) δ: 7.67 (2H, s), 7.05 (2H, s), 4.86-4.74 (2H, m), 4.22-4.12 (6H, m), 3.92 (6H, s), 3.83-3.73 (2H, m), 3.62-3.51 (2H, m), 3.29 (1H, m), 3.11 (2H, m), 2.96 (1H, m), 2.12-2.03 (2H, m), 1.82-1.77 (6H, m), 1.59-1.56 (2H, m), 0.67-0.41 (8H, m).
  • MS (APCI, ESI) m/z: 713 (M+H)+.
    • Step 3: Pentane-1,5-diylbis[oxy(5-methoxy-2-nitrobenzen-4,1-diyl)carbonyl (6S)-5-azaspiro[2.4]heptan-5,6-diylmethanediyl] diazetate (5-4)
  • The compound obtained in step 2 (5-3) (7.70 g, 10.8 mmol) was dissolved in pyridine (20 mL) and acetic anhydride (10 mL, 105.9 mmol), which was stirred at room temperature. The resultant was distilled under reduced pressure to afford the desired compound (5-4) (8.38 g, 97%).
  • 1H-NMR (DMSO-D6) δ: 7.68 (2H, s), 7.03 (2H, s), 4.47-4.46 (2H, m), 4.36-4.27 (4H, m), 4.13-4.11 (6H, m), 3.92 (6H, s), 3.16 (2H, m), 2.98 (2H, m), 2.17 (1H, m), 2.06 (6H, s), 1.84 (4H, m), 1.68 (1H, m), 1.58 (2H, m), 0.64-0.45 (8H, m).
  • MS (APCI, ESI) m/z: 797 (M+H)+.
    • Step 4: 1,5-Pentanediylbis[oxy(2-amino-5-methoxybenzen-4,1-diyl)carbonyl (6S)-5-azaspiro[2.4]heptan-5,6-diylmethanediyl] diacetate (5-5)
  • To a solution of the compound obtained in step 3 (5-4) (8.28 g, 10.4 mmol) in N,N-dimethylformamide (100 mL), 5% palladium carbon (moisture content: 54%, 1.00 g) was added, and the reaction solution was then vigorously stirred under a hydrogen atmosphere at room temperature for 6 hours. The resultant was filtered through Celite, and the filtrate was then distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [chloroform:methanol=100:0 (v/v) to 90:10 (v/v)] to afford the desired compound (5-5) (5.05 g, 66%).
  • 1H-NMR (DMSO-D6) δ: 6.66 (2H, s), 6.36 (2H, s), 5.11 (4H, s), 4.49 (2H, s), 4.19 (4H, m), 3.90 (4H, m), 3.62 (6H, s), 3.48-3.46 (2H, m), 3.33 (2H, s), 3.23-3.20 (2H, m), 2.01 (6H, s), 1.78-1.74 (6H, m), 1.55 (2H, m), 0.61-0.58 (4H, m), 0.49-0.48 (4H, m).
  • MS (APCI, ESI) m/z: 737 (M+H)+.
    • Step 5: {(6S)-5-[4-({5-[4-({(6S)-6-[(Acetyloxy)methyl]-5-azaspiro[2.4]hept-5-yl}carbonyl)-5-amino-2-methoxyphenoxy]pentyl}oxy)-5-methoxy-2-{[(prop-2-en-1-yloxy)carbonyl]amino}benzoyl]-5-azaspiro[2.4]hept-6-yl}methyl acetate (monoallyloxycarbonyl form) (5-6)
  • To a solution of the compound obtained in step 4 (5-5) (5.05 g, 6.85 mmol) in dichloromethane (100 mL), pyridine (1.10 mL, 13.7 mmol) was added, and allyl chloroformate (0.725 mL, 6.85 mmol) was added thereto under a nitrogen atmosphere at −78° C., and the resultant was stirred for 2 hours. The resultant was distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=70:30 (v/v) to 100:0 (v/v), chloroform:methanol=100:0 (v/v) to 90:10 (v/v)] to afford the bisallyloxycarbonyl form (5-6b) (1.36 g, 22%) and monoallyloxycarbonyl form (5-6) (2.63 g, 47%) as the desired compound.
  • Pentane-1,5-diylbis[oxy(5-methoxy-2-{[(prop-2-en-1-yloxy)carbonyl]amino}benzen-4,1-diyl)carbonyl(6S)-5-azaspiro[2.4]heptan-5,6-diylmethanediyl] diacetate (bisallyloxycarbonyl form) (5-6b):
  • 1H-NMR (DMSO-D6) δ: 9.14 (2H, s), 7.14 (2H, s), 6.85 (2H, s), 5.94 (2H, m), 5.33 (2H, m), 5.21 (2H, m), 4.55 (4H, m), 4.47 (1H, s), 4.23 (3H, s), 3.96 (4H, m), 3.74 (6H, s), 3.34 (6H, s), 3.31 (2H, m), 3.21 (2H, m), 2.04 (6H, s), 1.79 (4H, m), 1.67 (2H, m), 1.56 (2H, m), 0.56-0.48 (8H, m).
  • MS (APCI, ESI) m/z: 905 (M+H)+.
  • Monoallyloxycarbonyl form (5-6):
  • 1H-NMR (DMSO-D6)
  • δ: 9.14 (1H, s), 7.14 (1H, s), 6.85 (1H, s), 6.65 (1H, s), 6.35 (1H, s), 5.95 (1H, m), 5.33 (1H, m), 5.22 (1H, m), 5.11 (2H, s), 4.55 (2H, m), 4.48 (2H, s), 4.23-4.14 (4H, m), 3.96 (2H, m), 3.90 (2H, m), 3.74 (3H, s), 3.63 (3H, s), 3.49 (1H, m), 3.38-3.30 (4H, m), 3.21 (1H, m), 2.04 (3H, s), 2.01 (3H, s), 1.77 (5H, m), 1.68 (1H, m), 1.56 (2H, m), 0.63-0.48 (8H, m).
  • MS (APCI, ESI) m/z: 821 (M+H)+.
    • Step 6: N-[(2-Propen-1-yloxy)carbonyl]-L-valyl-N-{4-[({[2-({(6S)-6-[(acetyloxy)methyl]-5-azaspiro[2.4]hept-5-yl}carbonyl)-5-({5-[4-({(6S)-6-[(acetyloxy)methyl]-5-azaspiro[2.4]hept-5-yl}carbonyl)-2-methoxy-5-{[(2-propen-1-yloxy)carbonyl]amino}phenoxy]pentyl}oxy)-4-methoxyphenyl]carbamoyl}oxy)methyl]phenyl}-L-alaninamide (5-7)
  • The monoallyloxycarbonyl form obtained in step 5 (5-6) (2.00 g, 2.44 mmol) was reacted with N-[(prop-2-en-1-yloxy)carbonyl]-L-valyl-N-[4-(hydroxymethyl)phenyl]-L-alaninamide (1.10 g, 2.92 mmol, WO2011130598) in the same manner as in step 6 of Example 10-1 to afford the desired compound (5-7) (2.64 g, 89%).
  • 1H-NMR (DMSO-D6) δ: 10.02 (1H, s), 9.14 (2H, s), 8.18 (1H, m), 7.59 (2H, m), 7.33 (2H, m), 7.27 (1H, m), 7.14 (2H, s), 6.85 (2H, s), 5.99-5.86 (2H, m), 5.31 (2H, n), 5.19 (2H, m), 5.03 (2H, s), 4.55 (2H, m), 4.48 (2H, n), 4.41 (2H, m), 4.23-4.21 (3H, m), 3.94-3.91 (4H, m), 3.88-3.86 (2H, m), 3.74 (3H, s), 3.74 (3H, s), 3.34 (4H, s), 3.32-3.30 (2H, m), 3.20-3.18 (2H, m), 2.03 (6H, s), 1.96 (1H, m), 1.79 (4H, s), 1.66 (1H, m), 1.55 (2H, s), 1.30 (3H, m), 0.88 (3H, m), 0.83 (3H, m), 0.54-0.49 (8H, m).
  • MS (APCI, ESI) m/z: 1224 (M+H)+.
    • Step 7: N-[(2-Propen-1-yloxy)carbonyl]-L-valyl-N-[4-({[(2-{[(6S)-6-(hydroxymethyl)-5-azaspiro[2.4]hept-5-yl]carbonyl}-5-{[5-(4-{[(6S)-6-(hydroxymethyl)-5-azaspiro[2.4]hept-5-yl]carbonyl}-2-methoxy-5-{[(2-propen-1-yloxy)carbonyl]amino}phenoxy)pentyl]oxy}-4-methoxyphenyl)carbamoyl]oxy}methyl)phenyl]-L-alaninamide (5-8)
  • To a solution of the compound obtained in step 6 (5-7) (2.64 g, 2.16 mmol) in methanol (10 mL), potassium carbonate (1.49 g, 10.8 mmol) was added, and the resultant was stirred at room temperature for 3 hours. A saturated aqueous ammonium chloride (100 mL) was added to the reaction mixture, which was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate. The resultant was distilled under reduced pressure to afford the desired compound (5-8) (2.21 g, 90%).
  • 1H-NMR (DMSO-D6) δ: 10.04 (1H, s), 9.18 (1H, s), 8.18 (1H, m), 7.59 (2H, m), 7.33 (2H, m), 7.26 (1H, m), 7.22 (1H, s), 7.14 (2H, s), 6.89 (2H, s), 5.98-5.86 (2H, m), 5.31 (2H, m), 5.19 (2H, m), 5.04 (2H, s), 4.80 (2H, m), 4.55 (2H, m), 4.48 (2H, m), 4.41 (1H, m), 4.26 (2H, s), 3.96-3.94 (4H, m), 3.90-3.85 (1H, m), 3.74 (6H, s), 3.59 (2H, m), 3.33 (6H, s), 3.09 (1H, m), 1.93-1.83 (8H, m), 1.57-1.54 (2H, m), 1.30 (3H, m), 0.88 (3H, m), 0.83 (3H, m), 0.52-0.43 (8H, m).
  • MS (APCI, ESI) m/z: 1140 (M+H)+.
    • Step 8: N-[(2-Propen-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11a′S)-11′-hydroxy-8′-{[5-({(11a′S)-11′-hydroxy-7′-methoxy-5′-oxo-10′-[(2-propen-1-yloxy)carbonyl]-5′,10′,11′,11a′-tetrahydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl}oxy)pentyl]oxy}-7′-methoxy-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (5-9)
  • To a solution of the compound obtained in step 7 (5-8) (2.03 g, 1.78 mmol) in dichloromethane (50 mL), Dess-Martin periodinane (1.59 g, 3.74 mmol) was added, and the resultant was stirred at room temperature overnight. A saturated aqueous sodium hydrogen carbonate (100 mL) was added to the reaction mixture, which was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate. The resultant was distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [chloroform:methanol=100:0 (v/v) to 90:10 (v/v)] to afford the desired compound (5-9) (2.05 g, quantitative).
  • 1H-NMR (DMSO-D6) δ: 9.99 (1H, s), 8.16 (1H, m), 7.54 (2H, m), 7.32-7.22 (3H, m), 7.08-7.04 (2H, m), 6.80-6.72 (2H, m), 6.55 (2H, s), 5.94-5.86 (2H, m), 5.75 (2H, m), 5.31-5.04 (2H, m), 4.81 (1H, m), 4.62 (1H, m), 4.48-4.38 (4H, m), 4.00-3.87 (4H, m), 3.79-3.76 (7H, m), 3.54 (2H, m), 3.42-3.40 (2H, m), 3.33 (4H, s), 3.14 (2H, m), 2.35 (2H, m), 1.80-1.78 (4H, m), 1.59-1.56 (4H, m), 1.29 (3H, m), 0.87 (3H, m), 0.83 (3H, m), 0.70-0.59 (8H, m).
  • MS (APCI, ESI) m/z: 1136 (M+H)+.
    • Step 9: L-Valyl-N-{4-[({[(11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11a′S)-7′-methoxy-5′-oxo-5′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (5-10)
  • The compound obtained in step 8 (5-9) (2.05 g, 1.80 mmol) was reacted in the same manner as in step 12 of Example 10-3 to afford the desired compound (5-10) (1.02 g, 60%).
  • 1H-NMR (DMSO-D6) δ: 10.08 (1H, s), 7.57 (2H, m), 7.32-7.20 (3H, m), 7.05 (2H, s), 6.68-6.60 (3H, m), 5.74 (1H, m), 4.99-4.58 (4H, m), 3.99-3.94 (4H, m), 3.78-3.73 (6H, m), 3.66-3.38 (4H, m), 3.15-3.01 (3H, m), 2.40-2.34 (3H, m), 1.89-1.81 (6H, m), 1.57-1.53 (4H, m), 1.28 (3H, m), 0.88 (3H, m), 0.78 (3H, m), 0.64-0.55 (8H, m).
  • MS (APCI, ESI) m/z: 950 (M+H)+.
    • Step 10: N-[4-(11,12-Didehydrodibenzo[b,f]azocin-5 (6H)-yl)-4-oxobutanoyl]glycylglycyl-L-valyl-N-{4-[({[(11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11a′S)-7′-methoxy-5′-oxo-5′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (5-11)
  • The compound obtained in step 9 (5-10) (0.710 g, 0.747 mmol) and the compound obtained in step 1 of Example 10-2 (2-2) (0.313 g, 0.747 mmol) were dissolved in mixed solvent of dichloromethane (1.5 mL) and methanol (0.1 mL). Thereto, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (0.264 g, 0.897 mmol) was added, and the resultant was stirred at room temperature for 1 hour. The resultant was distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [chloroform:methanol=100:0 (v/v) to 80:20 (v/v)] to afford the desired compound (5-11) (0.671 g, 66%).
  • 1H-NMR (DMSO-D6) δ: 9.91 (1H, s), 8.32 (1H, s), 8.23-7.91 (3H, m), 7.81-7.19 (14H, m), 7.04 (1H, m), 6.80-6.62 (3H, m), 5.77-5.75 (1H, m), 5.20 (1H, m), 5.01 (1H, m), 4.79 (1H, m), 4.46-4.35 (1H, m), 4.04 (4H, m), 3.86-3.38 (18H, m), 3.22-3.15 (2H, m), 2.67-2.63 (1H, m), 2.46-2.23 (3H, m), 2.09-1.91 (2H, m), 1.80-1.78 (5H, m), 1.57 (3H, m), 1.27 (3H, s), 1.11-1.04 (1H, m), 0.87-0.79 (6H, m), 0.63-0.55 (6H, m).
  • MS (APCI, ESI) m/z: 1351 (M+H)+.
    • Example 10-6: Drug-Linker 4
  • Figure US20220016257A1-20220120-C00046
    • Step 1: Methyl(6S)-5-[4-(benzyloxy)-5-methoxy-2-nitrobenzoyl]-5-azaspiro[2.4]heptane-6-carboxylate (6-2)
  • To a solution of 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid (6-1) (6.07 g, 20.0 mmol, Tetrahedron 1995, 51, 5617) and N,N-dimethylformamide (1.08 mL, 13.9 mmol) in dichloromethane (100 mL), oxalyl chloride (3.43 mL, 40.0 mmol) was added dropwise under ice-cooling over 5 minutes. The reaction solution was stirred at room temperature for 5 hours, and then distilled under reduced pressure, and the resulting residue was dissolved in dichloromethane (20 mL), which was distilled under reduced pressure. After this operation was repeated three times, the residue was suspended in dichloromethane (5 mL), to which excess amounts of diethyl ether and hexane were added, and the following filtration and drying under reduced pressure afforded the crude acyl chloride. The acyl chloride obtained was dissolved in dichloromethane and cooled to −40° C. (dry ice-acetonitrile bath), to which methyl (6S)-5-azaspiro[2.4]heptane-6-carboxylate hydrochloride (4.22 g, 22.0 mmol, Tetrahedron Letters 2012. 53. 3847) and triethylamine (3.36 mL, 24.2 mmol) were slowly added. The temperature of the reaction mixture was raised to room temperature overnight. To the reaction mixture, 1 N hydrochloric acid was added, and the reaction mixture was extracted with dichloromethane. The organic layer was washed with water, a saturated aqueous sodium hydrogen carbonate, and brine, and dried over anhydrous sodium sulfate. The resultant was distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=100:0 to 50:50] to afford the desired compound (6-2) (6.55 g, 80%).
  • MS (APCI, ESI) m/z: 441 (M+H)+
    • Step 2: (11a′S)-8′-(Benzyloxy)-7′-methoxy-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-5′,11′(10′H,11a′H)-dione (6-3)
  • To a solution of the compound obtained in step 1 (6-2) (6.55 g, 16.0 mmol) in ethanol (150 mL) and THF (150 mL), Raney nickel (7.00 g) was added under a nitrogen atmosphere. Hydrazine monohydrate (7 mL) was added to the reaction mixture, and the temperature was gradually raised to 50° C. After stirring at 50° C. for 2 hours, Raney nickel (3.00 g) and hydrazine monohydrate (3 mL) were added thereto, and the resultant was stirred for 1 hour. THF (100 mL) was added to the reaction mixture, which was filtered through Celite. The resultant was distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=100:0 (v/v) to 25:75 (v/v)] to afford the desired compound (6-3) (4.42 g, 73%).
  • 1H-NMR (CDCl3) δ: 7.82 (1H, s), 7.48 (1H, s), 7.42-7.35 (4H, m), 7.32-7.31 (1H, m), 6.44 (1H, s), 5.16 (2H, s), 4.16-4.10 (1H, m), 3.93 (3H, s), 3.78-3.76 (1H, m), 3.39-3.37 (1H, m), 2.45-2.43 (1H, m), 2.24-2.21 (1H, m), 0.83-0.61 (4H, m).
  • MS (APCI, ESI) m/z: 379 (M+H)+
    • Step 3: (11a′S)-8′-(Benzyloxy)-7′-methoxy-10′-{[2-(trimethylsilyl)ethoxy]methyl}-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-5′,11′(10′H,11a′H)-dione (6-4)
  • To a solution of the compound obtained in step 2 (6-3) (10.0 g, 26.4 mmol) in THF (150 mL), 2.6 mol/L normal-hexane solution of normal-butyllithium (12.0 mL, 31.8 mmol) was added slowly dropwise at −40° C. The reaction solution was stirred at −40° C. for 15 minutes, and 2-(chloromethoxy)ethyltrimethylsilane (5.57 mL, 31.7 mmol) was then added slowly dropwise thereto. After the reaction solution was stirred at room temperature for 3 hours, water was added thereto, and the resultant was extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over anhydrous sodium sulfate. After distillation under reduced pressure, the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=100:0 (v/v) to 30:70 (v/v)] to afford the desired compound (6-4) (11.8 g, 88%).
  • 1H-NMR (CDCl3) δ: 7.45-7.44 (2H, m), 7.37-7.32 (4H, m), 7.28 (1H, s), 5.48-5.46 (1H, m), 5.21 (2H, s), 4.50-4.48 (1H, m), 4.22-4.20 (1H, m), 3.95 (3H, s), 3.73-3.70 (2H, m), 3.62-3.60 (1H, m), 3.41-3.38 (1H, m), 2.45-2.43 (1H, m), 2.23-2.20 (1H, m), 0.98-0.96 (2H, m), 0.83-0.68 (4H, m), 0.04 (9H, s).
  • MS (APCI, ESI) m/z: 509 (M+H)+
    • Step 4: (11a′S)-8′-Hydroxy-7′-methoxy-10′-{[2-(trimethylsilyl)ethoxy]methyl}-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-5′,11′(10′H,11a′H)-dione (6-5)
  • To a solution of the compound obtained in step 3 (6-4) (18.7 g, 36.8 mmol) in THF (50 mL) and ethanol (100 mL), 5% palladium carbon catalyst (5.00 g) was added under a nitrogen atmosphere. The nitrogen balloon was immediately replaced with a hydrogen balloon, and the reaction mixture was stirred under a hydrogen atmosphere for 6 hours. The reaction mixture was diluted by addition of chloroform and filtered through Celite, and the filtrate was then distilled under reduced pressure, and the resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=100:0 (v/v) to 25:75 (v/v)] to afford the desired compound (6-5) (15.1 g, 98%).
  • 1H-NMR (CDCl3) δ: 7.38 (1H, s), 7.28 (1H, s), 6.01 (1H, s), 5.49-5.47 (1H, m), 4.70-4.68 (1H, m), 4.24-4.22 (1H, m), 3.96 (3H, s), 3.76-3.71 (2H, m), 3.66-3.64 (1H, m), 3.42-3.39 (1H, m), 2.47-2.45 (1H, m), 2.23-2.21 (1H, m), 1.01-0.99 (2H, m), 0.89-0.63 (4H, m), 0.03 (9H, s).
  • MS (APCI, ESI) m/z: 419 (M+H)+
    • Step 5: (11a′S)-8′-[(5-Bromopentyl)oxy]-7′-methoxy-10′-{[2-(trimethylsilyl)ethoxy]methyl}-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-5′,11′(10′H,11a′H)-dione (6-6)
  • The compound obtained in step 4 (6-5) (2.77 g, 6.62 mmol) was reacted in the same manner as in step 2 of Example 10-3 to afford the desired compound (6-6) (3.31 g, 88%).
  • 1H-NMR (CDCl3) δ: 7.36 (1H, s), 7.25 (1H, s), 5.55 (1H, m), 4.65 (1H, m), 4.24-4.23 (1H, m), 4.11-4.03 (2H, m), 3.93 (3H, s), 3.85-3.78 (1H, m), 3.72-3.69 (2H, m), 3.46-3.39 (3H, m), 2.47-2.44 (1H, m), 2.25-2.22 (1H, m), 1.95-1.91 (4H, m), 1.67-1.59 (1H, m), 1.03-0.95 (2H, m), 0.90-0.85 (1H, m), 0.70-0.66 (4H, m), 0.05 (9H, s).
    • Step 6: (11a′S)-8′-[(5-Bromopentyl)oxy]-7′-methoxy-1′,11a′-dihydro-5′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-5′-one (6-7)
  • The compound obtained in step 5 (6-6) (3.31 g, 5.83 mmol) was reacted in the same manner as in step 7 of Example 10-3 to afford the desired compound (6-7) (1.11 g, 45%).
  • 1H-NMR (CDCl3) δ: 7.81 (1H, m), 7.53 (1H, s), 6.82 (1H, s), 4.13-4.06 (2H, m), 3.97 (3H, s), 3.88-3.83 (1H, m), 3.69 (1H, m), 3.52-3.39 (3H, m), 2.55-2.52 (1H, m), 2.06-1.89 (5H, m), 1.67-1.63 (2H, m), 0.76-0.72 (4H, m).
    • Step 7: (11a′S)-8′-[(5-Bromopentyl)oxy]-7′-methoxy-1′, 10′,11′,11a′-tetrahydro-5′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-5′-one (6-8)
  • The compound obtained in step 6 (6-7) (2.56 g, 6.08 mmol) was reacted in the same manner as in step 8 of Example 10-3 to afford the desired compound (6-8) (1.15 g, 45%).
  • 1H-NMR (CDCl3) δ: 7.60 (1H, s), 6.07 (1H, s), 4.11-4.04 (1H, m), 3.99 (2H, m), 3.87-3.84 (1H, m), 3.85 (3H, s), 3.73 (1H, m), 3.58-3.53 (2H, m), 3.47-3.42 (3H, m), 2.03-1.78 (6H, m), 1.65-1.63 (2H, m), 0.77-0.56 (4H, m).
    • Step 8: Prop-2-en-1-yl (11a′S)-8′-[(5-bromopentyl)oxy]-7′-methoxy-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylate (6-9)
  • The compound obtained in step 7 (6-8) (1.15 g, 2.72 mmol) was reacted in the same manner as in step 9 of Example 10-3 to afford the desired compound (6-9) (1.14 g, 82%).
  • 1H-NMR (CDCl3) δ: 7.23 (1H, s), 6.69 (1H, s), 5.79 (1H, s), 5.13-5.10 (2H, m), 4.68-4.66 (1H, m), 4.48-4.45 (2H, m), 4.01 (2H, m), 3.92 (3H, s), 3.76 (1H, m), 3.54-3.37 (3H, m), 2.39 (1H, m), 1.95-1.90 (4H, m), 1.68-1.61 (3H, m), 1.44 (1H, m), 0.75-0.66 (4H, m).
    • Step 9: N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-8′-{[5-({(11a′S)-7′-methoxy-5′-oxo-10′-[(prop-2-en-1-yloxy)carbonyl]-5′,10′,11′,11a′-tetrahydro′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl}oxy)pentyl]oxy}-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (6-10)
  • The compound obtained in step 8 (6-9) (0.374 g, 0.737 mmol) was reacted with the compound obtained in step 10 of Example 10-1 (1-11) (0.452 g, 0.56 mmol) in the same manner as in step 10 of Example 10-3 to afford the desired compound (6-10) (0.589 g, 65%).
  • MS (APCI, ESI) m/z: 1234 (M+H)+
    • Step 10: N-[(Prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11a′S)-11′-hydroxy-7′-methoxy-8′-{[5-({(11a′S)-7′-methoxy-5′-oxo-10′-[(prop-2-en-1-yloxy)carbonyl]-5′,10′,11′,11a′-tetrahydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl}oxy)pentyl]oxy}-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (6-11)
  • The compound obtained in step 9 (6-10) (0.589 g, 0.477 mmol) was reacted in the same manner as in step 11 of Example 10-3 to afford the desired compound (6-11) (0.382 g, 71%).
  • 1H-NMR (CDCl3) δ: 8.90 (1H, s), 7.55 (2H, m), 7.25-7.21 (2H, m), 6.74 (2H, m), 6.38 (1H, s), 5.90-5.87 (5H, m), 5.33-5.09 (8H, m), 4.66-4.60 (8H, m), 3.98-3.91 (10H, m), 3.77-3.30 (12H, m), 2.42-2.36 (2H, m), 1.77-1.39 (6H, m), 0.91-0.70 (14H, m).
    • Step 11: L-Valyl-N-{4-[({[(11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11a′S)-7′-methoxy-5′-oxo-5′,10′,11′,11a′-tetrahydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (6-12)
  • The compound obtained in step 10 (6-11) (0.382 g, 0.341 mmol) was reacted in the same manner as in step 12 of Example 10-3 to afford the desired compound (6-12) (0.200 g, 62%).
  • MS (APCI, ESI) m/z: 952 (M+H)+
    • Step 12: N-[4-(11,12-Didehydrodibenzo[b,f]azocin-5 (6H)-yl)-4-oxobutanoyl]glycylglycyl-L-valyl-N-{4-[({[(11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11a′S)-7′-methoxy-5′-oxo-5′,10′,11′,11a′-tetrahydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alaninamide (6-13)
  • The compound obtained in step 11 (6-12) (0.0560 g, 0.0588 mmol) was reacted with the compound obtained in step 1 of Example 10-2 (2-2) (0.022 g, 0.053 mmol) in the same manner as in step 13 of Example 10-3 to afford the desired compound (6-13) (0.0500 g, 63%).
  • MS (APCI, ESI) m/z: 1354 (M+H)+
    • [Synthesis of Drug Moiety] Example 10-7: Drug 1
  • Figure US20220016257A1-20220120-C00047
    • Step 1: Prop-2-en-1-yl (2-{[(6S)-6-({[tert-butyl (dimethyl) silyl]oxy}methyl)-5-azaspiro [2.4]hept-5-yl]carbonyl}-4-methoxy-5-{[tri(propan-2-yl)silyl]oxy}phenyl)carbamate (7-1)
  • The compound obtained in step 5 of Example 1 (1-6) (4.59 g, 8.15 mmol) was reacted in the same manner as in step 9 of Example 10-3 to afford the desired compound (7-1) (4.86 g, 92%).
  • 1H-NMR (CDCl3) δ: 8.97 (1H, s), 7.77 (1H, s), 6.77 (1H, s), 5.97-5.94 (1H, m), 5.39-5.21 (2H, m), 4.67-4.59 (3H, m), 4.00-3.98 (1H, m), 3.74-3.66 (5H, m), 3.05-3.03 (1H, m), 2.30-2.28 (1H, m), 1.72-1.70 (1H, m), 1.30-1.27 (3H, m), 1.11-1.05 (18H, m), 0.99-0.91 (9H, m), 0.61-0.53 (4H, m), 0.10-0.06 (6H, m).MS (APCI, ESI) m/z: 647 (M+H)+
    • Step 2: Prop-2-en-1-yl (2-{[(6S)-6-(hydroxymethyl)-5-azaspiro[2.4]hept-5-yl]carbonyl}-4-methoxy-5-{[tri(propan-2-yl)silyl]oxy}phenyl)carbamate (7-2)
  • The compound obtained in step 1 (7-1) (4.86 g, 7.51 mmol) was reacted in the same manner as in step 7 of Example 10-1 to afford the desired compound (7-2) (3.42 g, 86%).
  • 1H-NMR (CDCl3) δ: 8.52 (1H, s), 7.71 (1H, s), 6.77 (1H, s), 6.00-5.94 (1H, m), 5.35-5.27 (2H, m), 4.65-4.64 (3H, m), 4.33-4.31 (1H, m), 3.82-3.77 (5H, m), 3.68-3.66 (1H, m), 3.15-3.13 (1H, m), 1.89-1.86 (2H, m), 1.30-1.26 (3H, m), 1.14-1.10 (18H, m), 0.66-0.51 (4H, m).
  • MS (APCI, ESI) m/z: 533 (M+H)+
    • Step 3: Prop-2-en-1-yl (11a′S)-11′-hydroxy-7′-methoxy-5′-oxo-8′-{[tri(propan-2-yl)silyl]oxy}-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylate (7-3)
  • The compound obtained in step 2 (7-2) (6.68 g, 12.5 mmol) was reacted in the same manner as in step 8 of Example 10-1 to afford the desired compound (7-3) (6.44 g, 97%).
  • 1H-NMR (CDCl3) δ: 7.20 (1H, s), 6.69 (1H, s), 5.89-5.78 (2H, m), 5.18-5.15 (2H, m), 4.62-4.60 (1H, m), 4.49-4.47 (1H, m), 3.85 (3H, s), 3.74-3.71 (1H, m), 3.59-3.57 (1H, m), 3.33-3.30 (2H, m), 2.43-2.40 (1H, m), 1.76-1.73 (1H, m), 1.28-1.20 (3H, m), 1.09-1.07 (18H, m), 0.74-0.65 (4H, m).
  • MS (APCI, ESI) m/z: 531 (M+H)+
    • Step 4: Prop-2-en-1-yl (11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-5′-oxo-8′-{[tri(propan-2-yl)silyl]oxy}-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylate (7-4)
  • The compound obtained in step 3 (7-3) (3.24 g, 6.10 mmol) was reacted in the same manner as in step 9 of Example 10-1 to afford the desired compound (7-4) (3.86 g, 98%).
  • 1H-NMR (CDCl3) δ: 7.20 (1H, s), 6.67 (1H, s), 6.01-5.98 (1H, m), 5.79-5.73 (1H, m), 5.14-5.10 (2H, m), 4.64-4.61 (1H, m), 4.37-4.34 (1H, m), 3.86 (3H, s), 3.72-3.69 (1H, m), 3.52-3.50 (1H, m), 3.29-3.26 (1H, m), 2.38-2.34 (1H, m), 1.55-1.51 (1H, m), 1.28-1.24 (3H, m), 1.15-1.07 (18H, m), 0.81-0.66 (13H, m), 0.21 (3H, s), 0.18 (3H, s).
  • MS (APCI, ESI) m/z: 645 (M+H)+
    • Step 5: Prop-2-en-1-yl (11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-8′-hydroxy-7′-methoxy-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylate (7-5)
  • The compound obtained in step 4 (7-4) (4.49 g, 6.96 mmol) was reacted in the same manner as in step 10 of Example 10-1 to afford the desired compound (7-5) (3.24 g, 95%).
  • 1H-NMR (CDCl3) δ: 7.25 (1H, s), 6.73 (1H, s), 6.02-6.00 (1H, m), 5.91 (1H, s), 5.77-5.75 (1H, m), 5.11-5.09 (2H, m), 4.64-4.62 (1H, m), 4.41-4.40 (1H, m), 3.95 (3H, s), 3.72-3.70 (1H, m), 3.54-3.53 (1H, m), 3.29-3.26 (1H, m), 2.36-2.34 (1H, m), 1.56-1.54 (1H, m), 0.79-0.67 (13H, m), 0.21 (3H, s), 0.20 (3H, s).
  • MS (APCI, ESI) m/z: 489 (M+H)+
    • Step 6: Prop-2-en-1-yl (11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-8′-{[5-({(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-[(prop-2-en-1-yloxy)carbonyl]-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl}oxy)pentyl]oxy}-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylate (7-6)
  • The compound obtained in step 5 (7-5) (0.080 g, 0.164 mmol) was reacted with the compound obtained in step 9 of Example 10-3 (3-10) (0.095 g, 0.163 mmol) in the same manner as in step 10 of Example 10-3 to afford the desired compound (7-6) (0.160 g, 98%).
  • 1H-NMR (DMSO-D6) δ: 7.44-7.42 (3H, m), 7.12-7.10 (2H, m), 7.05-7.03 (1H, m), 6.92-6.90 (2H, m), 6.61-6.59 (1H, m), 5.87-5.81 (3H, m), 5.10-5.07 (4H, m), 4.66-4.55 (3H, m), 4.43-4.39 (2H, m), 4.21-3.94 (5H, m), 3.83 (3H, s), 3.81 (3H, s), 3.76 (3H, s), 3.65-3.62 (1H, m), 3.56-3.54 (1H, m), 3.42-3.39 (1H, m), 3.22-3.14 (2H, m), 2.77-2.73 (1H, m), 2.42-2.33 (1H, m), 1.81-1.79 (4H, m), 1.55-1.44 (3H, m), 0.82 (9H, s), 0.72-0.53 (4H, m), 0.19 (3H, s), 0.17 (3H, s).
  • MS (APCI, ESI) m/z: 993 (M+H)+
    • Step 7: Prop-2-en-1-yl (11a′S)-11′-hydroxy-7′-methoxy-8′-{[5-({(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-[(prop-2-en-1-yloxy)carbonyl]-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl}oxy)pentyl]oxy}-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylate (7-7)
  • The compound obtained in step 6 (7-6) (160 mg, 0.161 mmol) was reacted in the same manner as in step 11 of Example 10-3 to afford the desired compound (7-7) (141 mg, quantitative).
  • 1H-NMR (DMSO-D6) δ: 7.44-7.42 (3H, m), 7.08-7.06 (3H, m), 6.92-6.90 (2H, m), 6.82-6.79 (1H, m), 6.56-6.54 (1H, m), 5.77-5.74 (3H, m), 5.09 (4H, s), 4.58-4.55 (3H, m), 4.43-4.41 (2H, m), 4.16-4.01 (5H, m), 3.81-3.81 (6H, m), 3.76 (3H, s), 3.64 (1H, s), 3.56-3.53 (1H, m), 3.42-3.38 (1H, m), 3.25-3.13 (2H, m), 2.74-2.70 (1H, m), 2.37-2.34 (1H, m), 1.82-1.79 (4H, m), 1.59-1.56 (3H, m), 0.66-0.62 (4H, m).
  • MS (APCI, ESI) m/z: 879 (M+H)+
    • Step 8: (11a′S)-7′-Methoxy-8′-[(5-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy}pentyl)oxy]-1′,11a′-dihydro-5′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-5′-one (7-8)
  • The compound obtained in step 7 (7-7) (141 mg, 0.161 mmol) was reacted in the same manner as in step 12 of Example 10-3 to afford the desired compound (7-8) (109.8 mg, 99%).
  • 1H-NMR (DMSO-D6) δ: 7.92-7.91 (1H, m), 7.45 (1H, s), 7.39-7.37 (2H, m), 7.33 (1H, s), 7.29 (1H, s), 6.92-6.89 (2H, m), 6.85 (1H, s), 6.56-6.54 (1H, m), 6.31 (1H, s), 4.19-4.12 (2H, m), 4.05-3.99 (1H, m), 3.95-3.93 (2H, m), 3.82-3.79 (4H, m), 3.76 (3H, s), 3.66 (3H, s), 3.52-3.46 (3H, m), 3.30-3.21 (2H, m), 2.78-2.74 (1H, m), 2.45-2.42 (1H, m), 2.06-2.05 (1H, m), 1.89-1.82 (4H, m), 1.60-1.58 (2H, m), 0.80-0.63 (4H, m).
  • MS (APCI, ESI) m/z: 693 (M+H)+
    • Example 10-8: Drug 2
  • Figure US20220016257A1-20220120-C00048
    • Step 1: [4-(Benzyl)-5-methoxy-2-nitrophenyl][(6S)-6-(hydroxymethyl)-5-azaspiro[2.4]hept-5-yl]methanone (8-1)
  • To a solution of the compound obtained in step 1 of Example 6 (6-2) (6.49 g, 14.7 mmol) in tetrahydrofuran (147 mL), lithium borohydride (0.642 g, 29.5 mmol) was added at 0° C., and the resultant was stirred at room temperature for 2 hours. To the reaction solution, 1 N hydrochloric acid was added, which was extracted with ethyl acetate. The organic layer obtained was washed with brine and dried over magnesium sulfate, and then distilled under reduced pressure. The crude product obtained (8-1) (6.94 g, quantitative) was used for the subsequent step.
  • MS (APCI, ESI) m/z: 413 (M+H)+
    • Step 2: (6S)-5-[4-(Benzyloxy)-5-methoxy-2-nitrobenzoyl]-5-azaspiro[2.4]heptane-6-carbaldehyde (8-2)
  • The compound obtained in step 1 (8-1) (4.50 g, 11.0 mmol) was reacted in the same manner as in step 8 of Example 10-1 to afford the desired compound (8-2) (1.94 g, 43%).
  • MS (APCI, ESI) m/z: 411 (M+H)+
    • Step 3: (11a′S)-8′-Hydroxy-7′-methoxy-1′, 10′,11′,11a′-tetrahydro-5′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-5′-one (8-3)
  • To a solution of the compound obtained in step 2 (8-2) (1.94 g, 4.73 mmol) in tetrahydrofuran (25 mL), ethyl acetate (25 mL), and methanol (25 mL), 5% palladium carbon (moisture content: 54%, 1.0 g) was added under a nitrogen atmosphere, and the reaction solution was then stirred under a hydrogen atmosphere at room temperature for 22 hours. After the reaction solution was filtered through Celite, the filtrate was distilled under reduced pressure. The resulting residue was purified by silica gel column chromatography [hexane:ethyl acetate=80:20 (v/v) to 0:100 (v/v)] to afford the desired compound (8-3) (1.20 g, 93%).
  • 1H-NMR (CDCl3) δ: 7.55 (1H, s), 6.16 (1H, s), 5.86 (1H, s), 4.08-4.02 (2H, m), 3.86 (3H, s), 3.72-3.69 (1H, m), 3.57-3.37 (3H, m), 2.04-2.01 (1H, m), 1.78-1.75 (1H, m), 0.79-0.53 (4H, m).
  • MS (APCI, ESI) m/z: 275 (M+H)+
    • Step 4: Prop-2-en-1-yl (11a′S)-8′-[(5-bromopentylo)oxy]-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylat (8-4)
  • The compound obtained in step 5 of Example 10-7 (7-5) (0.300 g, 0.614 mmol) was reacted in the same manner as in step 2 of Example 10-3 to afford the desired compound (8-4) (0.388 g, 99%).
  • 1H-NMR (CDCl3) δ: 7.24 (1H, s), 6.60 (1H, s), 6.02-5.98 (1H, m), 5.80-5.75 (1H, m), 5.11-5.06 (2H, m), 4.68-4.64 (1H, m), 4.40-4.38 (1H, m), 4.02-3.98 (2H, m), 3.92 (3H, s), 3.72-3.69 (1H, m), 3.54-3.52 (1H, m), 3.46-3.41 (2H, m), 3.29-3.26 (1H, m), 2.38-2.34 (1H, m), 1.94-1.87 (4H, m), 1.65-1.62 (2H, m), 1.55-1.55 (1H, m), 0.86 (9H, s), 0.75-0.67 (4H, m), 0.24-0.22 (6H, m).
  • MS (APCI, ESI) m/z: 639 [81Br, (M+H)+], 637 [79Br, (M+H)+].
    • Step 5: Prop-2-en-1-yl (11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-8′-[(5-{([(1a′S)-7′-methoxy-5′-oxo-5′,10′,11′,11a′-tetrahydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylate (8-5)
  • The compound obtained in step 4 (8-4) (0.203 g, 0.318 mmol) was reacted with the compound obtained in step 3 (8-3) (0.131 g, 0.478 mmol) in the same manner as in step 10 of Example 10-3 to afford the desired compound (8-5) (0.0880 g, 33%).
  • MS (APCI, ESI) m/z: 831 (M+H)+
    • Step 6: Prop-2-en-1-yl (11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11a′S)-7′-methoxy-5′-oxo-5′,10′,11′,11a′-tetrahydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylate (8-6)
  • The compound obtained in step 5 (8-5) (0.0880 g, 0.106 mmol) was reacted in the same manner as in step 11 of Example 10-3 to afford the desired compound (8-6) (0.0500 g, 66%).
  • MS (APCI, ESI) m/z: 717 (M+H)+
    • Step 7: (11a′S)-7′-Methoxy-8′-[(5-{[(11a′S)-7′-methoxy-5′-oxo-5′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl]oxy}pentyl)oxy]-1′,10′,11′,11a′-tetrahydro-5′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-5′-one (8-7)
  • The compound obtained in step 6 (8-6) (0.0500 g, 0.0698 mmol) was reacted in the same manner as in step 12 of Example 10-3 to afford the desired compound (8-7) (0.0330 g, 77%).
  • 1H-NMR (CDCl3) δ: 7.80 (1H, m), 7.58 (1H, s), 7.52 (1H, s), 6.81 (1H, s), 6.05 (1H, s), 4.17-3.97 (5H, m), 3.94 (3H, s), 3.87 (1H, m), 3.84 (3H, s), 3.72-3.68 (3H, m), 3.51-3.45 (5H, m), 2.54-2.51 (1H, m), 2.03-1.90 (6H, m), 1.75-1.68 (2H, m), 0.66 (8H, m).
  • MS (APCI, ESI) m/z: 615 (M+H)+
    • Example 10-9: Drug 3
  • Figure US20220016257A1-20220120-C00049
    • Step 1: Di-2-propen-1-yl {1,5-pentanediylbis[oxy(6-{[(6S)-6-(hydroxymethyl)-5-azaspiro[2.4]hept-5-yl]carbonyl}-4-methoxybenzen-3, 1-diyl)]}biscarbamate (9-1)
  • Bisallyloxycarbonyl form (5-6b) (0.460 g, 0.508 mmol), obtained in step 5 of Example 10-5, was reacted in the same manner as in step 7 of Example 10-5 to afford the desired compound (9-1) (0.421 g, quantitative).
  • 1H-NMR (DMSO-D6) δ: 9.19 (2H, s), 7.22 (2H, s), 6.89 (2H, s), 5.97-5.92 (2H, m), 5.33 (2H, m), 5.22 (2H, m), 4.81 (2H, m), 4.55 (4H, m), 4.26 (2H, s), 3.96 (4H, m), 3.74 (6H, s), 3.62 (2H, m), 3.56 (2H, s), 3.37 (2H, m), 3.11 (2H, m), 1.88-1.78 (8H, m), 1.56-1.54 (2H, m), 0.54-0.43 (8H, m).
  • MS (APCI, ESI) m/z: 821 (M+H)+.
    • Step 2: Diprop-2-en-1-yl (11a′S, 11a′S)-8′,8″-[pentan-1,5-diylbis(oxy)]bis(11′-hydroxy-7′-methoxy-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylate) (9-2)
  • The compound obtained in step 1 (9-1) (0.421 g, 0.513 mmol) was reacted in the same manner as in step 8 of Example 10-5 to afford the desired compound (9-2) (0.326 g, 78%).
  • 1H-NMR (DMSO-D6) δ: 7.07 (2H, s), 6.80 (2H, s), 6.55 (2H, m), 5.84-5.81 (2H, m), 5.75 (2H, m), 5.09-5.05 (4H, m), 4.62 (2H, mz), 4.40 (2H, m), 3.98 (4H, m), 3.81 (6H, s), 3.54 (2H, m), 3.43-3.37 (2H, m), 3.14 (2H, m), 2.35 (2H, m), 1.81-1.79 (4H, m), 1.59-1.56 (4H, m), 0.70-0.59 (8H, m).MS (APCI, ESI) m/z: 817 (M+H)+.
    • Step 3: (11a′S,11a″″S)-8′,8″-[1,5-Pentanediylbis(oxy)]bis(7′-methoxy-1′,11a′-dihydro-5′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-5′-one) (9-3)
  • The compound obtained in step 2 (9-2) (0.326 g, 0.399 mmol) was reacted in the same manner as in step 12 of Example 10-3 to afford the desired compound (9-3) (0.208 g, 85%).
  • 1H-NMR (DMSO-D6) δ: 7.91 (2H, m), 7.32 (2H, s), 6.84 (2H, s), 4.11 (2H, m), 4.06 (2H, m), 3.82 (6H, s), 3.51-3.31 (6H, m), 2.43 (2H, m), 2.05 (2H, m), 1.82-1.80 (4H, m), 1.60-1.58 (2H, m), 0.79-0.77 (2H, m), 0.68-0.64 (6H, m).MS (APCI, ESI) m/z: 613 (M+H)+.
    • Example 10-10: Drug 4
  • Figure US20220016257A1-20220120-C00050
    Figure US20220016257A1-20220120-C00051
    • Step 1: (2R,11aS)-2,8-Dihydroxy-7-methoxy-10-{[2-(trimethylsilyl)ethoxy]methyl}-2,3-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-5,11 (10H,11aH)-dione (10-1)
  • The compound obtained in step 1 of Example 10-3 (3-2) (5.00 g, 9.66 mmol) was reacted in the same manner as in step 3 of Example 10-3 to afford the desired compound (10-1) (3.95 g, 100%).
  • MS (APCI, ESI) m/z: 409 (M+H)+
    • Step 2: (2R,11aS)-2-Hydroxy-7-methoxy-10-{[2-(trimethylsilyl)ethoxy]methyl}-8-{[tri(propan-2-yl)silyl]oxy}-2,3-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-5,11 (10H,11aH)-dione (10-2)
  • To a solution of the compound obtained in step 1 (10-1) (3.95 g, 9.67 mmol) in dichloromethane (97 mL), imidazole (1.65 g, 24.2 mmol), triisopropylsilyl chloride (2.46 mL, 11.6 mmol) and dimethylformamide (5 mL) were added, and the resultant was stirred at room temperature for 21 hours. Water was added to the reaction solution, which was extracted with chloroform, and the organic layer obtained was washed with water, and then distilled under reduced pressure. The resulting residue was purified by silica gel chromatography [hexane:ethyl acetate=100:0 (v/v) to 20:80 (v/v)] to afford the desired compound (10-2) (4.78 g, 87%).
  • MS (APCI, ESI) m/z: 565 (M+H)+
    • Step 3: (11aS)-7-Methoxy-10-{[2-(trimethylsilyl)ethoxy]methyl}-8-{[tri(propan-2-yl)silyl]oxy}-1H-pyrrolo[2,1-c][1,4]benzodiazepine-2,5,11 (3H,10H,11aH)-trione
  • The compound obtained in step 2 (4.78 g, 8.43 mmol) was reacted in the same manner as in step 4 of Example 10-3 to afford the desired compound (10-3) (2.36 g, 50%).
  • MS (APCI, ESI) m/z: 563 (M+H)+
    • Step 4: (11aS)-7-Methoxy-5,11-dioxo-10-{[2-(trimethylsilyl)ethoxy]methyl}-8-{[tri(propan-2-yl)silyl]oxy}-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl trifluoromethane sulfonate (10-4)
  • The compound obtained in step 3 (10-3) (1.53 g, 2.72 mmol) was reacted in the same manner as in step 5 of Example 10-3 to afford the desired compound (1.27 g, 69%).
  • 1H-NMR (CDCl3) δ: 7.31 (2H, s), 7.15 (1H, m), 5.52 (1H, m), 4.65 (1H, m), 4.57 (1H, m), 3.95-3.89 (1H, m), 3.87 (3H, s), 3.75-3.58 (2H, m), 3.18-3.14 (1H, m), 1.33-1.25 (3H, m), 1.10 (18H, m), 1.00-0.96 (2H, m), 0.03 (9H, s).
    • Step 5: (11aS)-7-Methoxy-2-(4-methoxyphenyl)-10-{[2-(trimethylsilyl)ethoxy]methyl}-8-{[tri(propan-2-yl)silyl]oxy}-1H-pyrrolo[2,1-c][1,4]benzodiazepine-5,11 (10H,11aH)-dione (10-5)
  • The compound obtained in step 4 (10-4) (0.519 g, 0.747 mmol) was reacted in the same manner as in step 6 of Example 10-3 to afford the desired compound (10-5) (0.511 g, quantitative).
  • 1H-NMR (CDCl3) δ: 7.41-7.31 (5H, m), 6.91-6.85 (2H, m), 5.52 (1H, m), 4.64 (1H, m), 4.57 (1H, m), 3.97-3.90 (1H, m), 3.88 (3H, s), 3.83 (3H, s), 3.75-3.56 (2H, m), 3.19-3.09 (1H, m), 1.36-1.23 (3H, m), 1.11 (18H, m), 1.02-0.97 (2H, m), 0.03 (9H, s).
  • MS (APCI, ESI) m/z: 653 [(M+H)+]
    • Step 6: (11aS)-7-Methoxy-2-(4-methoxyphenyl)-8-{[tri(propan-2-yl)silyl]oxy}-1, 11a-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (10-6)
  • The compound obtained in step 5 (10-5) (0.178 g, 0.272 mmol) was reacted in the same manner as in step 7 of Example 10-3 to afford the desired compound (10-6) (0.094 g, 68%).
  • 1H-NMR (CDCl3) δ: 7.87 (1H, m), 7.51 (1H, s), 7.41-7.39 (1H, m), 7.36-7.33 (2H, m), 6.93-6.89 (2H, m), 6.86 (1H, s), 4.44-4.38 (1H, m), 3.90 (3H, s), 3.83 (3H, s), 3.61-3.53 (1H, m), 3.41-3.34 (1H, m), 1.33-1.25 (3H, m), 1.11-1.06 (18H, m).
  • MS (APCI, ESI) m/z: 507 [(M+H)+]
    • Step 7: (11aS)-7-Methoxy-2-(4-methoxyphenyl)-8-{[tri(propan-2-yl)silyl]oxy}-1,10,11,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one (10-7)
  • The compound obtained in step 6 (10-6) (0.063 g, 0.124 mmol) was used and reacted in the same manner as in step 8 of Example 10-3 to afford the desired compound (10-7) (0.046 g, 72%).
  • 1H-NMR (CDCl3) δ: 7.53-7.48 (2H, m), 7.33-7.29 (2H, m), 6.90-6.86 (2H, m), 6.13-6.11 (1H, m), 4.36-4.29 (1H, m), 4.11 (1H, s), 3.82 (3H, s), 3.79 (3H, s), 3.59-3.50 (2H, m), 3.40-3.31 (1H, m), 2.78-2.68 (1H, m), 1.31-1.20 (3H, m), 1.13-1.02 (18H, m).MS (APCI, ESI) m/z: 509 [(M+H)+]
    • Step 8: Prop-2-en-1-yl (11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-8-{[tri(propan-2-yl)silyl]oxy}-11,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10 (5H)-carboxylate (10-8)
  • The compound obtained in step 7 (10-7) (0.046 g, 0.090 mmol) was used and reacted in the same manner as in step 9 of Example 10-3 to afford the desired compound (10-8) (0.03 g, 56%).
  • 1H-NMR (CDCl3) δ: 7.39-7.36 (1H, m), 7.31-7.28 (2H, m), 7.22 (1H, s), 6.90-6.86 (3H, m), 6.75-6.72 (1H, m), 5.82-5.69 (1H, m), 5.18-5.08 (2H, m), 4.59-4.52 (1H, m), 4.48-4.39 (1H, m), 4.39-4.29 (1H, m), 4.23-4.12 (1H, m), 3.86 (3H, s), 3.82 (3H, s), 3.64-3.58 (1H, m), 3.32-3.25 (1H, m), 2.73-2.65 (1H, m), 1.30-1.20 (2H, m), 1.12-1.06 (18H, m).
  • MS (APCI, ESI) m/z: 593 [(M+H)+]
    • Step 9: Prop-2-en-1-yl (11aS)-8-hydroxy-7-methoxy-2-(4-methoxyphenyl)-5-oxo-11,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10 (5H)-carboxylate (10-9)
  • The compound obtained in step 8 (10-8) (0.030 g, 0.050 mmol) was reacted in the same manner as in step 10 of Example 10-1 to afford the desired compound (10-9) (0.015 g, 0.034 mmol).
  • 1H-NMR (CDCl3) δ: 7.39-7.25 (4H, m), 6.92-6.78 (3H, m), 6.03-5.92 (1H, m), 5.86-5.68 (1H, m), 5.20-5.07 (2H, m), 4.66-4.57 (1H, m), 4.52-4.40 (1H, m), 4.40-4.27 (1H, m), 4.27-4.16 (1H, m), 3.95 (3H, s), 3.82 (3H, s), 3.66-3.59 (1H, m), 3.32-3.21 (1H, m), 2.74-2.64 (1H, m).
  • MS (APCI, ESI) m/z: 437 [(M+H)+]
    • Step 10: Prop-2-en-1-yl (11a′S)-8′-(3-bromopropoxy)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylate (10-10)
  • The compound obtained in step 5 of Example 10-7 (0.131 g, 0.268 mmol) was reacted in the same manner as in step 1 of Example 10-4 to afford the desired compound (10-10) (0.086 g, 52%).
  • 1H-NMR (CDCl3) δ: 7.24 (1H, s), 6.65 (1H, s), 6.02 (1H, m), 5.87-5.71 (1H, m), 5.15-5.04 (2H, m), 4.72-4.62 (1H, m), 4.44-4.32 (1H, m), 4.23-4.07 (3H, m), 3.92 (3H, s), 3.77-3.47 (4H, m), 3.28 (1H, m), 2.37 (3H, m), 1.57-1.52 (1H, m), 0.86 (9H, s), 0.82-0.57 (4H, m), 0.21 (6H, m).
  • MS (APCI, ESI) m/z: 611 [81Br, (M+H)+], 609 [79Br, (M+H)+]
    • Step 11: Prop-2-en-1-yl (11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-8′-[3-({(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-[(prop-2-en-1-yloxy)carbonyl]-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-8-yl}oxy)propoxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylate (10-11)
  • The compound obtained in step 10 (10-10) (0.015 g, 0.034 mmol) and the compound obtained in step 9 (10-9) (0.030 g, 0.048 mmol) were reacted in the same manner as in step 10 of Example 10-3 to afford the desired compound (10-11) (0.032 g, 96%).
  • MS (APCI, ESI) m/z: 965 [(M+H)+]
    • Step 12: Prop-2-en-1-yl (11a′S)-11′-hydroxy-7′-methoxy-8′-[3-({(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-[(prop-2-en-1-yloxy)carbonyl]-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-8-yl}oxy)propoxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carboxylate (10-12)
  • The compound obtained in step 11 (10-11) (0.031 g, 0.032 mmol) was reacted in the same manner as in step 11 of Example 10-3 to afford the desired compound (10-12) (0.026 g, 95%).
  • MS (APCI, ESI) m/z: 851 [(M+H)+]
    • Step 13: (11a′S)-7′-Methoxy-8′-(3-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-8-yl]oxy}propoxy)-1′,11a′-dihydro-5′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-5′-one (10-13)
  • The compound obtained in step 12 (10-12) (0.026 g, 0.030 mmol) was reacted in the same manner as in step 12 of Example 10-3 to afford the desired compound (10-13) (0.018 g, 88%).
  • 1H-NMR (CDCl3) δ: 7.80 (1H, m), 7.54-7.51 (3H, m), 7.33-7.29 (2H, m), 6.91-6.85 (3H, m), 6.14 (1H, s), 4.35-4.17 (6H, m), 3.95 (3H, s), 3.85 (3H, s), 3.82 (3H, s), 3.76-3.25 (5H, m), 2.79-2.69 (1H, m), 2.52 (1H, m), 2.45-2.35 (1H, m), 2.03-1.96 (1H, m), 1.28-1.23 (2H, m), 0.78-0.69 (4H, m).
  • MS (APCI, ESI) m/z: 665 [(M+H)+]
    • Example 11: [N3-PEG (3)]-MSG1-Ox Synthesis of [N3-PEG (3)]-MSG1
  • Figure US20220016257A1-20220120-C00052
  • (In the figure, the schematic diagram in the right of the structural formula represents the corresponding structure in the schematic diagram of an intermediate as represented by the reaction formula of each of Examples 12, 13, 14, 15.)
  • Step 1: (MSG1-)Asn
  • The commercially available product monosialo-Asn free (1S2G/1G2S-10NC-Asn, produced by GlyTech, Inc.) (referred to as “(MSG-)Asn”) (500 mg) was subjected to separation/purification by reversed-phase HPLC under the conditions described below, to separate into (MSG1-)Asn eluted as the 1st main peak (retention time: around 15 to 19 min) and (MSG2-)Asn eluted as the 2nd main peak (retention time: around 21 to 26 min). The eluent used was a 0.1% formic acid aqueous solution, the apparatus used was an ELS-PDA trigger preparative system (produced by JASCO Corporation), the column used was an Inertsil ODS-3 (10 um, 30ϕ×250 mm, produced by GL Sciences, Inc.), and the flow rate was 30 mL/min. Fractions belonging to the first peak UV-detected (210 nm) during the elution were collected together, and freeze-dried to afford the desired compound (238 mg).
  • Step 2: MSG1
  • The compound obtained in step 1 (229 mg) was dissolved in 200 mM phosphate buffer solution (pH 6.25) (1145 μL), to which an aqueous solution (100 μL) of EndoM (produced by Tokyo Chemical Industry Co., Ltd., 1 U/mL)) was added, and the resultant was incubated at 35° C. for 6 days. After the completion of the reaction, the reaction solution was subjected to ultrafiltration with a VIVASPIN 15R (Hydrosart membrane, 30K, 6,000 g), and the filtered solution obtained was subjected to separation/purification by reversed-phase HPLC. The eluent used was a 0.1% trifluoroacetic acid aqueous solution, the apparatus used was an ELS-PDA trigger preparative system (produced by JASCO Corporation), and the column used was an Inertsil ODS-3 (produced by GL Sciences, Inc.). Fractions containing the desired compound UV-detected (210 nm) during the elution were collected together, and freeze-dried to afford the desired compound (117 mg).
  • Step 3: [N3-PEG (3)]-MSG1
  • Into a 5 mL sampling tube (Ina-Optica Co., Ltd.), an aqueous solution (1.2 mL) of 11-azide-3,6,9-trioxaundecane-1-amine (0.108 mL, 0.541 mmol) and MSG1 obtained in step 2 (117 mg, 0.068 mmol) were added, and the resultant was stirred for 1 hour and then freeze-dried. Into the 5 mL sampling tube after freeze-drying, an N,N-dimethylformamide solution (1.2 mL) of O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (103 mg, 0.27 mmol) and diisopropylethylamine (0.046 mL, 0.27 mmol) were added, followed by stirring at 37° C. for 3 hours. After the completion of the reaction, the reaction solution was transferred into a centrifuge tube (50 mL) into which diethyl ether (20 mL) had been added in advance. The solid matter was precipitated by using a small centrifuge (Hitachi Koki Co., Ltd., CF16RX) and the supernatant was removed. Further, diethyl ether (10 mL) was added, and the resultant was centrifuged and decanted. Subsequently, acetonitrile (10 mL) was added, and the resultant was centrifuged and decanted. This operation was repeated twice, and then the resultant was dried under reduced pressure to afford a crude product. The resulting solid matter was subjected to purification by reversed-phase HPLC in the same conditions as in step 2 to afford the desired compound (94.2 mg).
  • Step 4: [N3-PEG (3)]-MSG1-Ox
  • Into a 5 mL sampling tube (produced by Ina-Optica Co., Ltd), the compound synthesized in step 3 (100 mg) and an aqueous solution (520 μL) of 2-chloro-1,3-dimethyl-1H-benzimidazol-3-ium-chloride (produced by FUSHIMI Pharmaceutical Co., Ltd. 56 mg, 0.257 mmol) was added. To the reaction solution after being ice-cooled, an aqueous solution (520 μL) of tripotassium phosphate (165 mg, 0.78 mmol) was added, followed by stirring under ice-cooling for 3 hours. The resulting reaction solution was subjected to ultrafiltration with an Amicon Ultra (Ultracel 30K, produced by Merck Millipore) to remove the solid matter. The filtered solution was purified by gel filtration chromatography. The apparatus used was a Purif-Rp2 (produced by Shoko Scientific Co., Ltd.), the column used was a HiPrep 26/10 Desalting (produced by GE Healthcare), the mobile phase used was 0.03%-NH3 aqueous solution, and the flow rate was 10 mL/min and the fraction volume was 10 mL. Fractions containing the desired compound UV-detected (220 nm) during the elution were collected together, to which a 1 N aqueous solution of sodium hydroxide (104 μL, 0.104 mmol) was added, and the resultant was freeze-dried to afford the desired compound (84 mg).
  • In Examples 12 to 16, preparation of a glycan-remodeled antibody will be described.
    • Example 12: H01L02 Antibody-[MSG1-N3]2
  • Figure US20220016257A1-20220120-C00053
  • (This formula represents a linker structure in which an azide group has been introduced to a sialic acid at the non-reducing terminal of an MSG1-type N297 glycan. In Example 12, linker structures of intermediates formed by introducing an azide group to an N297 glycan are the same as the structure represented by the formula.)
    • Step 1: Preparation of (Fucα1,6)GlcNAc-H01L02 Antibody
  • To H01L02 antibody solution (ca. 21.1 mg/mL) (50 mM phosphate buffer (pH 6.0)) (4.07 ml), 0.233 mL of wild-type EndoS solution (7.7 mg/mL, PBS) was added, and the solutions were incubated at 37° C. for 4 hours. The progress of the reaction was checked by an Experion electrophoresis station (produced by Bio-Rad Laboratories, Inc.). After completion of the reaction, purification by affinity chromatography and purification with a hydroxyapatite column were performed in accordance with the following methods.
  • (1) Purification by Affinity Chromatography
  • Purification apparatus: AKTA avant (produced by GE Healthcare)
  • Column: HiTrap rProtein A FF (5 mL) (produced by GE Healthcare)
  • Flow rate: 5 ml/min (1.25 ml/min in charging)
  • Each reaction solution obtained above was purified in multiple separate operations. In application of the sample, the reaction solution was added to the upper part of the column, and 4 CV of binding buffer (20 mM phosphate buffer (pH 6.0)) was flowed at 1.25 mL/min and 5 CV (column volume) thereof was further flowed at 5 mL/min. In an intermediate washing step, 15 CV of washing solution (20 mM phosphate buffer (pH 7.0), 0.5 M sodium chloride solution) was flowed. In elution, 6 CV of elution buffer (ImmunoPure IgG Eution buffer, produced by Pierce) was flowed. The eluate was immediately neutralized with 1 M Tris buffer (pH 9.0). Fractions containing the desired compound were subjected to buffer exchange to 5 mM phosphate buffer/50 mM 2-morpholinoethanesulfonic acid (MES) solution (pH 6.8) by using common operation C.
  • (2) Purification by Hydroxyapatite Chromatography
  • Purification apparatus: AKTA avant (produced by GE Healthcare)
  • Column: Bio-Scale Mini CHT Type I cartridge (5 mL) (produced by Bio-Rad Laboratories, Inc.)
  • Flow rate: 5 mL/min (1.25 mL/min in charging)
  • The solution obtained in (1) was to the upper part of the column, and 4 CV of solution A (5 mM phosphate buffer, 50 mM 2-morpholinoethanesulfonic acid (MES) solution (pH 6.8)) was flowed at 1.25 mL/min and 3 CV thereof was further flowed at 5 mL/min. Thereafter, elution was performed with solution A and solution B (5 mM phosphate buffer, 50 mM 2-morpholinoethanesulfonic acid (MES) (pH 6.8) and 2 M sodium chloride). The elution conditions were solution A:solution B=100:0 to 0:100 (15 CV). Further, 5 CV of washing solution (500 mM phosphate buffer (pH 6.5)) was flowed.
  • Fractions containing the desired compound were subjected to buffer exchange by using common operation C to afford a 11.4 mg/mL (Fucα1,6)GlcNAc-H01L02 antibody solution (50 mM phosphate buffer (pH 6.0)) (5.00 mL).
    • Step 2: Preparation of H01L02 Antibody-[MSG1-N3]2
  • To the 11.4 mg/mL (Fucα1,6)GlcNAc-H01L02 antibody solution (50 mM phosphate buffer (pH 6.0)) obtained in step 1 (5.00 mL), a solution (0.180 mL) of the glycan synthesized in step 4 of Example 11 (9.00 mg) in 50 mM phosphate buffer (pH 6.0) and 5.10 mg/mL EndoS D233Q/Q303L solution (PBS) (0.230 mL) were added, and the resultant was incubated at 30° C. for 3 hours. The progress of the reaction was checked by using an Experion electrophoresis station (produced by Bio-Rad Laboratories, Inc.). After the reaction, purification by affinity chromatography and purification by hydroxyapatite chromatography were performed as in step 1, and fractions containing the desired compound were then subjected to buffer exchange to phosphate buffered saline (pH 6.0) by using common operation C to afford a 9.91 mg/mL H01L02 antibody-[MSG1-N3]2 solution (phosphate buffered saline (pH 6.0)) (4.00 mL).
    • Example 13: H01L02A Antibody-[MSG1-N3]2
  • Figure US20220016257A1-20220120-C00054
    • Step 1: Preparation of (Fucα1,6)GlcNAc-H01L02A Antibody
  • The operation in step 1 of Example 12 was carried out with a ca. 21.6 mg/mL H01L02A antibody solution (50 mM phosphate buffer (pH 6.0)) (1.85 mL) to afford a 14.6 mg/mL (Fucα1,6)GlcNAc-H01L02A antibody solution (50 mM phosphate buffer (pH 6.0)) (2.0 mL).
    • Step 2: Preparation of H01L02A Antibody-[MSG1-N3]2]
  • The operation in step 2 in Example 12 was carried out with the 14.6 mg/mL (Fucα1,6)GlcNAc-H01L02A antibody solution (50 mM phosphate buffer (pH 6.0)) (2.0 mL) obtained in step 1 to afford a 10.0 mg/mL H01L02A antibody-[MSG1-N3]2 solution (acetate buffer (pH 5.5, containing sorbitol)) (2.5 mL).
  • Example 14: H31L02A Antibody-[MSG1-N3]2
  • Figure US20220016257A1-20220120-C00055
    • Step 1: Preparation of (Fucα1,6)GlcNAcH31L02A Antibody
  • The operation in step 1 of Example 12 was carried out with a ca. 23.2 mg/mL H31L02A antibody solution (50 mM phosphate buffer (pH 6.0)) (3.45 mL) to afford a 8.43 mg/mL (Fucα1,6)GlcNAc-H31L02A antibody solution (50 mM phosphate buffer (pH 6.0)) (6.1 mL).
    • Step 2: Preparation of H31L02A Antibody-[MSG1-N3]21
  • The operation in step 2 in Example 12 was carried out with the 8.43 mg/mL (Fucα1,6)GlcNAc-H31L02A antibody solution (50 mM phosphate buffer (pH 6.0)) (5.00 mL) obtained in step 1 to afford a 6.52 mg/mL H31L02A antibody-[MSG1-N3]2 solution (phosphate buffer saline (pH 6.0)) (4.00 mL).
    • Example 15: H11L02A Antibody-[MSG1-N3]2
  • Figure US20220016257A1-20220120-C00056
    • Step 1: Preparation of (Fucα1,6)GlcNAc-H11L02A Antibody
  • The operation in step 1 of Example 12 was carried out with a ca. 24.2 mg/mL H11L02A antibody solution (50 mM phosphate buffer (pH 6.0)) (3.0 mL) to afford a 20.42 mg/mL (Fucα1,6)GlcNAc-H11L02A antibody solution (50 mM phosphate buffer (pH 6.0)) (2.7 mL).
    • Step 2: Preparation of H11L02A Antibody-[MSG1-N3]2]
  • The operation in step 2 in Example 12 was carried out with the 20.39 mg/mL (Fucα1,6)GlcNAc-H11L02A antibody solution (50 mM phosphate buffer (pH 6.0)) (1.55 mL) obtained in step 1 to afford a 10.26 mg/mL H11L02A antibody-[MSG1-N3]2 solution (acetate buffer (pH 5.5, containing sorbitol)) (2.6 mL).
    • Example 16: Anti-LPS Antibody-[MSG1-N3]2]2
  • Figure US20220016257A1-20220120-C00057
    • Step 1: Preparation of (Fucα1,6)GlcNAc-anti-LPS Antibody
  • The operation in step 1 of Example 12 was performed using a ca. 17 mg/mL anti-LPS antibody solution (25 mM histidine solution (pH 6.0), 5% sorbitol solution) (6.6 mL) to afford a 21.03 mg/mL (Fucα1,6)GlcNAc-anti-LPS antibody solution (50 mM phosphate buffer (pH 6.0)) (5.4 mL).
    • Step 2: Preparation of Anti-LPS Antibody-[MSG1-N3]2]
  • The operation in step 2 of Example 12 was performed using the 21.03 mg/mL (Fucα1,6)GlcNAc-anti-LPS antibody solution (50 mM phosphate buffer (pH 6.0)) obtained in step 1 (5.4 mL) to afford a 9.89 mg/mL anti-LPS antibody-[MSG1-N3]2 solution (phosphate buffered saline (pH 6.0)) (7.9 mL).
  • In Examples 17 to 27, synthesis of ADCs will be described.
    • Example 17: ADC1
  • The ADC described in Example 17 was synthesized, as illustrated in the following reaction formula, by conjugating the antibody obtained in step 2 of Example 12 with the drug-linker obtained in step 13 of Example 10-3 (3-14). In the formula, R represents the drug-linker used in the Example.
  • Figure US20220016257A1-20220120-C00058
    Figure US20220016257A1-20220120-C00059
  • The triazole ring to be formed in step 1 has geometric isomers, and the compound obtained in step 1 of Example 17 has a linker as a mixture of the two structures shown above as R.
  • Step 1: Conjugation of Antibody and Drug-Linker
  • To a phosphate buffered saline (pH 6.0) solution of the antibody (6.76 mg/mL, 1.50 mL) obtained in step 2 of Example 12, 1,2-propanediol (1.42 mL) and a 10 mM dimethyl sulfoxide solution of the compound obtained in step 13 of Example 10-3 (3-14) (0.0836 mL; 12 equivalents per antibody molecule) were added at room temperature, and the resultant was reacted using a tube rotator (MTR-103, AS ONE Corporation) at room temperature for 48 hours.
  • Purification operation: The solution was purified by using common operation D to afford 6.00 mL of a solution of the desired compound.
  • Characterization: The following characteristic values were obtained by using common operations E and F.
  • Antibody concentration: 1.37 mg/mL, antibody yield: 8.23 mg (81%), average number of conjugated drug molecules per antibody molecule (n): 1.7
    • Example 18 ADC2
  • The ADC described in Example 18 was synthesized, as illustrated in the following reaction formula, by conjugating the antibody obtained in step 2 of Example 13 with the drug-linker obtained in step 12 of Example 10-4 (4-12). In the formula, R represents the drug-linker used in the Example.
  • Figure US20220016257A1-20220120-C00060
    Figure US20220016257A1-20220120-C00061
  • The triazole ring to be formed in step 1 has geometric isomers, and the compound obtained in step 1 of Example 18 has a linker as a mixture of the two structures shown above as R.
  • Step 1: Conjugation of Antibody and Drug-Linker
  • To a 10 mM acetate buffer, 5% sorbitol (pH 5.5) solution of the antibody (10.0 mg/mL, 100 μL) obtained in step 2 of Example 13, 1,2-propanediol (25 μL) and a mixed solution of a 10 mM dimethyl sulfoxide solution of the compound obtained in step 12 of Example 10-4 (4-12) (8 μL; 12 equivalents per antibody molecule) and 1,2-propane diol (67 μL) were added at room temperature, and the resultant was reacted using a tube rotator (MTR-103, AS ONE Corporation) at room temperature for 48 hours.
  • Purification operation: The solution was purified by using common operation D to afford 1.2 mL of a solution of the desired compound.
  • Characterization: The following characteristic values were obtained by using common operations E and F.
  • Antibody concentration: 0.56 mg/mL, antibody yield: 0.67 mg (67%), average number of conjugated drug molecules per antibody molecule (n): 1.9
    • Example 19: ADC3
  • The ADC described in Example 19 was synthesized by conjugating the antibody obtained in step 2 of Example 13 with the drug-linker obtained in step 10 of Example 10-5 (5-11).
  • Figure US20220016257A1-20220120-C00062
  • The triazole ring to be formed in step 1 has geometric isomers, and the compound obtained in step 1 of Example 19 has a linker as a mixture of the two structures shown above as R.
  • Step 1: Conjugation of Antibody and Drug-Linker
  • To a 10 mM acetate buffer, 5% sorbitol (pH 5.5) solution of the antibody (10.0 mg/mL, 100 μL) obtained in step 2 of Example 13, 1,2-propanediol (25 μL) and a mixed solution of a 10 mM dimethyl sulfoxide solution of the compound obtained in step 10 of Example 10-5 (5-11) (8 μL; 12 equivalents per antibody molecule) and 1,2-propane diol (67 μL) were added at room temperature, and the resultant was reacted using a tube rotator (MTR-103, AS ONE Corporation) at room temperature for 48 hours.
  • Purification operation: The solution was purified by using common operation D to afford 1.2 mL of a solution of the desired compound.
  • Characterization: The following characteristic values were obtained by using common operations E and F.
  • Antibody concentration: 0.53 mg/mL, antibody yield: 0.64 mg (64%), average number of conjugated drug molecules per antibody molecule (n): 1.9
    • Example 20: ADC4
  • The ADC described in Example 20 was synthesized by conjugating the antibody obtained in step 2 of Example 13 with the drug-linker obtained in step 12 of Example 10-6 (6-13).
  • Figure US20220016257A1-20220120-C00063
  • The triazole ring to be formed in step 1 has geometric isomers, and the compound obtained in step 1 of Example 20 has a linker as a mixture of the two structures shown above as R.
  • Step 1: Conjugation of Antibody and Drug-Linker
  • To a 10 mM acetate buffer, 5% sorbitol (pH 5.5) solution of the antibody (10.0 mg/mL, 100 μL) obtained in step 2 of Example 13, 1,2-propanediol (25 μL) and a mixed solution of a 10 mM dimethyl sulfoxide solution of the compound obtained in step 12 of Example 10-6 (6-13) (8 μL; 12 equivalents per antibody molecule) and 1,2-propane diol (67 μL) were added at room temperature, and the resultant was reacted using a tube rotator (MTR-103, AS ONE Corporation) at room temperature for 48 hours.
  • Purification operation: The solution was purified by using common operation D to afford 1.2 mL of a solution of the desired compound.
  • Characterization: The following characteristic values were obtained by using common operations E and F.
  • Antibody concentration: 0.56 mg/mL, antibody yield: 0.67 mg (67%), average number of conjugated drug molecules per antibody molecule (n): 1.9
    • Example 21: ADC5
  • The ADC described in Example 21 was synthesized by conjugating the antibody obtained in step 2 of Example 13 with the drug-linker obtained in step 13 of Example 10-3 (3-14).
  • Figure US20220016257A1-20220120-C00064
  • The triazole ring to be formed in step 1 has geometric isomers, and the compound obtained in step 1 of Example 21 has a linker as a mixture of the two structures shown above as R.
  • Step 1: Conjugation of Antibody and Drug-Linker
  • To a 10 mM acetate buffer, 5% sorbitol (pH 5.5) solution of the antibody (10.0 mg/mL, 1.70 mL) obtained in step 2 of Example 13, 1,2-propanediol (0.850 mL) and a mixed solution of a 10 mM dimethyl sulfoxide solution of the compound obtained in step 13 of Example 10-3 (3-14) (0.141 mL; 12 equivalents per antibody molecule) and 1,2-propane diol (0.710 mL) were added at room temperature, and the resultant was reacted using a tube rotator (MTR-103, AS ONE Corporation) at room temperature for 48 hours.
  • Purification operation: The solution was purified by using common operation D to afford 10.5 mL of a solution of the desired compound.
  • Characterization: The following characteristic values were obtained by using common operations E and F.
  • Antibody concentration: 1.19 mg/mL, antibody yield: 12.5 mg (73%), average number of conjugated drug molecules per antibody molecule (n): 1.8
    • Example 22: ADC6
  • The ADC described in Example 22 was synthesized, as illustrated in the following reaction formula, by conjugating the antibody obtained in step 2 of Example 14 with the drug-linker obtained in step 13 of Example 10-3 (3-14). In the formula, R represents the drug-linker used in the Example.
  • Figure US20220016257A1-20220120-C00065
    Figure US20220016257A1-20220120-C00066
  • The triazole ring to be formed in step 1 has geometric isomers, and the compound obtained in step 1 of Example 22 has a linker as a mixture of the two structures shown above as R.
  • Step 1: Conjugation of Antibody and Drug-Linker
  • To a phosphate buffered saline (pH 6.0) solution of the antibody (10.1 mg/mL, 0.400 mL) obtained in step 2 of Example 14, 1,2-propanediol (0.367 mL) and a 10 mM dimethyl sulfoxide solution of the compound obtained in step 13 of Example 10-3 (3-14) (0.0333 mL; 12 equivalents per antibody molecule) were added at room temperature, and the resultant was reacted using a tube rotator (MTR-103, AS ONE Corporation) at room temperature for 48 hours.
  • Purification operation: The solution was purified by using common operation D to afford 3.50 mL of a solution of the desired compound.
  • Characterization: The following characteristic values were obtained by using common operations E and F.
  • Antibody concentration: 0.820 mg/mL, antibody yield: 2.88 mg (81%), average number of conjugated drug molecules per antibody molecule (n): 1.9
  • The ADCs described in Examples 23 to 26 were synthesized, as illustrated in the following reaction formula, by conjugating the antibody obtained in step 2 of Example 15 with the drug-linker obtained in Examples 10-3 to 10-6. In the formula, R differs between the drug-linkers used in those Examples.
    • Example 23: ADC7
  • Figure US20220016257A1-20220120-C00067
    Figure US20220016257A1-20220120-C00068
  • The triazole ring to be formed in step 1 has geometric isomers, and the compound obtained in step 1 of Example 23 has a linker as a mixture of the two structures shown above as R.
  • Step 1: Conjugation of Antibody and Drug-Linker
  • To a 10 mM acetate buffer, 5% sorbitol (pH 5.5) solution of the antibody (10.54 mg/mL, 0.4 mL) obtained in step 2 of Example 15, 1,2-propanediol (0.100 mL) and a mixed solution of a 10 mM dimethyl sulfoxide solution of the compound obtained in step 13 of Example 10-3 (3-14) (0.035 mL; 12 equivalents per antibody molecule) and 1,2-propane diol (0.266 mL) were added at room temperature, and the resultant was reacted using a tube rotator (MTR-103, AS ONE Corporation) at room temperature for 48 hours.
  • Purification operation: The solution was purified by using common operation D to afford 2.5 mL of a solution of the desired compound.
  • Characterization: The following characteristic values were obtained by using common operations E and F.
  • Antibody concentration: 1.01 mg/mL, antibody yield: 2.53 mg (73%), average number of conjugated drug molecules per antibody molecule (n): 1.9
    • Example 24: ADC8
  • Figure US20220016257A1-20220120-C00069
  • The triazole ring to be formed in step 1 has geometric isomers, and the compound obtained in step 1 of Example 24 has a linker as a mixture of the two structures shown above as R.
  • Step 1: Conjugation of Antibody and Drug-Linker
  • To a 10 mM acetate buffer, 5% sorbitol (pH 5.5) solution of the antibody (2.8 mg/mL, 0.3 mL) obtained in step 2 of Example 15, 1,2-propanediol (75 μL) and a mixed solution of a 10 mM dimethyl sulfoxide solution of the compound obtained in step 12 of Example 10-4 (4-12) (7 μL; 12 equivalents per antibody molecule) and 1,2-propane diol (218 μL) were added at room temperature, and the resultant was reacted using a tube rotator (MTR-103, AS ONE Corporation) at room temperature for 48 hours.
  • Purification operation: The solution was purified by using common operation D to afford 2.5 mL of a solution of the desired compound.
  • Characterization: The following characteristic values were obtained by using common operations E and F.
  • Antibody concentration: 0.22 mg/mL, antibody yield: 0.56 mg (67%), Average number of conjugated drug molecules per antibody molecule (n): 1.8
    • Example 25: ADC9
  • Figure US20220016257A1-20220120-C00070
  • The triazole ring to be formed in step 1 has geometric isomers, and the compound obtained in step 1 of Example 25 has a linker as a mixture of the two structures shown above as R.
  • Step 1: Conjugation of Antibody and Drug-Linker
  • To a 10 mM acetate buffer, 5% sorbitol (pH 5.5) solution of the antibody (2.8 mg/mL, 300 μL) obtained in step 2 of Example 15, 1,2-propanediol (75 μL) and a mixed solution of a 10 mM dimethyl sulfoxide solution of the compound obtained in step 10 of Example 10-5 (5-11) (7 μL; 12 equivalents per antibody molecule) and 1,2-propane diol (218 μL) were added at room temperature, and the resultant was reacted using a tube rotator (MTR-103, AS ONE Corporation) at room temperature for 48 hours.
  • Purification operation: The solution was purified by using common operation D to afford 2.5 mL of a solution of the desired compound.
  • Characterization: The following characteristic values were obtained by using common operations E and F.
  • Antibody concentration: 0.25 mg/mL, antibody yield: 0.62 mg (64%), average number of conjugated drug molecules per antibody molecule (n): 1.8
    • Example 26: ADC10
  • Figure US20220016257A1-20220120-C00071
  • The triazole ring to be formed in step 1 has geometric isomers, and the compound obtained in step 1 of Example 26 has a linker as a mixture of the two structures shown above as R.
  • Step 1: Conjugation of Antibody and Drug-Linker
  • To a 10 mM acetate buffer, 5% sorbitol (pH 5.5) solution of the antibody (2.8 mg/mL, 300 μL) obtained in step 2 of Example 15, 1,2-propanediol (75 μL) and a mixed solution of a 10 mM dimethyl sulfoxide solution of the compound obtained in step 12 of Example 10-6 (6-13) (7 μL; 12 equivalents per antibody molecule) and 1,2-propane diol (218 μL) were added at room temperature, and the resultant was reacted using a tube rotator (MTR-103, AS ONE Corporation) at room temperature for 48 hours.
  • Purification operation: The solution was purified by using common operation D to afford 2.5 mL of a solution of the desired compound.
  • Characterization: The following characteristic values were obtained by using common operations E and F.
  • Antibody concentration: 0.25 mg/mL, antibody yield: 0.62 mg (74%), average number of drug molecules conjugated per antibody molecule (n): 1.8
  • The ADC described in Example 27 was synthesized, as illustrated in the following reaction formula, by conjugating the antibody obtained in step 2 of Example 16 with the drug-linker obtained in step 13 of Example 10-3 (3-14). In the formula, R represents the drug-linker used in the Example.
    • Example 27: ADC11
  • Figure US20220016257A1-20220120-C00072
    Figure US20220016257A1-20220120-C00073
  • The triazole ring to be formed in step 1 has geometric isomers, and the compound obtained in step 1 of Example 27 has two types of the linkers different in structure.
  • Step 1: Conjugation of Antibody and Drug-Linker
  • To a phosphate buffered saline (pH 6.0) solution of the antibody (9.89 mg/mL, 0.40 mL) obtained in step 2 of Example 16, 1,2-propanediol (0.367 mL) and a 10 mM dimethyl sulfoxide solution of the compound obtained in step 13 of Example 10-3 (3-14) (0.0328 mL; 12 equivalents per antibody molecule) were added at room temperature, and the resultant was reacted using a tube rotator (MTR-103, AS ONE Corporation) at room temperature for two days.
  • Purification operation: The solution was purified by using common operation D to afford 2.50 mL of a solution of the desired compound.
  • Characterization: The following characteristic values were obtained by using common operations E and F.
  • Antibody concentration: 1.16 mg/mL, antibody yield: 2.89 mg (72%), average number of conjugated drug molecules per antibody molecule (n): 1.8
    • Example 28] Configuration Analysis of the Compound (1-11) Shown in Example 10-1
  • The compound (1-11) described in [Example 10-1: intermediate 1] was analyzed for absolute steric configuration of the 11′-position based on the correlation (following figure) obtained by Selective 1D ROESY spectrum. Correlation was observed between 1′α-H and 11′-H; between 3′α-H and 11′-H; and between 1′β-H and 3′β-H. From the analysis, it was found that the absolute steric configuration of the 11′-position is S configuration.
  • Significant correlation obtained in Selective 1D ROESY spectrum 1H-NMR used in correlation analysis by Selective 1D ROESY spectrum
  • 1HNMR (500 MHz, CDCl3, 27° C.) δ: 8.76 (1H, s), 7.43 (2H, brd), 7.20 (1H, s), 7.08 (2H, d, J=8.3 Hz), 7.00 (1H, br), 6.66 (1H, s), 6.44 (1H, s), 6.00 (1H, H11′, d, J11′, 11′a=9.2 Hz), 5.89 (1H, m), 5.53 (1H, brd), 5.30 (1H, d, J=17.2 Hz), 5.20 (1H, d, J=10.3 Hz), 5.15 (1H, d, JABq=12.5 Hz), 4.85 (1H, d, JABq=12.5 Hz), 4.66 (1H, m), 4.604.52 (2H, m), 4.07 (1H, m), 3.84 (3H, s), 3.71 (1H, H-3′β, d, Jgem=11.7 Hz), 3.53 (1H, H-11′a, m), 3.26 (1H, H-3′α, d, Jgem=11.7 Hz), 2.35 (1H, H-1′ β, dd, J1′ β, 11′a=8.30 Hz, Jgem=13.1 Hz), 2.14 (1H, m), 1.54 (1H, H-1′ α, d, Jgem=13.1 Hz), 1.41 (3H, d, J=6.90 Hz), 0.95 (3H, d, J=6.80 Hz), 0.92 (3H, d, J=6.80 Hz), 0.81 (9H, s), 0.80-0.70 (1H, m), 0.70-0.59 (3H, m), 0.2-0.06 (6H, m)
  • As a result, it was determined that absolute steric configurations of drug- linkers 1,2 and 4 and the 11′-position of these synthetic intermediates, which were synthesized by using compounds (1-9), (1-10) and (1-11) described in [Example 10-1: Intermediate 1] and compound (1-11) are each S. It was also determined that absolute steric configurations of drug-linker 3 and an intermediate (the 11′-position) are each S.
  • Accordingly, steps 1 to 10 described in [Example 10-1: intermediate 1] are shown as follows:
  • Figure US20220016257A1-20220120-C00074
    • (1-9): N-[(prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11′S,11a′S)-11′-hydroxy-7′-methoxy-5′-oxo-8′-{[tri(propan-2-yl)silyl]oxy}-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
    • (1-10): N-[(prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11′S,11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-5′-oxo-8′-{[tri(propan-2-yl)silyl]oxy}-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
    • (1-11): N-[(prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11′S,11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-8′-hydroxy-7′-methoxy-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
  • Steps 1 to 13 shown in [Example 10-3: Drug-linker 1] are shown as follows:
  • Figure US20220016257A1-20220120-C00075
    • (3-11): N-[(prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11′S,11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-8′-{[5-({(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-[(prop-2-en-1-yloxy) carbonyl]-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c] [1,4]benzodiazepine-8-yl}oxy)pentyl]oxy}-5′-oxo-11′,11a′-dihydro-1′H-spiro [cyclopropane-1,2′-pyrrolo [2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
    • (3-12): N-[(prop-2-en-1-yloxy) carbonyl]-L-valyl-N-({{4-[({[(11′S,11a′S)-11′-hydroxy-7′-methoxy-8′-{[5-({(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-[(prop-2-en-1-yloxy) carbonyl]-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-8-yl}oxy)pentyl]oxy}-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
    • (3-13): L-valyl-N-{4-[({[(11′S,11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-8-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide (3-13)
    • (3-14): N-[4-(11,12-didehydrodibenzo[b,f]azocine-5 (6H)-yl)-4-oxobutanoyl]glycylglycyl-L-valyl-N-{4-[({[(11′S,11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-8-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
  • Steps 1 to 12 shown in [Example 10-4: Drug-linker 2] are shown as follows.
  • Figure US20220016257A1-20220120-C00076
    • (4-9): N-{[(prop-2-en-1-yl)oxy]carbonyl}-L-valyl-N-[4-({[(11′S,11′aS)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-8′-(3-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-{[(prop-2-en-1-yl)oxy]carbonyl}-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c] [1,4]benzodiazepine-8-yl]oxy}propoxy)-5′-oxo-11′,11′a-dihydro-1′H,3′H-spiro [cyclopropane-1,2′-pyrrolo [2,1-c] [1,4]benzodiazepine]-10′(5′H)-carbonyl]oxy}methyl) phenyl]-L-alanine amide
    • (4-10): N-{[(prop-2-en-1-yl)oxy]carbonyl}-L-valyl-N-[4-({[(11′S,11′aS)-11′-hydroxy-7′-methoxy-8′-(3-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-10-{[(prop-2-en-1-yl)oxy]carbonyl}-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-8-yl]oxy}propoxy)-5′-oxo-11′,11′a-dihydro-1′H,3′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carbonyl]oxy}methyl) phenyl]-L-alanine amide
    • (4-11): L-valyl-N-[4-({[(11′S,11′aS)-11′-hydroxy-7′-methoxy-8′-(3-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-8-yl]oxy}propoxy)-5′-oxo-11′,11′a-dihydro-1′H,3′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carbonyl]oxy}methyl) phenyl]-L-alanine amide
    • (4-12): N-[4-(11,12-didehydrodibenzo[b,f]azocine-5 (6H)-yl)-4-oxobutanoyl]glycylglycyl-L-valyl-N-[4-({[(11′S,11′aS)-11′-hydroxy-7′-methoxy-8′-(3-{[(11aS)-7-methoxy-2-(4-methoxyphenyl)-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-8-yl]oxy}propoxy)-5′-oxo-11′,11′a-dihydro-1′H,3′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-carbonyl]oxy}methyl) phenyl]-L-alanine amide
  • Steps 1 to 10 shown in [Example 10-5: Drug-linker 3] are shown as follows.
  • Figure US20220016257A1-20220120-C00077
    • (5-9): N-[(2-propen-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11′S,11a′S)-11′-hydroxy-8′-{[5-({(11′S,11a′S)-11′-hydroxy-7′-methoxy-5′-oxo-10′-[(2-propen-1-yloxy)carbonyl]-5′,10′,11′,11a′-tetrahydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl}oxy)pentyl]oxy}-7′-methoxy-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
    • (5-10): L-valyl-N-{4-[({[(11′S,11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11a′S)-7′-methoxy-5′-oxo-5′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
    • (5-11): N-[4-(11,12-didehydrodibenzo[b,f]azocine-5 (6H)-yl)-4-oxobutanoyl]glycylglycyl-L-valyl-N-{4-[({[(11′S,11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11a′S)-7′-methoxy-5′-oxo-5′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
  • Step 1 to 12 shown in [Example 10-6: Drug-linker 4] are shown as follows:
  • Figure US20220016257A1-20220120-C00078
    • (6-10): N-[(prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11′S,11a′S)-11′-{[tert-butyl(dimethyl)silyl]oxy}-7′-methoxy-8′-{[5-({(11a′S)-7′-methoxy-5′-oxo-10′-[(prop-2-en-1-yloxy)carbonyl]-5′,10′,11′,11a′-tetrahydro′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl}oxy)pentyl]oxy}-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
    • (6-11): N-[(prop-2-en-1-yloxy)carbonyl]-L-valyl-N-{4-[({[(11′S,11a′S)-11′-hydroxy-7′-methoxy-8′-}[5-({(11a′S)-7′-methoxy-5′-oxo-10′-[(prop-2-en-1-yloxy)carbonyl]-5′,10′,11′,11a′-tetrahydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl}oxy)pentyl]oxy}-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
    • (6-12): L-valyl-N-{4-[({[(11′S,11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11a′S)-7′-methoxy-5′-oxo-5′,10′,11′,11a′-tetrahydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
    • (6-13): N-[4-(11,12-didehydrodibenzo[b,f]azocine-5 (6H)-yl)-4-oxobutanoyl]glycylglycyl-L-valyl-N-{4-[({[(11′S,11a′S)-11′-hydroxy-7′-methoxy-8′-[(5-{[(11a′S)-7′-methoxy-5′-oxo-5′,10′,11′,11a′-tetrahydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-8′-yl]oxy}pentyl)oxy]-5′-oxo-11′,11a′-dihydro-1′H-spiro[cyclopropane-1,2′-pyrrolo[2,1-c][1,4]benzodiazepine]-10′(5′H)-yl]carbonyl}oxy)methyl]phenyl}-L-alanine amide
  • In the formulas of ADCs obtained in Examples 17 to 27, R represents the following.
  • R described in Example 17, 21,22, 23 or 27:
  • Figure US20220016257A1-20220120-C00079
  • R described in Example 18 or 24:
  • Figure US20220016257A1-20220120-C00080
  • R described in Example 19 or 25:
  • Figure US20220016257A1-20220120-C00081
  • R described in Example 20 or 26:
  • Figure US20220016257A1-20220120-C00082
    • Reference Example 2: Production of NOV0712-Drug Conjugate Reference Example 2)-1 Production of Antibody-Drug Conjugate NOV0712-DM4
  • Conjugation of antibody and drug-linker: NOV0712 produced in Reference Example 1 was adjusted to 9.7 mg/mL with 20 mM HEPES8.1 (HEPES, 1 M Buffer Solution (20 mL) manufactured by Life Technologies Corp. was pH-adjusted to 8.1 with 1 M sodium hydroxide, and then brought to 1 L with distilled water) by using common procedures B (using 1.51 mLmg−1 cm−1 as 280 nm absorption coefficient) and C described in production method 1. The solution was incubated at 20° C. for 10 minutes. Subsequently, a 10 mM solution of 1-(2,5-dioxopyrrolidin-1-yloxy)-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid described in WO2016/024195 in DMA (0.366 mL; 5.2 equivalents per antibody molecule), a 10 mM solution of N2′-deacetyl-deacetyl-N2′-(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4) in DMA (0.366 mL; 6.8 equivalents per antibody molecule), and 0.243 mL of DMA were added thereto, and the obtained mixture was incubated at 20° C. for 16 hours to conjugate the drug linker to the antibody. Subsequently, an aqueous solution of 1 M acetic acid was added thereto to adjust the pH to 5.0, and the obtained mixture was further stirred at room temperature for 20 minutes to terminate the reaction of the drug linker.
  • Purification: The above-described solution was purified by common procedure D described in production method 1 to obtain 28 mL of a solution containing the title antibody-drug conjugate “NOV0712-DM4”.
  • Characterization: Using common procedure E (using εA,280=200500, εA,252=76295, εD,280=43170, and εD,252=23224) described in production method 1, the following characteristic values were obtained.
  • Antibody concentration: 2.58 mg/mL, antibody yield: 72.2 mg (93%), average number of conjugated drug molecules per antibody molecule (n): 3.0
    • Example 29: Evaluation of In Vitro Activity of Antibody-Drug Conjugate
  • Evaluation of in vitro cell growth inhibition activity of antibody-drug conjugate against CDH6-positive human tumor cell line
  • Human ovarian tumor cell lines NIH: OVCAR-3, OV-90 and PA-1, and human renal-cell tumor cell line 786-O (all obtained from ATCC), in which expression of CDH6 was confirmed in Example 2)-3, were cultured under conditions of 37° C. and 5% CO2 and seeded over a 96-well plate such that each cell line has a density (per 100 μL/well) described in FIG. 9 and cultured under conditions of 37° C. and 5% CO2. The following day, each of an antibody-drug conjugates, e.g., ADC11 (prepared in Example 27), ADC1 (prepared in Example 17), ADC5 (prepared in Example 21), ADC7 (prepared in Example 23) and ADC6 (prepared in Example 22) diluted in 5-fold common ratio was added so as to obtain a final concentration 100 (nM) to 0.000256 (nM). After culturing for 6 days, the number of live cells was measured by the quantification of ATP using CellTiter-Glo™ Luminescent Cell viability Assay (Promega). The IC50 value representing cell growth inhibitory activity was calculated in accordance with the following expression and the third place after the decimal point was rounded to the second decimal point.

  • IC50 (nM)=antilog((50−d)×(LOG 10(b)−LOG 10(a))/(d−c)+LOG 10(b))
  • a: test agent concentration a
  • b: test agent concentration b
  • c: viable-cell rate at test agent concentration a
  • d: viable-cell rate at test agent concentration b
  • a, b satisfy the relationship: a>b at two points sandwiching a viable cell rate of 50%
  • IC50 values (nM) of cell lines to which individual antibody-drug conjugates are added are shown in FIG. 9. In three ovarian tumor cell lines exhibiting a high CDH6 expression level in vitro, IC50 values of three types of anti-CDH6 antibody-drug conjugates are extremely low, compared to IC50 value of ADC11, i.e., an antibody-drug conjugate not binding to CDH6. From this, it was demonstrated that these three types of anti-CDH6 antibody-drug conjugates have an extremely strong cell growth inhibitory activity in a CDH6-expression-specific manner, in addition, the binding activity (Table 3) of an antibody to CDH6 has a correlation with the cell growth inhibitory activity of an antibody-drug conjugate. Also in a renal-cell tumor cell line having a low in-vitro CDH6 expression level, a similar tendency was confirmed (FIG. 9).
    • Example 30: In Vivo Antitumor Effect 1 of Antibody-Drug Conjugate
  • The antitumor effects of the antibody-drug conjugates were evaluated using animal models derived from immunodeficient mice by the inoculation of CDH6-positive human tumor cell line cells. Four- to 5-week-old BALB/c nude mice (CAnN.Cg-Foxnl[nu]/CrlCrlj[Foxnlnu/Foxnlnu], Charles River Laboratories Japan Inc.) and SCID mice (CB17/Icr-Prkdc[scid]/CrlCrlj, Charles River Laboratories Japan Inc.) were acclimatized for 3 days or longer under SPF conditions before use in the experiment. The mice were fed with a sterilized solid diet (FR-2, Funabashi Farms Co., Ltd) and given sterilized tap water (which had been prepared by adding a 5 to 15 ppm sodium hypochlorite solution to tap water). The long diameter and short diameter of the inoculated tumor were measured twice a week using electronic digital calipers (CD-15CX, Mitutoyo Corp.), and the volume of the tumor was then calculated according to the following expression.

  • Tumor volume (mm3)=½×Long diameter (mm)×[Short diameter (mm)]2
  • Each antibody-drug conjugate was diluted with ABS buffer (10 mM acetate buffer, 5% sorbitol, pH 5.5) (Nacalai Tesque, Inc.), and the dilution was intravenously administered at a dose shown in each Example to the tail of each mouse. ABS buffer was administered in the same manner as above to a control group (vehicle group). Six mice per group were used in the experiment.
  • 30)-1 Anti-Tumor Effect (1)
  • The CDH6-positive human ovarian tumor cell line OV-90 (ATCC), the CDH6 expression of which had been confirmed in Example 2)-3, was suspended in Matrigel (Corning Inc.), and the cell suspension was subcutaneously inoculated at a dose of 2.5×106 cells to the right flank region of each female nude mouse (Day 0). On Day 14, the mice were randomly grouped. On the day of grouping, ADC1 produced in Example 17, or ADC11 produced in Example 27 was intravenously administered at doses of 0.4 mg/kg to the tail of each mouse. Also, NOV0712-DM4 produced in Reference Example 2)-1 was intravenously administered at doses of 10 mg/kg to the tail of each mouse. The results are shown in FIG. 10. The abscissa depicts the number of days after administration, and the ordinate depicts tumor volume. The error range depicts a SE value.
  • In this tumor model administered with NOV0712-DM4, regrowth of tumor was observed 30 days after administration; however, ADC1 exhibited a strong tumor regression effect at an extremely low dose of 0.4 mg/kg and sustained the strong anti-tumor effect for a long period of 42 days after administration. ADC11 as a control, which binds neither mouse tumor cells nor inoculated human tumor cells used in the anti-tumor test, did not show an anti-tumor effect. It was confirmed that there is no weight loss in all drug administration groups, compared to the control group (the ABS buffer administration group).
  • 30)-2 Anti-Tumor Effect (2)
  • The CDH6-positive human renal cell tumor cell line Caki-1 (ATCC), the CDH6 expression of which had been confirmed in Example 2)-3, was suspended in Matrigel (Corning Inc.), and the cell suspension was subcutaneously inoculated at a dose of 2.5×106 cells to the right flank region of each female nude mouse (Day 0). On Day 13, the mice were randomly grouped. On the day of grouping, the antibody-drug conjugates ADC1 produced in Example 17, or ADC11 produced in Example 27 was intravenously administered at a dose of 0.4 mg/kg to the tail of each mouse. Also, NOV0712-DM4 produced in Reference Example 2)-1 was intravenously administered at doses of 10 mg/kg to the tail of each mouse. The results are shown in FIG. 11. The abscissa depicts the number of days after administration, and the ordinate depicts tumor volume. The error range depicts a SE value.
  • In this tumor model, NOV0712-DM4 exhibited no antitumor effect at the dose of 10 mg/kg. On the other hand, ADC1 exerted an antitumor effect at an extremely low dose of 0.4 mg/kg. ADC11 as a control, which binds neither mouse tumor cells nor inoculated human tumor cells used in the antitumor test, did not show an anti-tumor effect at a dose of 0.4 mg/kg (FIG. 11). From this, it was shown that the anti-tumor effect exhibited by ADC1 is specifically obtained depending on the expression of CDH6 in tumor cells. It was demonstrated that ADC1 of the present invention is an antibody-drug conjugate having an extremely strong anti-tumor effect compared to conventional conjugate, NOV0712-DM4. It was confirmed that there is no weight loss in all drug administration groups, compared to the control group (the ABS buffer administration group).
  • 30)-3 Anti-Tumor Effect (3)
  • The CDH6-positive human ovarian tumor cell line NIH:OVCAR-3 (ATCC), the CDH6 expression of which had been confirmed in Example 2)-3, was suspended in Matrigel (Corning Inc.), and the cell suspension was subcutaneously inoculated at a dose of 1×107 cells to the right flank region of each female nude mouse (Day 0). On Day 28, the mice were randomly grouped. On the day of grouping, ADC1 produced in Example 17, ADC5 produced in Example 21, ADC6 produced in Example 22, or ADC11 produced in Example 27 was intravenously administered at doses of 0.4 mg/kg to the tail of each mouse. The results are shown in FIG. 12. The abscissa depicts the number of days after administration, and the ordinate depicts tumor volume. The error range depicts a SE value.
  • In this tumor model, ADC6 exhibited the strongest anti-tumor effect, ADC1 and ADC5 exhibited almost the same second strongest anti-tumor effect. From this, it was shown that substitution of leucine residues at positions 234 and 235 (specified based on the EU index) of a human-antibody heavy chain with alanine residues hardly at all affects the anti-tumor effect of an antibody-drug conjugate. ADC11 as a control did not exhibit an anti-tumor effect at a dose of 0.4 mg/kg (FIG. 12). From this, it was shown that the antitumor effects exhibited by ADC1, ADC5 and ADC5 are specifically obtained depending on the expression of CDH6 in tumor cells. It was confirmed that there is no weight loss in all drug administration groups, compared to the control group (the ABS buffer administration group).
  • 30)-4 Anti-Tumor Effect (4)
  • The CDH6-positive human ovarian tumor cell line OV-90 (ATCC), the CDH6 expression of which had been confirmed in Example 2)-3, was suspended in Matrigel (Corning Inc.), and the cell suspension was subcutaneously inoculated at a dose of 2.5×106 cells to the right flank region of each female nude mouse (Day 0). On Day 17, the mice were randomly grouped. On the day of grouping, ADC1 produced in Example 17, ADC5 produced in Example 21, ADC7 produced in Example 23, or ADC6 produced in Example 22 was intravenously administered at doses of 0.2 mg/kg or 0.4 mg/kg to the tail of each mouse. The results are shown in FIG. 13. The abscissa depicts the number of days after administration, and the ordinate depicts tumor volume. The error range depicts a SE value.
  • In this tumor model, ADC5 and ADC6 each exhibited the strongest anti-tumor effect at a dose of 0.4 mg/kg and ADC7 exhibited the second strongest anti-tumor effect at a dose of 0.4 mg/kg (FIG. 13). From the results of administration of ADC5 (0.4 mg/kg) and ADC5 (0.2 mg/kg), it was confirmed that the anti-tumor effect changes depending on the dose. At a dose of 0.2 mg/kg, ADC1 and ADC5 exhibited substantially the same anti-tumor effect. From this, it was shown that substitution of leucine residues at positions 234 and 235 (specified based on the EU index) of a human antibody heavy chain with alanine residues hardly at all affects the anti-tumor effect of an antibody-drug conjugate. It was confirmed that there is no weight loss in all drug administration groups, compared to the control group (the ABS buffer administration group).
  • 30)-5 Anti-Tumor Effect (5)
  • The CDH6-positive human ovarian tumor cell line PA-1 (ATCC), the CDH6 expression of which had been confirmed in Example 2)-3, was suspended in Matrigel (Corning Inc.), and the cell suspension was subcutaneously inoculated at a dose of 7.5×106 cells to the right flank region of each female nude mouse (Day 0). On Day 17, the mice were randomly grouped. On the day of grouping, ADC5 produced in Example 21, ADC6 produced in Example 22, or ADC11 produced in Example 27 was intravenously administered at doses of 0.4 mg/kg to the tail of each mouse. The results are shown in FIG. 14. The abscissa depicts the number of days after administration, and the ordinate depicts tumor volume. The error range depicts a SE value.
  • In this tumor model, ADC5 exhibited the strongest anti-tumor effect. It was confirmed that tumors are not observed for a long period of 35 days. ADC6 exhibited the second strongest anti-tumor effect (FIG. 14). It was confirmed that there is no weight loss in all drug administration groups, compared to the control group (the ABS buffer administration group).
  • 30)-6 Anti-Tumor Effect (6)
  • The CDH6-positive human renal cell tumor cell line 786-O (ATCC), the CDH6 expression of which had been confirmed in Example 2)-3, was suspended in Matrigel (Corning Inc.), and the cell suspension was subcutaneously inoculated at a dose of 5×106 cells to the right flank region of each male SCID mouse (Day 0). On Day 38, the mice were randomly grouped. On the day of grouping, ADC5 produced in Example 21, or ADC6 produced in Example 22 was intravenously administered at a dose of 0.4 mg/kg to the tail of each mouse. Also, ADC11 produced in Example 27 was intravenously administered at a dose of 0.4 mg/kg to the tail of each mouse. The results are shown in FIG. 15. The abscissa depicts the number of days after administration, and the ordinate depicts tumor volume. The error range depicts a SE value.
  • In this tumor model, ADC5 and ADC6 exhibited a strong anti-tumor effect (FIG. 15). ADC11 (control) did not exhibit anti-tumor effect (FIG. 15). From this, it was shown that anti-tumor effects of ADC5 and ADC6 are specifically obtained depending on the expression of CDH6 in tumor cells. It was confirmed that there is no weight loss in all drug administration groups, compared to the control group (the ABS buffer administration group).
    • INDUSTRIAL APPLICABILITY
  • The present invention provided an anti-CDH6 antibody having internalization activity and an antibody-drug conjugate comprising the antibody. The antibody-drug conjugate can be used as a therapeutic drug for cancer, and the like.
    • FREE TEXT OF SEQUENCE LISTING SEQ ID No: 1: Human CDH6 ORF SEQ ID No: 2: EC1 SEQ ID No: 3: EC2 SEQ ID No: 4: EC3 SEQ ID No: 5: EC4 SEQ ID No: 6: EC5
  • SEQ ID No: 7: Cynomolgus monkey CDH6 ORF
    SEQ ID No: 8: Cynomolgus monkey CDH6 primer 1
    SEQ ID No: 9: Cynomolgus monkey CDH6 primer 2
    SEQ ID No: 10: rG019 light-chain variable region amino acid sequence
    SEQ ID No: 11: rG019 light-chain variable region nucleotide sequence
    SEQ ID No: 12: rG019 CDRL1
    SEQ ID No: 13: rG019 CDRL2
    SEQ ID No: 14: rG019 CDRL3
    SEQ ID No: 15: rG019 heavy-chain variable region amino acid sequence
    SEQ ID No: 16: rG019 heavy-chain variable region nucleotide sequence
    SEQ ID No: 17: rG019 CDRH1
    SEQ ID No: 18: rG019 CDRH2
    SEQ ID No: 19: rG019 CDRH3
    SEQ ID No: 20: DNA fragment comprising DNA sequence encoding human light chain signal sequence and human κ chain constant region
    SEQ ID No: 21: DNA fragment comprising DNA sequence encoding human heavy chain signal sequence and human IgG1 constant region
    SEQ ID No: 22: DNA fragment comprising a DNA fragment encoding chG019 light chain
    SEQ ID No: 23: chG019 light chain full-length amino acid sequence
    SEQ ID No: 24: chG019 light chain full-length nucleotide sequence
    SEQ ID No: 25: chG019 light-chain variable region nucleotide sequence
    SEQ ID No: 26: chG019 heavy chain full-length amino acid sequence
    SEQ ID No: 27: chG019 heavy chain full-length nucleotide sequence
    SEQ ID No: 28: chG019 heavy-chain variable region amino acid sequence
    SEQ ID No: 29: chG019 heavy-chain variable region nucleotide sequence
    SEQ ID No: 30: chG019 CDRH2
    SEQ ID No: 31: hL02 light chain full-length amino acid sequence
    SEQ ID No: 32: hL02 light chain full-length nucleotide sequence
    SEQ ID No: 33: hL02 light-chain variable region amino acid sequence
    SEQ ID No: 34: hL02 light-chain variable region nucleotide sequence
    SEQ ID No: 35: hL03 light chain full-length amino acid sequence
    SEQ ID No: 36: hL03 light chain full-length nucleotide sequence
    SEQ ID No: 37: hL03 light-chain variable region amino acid sequence
    SEQ ID No: 38: hL03 light-chain variable region nucleotide sequence
    SEQ ID No: 39: hH01 heavy chain full-length amino acid sequence
    SEQ ID No: 40: hH01 heavy chain full-length nucleotide sequence
    SEQ ID No: 41: hH01 heavy-chain variable region amino acid sequence
    SEQ ID No: 42: hH01 heavy-chain variable region nucleotide sequence
    SEQ ID No: 43: hH02 heavy chain full-length amino acid sequence
    SEQ ID No: 44: hH02 heavy chain full-length nucleotide sequence
    SEQ ID No: 45: hH02 heavy-chain variable region amino acid sequence
    SEQ ID No: 46: hH02 heavy-chain variable region nucleotide sequence
    SEQ ID No: 47: hH04 heavy chain full-length amino acid sequence
    SEQ ID No: 48: hH04 heavy chain full-length nucleotide sequence
    SEQ ID No: 49: hH04 heavy-chain variable region amino acid sequence
    SEQ ID No: 50: hH04 heavy-chain variable region nucleotide sequence
    SEQ ID No: 51: NOV0712 light chain full-length amino acid sequence
    SEQ ID No: 52: Nucleotide sequence encoding amino acid sequence shown in SEQ ID No. 51
    SEQ ID No: 53: NOV0712 heavy chain full-length amino acid sequence
    SEQ ID No: 54: Nucleotide sequence encoding amino acid sequence shown in SEQ ID No. 53
    SEQ ID No: 55: hH11 heavy-chain variable region amino acid sequence
    SEQ ID No: 56: hH11 heavy-chain variable region nucleotide sequence of
    SEQ ID No: 57: hH11 CDRH1
    SEQ ID No: 58: hH11 CDRH2
    SEQ ID No: 59: hH11 CDRH3
    SEQ ID No: 60: hH31 heavy-chain variable region amino acid sequence
    SEQ ID No: 61: hH31 heavy-chain variable region nucleotide sequence
    SEQ ID No: 62: hH31 CDRH1
    SEQ ID No: 63: hH31 CDRH2
    SEQ ID No: 64: hH31 CDRH3
    SEQ ID No: 65: hH01A heavy chain full-length amino acid sequence
    SEQ ID No: 66: hH01A heavy chain full-length nucleotide sequence
    SEQ ID No: 67: hH11A heavy chain full-length amino acid sequence
    SEQ ID No: 68: hH11A heavy chain full-length nucleotide sequence
    SEQ ID No: 69: hH31A heavy chain full-length amino acid sequence
    SEQ ID No: 70: hH31A heavy chain full-length nucleotide sequence
    SEQ ID No: 71: DNA fragment comprising DNA sequence encoding amino acid of human heavy chain signal sequence and human IgG1 LALA constant region
    SEQ ID No: 72: anti-LPS antibody light chain full-length amino acid sequence
    SEQ ID No: 73: anti-LPS antibody heavy chain full-length amino acid sequence

Claims (65)

1. An antibody-drug conjugate represented by the following formula (X):
Figure US20220016257A1-20220120-C00083
wherein m2 represents an integer of 1 or 2,
Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof,
L represents a linker linking a glycan bonding to N297 of Ab (N297 glycan) and D,
N297 glycan may be a remodeled glycan, and
D is any one of the following formulas:
Figure US20220016257A1-20220120-C00084
wherein the asterisk (*) represents bonding to L.
2. The antibody-drug conjugate according to claim 1, wherein the antibody or a functional fragment thereof exhibits competitive inhibitory activity, for binding to the amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4, against at least any one antibody selected from the group consisting of the following antibodies (1) to (8):
(1) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 23 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 26,
(2) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 39,
(3) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43,
(4) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43,
(5) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 47,
(6) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65,
(7) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67, and
(8) an antibody having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
3. The antibody-drug conjugate according to claim 1, wherein the antibody or a functional fragment thereof comprises CDRL1, CDRL2 and CDRL3; and CDRH1, CDRH2 and CDRH3 selected from the group consisting of the following (1) to (4):
(1) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14; and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 18 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19,
(2) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID No: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14; and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 30 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19,
(3) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14; and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59, and
(4) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14 and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 62, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 63 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 64.
4. The antibody-drug conjugate according to claim 1, wherein the antibody or a functional fragment thereof comprises any one light chain variable region selected from the group consisting of the following variable regions (1) to (4):
(1) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33,
(2) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 37,
(3) an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region except CDR sequences in the amino acid sequence of (1) or (2) and
(4) an amino acid sequence having a deletion, substitution or addition of one or several amino acids in the sequence of a framework region except CDR sequences in the amino acid sequences of (1) to (3); and
any one heavy chain variable region selected from the group consisting of the following variable regions (5) to (11):
(5) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 41,
(6) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 45,
(7) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 49,
(8) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 55,
(9) a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 60,
(10) an amino acid sequence having a sequence identity of at least 95% to the sequence of a framework region other than at each CDR sequence in the amino acid sequences of (5) to (9), and
(11) an amino acid sequence having a deletion, substitution or addition of one or several amino acids in the sequence of a framework region other than at each CDR sequence in the amino acid sequences of (5) to (10).
5. The antibody-drug conjugate according to claim 1, wherein the antibody or a functional fragment thereof comprises any one of the following (1) to (6):
(1) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 41,
(2) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 45,
(3) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 37 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 45,
(4) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 49,
(5) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 55, and
(6) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 60.
6. The antibody-drug conjugate according to claim 1, wherein the antibody or a functional fragment thereof has any one of the following (1) to (7):
(1) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 39,
(2) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43,
(3) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43,
(4) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 47,
(5) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65,
(6) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67, and
(7) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
7. The antibody-drug conjugate according to claim 6, wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 39.
8. The antibody-drug conjugate according to claim 6, wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43.
9. The antibody-drug conjugate according to claim 6, wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43.
10. The antibody-drug conjugate according to claim 6, wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 47.
11. The antibody-drug conjugate according to claim 6, wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65.
12. The antibody-drug conjugate according to claim 6, wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67.
13. The antibody-drug conjugate according to claim 6, wherein the antibody or a functional fragment thereof has a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
14. The antibody-drug conjugate according to claim 1, wherein
L is represented by -Lb-La-Lp-NH—B—CH2—O(C═O)—*,
wherein the asterisk * represents bonding to the nitrogen atom at the N10′-position of D,
B represents a 1,4-phenyl group, a 2,5-pyridyl group, a 3,6-pyridyl group, a 2,5-pyrimidyl group or a 2,5-thienyl group,
Lp represents any one selected from the group consisting of:
-GGVA-, -GG-(D-)VA-, -VA-, -GGFG-, -GGPI-, -GGVCit-, -GGVK- and -GGPL-,
La represents any one selected from the group consisting of:
—C(═O)—CH2CH2—C(═O)—,
—C(═O)—(CH2CH2)2—C(═O)—,
—C(═O)—CH2CH2—C(═O)—NH—(CH2CH2)2—C(═O)—,
—C(═O)—CH2CH2—C(═O)—NH—(CH2CH2O)2—CH2—C(═O)—,
—C(═O)—CH2CH2—NH—C(═O)—(CH2CH2O)4—CH2CH2—C(═O)—,
—CH2—OC(═O)— and
—OC(═O)—,
and
Lb represents the following formula:
Figure US20220016257A1-20220120-C00085
Figure US20220016257A1-20220120-C00086
wherein, in each structural formula of Lb shown above, each asterisk * represents bonding to La, and each wavy line represents bonding to the glycan presented by Ab or a remodeled glycan.
15. The antibody-drug conjugate according to claim 1, wherein
L represents any one selected from the group consisting of the following structural formulas:
—Z1—C(═O)—CH2CH2—C(═O)-GGVA-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—C(═O)-GG-(D-)VA-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—C(═O)-VA-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—(CH2CH2)2—C(═O)-VA-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—C(═O)-GGPI-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—C(═O)-GGFG-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—C(═O)-GGVCit-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—C(═O)-GGVK-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—C(═O)-GGPL-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—C(═O)—NH—(CH2CH2)2—C(═O)-VA-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—C(═O)—NH—(CH2CH2O)2—CH2—C(═O)-VA-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—NH—C(═O)—(CH2CH2O)4—CH2CH2—C(═O)—VA-NH—B—CH2—OC(═O)—,
—Z2—OC(═O)-GGVA-NH—B—CH2—OC(═O)— and
—Z3—CH2—OC(═O)-GGVA-NH—B—CH2—OC(═O)—
wherein Z1 represents the following structural formula:
Figure US20220016257A1-20220120-C00087
Z2 represents the following structural formula:
Figure US20220016257A1-20220120-C00088
Z3 represents the following structural formula:
Figure US20220016257A1-20220120-C00089
wherein, in each structural formula represented for Z1, Z2 and Z3, each asterisk * represents bonding to the C(═O), O or CH2 neighboring Z1, Z2 or Z3; each wavy line represents bonding to the glycan presented by Ab or a remodeled glycan, and
B represents a 1,4-phenyl group.
16. The antibody-drug conjugate according to claim 1, wherein
L represents any one selected from the group consisting of:
—Z1—C(═O)—CH2CH2—C(═O)-GGVA-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—C(═O)-VA-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—(CH2CH2)2—C(═O)-VA-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—C(═O)-GGVCit-NH—B—CH2—OC(═O)—, —Z1—C(═O)—CH2CH2—C(═O)—NH—(CH2CH2)2—C(═O)-VA-NH—B—CH2—OC(═O)—,
—Z1—C(═O)—CH2CH2—C(═O)—NH—(CH2CH2O)2—CH2—C(═O)—VA-NH—B—CH2—OC(═O)— and
—Z1—C(═O)—CH2CH2—NH—C(═O)—(CH2CH2O)4—CH2CH2—C(═O)—VA-NH—B—CH2—OC(═O)—,
wherein B represents a 1,4-phenyl group, and Z1 represents the following structural formula:
Figure US20220016257A1-20220120-C00090
wherein in the structural formula for Z1, each asterisk * represents bonding to the C(═O) neighboring Z1 and each wavy line represents bonding to the glycan bonding to N297 of Ab (N297 glycan) or bonding to a remodeled glycan.
17. The antibody-drug conjugate according to claim 1, wherein the antibody is IgG1, IgG2 or IgG4.
18. The antibody-drug conjugate according to claim 1, wherein the N297 glycan is a remodeled glycan.
19. The antibody-drug conjugate according to claim 1, wherein the N297 glycan is N297-(Fuc)MSG1, N297-(Fuc)MSG2, or a mixture thereof, or N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
Figure US20220016257A1-20220120-C00091
wherein the wavy line represents bonding to Asn297 of the antibody,
*-L(PEG)- in the N297 glycan represents *—(CH2CH2—O)n5-CH2CH2—NH—, wherein n5 represents an integer of 2 to 5, the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the β-Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the individual structural formulas.
20. The antibody-drug conjugate according to claim 19, wherein n5 represents 3.
21. An antibody-drug conjugate represented by the following formula (XII):
Figure US20220016257A1-20220120-C00092
wherein, in each structural formula shown above,
m2 represents an integer of 1 or 2,
Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO. 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof,
the N297 glycan of Ab represents any one of N297-(Fuc)MSG1, N297-(Fuc)MSG2, and a mixture thereof, and N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas,
Figure US20220016257A1-20220120-C00093
wherein each wavy line represents bonding to Asn297 (N297) of the antibody,
*-L(PEG)- in the N297 glycan represents *—(CH2CH2—O)3—CH2CH2—NH—, wherein
the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the β-Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the corresponding structural formula.
22. The antibody-drug conjugate according to claim 21, wherein the compound represented by formula (XII) is represented by the following formula (XII′):
Figure US20220016257A1-20220120-C00094
23. An antibody-drug conjugate represented by the following formula (XIII):
Figure US20220016257A1-20220120-C00095
wherein, in each structural formula shown above,
m2 represents an integer of 1 or 2,
Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof, and
the N297 glycan of Ab represents any one of N297-(Fuc)MSG1, N297-(Fuc)MSG2, and a mixture thereof, and N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas,
Figure US20220016257A1-20220120-C00096
wherein each wavy line represents bonding to Asn297 (N297) of the antibody,
*-L(PEG)- in the N297 glycan represents *—(CH2CH2—O)3—CH2CH2—NH—, wherein the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the β-Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the individual structural formulas.
24. The antibody-drug conjugate according to claim 23, wherein the compound represented by formula (XIII) is represented by the following formula (XIII′):
Figure US20220016257A1-20220120-C00097
25. An antibody-drug conjugate represented by the following formula (XIV):
Figure US20220016257A1-20220120-C00098
wherein, in each structural formula shown above,
m2 represents an integer of 1 or 2,
Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof, and
the N297 glycan of Ab represents any one of N297-(Fuc)MSG1, N297-(Fuc)MSG2, and a mixture thereof, and N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
Figure US20220016257A1-20220120-C00099
wherein each wavy line represents bonding to Asn297 (N297) of the antibody,
*-L(PEG)- in the N297 glycan represents *—(CH2CH2—O)3—CH2CH2—NH—, wherein the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the β-Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the individual structural formulas.
26. The antibody-drug conjugate according to claim 25, wherein the compound represented by formula (XIV) is represented by the following formula (XIV′):
Figure US20220016257A1-20220120-C00100
27. An antibody-drug conjugate represented by the following formula (XV):
Figure US20220016257A1-20220120-C00101
wherein, in each structural formula shown above,
m2 represents an integer of 1 or 2,
Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof, and
the N297 glycan of Ab represents any one of N297-(Fuc)MSG1, N297-(Fuc)MSG2, and a mixture thereof, and N297-(Fuc)SG, with N297-(Fuc)MSG1, N297-(Fuc)MSG2, and N297-(Fuc)SG having structures represented by the following formulas:
Figure US20220016257A1-20220120-C00102
wherein each wavy line represents bonding to Asn297 (N297) of the antibody,
*-L(PEG)- in the N297 glycan represents *—(CH2CH2—O)3—CH2CH2—NH—, wherein the amino group at the right end is bound via an amide bond to the carboxylic acid at the 2-position of the sialic acid at the non-reducing terminal in each or either one of the 1-3 and 1-6 branched chains of the β-Man in the N297 glycan, and each asterisk * represents bonding to the nitrogen atom at the 1- or 3-position of the triazole ring in the individual structural formulas.
28. The antibody-drug conjugate according to claim 27, wherein the compound represented by formula (XV) is represented by the following formula (XV′):
Figure US20220016257A1-20220120-C00103
29. The antibody-drug conjugate according to claim 21, wherein the antibody or a functional fragment thereof comprises CDRL1, CDRL2 and CDRL3 and CDRH1, CDRH2 and CDRH3 selected from the group consisting of the following (1) to (4):
(1) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14 and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 18 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19,
(2) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14 and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 17, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 30 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 19,
(3) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14 and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59, and
(4) CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14 and CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 62, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 63 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 64.
30. The antibody-drug conjugate according to claim 21, wherein the antibody or a functional fragment thereof comprises any one of the following (1) to (6):
(1) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 41,
(2) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 45,
(3) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 37 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 45,
(4) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 49,
(5) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 55 or
(6) a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 60.
31. The antibody-drug conjugate according to claim 21, wherein the antibody or a functional fragment thereof comprises any one of the following (1) to (7):
(1) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 39,
(2) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43,
(3) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43,
(4) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 47,
(5) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65,
(6) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67 and
(7) a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
32. The antibody-drug conjugate according to claim 31, wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 39.
33. The antibody-drug conjugate according to claim 31, wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43.
34. The antibody-drug conjugate according to claim 31, wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 35 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 43.
35. The antibody-drug conjugate according to claim 31, wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 47.
36. The antibody-drug conjugate according to claim 31, wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65.
37. The antibody-drug conjugate according to claim 31, wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67.
38. The antibody-drug conjugate according to claim 31, wherein the antibody or a functional fragment thereof comprises a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
39. The antibody-drug conjugate according to claim 1, wherein the average number of conjugated drug molecules per antibody molecule in the antibody-drug conjugate is 1 to 3.
40. The antibody-drug conjugate according to claim 1, wherein the average number of conjugated drug molecules per antibody molecule in the antibody-drug conjugate is 3 to 5.
41. The antibody-drug conjugate according to claim 1, wherein the antibody contains a heavy chain having one or two or more modifications selected from the group consisting of N-linked glycosylation, O-linked glycosylation, N-terminal processing, C-terminal processing, deamidation, isomerization of aspartic acid, oxidation of methionine, addition of a methionine residue to the N-terminus, amidation of a proline residue, and a deletion of one or two amino acids from the carboxyl terminus.
42. The antibody-drug conjugate according to claim 1, wherein the lysine residue at the carboxyl terminus of a heavy chain is deleted.
43. A method for producing a glycan-remodeled antibody, the method comprising the steps of:
i) producing an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof,
ii) treating the antibody obtained in step i) with hydrolase to produce a (Fucα1,6)GlcNAc-antibody; and
iii)-1 reacting the (Fucα1,6)GlcNAc-antibody and a glycan donor molecule in the presence of a transglycosidase, the glycan donor molecule obtained by introducing a PEG linker having an azide group to the carbonyl group of carboxylic acid at the 2-position of a sialic acid in MSG (9) or SG (10) and oxazolinating the reducing terminal, or
iii)-2 reacting the (Fucα1,6)GlcNAc-antibody and a glycan donor molecule in the presence of a transglycosidase, the glycan donor molecule obtained by introducing a PEG linker having an azide group to the carbonyl group of carboxylic acid at the 2-position of a sialic acid in (MSG-)Asn or (SG-)Asn with an α-amino group optionally protected and to the carbonyl group of carboxylic acid in the Asn, causing action of hydrolase, and then oxazolinating the reducing terminal.
44. A method for producing an antibody-drug conjugate according to claim 1, comprising the step of reacting the glycan-remodeled antibody obtained by the method for producing a glycan-remodeled antibody, the method comprising the steps of:
i) producing an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof,
ii) treating the antibody obtained in step i) with hydrolase to produce a (Fucα1,6)GlcNAc-antibody; and
iii)-1 reacting the (Fucα1,6)GlcNAc-antibody and a glycan donor molecule in the presence of a transglycosidase, the glycan donor molecule obtained by introducing a PEG linker having an azide group to the carbonyl group of carboxylic acid at the 2-position of a sialic acid in MSG (9) or SG (10) and oxazolinating the reducing terminal, or
iii)-2 reacting the (Fucα1,6)GlcNAc-antibody and a glycan donor molecule in the presence of a transglycosidase, the glycan donor molecule obtained by introducing a PEG linker having an azide group to the carbonyl group of carboxylic acid at the 2-position of a sialic acid in (MSG-)Asn or (SG-)Asn with an α-amino group optionally protected and to the carbonyl group of carboxylic acid in the Asn, causing action of hydrolase, and then oxazolinating the reducing terminal and a drug linker.
45. The antibody-drug conjugate according to claim 1, produced by the method for producing an antibody-drug conjugate according to claim 1, comprising the step of reacting the glycan-remodeled antibody obtained by the method for producing a glycan-remodeled antibody, the method comprising the steps of:
i) producing an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof,
ii) treating the antibody obtained in step i) with hydrolase to produce a (Fucα1,6)GlcNAc-antibody; and
iii)-1 reacting the (Fucα1,6)GlcNAc-antibody and a glycan donor molecule in the presence of a transglycosidase, the glycan donor molecule obtained by introducing a PEG linker having an azide group to the carbonyl group of carboxylic acid at the 2-position of a sialic acid in MSG (9) or SG (10) and oxazolinating the reducing terminal, or
iii)-2 reacting the (Fucα1,6)GlcNAc-antibody and a glycan donor molecule in the presence of a transglycosidase, the glycan donor molecule obtained by introducing a PEG linker having an azide group to the carbonyl group of carboxylic acid at the 2-position of a sialic acid in (MSG-)Asn or (SG-)Asn with an α-amino group optionally protected and to the carbonyl group of carboxylic acid in the Asn, causing action of hydrolase, and then oxazolinating the reducing terminal.
46. An antibody or a functional fragment thereof, comprising a light chain variable region, which contains CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14, and a heavy chain variable region, which contains CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59.
47. An antibody or a functional fragment thereof, comprising a light chain variable region, which contains CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14; and a heavy chain variable region, which contains CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 62, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 63 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 64.
48. The antibody or a functional fragment thereof according to claim 46, comprising a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 55.
49. The antibody or a functional fragment thereof according to claim 47, comprising a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 33 and a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 60.
50. The antibody or a functional fragment thereof according to claim 46, having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 67.
51. The antibody or a functional fragment thereof according to claim 47, having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 69.
52. An antibody or a functional fragment thereof having a light chain consisting of the amino acid sequence at positions 21 to 233 in SEQ ID NO: 31 and a heavy chain consisting of the amino acid sequence at positions 20 to 471 in SEQ ID NO: 65.
53. A polynucleotide encoding the antibody according to claim 46.
54. An expression vector containing the polynucleotide according to claim 53.
55. A host cell transformed with the expression vector according to claim 54.
56. A method for producing the antibody or a functional fragment thereof according to claim 46, comprising a step of culturing the host cell transformed with the expression vector containing the polynucleotide encoding the antibody according to claim 46 and collecting the targeted antibody from the culture obtained from the step of culturing.
57. An antibody or a functional fragment thereof, obtained by the method according to claim 56.
58. A pharmaceutical composition containing the antibody-drug conjugate according to claim 1 or an antibody or a functional fragment thereof, comprising a light chain variable region, which contains CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14, and a heavy chain variable region, which contains CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59.
59. The pharmaceutical composition according to claim 58, which is an antitumor drug.
60. The pharmaceutical composition according to claim 59, wherein the tumor is a tumor expressing CDH6.
61. The pharmaceutical composition according to claim 60, wherein the tumor is renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, bile duct cancer, lung cancer, small-cell lung cancer, non-small cell lung cancer, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor or neuroblastoma.
62. A method for treating a tumor, which comprises administering the antibody-drug conjugate according to claim 1, the antibody or a functional fragment thereof, comprising a light chain variable region, which contains CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14, and a heavy chain variable region, which contains CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59 or the pharmaceutical composition containing the antibody-drug conjugate according to claim 1 or an antibody or a functional fragment thereof, comprising a light chain variable region, which contains CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14, and a heavy chain variable region, which contains CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59 to an individual.
63. The treatment method according to claim 62, wherein the tumor is a tumor having CDH6 expressed therein.
64. The treatment method according to claim 62, wherein the tumor is renal cell carcinoma, renal clear cell carcinoma, papillary renal cell carcinoma, ovarian cancer, ovarian serous adenocarcinoma, thyroid cancer, bile duct cancer, lung cancer, small-cell lung cancer, non-small cell lung cancer, glioblastoma, mesothelioma, uterine cancer, pancreatic cancer, Wilms' tumor or neuroblastoma.
65. The treatment method according to claim 62, which comprises administering the antibody-drug conjugate represented by the following formula (X):
Figure US20220016257A1-20220120-C00104
wherein m2 represents an integer of 1 or 2,
Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof,
L represents a linker linking a glycan bonding to N297 of Ab (N297 glycan) and D,
N297 glycan may be a remodeled glycan, and
D is any one of the following formulas:
Figure US20220016257A1-20220120-C00105
wherein the asterisk (*) represents bonding to L, the antibody or a functional fragment thereof, comprising a light chain variable region, which contains CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14, and a heavy chain variable region, which contains CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59, or the pharmaceutical composition containing the antibody-drug conjugate represented by the following formula (X):
Figure US20220016257A1-20220120-C00106
wherein m2 represents an integer of 1 or 2,
Ab represents an IgG antibody specifically binding to an amino acid sequence comprising the amino acid sequence shown in SEQ ID NO: 4 and having internalization ability that permits cellular uptake, or a functional fragment thereof,
L represents a linker linking a glycan bonding to N297 of Ab (N297 glycan) and D,
N297 glycan may be a remodeled glycan, and
D is any one of the following formulas:
Figure US20220016257A1-20220120-C00107
wherein the asterisk (*) represents bonding to L
or an antibody or a functional fragment thereof, comprising a light chain variable region, which contains CDRL1 consisting of the amino acid sequence shown in SEQ ID NO: 12, CDRL2 consisting of the amino acid sequence shown in SEQ ID NO: 13 and CDRL3 consisting of the amino acid sequence shown in SEQ ID NO: 14, and a heavy chain variable region, which contains CDRH1 consisting of the amino acid sequence shown in SEQ ID NO: 57, CDRH2 consisting of the amino acid sequence shown in SEQ ID NO: 58 and CDRH3 consisting of the amino acid sequence shown in SEQ ID NO: 59 and at least one antitumor drug to an individual, simultaneously, separately or continuously.
US17/293,577 2018-11-14 2019-11-13 Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate Pending US20220016257A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2018214110 2018-11-14
JP2018-214110 2018-11-14
JP2019-057327 2019-03-25
JP2019057327 2019-03-25
PCT/JP2019/044588 WO2020100954A1 (en) 2018-11-14 2019-11-13 (anti-cdh6 antibody)-(pyrrolobenzodiazepine derivative) conjugate

Publications (1)

Publication Number Publication Date
US20220016257A1 true US20220016257A1 (en) 2022-01-20

Family

ID=70732133

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/293,577 Pending US20220016257A1 (en) 2018-11-14 2019-11-13 Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate

Country Status (11)

Country Link
US (1) US20220016257A1 (en)
EP (1) EP3882349A4 (en)
JP (1) JP7401456B2 (en)
KR (1) KR20210091711A (en)
CN (1) CN113166764A (en)
AU (1) AU2019379418A1 (en)
BR (1) BR112021009251A2 (en)
CA (1) CA3119956A1 (en)
SG (1) SG11202104993SA (en)
TW (1) TW202031298A (en)
WO (1) WO2020100954A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202109860VA (en) * 2019-03-25 2021-10-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
KR20210143237A (en) * 2019-03-25 2021-11-26 다이이찌 산쿄 가부시키가이샤 Antibody-pyrrolobenzodiazepine derivative conjugate
EP3949988A4 (en) * 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
AU2022353890A1 (en) 2021-09-30 2024-04-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pyrrolo benzodiazepine derivative, and conjugate, preparation method and use thereof
WO2023104188A1 (en) * 2021-12-10 2023-06-15 Multitude Therapeutics Inc. Anti-cdh6 antibodies and antibody-drug conjugates thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (en) 1990-07-10 1999-10-15 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
DK0605522T3 (en) 1991-09-23 2000-01-17 Medical Res Council Process for producing humanized antibodies
ATE463573T1 (en) 1991-12-02 2010-04-15 Medimmune Ltd PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
EP2261229A3 (en) 1998-04-20 2011-03-23 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2270148A3 (en) 1999-04-09 2011-06-08 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ES2639222T5 (en) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Cells that produce antibody compositions
US7763534B2 (en) 2007-10-26 2010-07-27 Tela Innovations, Inc. Methods, structures and designs for self-aligning local interconnects used in integrated circuits
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
EA024730B1 (en) 2010-04-15 2016-10-31 Медимьюн Лимитед Pyrrolobenzodiazepine compounds, conjugates thereof, pharmaceutical compositions comprising said conjugates, and use of said conjugates
CN103068405A (en) 2010-04-15 2013-04-24 西雅图基因公司 Targeted pyrrolobenzodiazapine conjugates
JP5891241B2 (en) 2010-12-20 2016-03-22 ギリアード サイエンシーズ， インコーポレイテッド Combinations for treating HCV
CA2862925C (en) 2012-02-10 2020-01-21 University Of Maryland, Baltimore Chemoenzymatic glycoengineering of antibodies and fc fragments thereof
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
KR20230142808A (en) 2012-10-11 2023-10-11 다이이찌 산쿄 가부시키가이샤 Method for producing a glycinamide compound
HUE042731T2 (en) 2012-10-12 2019-07-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
RS58873B1 (en) 2013-02-22 2019-08-30 Abbvie Stemcentrx Llc Antidll3-antibody-pbd conjugates and uses thereof
AU2014312210A1 (en) 2013-08-28 2016-04-07 Abbvie Stemcentrx Llc Engineered anti-DLL3 conjugates and methods of use
RU2016116949A (en) 2013-09-30 2017-11-10 Дайити Санкио Компани, Лимитед ANTI-LPS O11-ANTIBODY
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EA033456B1 (en) 2013-12-16 2019-10-31 Genentech Inc Antibody-drug conjugates comprising peptidomimetic linkers
KR102535900B1 (en) 2013-12-25 2023-05-26 다이이찌 산쿄 가부시키가이샤 Anti-trop2 antibody-drug conjugate
PE20170903A1 (en) 2014-08-12 2017-07-12 Novartis Ag DRUG CONJUGATES WITH ANTI-CDH6 ANTIBODIES
US9381256B2 (en) 2014-09-03 2016-07-05 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
US11559581B2 (en) 2015-01-09 2023-01-24 Oxford University Innovation Limited Antibody conjugates and methods of making the antibody conjugates
ES2783624T3 (en) 2015-01-14 2020-09-17 Bristol Myers Squibb Co Benzodiazepine dimers, conjugates thereof, and methods of preparation and use
US9504694B2 (en) 2015-03-19 2016-11-29 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
EP3313845B1 (en) 2015-06-29 2020-08-12 ImmunoGen, Inc. Conjugates of cysteine engineered antibodies
IL256295B2 (en) 2015-06-30 2023-11-01 Seagen Inc Anti-ntb-a antibodies and related compositions and methods
AU2016294206B9 (en) 2015-07-16 2021-12-23 Daiichi Sankyo Company, Limited Novel endos mutant enzyme
GB201513607D0 (en) 2015-07-31 2015-09-16 Feingold Jay M Pyrrolobenzodiazepine-antibody conjugates
CN115300640A (en) * 2015-08-10 2022-11-08 杭州多禧生物科技有限公司 Novel linkers and their use for specific coupling of drugs and biomolecules
GB201602363D0 (en) * 2016-02-10 2016-03-23 Adc Therapeutics Sa And Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR102493562B1 (en) * 2016-07-01 2023-01-30 다이이찌 산쿄 가부시키가이샤 Molecular conjugates containing hANP-Fc
EP3572428A4 (en) * 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
TWI794230B (en) * 2017-05-15 2023-03-01 日商第一三共股份有限公司 Anti cdh6 antibodies and anti cdh6 antibody drug conjugates, as well as manufacturing method thereof
CN111164208B (en) * 2017-09-29 2023-08-04 第一三共株式会社 Antibody-pyrrolobenzodiazepine derivative conjugates
KR20210143237A (en) * 2019-03-25 2021-11-26 다이이찌 산쿄 가부시키가이샤 Antibody-pyrrolobenzodiazepine derivative conjugate
SG11202109860VA (en) * 2019-03-25 2021-10-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
EP3949988A4 (en) * 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor

Also Published As

Publication number Publication date
TW202031298A (en) 2020-09-01
EP3882349A4 (en) 2023-04-05
EP3882349A1 (en) 2021-09-22
JP7401456B2 (en) 2023-12-19
BR112021009251A2 (en) 2021-08-10
JPWO2020100954A1 (en) 2021-09-30
CN113166764A (en) 2021-07-23
WO2020100954A1 (en) 2020-05-22
SG11202104993SA (en) 2021-06-29
KR20210091711A (en) 2021-07-22
AU2019379418A1 (en) 2021-06-03
CA3119956A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
US11077202B2 (en) Anti-CDH6 antibody and anti-CDH6 antibody-drug conjugate
US11583590B2 (en) Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor
US11185594B2 (en) (Anti-HER2 antibody)-drug conjugate
WO2020196474A1 (en) Antibody-pyrrolobenzodiazepine derivative conjugate
US20220168438A1 (en) Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
US20220016257A1 (en) Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
EP4257154A1 (en) Bioactive substance conjugate, preparation method therefor and use thereof
JP2020099351A (en) Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
US20220177601A1 (en) Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
WO2024092067A1 (en) Cd70 antibody drug conjugates and methods of using the same

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

AS Assignment

Owner name: DAIICHI SANKYO COMPANY, LIMITED, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAITO, ATSUKO;HARADA, NAOYA;YONEDA, KOZO;AND OTHERS;SIGNING DATES FROM 20210513 TO 20210517;REEL/FRAME:056898/0261

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION